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Introduction
"Virtually every life process involves peptides in some way"1a
Life is only possible if there is a high level of regulation to control every event in every living
cell at any time. This regulation is achieved through the ability of the molecules of life to
recognise and identify each other. A typical cell contains a number of molecules (receptors)
exposed to the environment and in communication with it. Other molecules in the
environment contain specific components called ligands.
Figure 1. Molecular recognition at the cell surface. Cartoon reproduced from Sigma
Chemical & Co.1b
Receptor-ligand interactions are recognised as the fundamental governing processes in
biology and medicine, as they are responsible for transmitting informations about events
inside and outside the cell and for prompting appropriate responses (Figure 1). Human
diseases can be ultimately associated with receptor-ligand interactions, such as the altered
function of a mutated receptor gene or the tropism of a virus for a cell surface.
The strong interaction between a ligand and its receptor depends on their complementarity in
shape, surface potential and other non-covalent forces (hydrogen-bonds and hydrophobicity).
Many ligands are peptides (examples are given in Table 1), and in this case the recognition
requirements can be summarised in only three points: the primary, secondary, and tertiary
ligand structure.
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Table 1. A few examples of biologically active peptides.
Name Sequence Biological properties
Insuline
Angiotensine II (human)
Somatostatin
DRVYIHPF
AGCKNFFWKTFTSC
                         GIVEQCCTSIC
SLYQLENYCNFVNQHLCGSH
LVEALYLVCGERGFFYYPKT
Increases blood pressure 
(hypertensive agent).
Inhibits secretion of insulin, 
glucagon and gastrin.
Regulate glucose metabolism 
in tissues.
Endomorphine-2 TPFF-NH2
Endogenous ligand at the
µ-opiate receptor. Analgesic.
Bombesin
Endogenous 
neurotransmitter in many
animals including mammals. 
Affects vascular and other
smooth muscle, gastric
secretion and renal
circulation and function.
Pyr-QRLGNQWAVGHLM-NH2
The central role played by peptides in the organism makes them a major target of
investigation in pharmacology and drug design, and indeed a variety of peptide-based drugs
are currently developed as therapeutics in the treatment of cancer,2a pain management,2b viral
infections,2c and other diseases.2d However, the peculiar chemical and physical properties of
peptides introduce additional difficulties over small-molecule drugs for their adoption as
therapeutics in clinical practice. At least two basic issues have to be addressed in the
development of a pharmacologically active peptide:
• the poor oral bio-availability due to the chemical degradation in the stomach and intestines,
as well as the low absorption rate in the intestinal system. Moreover, peptides have often a
short systemic half-life, because they are rapidly hydrolysed by proteolytic enzymes in
blood and tissues. A further obstacle to the delivery of peptide drugs in the organism is
constituted by the blood-brain-barrier.1c
• the complex elucidation of the conformation-activity relationship that is the key-point to be
addressed in order to explain the mechanism of the biological action and eventually design
analogues with improved pharmacological activity.
Many strategies have been developed in order to improve the systemic availability and
stability of peptide drugs in the organism. For example, their inclusion into biodegradable
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polymer micro-beads or their embedment into liposomes allows oral administration and
controlled rate delivery of the drug.3a-b
A further promising approach to improve the stability of peptide drugs is the introduction of
residues not recognised by peptidases in the primary peptides sequence. Insertion of
non-natural residues in the primary sequence constitutes also a powerful tool for the
inspection of peptides structure. In fact, the introduction of conformation stabilising building
blocks can prevent the mutual exchange of conformers and possibly “freeze“ the biologically
active structure, which can be subsequently investigated by established spectroscopic
techniques. Moreover, the synthesis of structurally defined building blocks which can be
inserted as non-natural residues in a peptide, opens the exciting possibility of inducing a
targeted modification into the secondary structure of a native peptide, thereby modulating
their biological properties and activity.
Compounds that are able to mimic the critical features of the molecular recognition process of
the parent peptide and thereby block or reproduce its action are named peptidomimetics.
I.1 α-Amino acids analogues as building blocks for peptidomimetics
A number of building blocks not belonging to the 20 proteinogenic amino acids have been
devised as replacement for α-amino acids in a natural peptide sequence (Figure 2).
Figur
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Such units can stabilise and/or induce secondary structure motives in peptides, due to the lack
of side chains (glycine, β-alanine), due to their chirality (D-amino acids), or due to the
prolongation of the peptide back-bone (β-amino acids) or to some constraining features which
can rigidify the peptide structure (α,α-dialkyl and cyclic amino acids). The application of
some of these building blocks as unnatural constituents of peptides will be described in the
following sections, in particular greater attention will be devoted to the effect of cyclopropane
containing units.
I.1.1 α-Amino acids
The replacement of an amino acid of the original bioactive sequence with another natural
amino acid is the most obvious way to investigate a peptide active conformation.4c
Among the 20 natural amino acids, in particular the incorporation of glycine and proline has a
strong effect on peptides structure. Glycine, due to the lack of chirality at the α-carbon and
the absence of a side chain, adopts conformations that are inaccessible to the other amino
acids. Glycine is commonly found in β-sheets4c (Figure 3) or in turns (Figure 4) while it is
known to terminate helices.4d
Figure 3. Parallel and antiparallel β-sheets.
Proline,4c in direct contrast to glycine, involves an additional constraint on the backbone
caused by its cyclic structure. It can fit neither into helices nor into β-sheets because it has no
NH available to take part in the hydrogen-bonding network. Proline is able, however, to act as
turn inducing element4e due to its cyclic nature and to its unique capability to tolerate cis as
well as trans peptide bonds.
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ϕ (i+1) ψ (i+1) ϕ (i+2)
Type I -60 -30 -90
Type II -60 120 80
Type III -60 -30 -60
Figure 4. Turns: the type of turn is determined by the ϕ (rotation around the
ψ (rotation around the Cα-C=O bond) dihedral angles.
D-α-amino acids increase the proteolytic stability of peptides, and therefore
role in drug design. Moreover, D-amino acids favour reverse turns (Figure
helices.5a Their unique ability is to induce a particular type of β-turn, so cal
mirror image, so called type II’ depending on whether it is found at the r
corner of the turn (i.e. position i+2 or i+1). In contrast, the combination of t
can induce so called type I β-turns.5b The ability to stabilise type II’ β-tur
interest since it does not often occur in L-peptides but can be decisive 
recognition of some peptides toward their receptors. An example is the
peptides, containing the binding sequence Arg-Gly-Asp, toward αvβ3-integr
human tumour metastasis and in angiogenesis.5c
I.1.2 N- Methyl and α,α-dialkyl amino acids
N-Methyl amino acids are commonly found in naturally occurring peptide
are generally not recognised by proteases since the lack of the NH in th
alters the hydrogen bonding pattern. Like proline, they also tolerate cis pe
can be used as effective reverse-turn constraints when they are placed 
position of a turn, especially when D-proline is occurring in the preceding po
γ-turn β-turn
type I
β-turn
type IIγ-turnβ-turn
type IIIψ (i+2)
0
0
-30
 Cα-N bond) and
 play an important
 4) but destabilise
led type II, and its
ight or at the left
wo D-amino acids
ns is of particular
for the molecular
 affinity of RGD
ines, implicated in
 antibiotics. They
e backbone chain
ptide bonds. They
at the i+1 or i+2
sition.5d
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Figure 5. α- and 310-helices.
Prominent among the α,α-dialkyl amino acids is amino iso butyric acid (Aib) commonly
found in a family of natural antibiotics produced by microbial sources. Tetrasubstitution of
the α-carbon atom generates severe steric hindrance, therefore, as a consequence of the
Torpe-Ingold effect,6 the folding of Aib containing peptides in 310-, α-helices (Figure 5) and
β-turns (Figure 7) is favoured compared to the extended structures.7a,b Analogous results were
obtained with other types of α,α-dialkyl glycines.7c-e
I.1.2.1 α-Cyclopropyl amino acids
Among the α,α-disubstituted amino acids some cycloaliphatic residues4a were investigated. A
particular role is played by 1-aminocyclopropane carboxylic acid (α-ACC) 1 (Figure 6).
CO2HH2N
1
CO2HH2N
2
CO2HH2N
3
N
H
H2N
NH
Figure 6. Naturally occurring α-ACCs.
α-ACC 1 is a natural amino acid which was first isolated from cider apples and perry pears
and was identified as an intermediate in the biosynthesis of ethylene.7e,g Besides α-ACC 1,
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many analogues could be isolated from plants: Coronatine 2 and Carnosadine 3 are only two
examples (Figure 6) and many other cyclopropane containing amino acids not occurring in
nature were later synthesised.7a-b
Theoretical calculations8a-c showed that α-ACC, due to the additional constrain introduced by
the cyclopropane ring, behaves quite differently from Aib since it favours folding of the
peptide chain by formation of a C7-helix or γ-turn8a-d (Figure 7). Peptides consisting of three
or four α-ACC units have a propensity to fold into distorted type I β-bends and irregular
310-helices.8e-g
N
H
HN
O
O
HN
NHHN
O
OO
Figure 7. Aib favours β-turns, α-ACC γ-turns.
Many bioactive peptides containing α-ACC 1 have been so far synthesised: the aspartame
analogue Asp-ACC-OnPr, which has 250-300 times higher sweetness potency than sucrose;
N-benzoyl-ACC-Phe-OH and N-benzoyl-ACC-Pro-OH, which showed time-dependent
inhibition of carboxypeptidase A; ACC7-oxytocin, which has lower bioactivity than oxytocin,
are only a few examples.8h
I.1.3 Peptide bond isosters
Many amide bond isosters have been devised (in Figure 8 only few examples are shown).
These analogues resemble the peptide bond to varying degrees, but they are more resistant to
proteolytic cleavage and, furthermore, they display improved passive diffusion across
biological membranes.4a,b
H
N
O
O
O OH
amide ester alkene hydroxy ethylene moiety
Figure 8. Amide bond isosters.
β-turn (C10 ring) γ-turn (C7 ring)
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Depsipeptides are homologues of peptides in which some of the backbone amide linkages are
replaced by ester bonds. The ester bond, among the amide bond isosters, is the one which can
particularly well mimic the conformational properties of the parent amide bond: both groups
are planar due to the electronic resonance, and although the ester bond lacks the proton of the
amide NH to build hydrogen bonds, they are able to form loops. This feature can be useful to
investigate the conformation preferences of short peptides avoiding the complication to find
out which of the many NHs is hydrogen bonded.9a,b
Trans disubstituted alkene units can mimic trans configurated peptide bonds but are inert to
peptidases. They are known to promote β-turns and β-hairpins,10a,b and are able to play an
unusual role as hydrogen-bond acceptors.10b
Among the hydroxy ethylene amide bond isosters, the dipeptide mimics 4a and 4b
(Scheme 1) are an interesting example of the ability of cyclopropane derivatives to control the
backbone folding due to their constrained ring and to the forced cis- or trans- relationship
between the substituents.11a-d
N
H
H
N
O
O
R1
R2
O
HO
N
H
R1
R2
O
R2
OHH
N
R1
C replacement
4a
4b
Scheme 1. The dipeptide mimics 4a and 4b.
The trans 4a proved to stabilise extended conformations in α-peptides, an important, although
difficult task to accomplish, since structural elements mimicking β-strands are not so
extensively investigated.11a,d The cis 4b was designed to initiate a reverse turn which,
however, was not formed in the solid state.11d Nevertheless both dipeptide mimics and related
derivatives displayed interesting pharmacological properties as inhibitors of
farnesyltransferase, as enkephalin analogues and as inhibitors of HIV-1 protease.11a,c,d
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I.1.4 β-amino acids and β-peptides
β-amino acids are the higher homologues of α-amino acids having an additional methylene
group which does not lead to decreased capability of folding but rather to new stable
secondary structures occurring in much shorter oligomers than in α-peptides.12a β-amino acids
can be Cα as well as Cβ substituted (and for each, obviously, L and D configurations are
possible) thus providing a wide range of possible stereochemical combinations.12b As well as
α-peptides, β-peptides are also able to fold into helical, sheet- and turn-like structures.
The most common secondary structures in β-peptides are helices, left (L) and right (R)
handed, with various hydrogen bonding patterns (a brief overview is given in Table 2).12a,c,d In
contrast to α-peptides requiring 12 to 15 residues to form stable helices in organic protic
solvents, for β-peptides already six residues are sufficient.12a,b,e Some features in β-helices
resemble those of α-helices: constrain on the side chain (due to the inclusion of the Cα-Cβ
bond within a ring) favours the helix folding12f while incorporation of β-alanine (higher
analogue of glycine) breaks the helices.12g
Table 2. Helical conformations in β-peptides. Helices 12/10/12 occur in mixed β-peptides
containing Cα- and Cβ- monosubstituted β-amino acids.
hydrogen bonding  pattern helix type
L+2, R+2
L-3, R-3
12/10/12
O N
H
HN O
NHN
H
O
C10
C12
O
H
N
HN
O
NN
H
O
C12
H
O
C12
i i+2
i i-3
Alternating C10 and C12
hydrogen bond pattern
N
HN
O N
H
O
O
O
H
C14
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The formation of sheet-like secondary structures is more difficult, however, great progress has
already been accomplished toward this aim. Antiparallel β-sheet like arrangements were
obtained by introduction of typical turn inducing moieties: α-depsipeptides (D-Pro-Lac13a),
cyclisation,13b or β-nipecotic acid dimer.13c Parallel β-sheet like arrangement are on the other
hand rarely encountered.13d
Besides all the β-amino acids which have been synthesised until now, β-alanine (5) deserves
particular mentioning being an achiral β-amino acid which occurs in animal and plant
kingdom.14a
β-Alanine lacks a side chain and therefore permits the folding of β-alanine containing
peptides in a large number of well defined three-dimensional structures ranging from
extended to folded β-alanine conformation (Figure 9).14b
HN
O
HN Oαβ
µ
αβ
µ
extended conformation folded conformation
5 5
Figure 9. Extended and folded conformation of β-alanine are characterised by a value of the
µ dihedral angle of ±180±20° and ±60±20° respectively.
The folded conformation of β-alanine has been observed in cyclic peptides7a,15a-i where
β-alanine promotes β-turns15b-d,g-h or γ-turns.15e,f Nevertheless β-alanine has low propensity to
be positioned at the corner of these turned structures unless other conformational constraints
exist.15i In linear peptides on the other hand, the most favourable conformation is the extended
one.16a,b Therefore β-alanine seems to have no intrinsic preference for the folded
conformation but can surprisingly stabilise peptide conformations by mimicking fragments of
various secondary structures, i.e. α-helix, β- and γ-turns.17a-d
I.1.4.1 β-ACCs
The effect of geminal substitution is interesting not only in α-peptides but also in
β-peptides:18a the 1-(aminoethyl)-cyclopropanecarboxylic acid 6 (Figure 10), the β-analogue
of α-ACC 1, displays a completely new folding pattern,18b namely a stair-like structure 7
constituted of C8 hydrogen bonded rings. The synthesis of 8 (the (1-aminocyclopropyl) acetic
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acid) and of its derivatives is already known18d-f but neither its oligomers nor otherwise 8
containing peptides have been yet synthesised.
HO2C NH2
H2N CO2H
OHN
O N
H
C8
6 7 8
Figure 10. Geminal β-ACC.
Another way to introduce the cyclopropyl ring constrain into an amino acid is shown with the
β-ACC 9 (Figure 11), a β-alanine analogue in which the rotation around the µ dihedral angle
is not possible (fixed folded conformation) and the relationship between the amino and
carboxy function is determined by the stereochemistry at the two stereocentres. As it has been
illustrated so far, constrained α- and β- amino acids are efficient building blocks to rigidify
peptides conformation and to induce their folding, and 9 in particular has attracted
considerable attention as a potential turn inducer.19a-d
NH2
HO2C
NHR1
R2O2C R
3
R1= CO2 Et, CO2-Napht, Cbz, Boc
R2= Me, Bn, Et
R3= Me, H
9 10
NHBoc
R1O2C CO2R
2
R1= Bn, R2= Me
R1= Me, R2= Bn
11
12
Figure 11. β-ACC 9 and related compounds 10, 11 and 12.
Unfortunately 9 and its derivatives are difficult to prepare due to the 1,2 donor-acceptor
disubstitution which leads to rapid ring opening20 in the absence of an electron withdrawing
group on the amino function. Moreover, the control of the stereochemistry on the centres at
the cyclopropane ring is an additional challenge.19a Therefore, only few syntheses of
compounds with a cis-β-ACC substructure of type 9 (10) (Figure 11) have been
developed.19a-h Despite many attempts toward this aim,19b-d only one general synthetic strategy
is known that permits the introduction of β-ACC derivatives into a peptide chain21a-d in
diastereomerically as well as enantiomerically pure form.21d This strategy makes use of the
building blocks 11 and 12, which can be obtained in five steps from N-Boc pyrrole (13),21d-g
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having the N-Boc/CO2Bn cis (11) or trans (12) to each other (Scheme 2). The additional
carboxy group present in 11 and 12 allows, moreover, to introduce other functionalities
imitating α-amino acids side chains.22
NHBoc
BnO2C CO2Me
N
BocNHBoc
BnO2C CO2Me
11 1213
Peptide
incorporation
Peptide
incorporation
Scheme 2. Cis β-ACC 11 and trans β-ACC 12.
I.1.4.2 β-Amino acids and α-peptides
The interest in the role of β-amino acids with respect to conformational studies of peptides, is
not limited to their oligomers, the so called β-peptides, but also applies to their effect on α-
peptides. The backbone and the hydrogen bonding pattern of a peptide will be considerably
modified upon incorporation of a β-amino acid.23a,b This may affect the overall conformation
and the pharmacological properties of biologically active peptides. A successful example in
this regard is the substitution of proline with its β-analogue, the 2-amino cyclopentane
carboxylic acid (14), in morphecitine (15), one of the most selective agonists for the opioid
µ-receptor (Figure 12).24a-b
HO2C NH2 H2N
N
HO
O
N
H
O
N
O
14
Ph
NH2
O
Tyr-Pro-Phe-Pro-NH2
15
Figure 12. 2-Aminocyclopentane carboxylic acid 14 and morphecitine 15.
Apart from being useful tools to investigate the structure of α-peptides, β-amino acids have
been used also in cyclic RGD peptides and their activity as agonists of blood platelet
aggregation has been examined.23a,b It is believed that β-amino acids in cyclic peptides act as
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pseudo γ-turn mimetics, thus giving the chance to regulate the orientation of the
pharmacophoric groups.23a
I.2 Aim of this work
Compounds 11 and 12 are highly constrained cyclic β-amino acids, a property which
promises interesting effects on the conformation of their derivatives.
The introduction of the β-ACC 11 in Neuropeptide Y analogues resulted in increased
selectivity25,† and bioactivity towards the different NPY receptors. Hence, the influence of 11
on the structure of short α-peptides has been addressed in the present work. The synthesis and
the conformational studies on 11 derivatives (Scheme 3) will be presented.
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CO2Me                                                                                      
e 3. β-ACC as possible folding-inducer in α-peptides.
ACC containing α-peptides have been synthesised in solution, which allows to control
oupling step, monitor the presence of side products and optimise the reaction
ons. Nevertheless solid phase synthesis would produce longer peptides within shorter
he most efficient and practicable solid phase synthesis is performed with the Fmoc
y, but it has been already demonstrated that Fmoc is not a suitable protecting group for
ACC because of the deprotection conditions.26 In contrast, preliminary acylation
ents on the N-allyloxycarbonyl (Alloc) protected β-ACC gave encouraging results,26
re the peptide coupling of the N-Alloc β-ACC (16a and 17) both in solution and on the
hase has also been developed in the present work (Scheme 4).
                                             
aboration with the research group of Prof. A. Beck-Sickinger, University of Leipzig. See Chapter 5.
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N
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O
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O R1
N
H
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O OR1
O
PGHN
R3
R1 = OMe, R2 =Bn
R1 = R2 =Me
OH
PGHN
O
R3
synthesis in solution
synthesis on solid phaseOH2N
O
CH2Ph
16a
17
18
19
Scheme 4. Coupling of the N-Alloc β-ACC derivatives: 16a in solution and 17 on the solid
phase.
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Chapter 1
1.1 Synthesis of peptides with one β-ACC unit
1.1.1 Coupling of the β-ACC at the N-terminus
The cis and trans β-ACC 11 and 12, respectively, were synthesised in five steps from
Boc-pyrrole either in racemic21a-d or enantiomerically pure form.21d
The coupling at the β-ACC N-terminus requires a particular protocol since the free amine on
the cyclopropyl ring 9 is not tolerated in the presence of an electron withdrawing group in
β-position which leads to ring opening products of the type 20a and 20b (Scheme 1).21a-d
NH2
HO
O
NH2
+
HO
O-
NH2
HO
O
9 20a 20b
Scheme 1. Ring opening at the N-unprotected β-ACC 9.
The protocol of choice21a-d to accomplish the coupling of β-ACC derivatives such as 11 is
based on the tert-butoxycarbonyl deprotection by treatment with a saturated solution of HCl
in ethyl acetate. The resulting racemic β-ACC ammonium salt (±)-21 or the enantiomerically
pure (+)-21 and (-)-21 (derived from (+)-11 having the RRS configuration and from (-)-11
having the SSR one) are stable (Scheme 2).
NHBoc
BnO2C CO2Me
NH3
+
BnO2C CO2Me
Cl-
3M HCl 
in ethyl acetate
3 h, 0 °C
(±)-11 (±)-21
NHBoc
BnO2C CO2Me
(+)-11 (RRS)
NHBoc
BnO2C CO2Me
(-)-11 (SSR)
NH3
+
BnO2C CO2Me
Cl-
(+)-21 (RRS)
NH3
+
BnO2C CO2Me
Cl-
(-)-21 (SSR)
Scheme 2. Deprotection of the β-ACC at the N-terminus.
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The salts 21 can then be liberated by the addition of a mild base in the presence of the
preactivated amino acid or acid chloride to arrive at the corresponding coupling products 22
(Scheme 3). Under these conditions no ring opening products are formed but, depending on
the reagents used in the coupling step, epimerisation at the cyclopropane ring leading to 23,
was observed (Scheme 3). The mechanism of this epimerisation and which particular
stereocentre is involved is not as yet completely understood, but experimental evidence
suggests that the cyclopropane stereocentre bearing the amino function could be labile.27
21
X R
O
1. EDC/HOBt/CH2Cl2
2. Pyridine
HN
BnO2C CO2Me
R
O
main product
22
HN
BnO2C CO2Me
R
O
epimer
23
+
NH3
+
BnO2C CO2Me
Cl-
Scheme 3. General coupling at the β-ACC N-terminus.
The coupling of the ammonium salt (±)-21 in dry CH2Cl2 with acetyl chloride in the presence
of triethyl amine afforded the N-acetyl-β-ACC (±)-24 in high yields and without
epimerisation (Scheme 4).
NHBoc
BnO2C CO2Me
HN
BnO2C CO2Me
O1. 3M HCl
3 h, 0 °C
(±)-11
in ethyl acetate
2. Acetyl chloride (1.8 eq.)
Triethyl amine (3.2 eq.)
CH2Cl2, 18 h
0 °Cr.t.
97 %
(±)-24
Scheme 4. Coupling of (±)-11 with acetyl chloride.
Analogously, N-protected amino acids can be coupled with 11 or 12 to dipeptides 25a-f and
26 under similar conditions (Table 1).
Chapter 1 17
Table 1. Dipeptides containing the β-ACC building block (11 or 12).
HN
BnO2C CO2Me
O
NR1PG
R2
NHBoc
BnO2C CO2Me
1. 3M HCl
in ethyl acetate
2. Activated amino acid
11 25a-f
HN
MeO2C CO2Bn
O
NHBocNHBoc
MeO2C CO2Bn
1. 3M HCl
in ethyl acetate
2. Activated amino acid
(±)−12 (±)-26
R2 Activating reagentsa) Epimerisation Yield
Me
Me
CH2Ph
R1
H
H
MeMe
PG
Boc
Boc
Boc
Fmoc
CH2CO2tBu Fmoc
H Fmoc
H
H
H
MeH Fmoc
β-ACC
(±)-11
(±)-11
H FmocH
(+)-11
(±)-11
(±)-11
(±)-11
(+)-11
(-)-11
a.a. eq.
1.5
1.5
1.5
1.7
1.2
1.2
1.5
1.5
_
_ 95 %
77 %
CH2CO2tBu FmocH (±)-11 1.2 20 %
 _ 72 %
66 %
_ 90 %
10 % 88 %
3 % 90 %
4 % 90 %
12 % 95 %
Productb)
(±)-25a
(±)-25a
(+)-25b
(±)-25c
(±)-25d
(±)-25e
(±)-25e
(+)-25f
(-)-25f
MeH Boc (±)-12 1.5 _ 88 % (±)-26
A
B
B
A
B
A
C
B
B
A
Entry
1
2
3
4
5
6
7
8
9
10
a) A: EDC (1.5 eq.), HOBt (1.5 eq.), NEt3 (1.1 eq.); B: EDC (2 eq.), Py (2 eq.); C: EDC (2 eq.), HOBt (2 eq.), 
NEt3 (1.1 eq.).
b) (+) and (-) do not signify the optical rotation of the dipeptides, but rather the optical
rotation of the β-ACC unit incorporated.
The use of HOBt should prevent the racemisation of the amino acid to be coupled and the
reaction should be more efficient leading to better yields (Table 1, entry 1). It was observed,
on the other hand, that in some cases the preactivation with HOBt leads to epimerisation (5-
20%) of the β-ACC (entries 1, 4 and 6), which is suppressed or decreased in its absence
(entries 2, 3, 5, 8-9). This effect seems to be caused by the larger steric hindrance of the
18 Chapter 1
amino acid hydroxy-benzotriazol ester compared to the amino acid-EDC isourea. In the case
of 25e (entry 6) the steric bulk of the amino acid (Fmoc protected at the N-terminus and tBu
protected at the side chain) increased not only the epimerisation but decreased also the yield
in the presence of HOBt. Surprisingly, the β-ACC 12 could be coupled with Boc-alanine
without epimerisation despite activation with HOBt. In this case another effect must be
considered, i.e. the steric bulk of the group cis to the reacting amino function. In 11 a benzyl
ester will result in bigger steric hindrance compared to 12, in which a methyl ester is in the cis
position.
It is possible to completely separate the two diastereomers of 25a by recrystallisation from
ethyl acetate/hexanes. The stereochemistry of the two isomers was determined by converting
the enantiomerically pure (+)-11 to (+)-25a and comparing the 1H NMR spectrum of (+)-25a
with the spectra of the two diastereomers isolated by recrystallisation as described above.
Separation of β-ACC containing dipeptides by recrystallisation was possible only with 25a.
All attempts to resolve the diastereomeric mixture of other dipeptides (even 26, the trans
analogue of 25a) resulted only in the enrichment of one diastereomer.
Further coupling (under the EDC/HOBt activating conditions) at the N-terminus of some of
the dipeptides listed in Table 1 afforded the corresponding tripeptides without epimerisation
problems (Table 2).
The tripeptide (-)-27a exhibits the same particular behaviour of (+)-25a toward
recrystallisation: when a mixture of (+)-27a and (-)-27a is recrystallised from
CH2Cl2/hexanes, (-)-27a only recrystallises.
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Table 2. Tripeptides containing the β-ACC building block 11 or 12.
HN
BnO2C CO2Me
O
NHBoc HN
BnO2C CO2Me
O H
N
O
NHBoc
R
(±)-26 (±)-28
(+)- and (-)-27b
(+)- and (-)-27a
a
(+)- and (-)-25a
(+)- and (-)-25a
HN
MeO2C CO2Bn
O
NHBoc
HN
MeO2C CO2Bn
O H
N
O
NHBoca
Yield
CH2Ph
H
H
Dipeptide
(+)-25a
(-)-25a
(+)-25a
(-)-25a
(±)-26 94 %
92 %
94 %
91 %
93 %
Product
(+)-27a
(-)-27a
(+)-27b
(-)-27b
(±)-28
CH2Ph
CH2Ph
Entry
1
2
3
4
5
a) Coupling procedure: i. 3 M HCl in ethyl acetate, 3 h, 0 °C.
ii. Amino acid (1.5 eq.), EDC (1.5 eq.), HOBt (1.5 eq.), NEt3 
(1.1 eq.), CH2Cl2, 18h, 0 °C→r.t..
R
1.1.2 Deprotection of the β-ACC C-terminus
The deprotection of the benzyl ester position at the C-terminus of the β-ACC ring to arrive at
the free acid can be achieved by hydrogenolysis in methanol with Pd/C and a pentane solution
of cyclohexadiene as the hydrogen source.21d The reaction proceeds overnight at room
temperature in high yields for the N-acetyl β-ACC 24 as well as for the N-Boc protected
derivatives 25a, 25c, 27a-b and 28 (Scheme 5).
20 Chapter 1
NHR
BnO2C CO2Me
NHR
HO2C CO2Me
Pd/C, cyclohexadiene
MeOH, r.t., 12 h
95-99 %
R = Ac
R = AlaNHBoc
R = AlaNMeBoc
R = Ala-PheNHBoc
R = Ala-GlyNHBoc
R = Ala-PheNHBoc
(±)-24
(+)- and (-)-25a
(±)-25c
(+)- and (-)-27a
(+)- and (-)-27b
(±)-28
(±)-29
(+)- and (-)-30a
(±)-30c
(+)- and (-)-31a
(+)- and (-)-31b
(±)-32
NHR
MeO2C CO2Bn
NHR
MeO2C CO2H
Pd/C, cyclohexadiene
MeOH, r.t., 12 h
96 %
Scheme 5. Hydrogenolysis of the benzyl ester on the N-acetyl or N-Boc β-ACC derivatives.
Under the same reaction conditions N-Fmoc protected β-ACC derivatives (25b, 25e and 25f)
gave lower yields or not pure products (25d and 25e), and the problem was particularly severe
for 25b (Scheme 6).
HN
BnO2C CO2Me
O
HN
HO2C CO2Me
O
Pd/C, cyclohexadiene
MeOH, r.t., overnight
NHFmoc
R
NHFmoc
R
R = Me
R = CH2Ph
R = CH2CO2
tBu
R = H
99 %
86 %
71 %
40 %(+)-25b
(±)-25d
(±)-25e
(+)-25f
 (+)-30b
(±)-30d
(±)-30e
 (+)-30f
HN
HO2C CO2Me
O
NH2
33
 (-)-25f R = H  62 %  (-)-30f
Scheme 6. Hydrogenolysis of the benzyl ester on the N-Fmoc β-ACC derivatives.
The hydrogenation of 25b required a longer reaction time than the other compounds, in fact,
after 18 h, the starting material was not yet completely consumed but 48 h were necessary to
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bring the reaction to completion (Table 3, entry 1). After filtration of the reaction mixture
over a celite pad, 30b was isolated together with the Fmoc deprotected dipeptide 33. It is
known that the Fmoc group undergoes hydrogenolysis but generally at a lower rate than
O-benzyl systems.28 In contrast, under the hydrogenolysis conditions described, the Fmoc
cleavage occurs together with the benzyl cleavage. The reaction of 25b was followed by TLC
and the work up was done as soon as the starting material spot disappeared, nevertheless, 33
was found. Hydrogenation of 25b at 1 atm of H2, in methanol with Pd/C resulted in only 42 %
yield of 30b along with partial Fmoc deprotection (Table 3, entry 2).
Table 3. Various hydrogenolysis conditions tested on 25b.
Entry Hydrogen source Solvent Time Yield of 30b
1
2
3
4
H2 (1atm)
HCO2H (85 %)
MeOH
MeOH
18 h
Product
2 h
Note
TLC monitoring  
difficult because of 
the high percentage 
of HCO2H
HCO2H (30 %)
HCO2H (20 %)5
HCO2H (6 %)
cyclohexadiene MeOH 48 h 40 % 30b + 33
6
MeOH/Benzene
1:1
MeOH/Benzene
1:1
MeOH/Benzene
33_
1:2
85 %2 h
1.5 h 98 % 30b
30b
42 % 30b + 33
30b1 h 94 %
Hydrogenolysis of a benzyl ester in the presence of a N-Fmoc group can be also achieved in
a 85 % solution of HCO2H in methanol with Pd/C.29 These conditions proved to be too
drastic for 25b: only Fmoc deprotection was observed. Therefore, different concentrations
of HCO2H were used to find the optimal methanol/HCO2H ratio that would only affect the
hydrogenolysis of the benzyl ester. By decreasing the HCO2H concentration another
problem arose: the low solubility of 25b in methanol, therefore mixtures of methanol and
benzene were used (Table 2, entries 4-6). The best results could be achieved for the
conditions shown at entry 4.
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1.1.3 Coupling at the β-ACC C-terminus
The coupling at the β-ACC C-terminus was performed under EDC/HOBt coupling conditions
(Table 4), but the β-ACC derivatives were not preactivated to prevent a possible
epimerisation of its benzotriazol-ester in the absence of the coupling partner.
When a secondary amine was coupled (leading to products 34, 35c and 36b), epimerisation
occurred to an extent ranging between 10 and 25 %. This coupling seems also to be sensitive
to the steric hindrance of the partner, which reacts with the β-ACC derivatives. Only in the
case of 34, the epimer could be isolated by chromatography column and from the coupling
constants at the cyclopropyl ring CHs (suggesting the presence of one proton trans related to
the others) it can be reasonably stated that the epimerised centre is that bearing the amino
function.
Table 4. Coupling at the β-ACC C-terminus. Reaction conditions: EDC/HOBt (1.5 eq.),
amine (as ammonium salt, 1.5 eq), triethylamine (1.5 eq.), dry CH2Cl2, r.t., 18 h.
HN
HO2C CO2Me
O
HN
CO2Me
O
N
O
(±)-29
HN
HO2C CO2Me
O HN
CO2Me
O
N
O
R1
(±)-29
R2
R3O
O
R1= R2= H, R3= Me
R1= H, R2= Me, R3= Bn(±)-35b
(±)-35a
R1= R2= Me, R3= Bn(±)-35c
(±)-34
N
H
CO2H
CO2Me
(+)- and (-)-30a R1= H(+)-36a and (-)-36a
R1= Me(+)-36b and (-)-36b
O
BocHN N
H
MeO2C
O
BocHN N
O
CO2Bn
R1
HNEt2
Starting  material Amine Product
R3O2C NHR
1
R2
BnO2C NHR
1
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The presence of an isomeric by-product in the coupling of 29 and 30a with a N-methyl amino
acid could have been also caused by rotamers, generated at the N-methyl-C=O peptide bond.
Nevertheless this possibility was excluded by NMR experiments performed on 35c in
DMSO-d6 between r.t. and 140 °C, in which no coalescence was observed.
The coupling of the β-ACC acids 31a-b and 32 (Table 5) with a dipeptide instead of an amino
acid proceeded in high yields (85-98 %) without epimerisation, suggesting that the
epimerisation determining factor is not the overall dimension of the amino partner but the
steric hindrance directly at the reactive amino function.
Table 5. Coupling at the β-ACC acids C-terminus. Reaction conditions: EDC/HOBt (1.5
eq.), dipeptide amine (as ammonium salt, 1.5 eq.), triethylamine (1.5 eq.), dry
CH2Cl2, r.t., 18 h.
N
H
CO2H
CO2Me
OH
N
O
BocHN
R1
N
H
CO2Me
OH
N
O
BocHN
R1 H
N
O
N
H
O
CO2R
2
R1
N
H
CO2H
CO2Me
OH
N
O
BocHN N
H
CO2Me
OH
N
O
BocHN
H
N
O
N
H
O
CO2Bn
R1= CH2Ph
R1= H
(+)-31a and (-)-31a
(+)-31b and (-)-31b R2= Me
R2= Bn
(±)-32 (±)-38
(+)-37a and (-)-37a
(+)-37b and (-)-37b
Acid Amine Product
PhH2C PhH2C CH2Ph
CO2R
2HN
O
H2N
R1
CO2Bn
H
N
O
H2N
CH2Ph
Compound (±)-38 is soluble only in DMSO, a solvent with a high hydrogen-bonding
capability, which could disrupt the peptide conformation. Therefore DMSO is not suitable for
structural investigations and (±)-38 was not further taken into account.
The pentapeptides 37a, although not easily soluble in CH2Cl2 or MeOH, but only in a mixture
of both solvents, were further investigated in their protected (37a) and unprotected (39) form
(Scheme 7).
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N
H
CO2Me
OH
N
O
BocHN
PhH2C H
N
O
N
H
O
CO2Bn
CH2Ph
N
H
CO2Me
OH
N
O
+H3N
PhH2C H
N
O
N
H
O
CO2H
CH2Ph
HCl 3 M in ethyl acetate
cyclohexadiene
Pd/C, MeOH
18 h, r.t.
3 h, 0 °C
(+)-37a
(-)-37a
(+)-39
(-)-39
Cl-
1.
2.
Scheme 7. The deprotection of the pentapeptides 37a was achieved under acidic conditions to
liberate the amino function and by hydrogenolysis to release the free acid.
1.2 Synthesis of multiple β-ACCs containing peptides
The epimerisation at the β-ACC ring becomes particularly severe when the coupling is
performed at the cyclopropane carboxy function with a partner containing another β-ACC
unit following the reactive residue (Scheme 8).
N
H
CO2Me
CO2H
O
PGHN N
H
CO2Me
O
R
O
H2N Epimerisation
Scheme 8. Epimerisation occurs in particular when both coupling partners contain a β-ACC unit.
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It was always possible to separate the products from their epimers by column
chromatography, but the epimers were never isolated pure, therefore, there are no
experimental data to support any hypothesis on which stereocentre epimerises.
Interestingly, the coupling of the tripeptides 36a with the β-ACC acids 30a proceeded in good
yields (93-96 %) although 15 % epimerisation occurred. In contrast, the coupling of the
β-ACC (+)-25a with (+)-30b, afforded consistently lower yields (71 %) and 22 %
epimerisation (Scheme 9).
N
H
CO2Me
CO2H
O
GPHN
N
H
CO2Me
O
R
O
BocHN
N
H
CO2Me
O
GPHN
H
N
O
N
H
O
CO2Me
R
O
HCl 3 M in
ethyl acetate
(+)-30a
(-)-30a
(+)-30b
(+)-36a
(-)-36a
(+)-25a
(+)-40 96 %
(-)-40 97 %
(+)-41 71 %
15 % epim.
15 % epim.
22 % epim.
R = AlaOBn
R = AlaOBn
R = OBn
PG = Boc
PG = Boc
PG = Fmoc
ii.
i.
EDC/HOBt
Py
Scheme 9. Synthesis of peptides containing multiple β-ACCs.
Other reaction conditions were tried to improve the yield of (+)-41 (Table 6), but no
substantial yield enhancement was observed.
Table 6. Reaction conditions for the coupling of (+)-25a and (+)-30b to afford (+)-41.
EDC/HOBt (1.5 eq.)
Py (1.5 eq.) 71 % 22 %
HBTU (2 eq.)
DIPEA (3 eq.)
EDC (2 eq.)
Py (1.5 eq.)
55 % 15 %
68 % 12 %
Reagents Yield Epimerisation
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Activation of (+)-30b with HOBt resulted in the best yield but also in the highest amount of
epimerisation. Less epimerisation was observed with HBTU as the activating agent, but at the
cost of a lower yield. The best compromise between yield and degree of epimerisation was
found with the EDC as the sole activation agent.
The free acid (+)-42 (Scheme 10) was obtained by hydrogenolysis of (+)-41 under the same
conditions used for the Fmoc-protected β-ACC dipeptides.
N
H
CO2Me
O
FmocHN
H
N
O
N
H
O
CO2Me
N
H
CO2Me
O
FmocHN
H
N
O
N
H
O
CO2H
CO2Me
CO2Bn
HCO2H 16 %
MeOH/benzene 1:1
2.5 h, r.t.
(+)-41
(+)-42
99 %
Pd/C
Scheme 10. Hydrogenolysis of the benzyl ester of tetrapeptide (+)-41.
Compounds (+)-40 and (-)-40 were completely deprotected under the same conditions used
for (+)-37a and (-)-37a to arrive at the corresponding ammonium salts (+)-43 and (-)-43
(Scheme 11).
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N
H
CO2Me
O
BocHN
H
N
O
N
H
O
CO2Me
N
H
CO2Me
O
+H3N
H
N
O
N
H
O
CO2Me
(+)-40 and (-)-40
(+)-43 and (-)-43
H
N
O
CO2Bn
H
N
O
CO2HCl-
1. HCl 3 M in ethyl acetate
2. cyclohexadiene
Pd/C, MeOH
18 h, r.t.
3 h, 0 °C
95 %
Scheme 11. Deprotection of pentapeptides (+)-40 and (-)-40.
The acid (+)-42 was subsequently coupled with the ammonium chloride (+)-44 to afford the
hexapeptide (+)-45 (Scheme 12). The coupling worked in only 48 % yield but epimerisation
had occurred to a lower extent compared to the previous couplings (Scheme 9).
N
H
CO2Me
O
FmocHN
H
N
O
N
H
O
CO2H
CO2Me
(+)-42
CO2Me
N
H
CO2Bn
O
+H3N(+)-25a +
HCl 3 M in
ethyl acetate
(+)-44
N
H
CO2Me
O
FmocHN
H
N
O
N
H
O
CO2Me
H
N
O
N
H
O
CO2Bn
CO2Me
(+)-45
EDC (2 eq.), Py (2 eq.)
CH2Cl2, r.t., 18 h
48 % (5 % epimer)
Cl-
Scheme 12. Synthesis of the hexamer (+)-45.
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Finally the hexapeptide (+)-45 was deprotected at the C-terminus to obtain the free acid
(+)-46 (Scheme 13) whose conformation is currently being investigated (see Chapter 5).
N
H
CO2Me
O
FmocHN
H
N
O
N
H
O
CO2Me
H
N
O
N
H
O
CO2H
CO2Me
(+)-45
(+)-46
HCO2H/MeOH 1:1
Pd/C
5 h, r.t.
88 %
Scheme 13. Hydrogenolysis of hexapeptide (+)-45.
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2.1 Introduction
The three-dimensional structure of peptides and proteins is governed by several factors,
among them, non-covalent forces such as hydrogen bonding, hydrophobic interactions,
electrostatic interactions and van der Waals forces. Hydrogen bonding is one of the most
important interactions related to protein folding. Although the energy associated to a
hydrogen-bond is small compared to a covalent bond, a complex hydrogen-bonding network
can have a great influence on protein structure.30a
The formation of secondary structural elements is mainly guided by hydrogen-bonding
patterns. α-Helices are constituted of repeating i←i+4 hydrogen bonds (the residue i acts as
hydrogen bond donor involving its amide N-H, the residue i+4 acts as hydrogen bond
acceptor involving its amide C=O). β-Sheets are stabilised by hydrogen bonds between two
strands which can be aligned in the same (parallel sheets) or in opposite (antiparallel) NC
direction. These two types of secondary structure are regular and consist of a repetitive motif.
There are other regular but not repetitive secondary structures: β- and γ-turns, in which the
polypeptide chain reverses its overall direction (therefore they are also called reverse-turns)
allowing for example the antiparallel β-sheet formation. Reverse turns play an important role
in molecular recognition: in proteins the interaction with other molecules takes place on
surfaces densely populated by turns which can expose and orient the pharmacophore to the
receptor.31a-c
The three-dimensional arrangement of the polypeptide chain stabilised by a i←i+3 hydrogen
bond (forming a ten membered ring, also designated C10) is called β-turn (Figure 1a).
Figure 1. a: type I β-turn. b: direct γ-turn. c: Greek
O O
bN
H
H
N
N
HO
ω ψ ϕ
ca letters corresponding to dihedral angles.
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There are also β-turns in which no hydrogen-bond occurs to hold together the chain direction
inversion, so called “open reverse turn”. A sequence of β-turns regularly following each other
forms a 310 helix.31a There are many different types of β-turns (the most common are type I, II
and III right handed and type I’, II’, III’ left handed, see Figure 4, Introduction) characterised
by specific values of the dihedral angles ϕ and ψ (Figure 1c). γ-Turns, on the other hand,
involve only three amino acids instead of four, and are stabilised by a i←i+2 hydrogen bond
(Figure 1b).
The importance of turns for the structure of proteins and their biological activity has increased
the interest to discover possibilities to induce their formation.
Among many others, the cyclopropane building block is supposed to be able to force turns
formation.11a-d The potential structure inducing effect of β-ACC 9 has been already
investigated by Molecular Modelling by Rao et al..19d The N-acetyl methyl amide derivative
47 was found to have a global minimum stabilised by a 8-membered hydrogen-bonded ring
(C8, Figure 2), while a local minimum (Figure 2) is stabilised by a hydrogen-bonded
6-membered ring (C6) and is 1.2 kcal/mol less stable than the C8 conformation.
O H
N
HN O
N
H O
NHMe
O
C8 C6
47 47
N
H O
NMe2
O
48
N
H O
NEt2
O
?
CO2Me
34
H2N CO2H
9
Figure 2. Hydrogen bonding patterns. C6 and C8: six- or eight- membered ring closed by a
hydrogen bond .
Unfortunately it is not yet possible to synthesise derivatives of 9 such as 47, but its close
analogue (±)-11 has been already successfully built into peptide sequences.21c The β-ACC
(±)-11, as well as 9, can be regarded as a conformationally restricted β-alanine 5 (Figure 3) in
which the folded conformation (Figure 9, Introduction) is blocked.
BocHN CO2Bn
CO2Me
H2N CO2H
(±)-11
β-alanine  5
Figure 3. β-Alanine (5) and β-ACC ((±)-11).
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The C6 hydrogen-bonded conformation is, on the other hand, not significantly populated in
the analogue derivative of β-alanine 48 (Figure 2).16b
The preferred conformations of 11 derivatives were investigated starting from (±)-34 (Figure
2) as model compound having only one possible hydrogen-bond. The results allowed to verify
the molecular modelling calculation performed on 47 and to compare the IR results with those
obtained on 48.
2.2 IR spectroscopy
In spite of some secondary structures lacking of hydrogen-bonding stabilisation31a-c hydrogen
bond detection remains a powerful tool to investigate the structure of peptides and proteins.
IR spectroscopy is particularly useful to examine intramolecular hydrogen-bonded and non
hydrogen-bonded states. The equilibration between these two states is slow on the IR time
scale, therefore distinct bands for hydrogen-bonded and non-hydrogen-bonded NHs can be
observed. In a non polar solvent non hydrogen-bonded NHs absorb usually above 3400 cm-1,
while the hydrogen-bonded ones absorb below 3400 cm-1.32a-b
The most suitable solvents to perform IR investigation in the amide A region (3500-
3200 cm-1) are CH2Cl2 and CHCl3. These solvents have relatively low polarities (ε: 9.1 and
4.8 at r.t., respectively) and do not interact and/or disrupt hydrogen bonds. Acetonitrile is
significantly more polar than either of the chlorocarbons, moreover the nitrile group is a
moderate hydrogen-bond acceptor.32b DMSO, finally, is a powerful hydrogen-bond acceptor,
therefore only the strongest intramolecular hydrogen-bonds persist in its solutions.
The concentration of the compounds under investigation is another factor to take into account.
At high concentration, in fact, intermolecular hydrogen bonds can occur, therefore a
calibration is necessary to determine the suitable concentration for the detection of
intramolecular hydrogen-bonds. The calibration was performed by NMR spectroscopy on
(±)-35a at 1 mM, 5 mM, 10 mM and 50 mM concentrations in CDCl3 (Figure 4). The
resonance of the NH protons is sensitive to hydrogen bonding: a proton resonates at lower
field when hydrogen-bonded compared to its non bonded state. At 1 mM, 5 mM and 10 mM
concentrations the resonance of the two NHs remains almost the same, while at 50 mM
concentration NH-2 (the number following a functional group symbol identifies the residue
counted starting from the N-terminus) shifts by 0.4 ppm down field due to the formation of a
new intermolecular hydrogen bond. Interestingly NH-1 does not shift also at 50 mM
concentration suggesting to be already intramolecularly hydrogen-bonded.
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6.106.206.306.406.506.606.706.806.907.007.107.207.307.40
     
HN
O
CO2Me
H
N
O
MeO2C
(±)-35a
1
2
Figure 4. NH resonances for (±)-35a at various concentrations in CDCl3 (400 MHz).
Further calibration experiments were done by means of IR spectroscopy on (±)-35a
(Figure 5a) to confirm the NMR results and on 49 (Figure 5b) to evaluate the same problem
on longer peptides.
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Figure 5. a: N-H stretching region FT-IR spectra for (±)-35a at 1 mM 
concentration at r.t. in CH2Cl2. b: N-H stretching region FT-IR spec
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As already demonstrated by NMR spectroscopy, (±)-35a experiences more extensive
hydrogen bonding at 50 mM than at 1mM concentration, on the other hand the pentapeptide
49 displays a significant enhancement of the hydrogen-bonding extent above 5 mM
concentration. Nevertheless, it has been demonstrated that 1 mM concentration is suitable to
detect intramolecular hydrogen-bonds without intermolecular contribution.
2.2.1 N-acetyl β-ACC derivatives
The carbamate and N-acetyl derivatives of β-ACC (±)-11 were first analysed (Table 1) and
the IR data were combined with molecular modelling calculation to get a first insight on the
potential hydrogen bonding pattern. A conformational search was performed with the
program Titan,33a in which the methods developed by Osawa and Montecarlo33b,34 have been
merged into a single simulated-annealing algorithm. The force field used was MMFF94
(Merck Molecular Force Field) parameterised especially for organic molecules and
biopolymers.33a,c For each calculation the peptide bond dihedral angles were constrained to
180°. Only the minima occurring within 3 kcal/mol from the first minimum were taken into
account. Hydrogen bonds were attributed for H--O distances shorter than 2.5 Å and N-H--O
angles larger than 110°.10a-b The calculations were performed on (-)-11 as well as on (+)-11
derivatives, but when the hydrogen bonding pattern resulted to be the same, only one
enantiomer/diastereomer is depicted in the following discussion. It should be stressed,
however, that such molecular modelling calculations were performed in vacuum, therefore
they do not take into account the solvent contribution, moreover the gain in energy due to the
hydrogen bonds is probably overestimated.
Often more than one hydrogen-bonding pattern is possible in the molecules investigated. The
discussion on each possibility should therefore take into account, besides the experimental
data, two other factors: the aptitude of the hydrogen-bond acceptor (tertiary amides >
secondary amides > esters ≥ carbamates > ketones)35a-e and the N-H--O angle which should be
larger than 100° and ideally as close to 180° as possible.30a-b
The β-ACC (±)-11 itself as well as (±)-17 does not exist in any hydrogen-bonded
conformation (N-H stretching occurring at 3422 and 3415 cm-1 respectively). In this case two
factors contribute to disfavour the formation of the hydrogen bond: the mild hydrogen-bond
acceptor capability of the ester carbonyl and the constraint N-H--O geometry (around 120°,
Figure 7 for compound (±)-34). As soon as a keto function is introduced (compound (±)-50)
affording a better hydrogen-bond geometry, about 50 % hydrogen-bond is observed
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(3344 cm-1 absorption). The keto group is a weaker hydrogen bond acceptor than the ester but
in this case the N-H--O angle is 150°, significantly close to linearity (Figure 6).
To confirm this hypothesis, molecular dynamics calculations were performed. The first
minimum calculated on (+)-50 uses the keto group as hydrogen-bond acceptor. The hydrogen
bond closes the conformation in a nine membered (C9) ring (Figure 6).
               
CO2MeN
O O
O
Ph
H
O
O
(+)-50
Figure 6. Lowest energy conformation for (+)-50.
To enhance the hydrogen donor and acceptor ability of the amino and carboxy functionalities
respectively, the acetylamino diethyl amide β-ACC (±)-34 (Figure 7) was investigated, being
in close analogy to the β-alanine derivative 48 (Figure 2). The IR spectrum of 48 (1 mM in
CH2Cl2) displays only one absorption at 3440 cm-1 at room temperature and at 3436 cm-1 at
205 K, 48, therefore, does not experience any hydrogen-bond, it exists prevalently in the
extended conformation.16b Compound (±)-34, in contrast, exists predominantly in the
hydrogen-bonded conformation (main N-H absorption at 3364 cm-1 and only a shoulder at
3423 cm-1).
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Figure 7. N-H stretching region FT-IR spectrum for (±)-34 (1 mM in CH2Cl2 at r.t.).
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In this case the strong hydrogen-bond acceptor capability of a tertiary amide carbonyl
overcomes the not optimal N-H--O geometry. This result was confirmed by molecular
modelling calculations suggesting that the most populated conformation is the hydrogen-
bonded C6 shown in Figure 8.
Figure 8. Conformational minimum for (
Surprisingly the C6 conformation is no
structure of (±)-34 no intramolecular hy
intermolecular one, connecting the NH
function of another symmetry related mo
middle). The dimers crystall packing is sh
Figure 9. Left: crystall structure of (±)-34. 
2 Å
°127+)-34.
 longer favoured in the solid state. In the X-ray
drogen-bond is found (Figure 9, left) but rather an
 of a molecule with the sp2 oxygen of the amide
lecule leading to the formation of dimers (Figure 9,
own in Figure 9, right side.
Middle: Hydrogen-bonded dimer. Right: Crystall cell.
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The glycine derivative (±)-35a shows three different absorptions in the N-H stretching region
(3385, 3420 and 3428 cm-1), two corresponding to non hydrogen-bonded and one to
hydrogen-bonded values (Table 1). Since (±)-35a displays three absorptions of the same
intensity but has only two NHs, it is clear that hydrogen-bonded conformations exchange with
linear, non hydrogen-bonded ones.
Figure 10. (+)-35a: (a) First ener
minimum, C9-hydrogen
The energy minima for (+)-35a w
minimum (Erel = 0.0 kcal/mol) fou
second minimum (Erel = 1.49 kcal/m
hydrogen acceptor function is the 
In the alanine derivative (±)-35b 
observed at 3416 and 3383 cm-1. 
conformation equilibrating at r.t. 
one predominantly populated C8-
(+)-35a in Figure 10a and a C6 as 
H
C8
a
     
gy minimum, C8-hydrogen bonded ring. (b) Second energy
-bonded ring.
ere investigated by a conformational search. The lowest
nd contains a C8-hydrogen bonded ring (Figure 10a), the
ol) has a C9-hydrogen-bonded ring (Figure 10b) where the
ester carbonyl.
two N-H absorptions of almost the same intensity can be
It seems as if there is at least one hydrogen bond in each
in CH2Cl2. A conformational search on (+)-35b resulted in
conformation (Erel = 0.0 kcal/mol) like the one shown for
second, but not significant, minimum (Erel = 2.51 kcal/mol).
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N
N O
H
O
O
MeO
C9
C8
C9
b
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Table 1. IR absorption in the amide A region. HB: hydrogen bonded.
CO2BnBocHN
CO2Me
CO2CH2COPhBocHN
CO2Me
CO2BnNH
CO2Me
non HB N-H HB N-H
3422
3415 3344
3415
33643423 
(shoulder)
3428 3385
3416 3383
3373
3420
O
N
H
CO2Me
O
NEt2
O
N
H
CO2Me
O H
N
O
CO2Me
N
H
CO2Me
O H
N
O
CO2Bn
N
H
CO2Me
O Me
N
O
CO2Bn
(cm-1) (cm-1)
(±)-11
(±)-50
(±)-24
(±)-34
(±)-35a
(±)-35b
(±)-35c
The N-methyl alanine derivative (±)-35c has only one absorption in the amide A IR region at
3373 cm-1. The only N-H on (±)-35c should be therefore hydrogen-bonded. A tertiary amide
carbonyl as hydrogen-bond acceptor is in fact a very good partner for hydrogen bonding.
Two possible hydrogen-bonding patterns were found for (+)-35c by a conformational search:
the first minimum is a C6 conformation (Erel = 0.0 kcal/mol); the second minimum (Erel = 0.13
kcal/mol) has an unusual hydrogen bond between the NH-1 and the π electrons of the phenyl
ring (Figure 11). Hydrogen bonds to π-acceptors have already been widely investigated.36a-g
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In proteins, on the other hand, they are rare since they are half as strong as a normal
N-H--O=C hydrogen bond,36h-i therefore this second minimum should be considered with
caution.Figure 11. (+)-35c: Second energy minimum. For reason
cyclopropane ring is not displayed.
2.2.2 NMR: chemical shifts variations
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of reduced temperature coefficients ∆δ/∆T) has been more rarely measured in non protic and
relatively non polar solvents the such as CD2Cl2 and CDCl3.16b,37a-c Temperature enhancement in
these solvents will result in a large chemical shift change for NHs involved in hydrogen-bonds,
which are no longer stable at higher kinetic energy values. Hydrogen-bonded NHs display a little
chemical shift change when their environment remains constant against temperature (i.e. the
hydrogen bond is not disrupted) and the same happens to completely solvent exposed NHs. There
is an exception to this last situation: small ∆δ/∆T values can be observed also in amide protons
equilibrating between hydrogen-bonded and non-hydrogen-bonded states when the enthalpy
difference between them is small.32a Conformation exchange unfortunately makes the
interpretation of the results obtained difficult, because the NHs involved in a hydrogen bond could
be different in different conformations. The H/D exchange experiment compares the time
requested by different NHs in a molecule to disappear from a 1H NMR spectrum in deuterated
solvents (commonly D2O or CD3OD).31a In fact hydrogen-bonded NHs exchange their proton
with deuterium slower than solvent exposed ones. When the hydrogen-bonds are not strong
enough to survive in methanol (protic solvent, high polar) the same result can be obtained in an
aprotic, apolar solvent such as CD2Cl2 or CDCl3 by addition of a small quantity of CD3OD.37c
The ∆δ/∆T values for (±)-34 and (±)-35a were measured in CDCl3 at 1 mM concentration
between 263 and 318 K (Figure 12).
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compatible with both strong hydrogen-bonded and non hydrogen-bonded states, while the
second value is indicative for a relative labile hydrogen-bond.
The H/D exchange for (±)-35a was measured in 0.2 M CD3OD in CDCl3 (Figure 13), but in
this solvent mixture after 60 h both NHs experienced 64 % deuterium exchange. Then the
solvent mixture was brought to 0.4 M CD3OD and after 21 h the NH-2 signal disappeared
while NH-1 exchanged 83 % of its proton with deuterium.
Finally, another factor suggests, for (±)-35a, NH-1 rather than NH-2 to be involved in a
hydrogen-bond: NH-1 resonates at lower field than the NH of (±)-17 (7.02 and 6.64 ppm
respectively) which is definitely non-hydrogen-bonded. The chemical shift of hydrogen-
bonded protons is, in general, higher than that of non-hydrogen-bonded ones.
NMR data would, therefore, support the hypothesis that (±)-35a exchanges between a C9
hydrogen-bonded (involving NH-1) and a linear, non-hydrogen-bonded, conformation.
(ppm)
6.556.606.656.706.756.806.856.906.957.007.057.107.157.207.25
Figure 13. (±)-35a H/D exchange. (a) CDCl3. (b) After 60 h in CD3OD 0.2 M in CDCl3. (c)
After 60 h in CD3OD 0.2 M in CDCl3 and 21 h in CD3OD 0.4 M in CDCl3.
No additional informations could be obtained by NMR spectroscopy for the conformational
preferences of (±)-35b, since the NH signals are hidden under the aromatic CH ones. The C8
conformation (for (+)-35a, Figure 10) remains nevertheless most probable as suggested by the
conformational search. Compound (±)-35c has only one NH group, therefore, NMR
experiments would be not indicative for the elaboration of its conformation.
2.2.3 Oligopeptides containing β-ACC as the C-terminal amino acid
Several peptides were synthesised to gain further insight into the structural influence of the
β-ACC building block at the C-terminus (Table 2).
The dipeptides 25a and 25b show about 50% hydrogen-bonding, while 25c has only one
absorption at 3391 cm-1, its conformations are therefore all hydrogen-bonded.
a
b
c
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Table 2. Derivatives of the β-ACC 11 and 12 at the N-terminus.
CO2BnNH
CO2Me
non HB N-H HB N-H
3430
3429 3392
3415 3342
(shoulder)
3416 3350 
(shoulder)
3415
O
CO2BnNH
CO2Me
3366
3391
BocHN
CO2BnNH
CO2Me
O
BocHN
CO2BnNH
CO2Me
OMe
N
OH
N
O
BocHN
PhH2C
CO2BnNH
CO2Me
OH
N
O
BocHN
PhH2C
CO2BnNH
CO2Me
OH
N
O
BocHN
Boc
(cm-1) (cm-1)
(+)-25a
(±)-25b
(±)-25c
(+)-27a
(±)-28
(+)-28b
CO2BnNH
CO2Me
3431
O
3365BocHN (-)-25a
3417 3343 
(shoulder)CO2BnNH
CO2Me
OH
N
O
BocHN
PhH2C
(-)-27a
3416
CO2BnNH
CO2Me
OH
N
O
BocHN
(-)-28b
Molecular modelling conformational searches were carried out in support of the experimental
data obtained. The first minimum for (+)-25a and (+)-25c resulted a C7-hydrogen-bonded ring
corresponding to a γ-turn centred on the alanine residue (Figure 14a). The following minima
found had higher energy values and often involved the sp3 rather than the sp2 oxygen atom of
the ester group (an example is given in Figure 14b for (+)-25a). Usually esters, amides and
carbamates act as hydrogen-bond acceptors at the sp2 oxygen atom, therefore these higher
energy minima should be carefully regarded.35e
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Figure 14. (+)-25a: (a) Global energy minimum, γ-turn (Erel = 0.0 kcal/mol). (b) Local energy
minimum (Erel = 1.82 kcal/mol), type C6’ hydrogen-bonded ring. For reasons of
clarity the Boc and phenyl groups are not displayed.
The conformational minima calculated for both 25b isomers suggest, in spite of (+)-25a, the
C6 (Erel = 0.0 kcal/mol) rather than the γ-turn conformation (Erel = 0.84 kcal/mol) to be
favourite.
The tripeptides (+)-27a, (-)-27a and (±)-28 show only a shoulder corresponding to hydrogen-
bonded NH. A linear, non hydrogen-bonded conformation is probably predominant. In the
absence of any hydrogen-bond, the linear conformation is the only one possible for both 27b
isomers.
2.2.4 Oligopeptides containing the β-ACC as the central residue
More complex derivatives having the β-ACC building block in the middle are shown in
Table 3. Compound 49 is the reference pentapeptide containing only natural amino acids. For
these more complex products molecular modelling calculations led to a large number of
possible conformations. NMR investigations on some of these products will be illustrated in
Chapter 4.
a b
CO2Me
N
H
HN
O
O
BuO
O
BnO
γ
C6'
1
2
t
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Table 3. Tri- and penta- peptides containing the β-ACC as the central unit.
non HB N-H HB N-H
BocHN
H
N
O
O
N
H
H
N
N
H
Ph
O
O
CO2Bn
Ph
N
H
CO2Me
OH
N
O
BocHN
H
N
O
N
H
O
CO2Bn
PhPh
N
H
CO2Me
OH
N
O
BocHN
H
N
O
N
H
O
CO2Bn
PhPh
CO2Me
N
H
O
BocHN
Me
N
O
CO2Bn
CO2Me
N
H
O
BocHN
H
N
O
CO2Bn
N
H
CO2Me
OH
N
O
BocHN
H
N
O
N
H
O
CO2Me
3412 3309
3416 3335
3420 3364
N
H
CO2Me
OH
N
O
BocHN
H
N
O
N
H
O
CO2Me
3426 3367
3415 3334
3419 3361
3426 3354
non HB/HB
2:1
1:1
1:4
2:3
2:5
2:3
>3:2
(cm-1) (cm-1)
(+)-36a
(-)-36b
(+)-37a
(-)-37a
(+)-37b
49
(-)-37b
(at  r.t.)
CO2Me
N
H
O
BocHN
H
N
O
CO2Bn 3426 3367 2:1(-)-36a
CO2Me
N
H
O
BocHN
Me
N
O
CO2Bn 3426 3354 1:1(+)-36b
The ratio between the hydrogen-bonded (HB) and the non hydrogen-bonded (non HB) NHs
(Table 3) was obtained by a gaussian fit based on a non linear simplex Nelder-Meade
algorithm.38 In Figure 15 the deconvolution of the IR amide A region is showed for (+)-37a
and (-)-37a.
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more hydrogen-bonded structure at lower temperatures. This feature was not observed in any
other of the investigated compounds.
2.2.5 Oligopeptides containing multiple β-ACCs
Finally peptides containing two or three β-ACC building blocks were examined (Table 4).
Table 4. Penta- and hexa- peptides containing two or three β-ACC building blocks.
N
H
CO2Me
OH
N
O
H
N
O
CO2BnN
H
CO2Me
O
BocHN
N
H
CO2Me
OH
N
O
H
N
O
CO2BnN
H
CO2Me
O
BocHN
N
H
O H
N
O
N
HNH
O
CO2Me CO2Me
CO2Bn
O
MeO2C NH
O
NHFmoc
non HB N-H HB N-H non HB/HB
N
H
CO2Me
OH
N
O
N
H
CO2Me
O
BocHN
CO2Bn
3421 3362 2:3
3419 3350 1:4
3418 3360 1:1
3399 3301 1:5
(-)-40
(+)-41
(+)-45
(cm-1) (cm-1)
(+)-40
As observed before, (+)-11 promotes in (+)-40 and (+)-41 less hydrogen-bonding than (-)-11
in (-)-40. In contrast, in (+)-45, the presence of three β-ACC (+)-11 building blocks seems to
exert a hydrogen-bonding enhancing effect. Five of the six NHs are hydrogen-bonded and the
wavenumber of the sixth (3399 cm-1) cannot be unambiguously attributed to a non hydrogen-
bonded state. This feature suggests the presence of a regular secondary structure such as a
helix, where each NH binds to the corresponding C=O at a definite residue distance.
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2.3 IR spectra in acetonitrile
Acetonitrile is a suitable non protic solvent for circular dichroism (CD) spectroscopy, while
CH2Cl2 and CHCl3 are not. This is due to the self-absorption of the solvent which starts below
190 nm (acetonitrile), 205 nm (CH2Cl2) and 220 nm (CHCl3). As it will be illustrated later on,
it is very important to be able to measure the CD spectrum of a peptide below 200 nm.
Acetonitrile is a weak hydrogen-bond acceptor, therefore it could disrupt the hydrogen-bonds
which resulted stable in CH2Cl2. In acetonitrile the solvent exposed NHs (engaged in a
hydrogen-bond with the solvent) are expected to give a band between 3370 and 3400 cm-1,12f
intramolecularly hydrogen-bonded NHs should absorb at the same wavelength as in CH2Cl2.
The main difficulty in the interpretation of IR spectra measured in acetonitrile has been the
broadness of the NH signals which made difficult to guess how many peaks were really
present and at which wavelength.
Table 5. Comparison between the NH absorptions in CH2Cl2 and acetonitrile.
CH2Cl2 Acetonitrile
(±)-11 3422 3409, 3376
(±)-34 3364 3368
(+)-27a 3417, 3343 3356
(+)-36a 3426, 3367 3362
(+)-37a 3412, 3309 3360
(cm-1) (cm-1)
The first compound investigated was (±)-11 (Table 5), which should serve as reference for the
non hydrogen-bonded NHs in acetonitrile. Two peaks were observed at 3409 and 3376 cm-1,
the second absorption belonging to solvent hydrogen-bonded NH. Compound (±)-34 gave, on
the other hand, only one absorption at 3368 cm-1. This value is only 4 cm-1 higher than in
CH2Cl2, therefore it seems like (±)-34 is keeping its C6 conformation. On the other hand the
absorption of (±)-34 in acetonitrile is also at a border value between hydrogen-bonded and
solvated NHs. Compound (+)-27a shows only one absorption at 3356 cm-1, i.e. at lower
values than normal ones for solvated NH in acetonitrile, nevertheless a higher hydrogen-
bonding extent in acetonitrile than in dichlormethane does not seem reasonable. The same
could be observed on (+)-36a which shows only one absorption at 3362 cm-1 and apparently
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there are no more solvated NHs. Compound (+)-37a has only one broad absorption at
3360 cm-1, 50 cm-1 higher than the hydrogen-bonded NH signal in CH2Cl2, probably the
hydrogen-bonded NHs signal overlaps the non hydrogen-bonded one.
Acetonitrile does not seem to be the solvent of choice for hydrogen-bonding investigations on
these peptides, in fact the solvated NH signal could coincide with the intramolecularly
hydrogen-bonded one (they both show a band around 3360-3390 cm-1).
2.4 Conclusions
The results obtained by IR spectroscopy on relatively small derivatives of the β-ACC (±)-11
and (±)-12 prove the capability of this building block to induce interesting hydrogen-bonding
patterns, among them the C6 and C8 conformations which were already predicted by
molecular modelling.19d The C6 ring is thought to induce and stabilise β-turn-like
conformations in α-peptides containing a β-amino acid.38 Nevertheless, the C6 conformation
seems to be stabilised only by the presence of a tertiary amide as hydrogen-bond acceptor
((±)-34 and (±)-35c), but becomes less favourable in longer peptides where better hydrogen-
bonding geometries can be achieved in other conformations. Moreover, C6 conformations
seem to arrange the N- and C-termini into opposite directions in a sort of extended chain
conformation (Figure 8) as a direct consequence of the dihedral angles requested to build the
corresponding C6 hydrogen-bond. This would disfavour the formation of turn-like
conformations in the β-ACC ((±)-11) derivatives. On the contrary, a hydrogen-bonded C8 ring
would force the N- and C-termini close to each other, favouring a reverse turn like
conformation. In dipeptides having the β-ACC unit at the C-terminus, a γ-turn conformation
is preferred. Depending on its orientation, a γ-turn can allow the formation of other hydrogen-
bonds supporting additional folding.
An influence of the β-ACC chirality on the hydrogen-bonding extent of its derivatives was
observed only on pentapeptides. On (+)-37a, (+)-37b and (+)-40, (+)-11 promotes less
extensive hydrogen-bonding than (-)-11 on (-)-37a, (-)-37b and (-)-40. In contrast, three
(+)-11 units are able to induce up to 80 % hydrogen-bonding.
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3.1 Circular Dichroism: an introduction
Circular dichroism (CD) spectroscopy is a powerful tool to detect the secondary structure of
proteins and peptides.31a-c,40 It is based on the property of asymmetric chromophores (or
symmetric chromophores in asymmetric environments) to absorb differently right- and left-
circular polarised light. Upon entrance into the absorbing sample, the two circular polarised
components, R and L, of the plane-polarised light have the same intensity and phase. If one
component has been absorbed to a grater degree than the other, the electric vector of the light
describes no longer a circle, but an ellipse (Figure 1). When leaving the cell, the new
elliptically polarised light is described by the angle θ, called ellipticity, which is proportional
to the difference in absorption of the two original circular rays. CD spectra are commonly
expressed in molar ellipticity (degree cm2 dmol-1) or mean residue ellipticity ([θ]R). In the
latter case the molar ellipticity is divided by the number of residues forming the peptide,
which allows direct comparison of the CD spectra of differently sized peptides.
Figure 1. Origin of the CD signal.
The peptide bond is the main chromophore in peptides and proteins, besides the aromatic side
chains. It is surrounded by an asymmetric environment due to the stereocentres of the amino
acids but mainly due to the three-dimensional arrangement of the peptide backbone (ϕ and ψ
dihedral angles, see Figure 1, Chapter 2). Therefore the CD absorption of the peptide bond is
highly sensitive to the peptide secondary structure.
Photon
beam
Right- and left- circular
polarised light
Optically active
sample
Preferential
absorption of right
hand polarisation
CD signal
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The range of frequencies where the peptide bond absorption can be observed is between 180
and 300 nm. The lowest energy transition of the peptide chromophore occurs between 210
and 220 nm and reflects the n→π* transition involving non-bonding electrons of the carbonyl
group. The second transition is observed around 190 nm and describes the π→π* involving
the π electrons of the carbonyl group. The intensity and energy of these transitions depend on
the ϕ and ψ dihedral angles, thus relates to the secondary structure. In the case of a typical
α-helix CD spectrum, the π→π* transition is split into two components, the parallel- and the
perpendicular-polarised component with respect to the helical axis (Figure 2).
Figure 2. Typical α-helix and random coil CD spectra.
The CD spectrum is a weighed average of all conformers equilibrating in solution, therefore
the typical CD pattern of a secondary structure can be observed only when the structure is
reasonably populated. Nevertheless, the CD method is a fast application for the inspection of
the conformational features of a peptide, whether any structural elements are present or not.
Depending on the CD results, it can be interesting to further investigate the structure of a
peptide with other spectroscopic methods.
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3.1.1 CD and β-turns
The application of CD spectroscopy to the identification of peptides and proteins secondary
structure is already well known.31a-c,40 The main secondary structures (α-helices, β-sheets,
310–helices) have been extensively investigated and characterised. Turns have also been
widely studied,31c but there are many difficulties to interpret their CD spectra. As already
pointed out in the previous chapter, there are many types of turns, depending on the number
of residues involved (β- and γ-turns) and on their three-dimensional arrangement (determined
by the ψ and ϕ dihedral angles).
Table 1. Classification of β-turns CD spectra observed on linear peptides.31c
Class Definition Conformation
A
B
C
C´
D
U
Negative band near 216 nm.
Stroger positive band
  between 195 and 200 nm.
Negative band near 175 nm.
Weak negative band 
  between 220 and 230 nm.
Stronger positive band
  between 200 and 210 nm.
Strong negative band predicted
 between 180 and 190 nm.
α-Helix like CD spectrum
α-Helix like CD spectrum
  with low intensity,
  blue shifted bands
Positive shoulder above 220 nm.
Positive band at 200 nm.
Negative band below 190 nm.
Low intensity, redshifted
  class B spectrum
Weak negative band or shoulder
  between 215 and 230 nm.
Strong negative band near or below
  200 nm.
β-sheet
β-turn type II
β-turns type I, II and II´
β-turns type I and III
L-a.a.-D-a.a. or L-a.a.-Gly
  sequence type II β-turns
β-turns
aperiodic (unordered,
  random coil or irregular)
To achieve a pure turn CD spectrum, a short peptide is required that exists predominantly in
only one turn type. Moreover, the CD spectrum can be unambiguously assigned to a specific
turn type only when other data give strong evidence for it (X-ray, NMR, IR). Unfortunately,
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short peptides are often a mixture of conformers equilibrating in solution, therefore a
classification of CD spectra for each turn type can be achieved on cyclic peptides (where the
conformational degrees of freedom are reduced) or on linear peptides containing strong turn-
inducing sequences (i.e. one proline residue).31c Based on such investigation, typical CD
patterns can be assigned to the different β-turns (Table 1). It should be stressed, however, that
a particular CD pattern may correspond to more than one type of β-turn, and that the
classification is achieved by statistical investigations, therefore a particular turn type may also
have a not typical CD spectrum.
3.1.2 Choice of the solvent
Because of the π→π* absorption frequency, the choice of the solvent is limited to those
which absorb below 190 nm. Chloroform and dichlormethane are not suitable for CD
spectroscopy because they absorb above 200 nm. This makes it difficult to correlate the
informations obtained by IR spectroscopy in dichlormethane with those obtained by CD in
other solvents. When IR spectra are measured in other solvents, only the C=O stretching
absorption region gives informations on the peptide structure. However, in this case, detection
of turns is difficult since no information on the hydrogen-bonding extent is obtainable.41a-b
Acetonitrile allows measurements above 195 nm in a 1 mm cell and above 190 nm in a
0.1 mm cell. It is a suitable non-protic solvent for CD measurements, but it is a weak
hydrogen-bond acceptor, therefore it is not easy to correlate the hydrogen-bond extent
detected in dichlormethane by IR spectroscopy with the CD observed in acetonitrile.
Suitable solvents, besides water, are alcohols such as methanol (absorption below 195 nm in a
1 mm cell and below 185 in a 0.1 mm cell) and particularly trifluoroethanol (TFE, absorption
below 190 nm in a 1 mm cell and below 180 nm in a 0.1 mm cell). TFE is known to have a
structure-stabilising effect, particularly on α-helices.42 Compared to the non fluorinated
analogue, TFE is 3-4 times more acidic, and therefore a good hydrogen-bond donor, but a
poor hydrogen-bond acceptor (Figure 3). While water may disrupt hydrogen bonds and
destabilise secondary structures, TFE, with its unique hydrogen-bonding properties, forms a
bifurcated hydrogen-bond with the carbonyl oxygen without disrupting the intramolecular
hydrogen-bond (Figure 3). The hydrogen-bonding network stabilising a secondary structure
remains therefore intact in TFE.
52 Chapter 3
F3C O H
hydrophobic
poor acceptor
good donor
C
O
N
H
C
O
N
O
H
H
H
C
O
N
H
H O
CF3
H2O
TFE
peptide hydrogen-bond
Figure 3. TFE: hydrogen-bonding ability and interaction mode with hydrogen-bonds in
peptides compared to water.
Moreover, the high hydrophobicity of the CF3 group allows TFE molecules to interact with
hydrophobic side chains enhancing the hydrophobicity of the molecule which could favour a
particular secondary structure.
Hexafluoroacetone (HFA) is also used in CD spectroscopy. The effect of this solvent on the
peptide secondary structure is not clear, as it can cause loss of structure43a-e as well as induce
and stabilise it.43f-g HFA is used in its hydrate form which has enhanced hydrogen-bond donor
and poor acceptor ability at the oxygen. Moreover, the two trifluoromethyl groups contribute
to the high hydrophobicity of this solvent and its water repelling properties (Figure 4, left).
HFA in its hydrate form is thought to coat the peptide surface with the trifluoromethyl groups
displacing the hydrogen-bond disrupting water molecules. On the other hand, its OH groups
enhance the peptide solubility in water (Figure 4, right).
F3C CF3
O
F3C CF3
HO OH2O
water repelling groups
H
poor acceptor
good donor
F3C
F3C
OH
OH
F3C
F3C
OH
OH
CF3
CF3
HO
HO
CF3
CF3
HO
HO
peptide backbone
Figure 4. Left: HFA hydrogen-bonding properties. Right: mode of interaction with the
peptide backbone resulting in structure stabilisation.
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If the interaction with a peptide follows this scheme, HFA should stabilise its structure. On
the other hand the peptide secondary structure could be broken if hexafluoroacetone builds
stable hydrogen bonds with its backbone.43b
3.1.3 Sample concentration
The concentration of the sample, besides the choice of the solvent, is another determining
factor to achieve a good CD spectrum. When the sample absorbs too much light in a certain
UV region, the high tension (HT) voltage of the photomultiplier will be too high and the
measurements are therefore not reliable. The optimal concentration to observe a good CD
spectrum should not give HT values above 800 V. For the peptides investigated in the present
work, a concentration around 10-3 M (in 0.1 mm cell) was found to give the best CD quality.
3.1.4 Contribution of aromatic groups
The UV spectra of the aromatic amino acids (phenylalanine, tyrosine and tryptophan) include
bands in the near UV region (240-300 nm) as well as in the peptide bond region (185-240
nm). The absorption of the aromatic side chains at lower wavelengths can interfere with the
secondary structure estimation if the chromophores are kept in an asymmetric environment
produced by the secondary structure of the peptide.31c In fact aromatic side chains tend to give
rise to positive absorptions in the 215-230 nm region.44
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3.2 CD spectra of β-ACC containing peptides
In Figure 5 the CD spectrum of the building blocks (+)-11 and (-)-11 is shown. As expected,
being enantiomers they display mirror image CD pattern having an intense
maximum/minimum at 203 nm.
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Figure 5. CD spectra of (+)- and (-)-11 in methanol.
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Figure 7. CD spectra of (+)-27b and (-)-27b in methanol.
The structure-inducing effect of the β-ACC building block (11) can be better appreciated on
tripeptides having 11 as the central residue, where it can exert a greater conformation-
directing effect.
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methanol, due to the partial overlap of the n→π* with the π→π* transition. In acetonitrile a
red-shift of the band was observed as well as the presence of a weak shoulder at 217 nm.
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Figure 9. CD spectra of (-)-36a in various solvents.
The CD pattern of (-)-36a (Figure 9) shows high solvent-dependence: in HFA it is a typical
class B spectrum, having a maximum at 212 nm and a minimum at 185 nm. The CD profile in
TFE is similar, but the maximum is much less intensive. In methanol and acetonitrile the
n→π* and the parallel π→π* transitions are red-shifted (220 and 200 nm respectively) these
spectra are characteristic for class D turns.
The N-methylation of the C-terminal alanine leads to a completely different CD spectrum
compared to (+)-36a (Figure 10). In each solvent (+)-36b displays a helix-like spectrum with
two negative bands at 222 and 201 nm and a positive one (visible only in TFE) at 183 nm.
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The CD pattern of (-)-36b does not depend on the solvent used and has a minimum at 230 nm
(Figure 11), typical for γ-turns.31c, 46 Molecular modelling calculations (conformational search
with the program Titan) confirmed these data, giving the γ-turn centred on alanine-1 as the
most populated (Figure 12).
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Compound (+)-37a, analogous of (+)-37b but containing two phenylalanines instead of
glycines, shows always class C spectra (228 nm / θR –5000, 210 nm / θR –12000, 190 nm /
θR +4500 in TFE), where the n→π* transition results red shifted compared to the α-helix
typical values, 222 nm (Figure 15). Such effect, although not typical, is not unusual in class C
spectra.45b However, this red-shift could be also explained as a γ-turn CD contribution (230
nm). In fact, the amino acids adjacent to the β-ACC unit often prefer a γ-turn arrangement
(see Chapter 2). The main feature of (+)-37a CD spectra is that they are not solvent
dependent, suggesting a significant conformational stability of the peptide.
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(θR 10000 instead of 20000). In methanol, the CD absorption between the two minima is
positive, as already observed for (-)-37a. The CD spectrum in HFA has a maximum at 216 nm
and a shoulder near 200 nm, suggesting the presence of β-turns (Figure 18).
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Figure 18. CD spectra of (-)-39 in various solvents.
As already observed for the pair (+)-37a/(+)-39, an inversion of the ratio of the transition
intensity at 211 vs. 225 nm is observed between the protected and deprotected form of (-)-37a
in TFE.
180 190 200 210 220 230
-15000
-12000
-9000
-6000
-3000
0
3000
6000
|
|
|
230
216
183
[θ
] R
 (d
eg
 c
m
2  d
m
ol
-1
)
Wavelength (nm)
Figure 19. CD spectra of (-)-40 in various 
CO2MeCO2Me
N
H
CO2Me
OH
N
O
+H3N
H
N
O
N
H
O
CO2H
(-)-39
PhH2C CH2Ph
Cl-240 250 260
 TFE
 MeOH
 acetonitrile
 HFA
solvents.
N
H
OH
N
O
H
N
O
CO2BnN
H
O
BocHN
(-)-40
64 Chapter 3
Compound (-)-40 and the corresponding unprotected pentapeptide (-)-43, show CD spectra
with the same profile in the same solvents (Figure 19, only (-)-40 is shown), but the intensity
is about 40% reduced in the case of the protected form. In acetonitrile (not used for (-)-43)
and in TFE the pentapeptide is unordered (negative strong band at 183 nm). The broad
positive band at 216 nm observed in HFA indicate the presence of β-turns. The same CD
profile was found for the pentapeptide (-)-39 containing only one β-ACC unit. In methanol a
class C type CD spectrum is observed.
The peptides containing two or three (+)-β-ACC units ((+)-41, (+)-42, (+)-40, (+)-43, (+)-45,
(+)-46) display very similar CD patterns, constant in acetonitrile, methanol and TFE (Table
2). In every case a broad minimum around 205 nm was observed, probably including the
n→π* and the parallel π→π* transitions, while the perpendicular π→π* absorption falls
around 185 nm, often weaker than the parallel component. Such spectra can be attributed to
class C.
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Table 2. CD pattern in TFE of compounds containing more than one (+)-β-ACC unit.
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3.3 Discussion
In this chapter the CD spectra of various derivatives of (-)-11 and (+)-11 have been shown.
They proved to be often structured already at the tripeptide level displaying β-turn-like CD
patterns.
A significant difference could be observed in the CD spectra of compounds differing only for
the β-ACC configuration: the peptides containing (-)-11 were unordered in several cases
((-)-36a, (-)-37b, (-)-40, (-)-43) while the derivatives of (+)-11  were more structured.
Moreover, the derivatives of (-)-11 were very sensitive to any change in solvent, often
exhibiting a solvent-induced conformation. HFA contributed to stabilise class B, D or C´ CD
patterns, which seems to be due to its “teflon coating” effect.43f-g In some spectra positive
components around 220 nm were observed, probably due to the contribution of the
phenylalanine aromatic side chain. In contrast, the structure of peptides containing (+)-11 was
weakly or not at all solvent dependent and a positive contribution around 220 nm of the
phenylalanine side chain was rarely observed ((+)-39) and, however, not as strong as on (-)-11
derivatives. This could be explained by a predominant contribution of the peptide back-bone
in this region, thus suggesting a well defined conformation. Finally, (-)-11 containing peptides
show CD spectra similar to those of the α-peptide 49. In some solvents they displayed β-turns
(class D) spectra and/or phenylalanine aromatic contribution. Similarities between (-)-11
derivatives and 49 were already found on the hydrogen bonding extent measured by IR
spectroscopy (Chapter 2). On the other hand, α-helix-like (class C) spectra were generally
observed for derivatives of (+)-11.
Compounds containing multiple (+)-11 displayed considerably constant CD patterns, without
any solvent dependence. In the previous chapter it was suggested, on the base of the IR
spectrum, that (+)-45 could have a helix-like conformation. Based on the CD investigation, it
can be stated that a helical turn conformation may be already present at the tetramer stage, i.e.
(+)-41, suggesting that the introduction of two units of (+)-11 is a powerful tool to induce and
stabilise secondary structure elements in short peptides.
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Chapter 4
4.1 General introduction
Several methods are available nowadays to determine the solution structure of peptides, e.g.
circular dichroism (CD) and IR-spectroscopy. However, only NMR data may deliver
structural information at atomic resolution. In addition, NMR allows to describe
conformational equilibria in solution. While a complete structure determination based upon
the methodology developed by Wüthrich and coworkers48 offers the most comprehensive
picture, a number of spectroscopic parameters exist to estimate whether a particular peptide is
uniquely folded in solution or not.31a-b
Hydrogen-bonds can be identified by measuring for the amide proton signals: a) the reduced
temperature coefficients (∆δ/∆T), b) the solvent or concentration-dependence of the chemical
shifts and c) the H/D exchange rate. As already pointed out in Chapter 2, all these methods are
based upon the assumption that a hydrogen-bonded NH is less sensitive with respect to
perturbations of environment variables (temperature, solvent, concentration...) than a fully
solvent exposed amide proton. Substantial difficulties for interpretation in such experiments
arise when conformational averaging occurs. Furthermore, solvent inaccessible NHs will
experience little temperature or solvent chemical shift dependence similar to hydrogen-
bonded NHs.31a-b
Since regular secondary structures are determined by well-defined ϕ and ψ dihedral angles,
additional informations about the structure can be derived from a measurement of the
magnitude of the scalar 3JHN,Hα coupling constants which have typical values for the common
secondary structural elements.
Finally, the most useful information can be obtained from the nuclear Overhauser effect
(NOE). A nucleus can relax through several mechanisms, and for protons the dipole-dipole
magnetisation transfer with adjacent protons (closer than 5 Å)49a-b is the most efficient. The
NOE is proportional to 1/r6 (r = distance between the two interacting nuclei), allowing to
determine spatial proximities of protons which may then be translated into a
three-dimensional model. The two dimensional NMR experiment that provides information
about the NOE between protons is called NOESY. The NOE can be positive or negative
depending on the frequency of overall tumbling of the molecule. It is positive for small
molecules and negative for large ones. For peptides of 10-20 residues the NOE in aqueous
solution can be very small. To avoid this problem the ROESY (rotating frame NOESY)
68 Chapter 4
experiment has been developed. Therein, the signal decay occurs in the spin-locked state and
the rotating frame NOE is always positive.
The principle of the reduced temperature coefficients in aprotic, apolar solvents have already
been illustrated in Chapter 2. In the current chapter ∆δ/∆T values have been measured also in
protic (CD3OH) or good hydrogen-bond acceptor (pyridine-d5) solvents. The effect of such
solvents on strongly or partially hydrogen-bonded NHs is the same as in CD2Cl2 or CDCl3
(small vs. large variation of the chemical shift). However, in protic solvents, hydrogen-bonds
are formed between the NHs and the solvent and the temperature dependence of the latter
allows to distinguish them from intermolecular H-bonds.
4.2 The structure of β-ACC derivatives investigated by high resolution NMR
4.2.1 Temperature coefficients
Although temperature coefficients have to be treated cautiously, they may be used to identify
possible hydrogen bonding sites in the presence of further structural information. Values more
positive than -6 ppb/K have been interpreted in literature to indicate that the corresponding
amide proton is involved into a hydrogen bond in aqueous systems50a and similar values have
been used by Seebach50b and Gellman50c for solutions in CD3OH. For the peptides that have
been structurally characterised in more detail by 2D NMR,† the temperature coefficients were
measured in CD3OH.
For the peptides that have been mainly characterised by IR and CD spectroscopy other
solvents like pyridine or chloroform were used to solve problems such as occurrence of the
NH signals in the aromatic region, low solubility of the peptides or broadening of the signals
probably due to conformers exchange. However, in the investigation of (+)-37a and (-)-37b,
the use of pyridine-d5 always resulted in high ∆δ/∆T values, thus proving the absence of
hydrogen bonds in this solvent. The measurements performed in CDCl3 ((+)-37b, (-)-37a and
(-)-40) and in CD3OH ((+)-40) often showed temperature coefficients with border values for
hydrogen-bonding, but in the absence of further 2D NMR investigations they are not
sufficient to prove the presence of hydrogen-bonds.
Detailed NMR studies were performed on peptides (+)-39, (-)-39, (+)-43 or (-)-43 containing
one or two β-ACC units (Table 1).
                                                          
† In collaboration with Dr. O. Zerbe, Department of Pharmacy, ETH Institute, Zürich, Switzerland.
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Table 1. (+)-39 (top left) and (-)-39 (top right), (+)-43 (bottom left) and (-)-43 (bottom right)
temperature coefficients measured at 500 MHz between 280 and 301 K, 10 mM in
CD3OH.
N
H
CO2Me
OH
N
O
+H3N
H
N
O
N
H
O
CO2H
(-)-39
PhH2C CH2Ph
Cl-
2
3
4
5
N
H
CO2Me
OH
N
O
+H3N
H
N
O
N
H
O
CO2H
(+)-39
PhH2C CH2Ph
Cl-
2
3
4
5
Amide NH ∆δ/∆T
(ppb/K)
Chemical shift (ppm)
at 280 K
Chemical shift (ppm)
at 280 K
NH-2
NH-3
NH-4
NH-5
-7.7
-7.7
-6.0
-9.4
8.74
8.39
8.62
8.08
-6.0
-6.7
-7.3
-7.8
8.75
8.23
8.81
8.07
∆δ/∆T
(ppb/K)
N
H
CO2Me
OH
N
O
H
N
O
CO2HN
H
CO2Me
O
+H3N
(-)-43
2
3
4
5
N
H
CO2Me
OH
N
O
H
N
O
CO2HN
H
CO2Me
O
+H3N
(+)-43
2
3
4
5Cl
- Cl-
Amide NH Chemical shift (ppm)
at 280 K
Chemical shift (ppm)
at 280 K
NH-2
NH-3
NH-4
NH-5
-6.7
-6.7
-6.1
-6.9
8.69
8.78
8.40
8.81
-4.0
-7.0
-4.7
-7.3
8.38
8.69
8.00
8.92
∆δ/∆T
(ppb/K)
∆δ/∆T
(ppb/K)
For the peptides (+)-39, (-)-39 and (+)-43 none of the values is low enough to unambiguously
identify participation in hydrogen bonding. However, for (-)-43 the amide protons of ACC-2
and ACC-4 display temperature coefficients indicative for hydrogen bonding.
When comparing the chemical shift of protons at the same position in the corresponding two
diastereomers it is striking that the largest differences for the amide protons are encountered
for residues ACC-2 and ACC-4 of (+)-43 and (-)-43. Moreover, the temperature coefficients
for the amide protons of only these two residues are significantly lowered in (-)-43. Since the
involvement in a hydrogen bond would lead to a change in the chemical shift, these
differences would be compatible with the findings from the temperature coefficients showing
that only one of the two diastereomers of 43 forms hydrogen bonds.
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Initially, the proton data were taken at concentrations of 10 mM in CD3OH. At that high
concentration aggregation has to be considered and therefore we repeated the measurements
with 2 mM solutions for the two diastereomers of 39 and 43 (Table 2 and Table 3).
Table 2. (+)-39 (left) and (-)-39 (right) temperature coefficients measured at 500 MHz
between 280 and 301 K, 2 mM in CD3OH.
Amide NH Chemical shift (ppm)
at 280 K
Chemical shift (ppm)a)
at 280 K
NH-2
NH-3
NH-4
NH-5
-7.4
-7.3
-5.8
-7.5
8.73
8.37
8.62
7.94
-
-6.4
-6.7
-7.0
-
8.23
8.81
8.04
a) NH-2 exchanges rapidly with the solvent already at 280 K.
(+)-39 (-)-39
∆δ/∆T
(ppb/K)
∆δ/∆T a)
(ppb/K)
The values of the temperature coefficients for (+)-39 at the two concentrations are very
similar except for NH-5 (-9.4 and –7.5 ppb/K respectively). For this amide proton additionally
the chemical shift experienced the most dramatic change. In total, these data may indicate that
dimer association takes place involving NH-5 for (+)-39. For the corresponding diastereomer
(-)-39 the resonance of the amide proton of NH-5 displays similar ∆δ/∆T at both
concentrations and the change in chemical shift is small. Furthermore, for both diastereomers
the resonance of NH-2 is significantly broadened at 2 mM but not at 10 mM concentrations.
This may also be due to exchange-broadening arising from monomer-dimer equilibria.
Table 3. (+)-43 (left) and (-)-43 (right) temperature coefficients measured at 500 MHz
between 280 and 301 K, 2 mM in CD3OH.
Amide NH Chemical shift (ppm)
at 280 K
Chemical shift (ppm)
at 280 K
NH-2
NH-3
NH-4
NH-5
-6.7
-6.1
-5.3
-6.2
8.66
8.78
8.39
8.79
-3.9
-6.7
-3.9
-6.7
8.37
8.68
8.01
8.90
(+)-43 (-)-43
∆δ/∆T
(ppb/K)
∆δ/∆T
(ppb/K)
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The concentration dependence of the temperature coefficients for the two-ACC residues
containing peptides (+)-43 and (-)-43 was also measured (Table 3). In essence, the
temperature dependence for the two diastereomers is similar at both concentrations.
Furthermore, the chemical shifts of the amide protons do not vary significantly with changes
in concentration so that dimerisation effect seems to play a much less pronounced role.
4.2.2 Chemical shift assignment derived from 2D NMR data
A more detailed picture of the solution conformation of peptides at atomic resolution can be
gained from 2D NMR data. In a first step of the analysis, the sequence-specific resonance
assignment has to be determined for all observable protons. In a second step, NOESY
crosspeaks have to be completely assigned and the volume integrals translated into distance
restraints. These restraints are then used in a molecular dynamics simulation to derive the
structure in solution.
For the resonance assignment the combination of a DQF-COSY,51a-b a 80 ms TOCSY51c-d and
a 500 ms ROESY51e-f experiments was used. Whereas the DQF-COSY displays crosspeaks
for protons that are scalarly coupled, the TOCSY includes all (scalar) correlations with other
protons that are in the same spin-system (Figure 1).
N
RHNOC CO2Me
H R
Hβ Hγ
Hα
R
N CONHR
H
βH3C Hα
β-ACC alanine
Figure 1. Correlations with NH proton visible in TOCSY for β-ACC and alanine
The spin-systems were identified from TOCSY and linked via sequential Hα/HN ROEs. The
side chain assignment was then performed by combined use of the DQF-COSY and TOCSY
data (Figure 2).
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Figure 2. (+)-39 COSY (left) and TOCSY (right) spectra taken at 500 MHz, 280 K, 10 mM in
CD3OH. a=α, b=β and g=γ.
After identification of the spin systems of the amino acids, their sequence positions were
determined from the ROESY spectrum (Figure 3).
Neighbouring amino acids usually display CHαi/NHi+1 cross peaks. For the β-ACC amino
acid it was not possible to find a CHα (β-ACC)/NH (β-ACC+1) cross peak because in a β-
amino acid the CHα is too far away from the NH of the following residue. Instead, a CHβ (β-
ACC)/NH (Ala-4) was found.
Chapter 4 73
(ppm) 8.80 8.60 8.40 8.20 8.00
4.8
4.4
4.0
3.6
3.2
2.8
(ppm)
Figure 3. (+)-39 ROESY NH/CHα region showing the NHi/CHαi+1 cross peaks connectivity.
Spectrum measured at 500 MHz, 280 K, 10 mM in CD3OH.
The analysis of the spectra yielded the assignments illustrated in Table 4.
Table 4. Assignments of the signal in the 1H NMR spectrum of (+)-39 and (-)-39, (+)-43 and (-)-43,
500 MHz, 280 K, 10 mM in CD3OH.
(-)-39 HN Hα Hβ Others
Phe-1 - 4.13 2.94, 3.44 δH 7.30, 7.30
εH 7.35, 7.35
ζH -
Ala-2 8.75 4.43 1.31
γH 2.24β-ACC-3 8.23 3.53 2.50
Me 3.71
Ala-4 8.81 4.29 1.24
Phe-5 8.07 4.61 3.11, 3.23 δH 7.26, 7.26
εH 7.21, 7.21
ζH -
(+)-39 HN Hα Hβ Others
Phe-1 - 4.08 3.00, 3.30 δH 7.30, 7.30
εH 7.34, 7.34
ζH -
Ala-2 8.74 4.31 1.31
γH 2.41β-ACC-3 8.39 3.59 2.47
Me 3.73
Ala-4 8.62 4.24 1.19
Phe-5 8.01 4.58 2.98, 3.18 δH 7.18, 7.18
εH 7.22, 7.22
ζH -
(-)-43 HN Hα Hβ Others
Ala-1 - 3.92 1.48
β-ACC-2 8.38 3.42 2.47 γH 2.38
Ala-3 8.69 4.25 1.34
Me 3.71
β-ACC-4 8.00 3.56 2.54
Ala-5 8.92 4.36 1.43
γH 2.34
Me 3.71
(+)-43 HN Hα Hβ Others
Ala-1 - 3.85
β-ACC-2 8.69 3.51 2.53 γH 2.47
Ala-3 8.78 4.18 1.30
Me ?
β-ACC-4 8.40 3.73 2.48
Ala-5 8.81 4.40 1.39
γH 2.34
Me ?
1.38
N
H
CO2Me
OH
N
O
+H3N
H
N
O
N
H
O
CO2H
(+)-39
CH2Ph
Cl-
2
3
4
51
PhH2C Hα
Hα
Hβ
Hα
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4.2.3 Structure calculation from NOE data
After integration of the peaks, the corresponding interproton distances were calibrated from
the volume integrals by DYANA, a program dedicated to NMR structure calculation.52 The
volume (V) of the peak corresponding to a NOE between two protons is proportional to the
sixth power of their distance (r):
V = k/r6
were k is a calibration constant. A known distance between two protons may serve to calibrate
k, then all the other distances can be calculated. In the current calculations k was derived
according to the known distance for the cyclopropylic Hα/Hβ of 2.4-2.5 Å.
4.2.3.1 The solution structures of pentapeptides containing one β-ACC unit
The number of restraints per residue and the number of long-range restraints indicate how
well a structure is defined. For the peptides (+)-39 and (-)-39, both values were comparably
high for a small peptide.
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Residue range |i-j|Figure 4. (+)-39 (top) and (-)-39 (bottom) distance restraints. Left: for each residue white =
intraresidual; pale grey = i-i+1; dark grey = long range. Right: restraints for the
whole molecule vs. the distance between the interacting residues.
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For (+)-39 as well as for (-)-39 a relatively large number of long range (≥ i-i+2) restraints
were found suggesting that the two peptides are at least partially well structured. An important
difference observed between (+)-39 and (-)-39 (Figure 4) distance restraints is that (+)-39 has
no i-i+4 long range restraints (i.e. between the first and the last residue), while (-)-39 has two
of them (Figure 5).
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(ppm)7.40 7.36 7.32 7.28 7.24 7.20 7.16
4.700
4.600
4.500
4.400
4.300
4.200
4.100
4.000
(ppm)
(ppm) 7.36 7.28 7.20 7.12
9.00
8.80
8.60
8.40
8.20
8.00
7.80
(ppm)
Figure 5. (-)-39: two ROESY expansions showing the two i-i+4 NOEs. a = α, d = δ, e = ε, Q
indicates the pseudoatoms.
The non-sequential distance restraints used in the calculations for (+)-39 and (-)-39 are shown
in Table 5.
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Table 5. Non-sequential distance restraints for (+)-39 and (-)-39.
QD(1)-HG
QD(1)-HA(4)
QD(1)-QB(4)
QD(1)-HN(5)
QD(1)-HA(5)
QE(1)-HA(3)
QB(2)-HA(5)       
QB(2)-HB2(5)     
QB(2)-HB3(5)
QB(2)-QD(5)
QB(2)-QE(5)
HB(3)-HN(5)
HB(3)-QD(5)
HB(3)-QE(5)
HG(3)-QE(5)
HB2(1)-HA(4)
HB3(1)-HN(3)
HB3(1)-HA(4)
QD(1)-HN(3)
QD(1)-HA(3)
QD(1)-HB(3)
QE(1)-HG(3)
QE(1)-HA(4)
QE(1)-QB(4)
HN(2)-HN(5)
HA(2)-QD(5)
HN(3)-HN(5)
HN(3)-QD(5)
HA(3)-QD(5)
HA(3)-QE(5)
(-)-39
HB(3)-QE(5)
HG(3)-QD(5)
HB3(1)-HN(3)
HB3(1)-HA(4)
QD(1)-HN(3)
QD(1)-HA(3)
QD(1)-HG(3)
QD(1)-HA(4)
QD(1)-QB(4)
QE(1)-HA(3)
HG(3)-QE(5)
QE(1)-HG(3)
QE(1)-QB(4)
HA(2)-QD(5)
QB(2)-HA(4)
QB(2)-QD(5)
HB(3)-QD(5)
(+)-39
Then, 40 randomized conformations were generated by DYANA and minimised in a
simulated annealing protocol by molecular dynamics in torsion angle space. DYANA uses the
NMR restraints as an additional energy contribution to the force field potential used in the
simulated annealing. This ensures that the final minimised structures are compatible with the
NMR restraints. Besides distance restraints, dihedral angles restraints can be implemented in
the DYANA calculation. Unfortunately, all the peptides investigated had 3JHN,Hα around 7 Hz,
which is the typical value for rotational averaged backbone angles.31a-b The peptide bond
(dihedral angle ω) is normally fixed to 180°, the standard value in peptide and proteins except
for N-methyl amino acids and proline.
After the calculation, the target functions (that reflects how well NOEs and the standard
force-field parameters are satisfied) among the best 20 conformations should be reasonably
small but not too similar. After superimposition of the backbone atoms of well-structured
parts the root mean square deviation (RMSD) among the best 20 conformations should be
< 0.5 Å for the backbone and < 1 Å for the side chains, and there should be no consistent
restraint violations.
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For (+)-39 and (-)-39 the RMSD for the backbone among the best 20 structures calculated
was good (0.59 Å and 0.63 Å, respectively) as it can be observed in Figure 6 for (+)-39. Only
few and not significant violations were found (Table 6) and the mean target function was
0.16  ± 4.10 * 10-2 for (+)-39 and 7.06 * 10-2 ± 4.37 * 10-3 for (-)-39.
Table 6. Distance restraints violations for (+)-39 and (-)-39.
Constraint mean  violation number of violated    structures
2Qβ/3Hβ
3Hα/4Hα
3Hβ/4HN
0.09
0.21
0.07
2
18
2
(+)-39
(-)-39
0.23 203Hα/3Hβ
One violation, however occurred on (+)-39: the sequential ROE between the alpha-protons
from β-ACC-3 and Ala-4 indicate that a portion of conformers displays a cis-peptide bond
between these two residues. Such a NOE between 3-CHα and 4-CHα would be possible if the
corresponding 3/4 peptide bond would be cis, because only in this case the corresponding
proton-proton distance would be below 5 Å (Figure 7). Cis-peptide bonds are rarely
encountered in peptides. However, for a Xxx-Pro peptide bond there is usually a low (< 10 %)
amount of the cis conformer. Whereas the cis-trans isomerisation for the Xxx-Pro bond is
Figure 6. Superimposition of the best 20 conformations calculated for (+)-39 visualised in the
program MOLMOL. Side chains are omitted for reasons of clarity.
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slow on the NMR time scale, the absence of a second set of peaks due to the cis form
indicates that the interconversion is fast for a Xxx-ACC peptide bond.
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Figure 7. Distance between 3-CHα and 4-CHα in the trans and cis configuration of the 3/4
peptide bond. The carbomethoxy group on the β-ACC is omitted for reasons of clarity.
The conformations minimised by DYANA can be visualised and elaborated by MOLMOL,53
a program devoted to manipulate the three-dimensional structure of biological
macromolecules. On both peptides the influence of the cyclopropane-amino acid is to revert
the chain direction by a sharp turn. The main difference between the two diastereomers lies in
the relative orientation of the N- and C-termini (Figure 8).
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Cl-Figure 8. Lowest energy structure for (+)-39 (left) and (-)-39 (right) visualised in the program
MOLMOL.
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Compound (+)-39 has an opened turned structure (Figure 8) sharper than (-)-39, where the
backbone of residues 1 and 5 extends into opposite directions giving the structure a distorted
Ω  shape. On the other hand, (-)-39 has a real turn like pattern with an helical outlook (Figure
8). Worth to note that the alanine side chains orientation in the sharper (+)-39 turn (i.e. the
side chains belonging to the direct neighbours of the β-ACC) are directed perpendicularly to
the loop plane, while in (-)-39 the alanine side chains lie on the turn plane and are directed
outside it.
Small linear peptides are usually unstructured or exists as mixtures of conformers. Particular
care must therefore be taken in order to prove that the conformers derived from the DYANA
calculations are indeed physically relevant and do not represent artefacts from the structure
calculation. It is clear that the presented structures are in exchange with differently folded
conformers as evident from the 3JHN,Hα scalar couplings. However, the NMR data bear
evidence that they exist in solution to a large extent. In fact, the NOEs have been calibrated so
that the fixed distance between Hα and Hβ of ACC corresponds to the correct value. All
NOEs have been assigned and used in the structure calculation. The target function was
reasonably low indicating that all NOEs (except the sequential Hα/Hα NOE) can be fitted
onto a single structure. Nevertheless, for a structured peptide in fast exchange with an
unstructured (random coil) form, the ROEs may still be compatible with a single structure
(but need not necessarily be). This situation was encountered for both diastereomers of 39 and
for (-)-43 (paragraph 4.2.3.2). On the other hand, when two or more conformational distinct
species are in exchange, large violations in the structure calculations are expected, since the
ROEs can not be fitted onto a single structure. This was indeed observed for (+)-43
(paragraph 4.2.3.2).
Another question is whether the structural difference between the two diastereomers is really
significant or due to a particular, wrongly assigned NOE in one of the two molecules. It was
therefore checked, how many NOEs support the structures and whether these NOEs may be
differently assigned. One of the two 1-CH2β (Phe)→4-CHα (Ala) NOEs is strong in (-)-39,
while the other 1-CH2β (Phe)→4-CHα (Ala) is weak. Both NOEs are weak in (+)-39.
Furthermore, the correlations encountered between the methyl group of Ala-2 and the
methylene group of Phe-5 (2-CH3β (Ala)→5-CH2β (Phe)) is only seen in (-)-39. Both NOE
support the type of turn that is found in the structure calculation for (+)-39. The NOEs occur
in non-crowded regions of the spectrum and cannot be differently assigned. In contrast, (+)-39
displays a 2-CH3β (Ala)→4-CHα (Ala) NOE not visible in the other diastereomer.
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No hydrogen-bonds were found in the ensemble of NMR-derived structures, compatible with
the data gained from the temperature coefficients that could not reveal their presence.
Finally, a ROESY at 2 mM concentration of (+)-39 was recorded in order to exclude that the
observed ROEs are intermolecular. In fact, in section 4.2.1, it has been noted that the
temperature coefficient of NH-5 of (+)-39 changed from -9.4 ppb at 10 mM concentration to
-7.5 ppb at 2 mM. Such effect can be due to a change in the state of aggregation. However,
the chemical shifts at 2 mM and 10 mM concentration are very similar and essentially the
same. Moreover, the same ROEs were observed upon dilution indicating that the structure is
concentration-independent. In particular, long-range contacts (i-i+3) such as
2-CHα (Ala)→5-CQδ (Phe) (Q = pseudo hydrogen atom) were visible at both concentrations.
Spectra of all peptides in aqueous solution (10 mM, pH = 3.1, acetate buffer) have been also
recorded. The signal dispersion was slightly poorer in that solvent for both diastereomers of
39 and many structurally important long-range ROEs were placed in overlapped regions of
the spectra. The clearly observed ROEs are similar in strength and hence, the peptides are
expected to have similar structures in water and in methanol. However, due to the problems in
assignment and integration in overlapping regions, no structure calculations were performed
for that solvent system.
4.2.3.2 The solution structures of peptides containing two β-ACC units
For the peptides (+)-43 and (-)-43 the number of distance restraints found in the NOESY
spectrum is large as in the previous case. As already observed for the diastereomer pair (-)-39
and (+)-39, (-)-43 presents i-i+4 restraints which are absent in (+)-43 (Figure 9).
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Figure 9. Number of distance restraints for the whole molecule vs. the distance between the
interacting residues. Left: (+)-43; right: (-)-43.
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The upper limit (non-sequential) restraints used for the DYANA calculations are listed in
Table 7.
Table 7. Non-sequential distance restraints for (+)-43 and (-)-43.
QB(1)-HA(3)
HA(2)-HA(4)
HB(2)-HN(4)
HB(2)-HA(4)
HB(2)-HA(5)
HG(2)-HA(5)
QB(3)-HA(5)
QB(1)-HA(4)
QB(19-HG(4)
HN(2)-HN(4)
HN(2)-HA(5)
HA(2)-HA(5)
HA(2)-QB(5)
HB2-HN(4)
HA(1)-HA(4)
HA(1)-HB(4)
HA(1)-HG(4)
HA(1)-HN(5)
HA(1)-HA(5)
QB(1)-HA(3)
QB(1)-HN(4)
HB(2)-HA(5)
(+)-43 (-)-43
The restrained molecular dynamics calculations performed by DYANA on (-)-43 gave
reasonable results, with a low mean target function (0.18 ± 0.18) and few violations of the
restraints. The RMSD for the backbone was higher than for (-)-39 (1.48 Å). However, there
are fewer protons in 43 than in 39, due to the absence of the phenylalanine side chains,
thereby reducing the number of cross peaks used to define the peptide structure. The
calculations converged to a helix-like structure tighter than that found for (-)-39 (Figure 10).
When looking at the primary sequence of 43 it is obvious that the molecule contains two
Ala-ACC-Ala segments. In (-)-39 this segment produced a turn. Fusing two of these segments
together would produce a helical-type fold similar to the structure calculated for (-)-43. Based
on the occurrence of the same 1→5 cross peaks on (-)-40 (the corresponding Boc/Bn
protected pentapeptide), this structure could also apply to (-)-40.
Figure 10. Lowest energy structure for (-)-43 visualised in the program MOLMOL.
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Applying the suitable MOLMOL option, no hydrogen bond could be found in (-)-43 structure.
In contrast, the reduced temperature coefficients indicate that NH-2 and NH-4 are probably
hydrogen bonded while the ∆δ/∆T values measured for (+)-43 are all typical for solvated NHs
(Table 1).
Looking for additional hydrogen-bonds compatible with the observed reduced temperature
coefficients, the best 20 conformations of (-)-43 were minimised with the program Spartan. In
each minimised structure a hydrogen bond closing a 13-membered ring between 2-NH (ACC)
and 4-C=O (ACC) was observed (Figure 11). The H--O distance was 2.6 Å before and 1.6 Å
after minimisation, the N-H--O angle was 86° before 137° after minimisation. Moreover, a γ-
turn centred on alanine-3 (hydrogen bond between 4-NH (ACC) and 2-C=O (ACC)),
obtainable by simple rotation of about 15° of the ϕ angle of the alanine-3, yielded a hydrogen
bond. The H--O distance was 2.6 Å before and 2.2 Å after minimisation, the N-H--O angle
was 96° before 145° after minimisation. The minimisation led to considerable energy
decrease compared to the starting conformations calculated by DYANA, but did not alter the
overall shape of (-)-43 structure. These data would confirm the ∆δ/∆T values measured for (-
)-43. However, since the calculation were performed in vacuum, solvation of amide functions
is absent and hydrogen-bonded structures are likely to be overestimated. In solution
interconversion between structures containing the corresponding hydrogen-bonds and
solvated forms most likely exist.
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Unfortunately, the calculations performed on (+)-43 did not converge to a distinct structure
and the target function calculated by DYANA was still high, indicating that more than one
conformer is significantly populated. Many restraint violations were found, in all the best 20
structures. Particularly one of them was severe, the 4CHα/5CHα (Table 8). As already
illustrated for (+)-39 (Figure 7), such NOE is indicative for a cis peptide bond between the 4th
and the 5th residue.
Table 8. Distance restraints violations on (+)-43.
Constraint mean  violation number of violated    structures
1Qβ/3Hα
2Hα/4Hα
4Hβ/5HN
(+)-43
2Hβ/4Hα
2Hβ/5Hα
4Hα/5Hα
0.69
0.68
0.86
0.53
1.67
0.43
20
20
20
20
20
20
Indeed the DYANA calculations are usually performed with the ω angle constrained to 180°.
Therefore the DYANA computations were repeated on (+)-39, (-)-39, (+)-43 and (-)-43
allowing ω to adopt values of zero or 180°. Table 9 indicates how often a cis bond is
encountered in the 20 lowest energy conformers.
On (+)-39, (-)-39 and (-)-43 few cis bonds were found, and occur principally in the highest
energy conformations. On the other hand, in (+)-43 a 4/5 cis bond occurred in any of 20
lowest structures and a 3/4 cis bond, although present in only 11 structures, was found in the
first 7 conformations (Table 9).
The DYANA calculations on (+)-43 were repeated with the 4/5 peptide bond fixed at 0°.
Unfortunately, although the violation 4CHα/5CHα disappeared, new strong violations
occurred. It is obvious that at least two conformations rapidly exchange in solution, one of
them has probably a cis peptide bond between the 4th and the 5th residue. Hence, the ensemble
of observed NOEs may not be fitted onto a single structure, and the calculations should
therefore be evaluated with great care.
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Table 9. Cis peptide bond occurrences in DYANA conformers.
# : indicates the presence of a cis peptide bond in the nth conformation.
1     5        10       5        20
1/2 0      #5#
2/3 #
3/4 #
4/5 #    ####
1/2 ####      ##5  ##
2/3 5    ## 0##   5   ### 0
3/4 ####5##         ##5#
4/5 ####5####0####5#### 0
Conformationscis peptide bond
(-)-43
(+)-43
1     5        10       5        20
###0###  5      ##0
#  ##  #
5#   #   0
1/2
3/4
4/5
1/2 #  5#    #
2/3 #
3/4 #    ## 0
4/5 ##
Conformationscis peptide bond
(+)-39
(-)-39
In this chapter it could be shown that short α-peptides containing one or two β-ACC units
have surprisingly well-defined structures in CD3OH. The constrained β-amino acid is capable
to induce turn-like structures: (-)-11 influence drives the turn toward a helix evolution ((-)-39
and (-)-43), while the (+)-11 generates in (+)-39 a Ω loop like divergence of the N- and
C-termini. Surprisingly, neither (+)-39 nor (-)-39 structures are hold together by any hydrogen
bond, in contrast, (-)-43 presents two hydrogen bonds. The presence of two (-)-β-ACC units
has a stronger stabilising effect on the peptide conformation. No convergence was obtained on
the (+)-43 structure calculations although a large number of distance constraints was found.
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Neuropeptide Y (NPY) is a 36 amino acid polypeptide hormone and neurotransmitter and is
expressed in the central and peripheral nervous system. NPY is involved in the regulation of
food intake, peripheral vascular resistance, sexual functioning, anxiety and stress response.54
Five different G protein coupled receptors (Y1, Y2, Y4, Y5 and y6) have been isolated,55 but
the exact role played by each of them in the various NPY activated bioprocesses is still object
of investigations. The identification of the biologically active NPY conformations is another
difficult but important target to achieve. NPY is a polypeptide having an α-helical structure
between the 15th and the 31st amino acid but the C-terminus (residues 32-36), which mainly
interacts with the receptor binding site, has no regular structure (Figure 1).56 The synthesis of
NPY analogues with a stabilised secondary structure at the C-terminus can clarify the role of
the NPY receptors and the bioactive conformation of NPY. If the analogue fits into only one
receptor, only the bioprocesses correlated to this receptor will be activated. On the other hand,
if the affinity of an analogue is higher than that of the natural sequence, its conformation
should be very close to the bioactive one.
                                 
Figure 1. Three-dimensional model of NPY derived from pancreatic polypeptide (PP) crystal
structure.
In collaboration with the research group of Prof. A. Beck-Sickinger dipeptides containing the
β-ACC residue were built into the NPY (or truncated NPY) sequence at the position 32 and/or
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34, the only choice at the C-terminus, since arginines at position 33 and 35 proved to be
essential for binding (Scheme 1).
CO2Me
N
H
CO2H
O
FmocHN
R
solid phase synthesis30
YR
R
IL
36
34
32
N
NPY analogues
Scheme 1. Synthesis of NPY analogues starting from β-ACC containing dipeptides 30.
In Table 1 the investigated57 NPY analogues containing the Ile-β-ACC,58 Arg-β-ACC58 and
Gly-β-ACC ((+)-30f, see Chapter 1) dipeptides are shown.† They are all truncated NPY
analogues (12 or 14 peptides) whose activity toward Y1, Y2 and Y5 receptors was compared
with the natural truncated sequence (cR35, Table 1).
As already pointed out in previous studies25 the influence of (+)-11 on the bioactivity of the
NPY analogues is positive, leading to biologically active ligands selective toward Y1, while
its enantiomer (-)-11 leads to inactive ligands.
In the series presented here (Table 1) once more the inefficacy of (-)-11 to produce active
ligands upon its incorporation into NPY analogues can be observed (cf. bV19 and bV20). The
(+)-11 building block incorpored at position 34 (cT5) seems to induce a good Y1 selectivity
while at position 32 (cQ33) no binding at all is encountered. This effect is unexpected since
the corresponding not truncated NPY analogues ([R/S-ACC32]-NPY, Table 1) gave good
binding values toward Y5.25 Therefore the dipeptide Gly-ACC ((+)-30f) was built in the 28-29
and 31-32 position (cR39). With glycine a greater degree of freedom was introduced aiming
to favour the formation of a β-turn interacting with the receptor. Unfortunately, the ligand
cR39 gave no relevant affinity to NPY receptors. On the other hand, two (+)-11 residues in
the 32 and 34 position bind very efficiently to Y1 and moderately to Y5. The selectivity and
affinity of these truncated NPY analogues are distinctively higher than the truncated natural
sequence (cR35).
In the positions 32 and 34 proline (cR43) and β-HGln (cT9) were also introduced to verify
whether the effect observed with β-ACC derivatives is only due to the presence of a cyclic
amino acid like proline or to the β-amino acid additional methylene group (β-HGln). In both
                                                          
† Solid phase synthesis and biological tests performed by Norman Koglin, research group of Prof. A.
Beck-Sickinger, Leipzig.
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cases (cT9 and cR43) no binding was observed thus confirming that the influence of β-ACC
on the structure and biological activity of the NPY analogues is due to its specific structural
features.
Table 1. Bioactivity of truncated NPY-analogues on the human (h) Y1- and Y2-receptors and
on rat (r) Y5-receptor. Substitutions on the natural sequence are bold.
!!!!!!" : (RRR)-β-ACC, # : (SSS)-β-ACC, q: β-HGln.
               - = 0-25 %, + = 25-50 %, ++ = > 50 % change in specific binding.
Code Sequence hY1 hY2 rY5
NPY YPSKPDNPGEDAPAEDLARYYSALRHYINLITRQRY-NH2
cR35 Ac-RHYINLITRQRY-NH2
++ ++ ++
- + -
bV19
Ac-RHYINLITR"R"RY-NH2
Ac-RHYINLITR#R#RY-NH2
Ac-RHYINLI"R"RY-NH2
bV20
cP8
Ac-RHYINLITR"RY-NH2
H-RHYINLI"RQRY-NH2
Ac-RHYG"LG"RQRY-NH2
cT5
cQ33
cR39
Ac-RHYINLITRqRY-NH2
Ac-RHYINLIPRPRY-NH2
cT9
cR43
- - -
++ - +
++ - +
++ - -
- - -
- - -
- - +
- - -
[R/S-ACC32]-NPY YPSKPDNPGEDAPAEDLARYYSALRHYINLI >1000 >1000 43a)"#
a) IC50 [nM]. Synthesis and biological tests by Dr. Chiara Cabrele.
25
 RQRY-NH2
These results confirm that the (+)-11 building block exerts a significant influence on the
structure of α-peptides, particularly if two (+)-β-ACC units are present at position 32 and 34.
Interestingly the CD spectra of cP8 in buffer with or without the addition of TFE (30 %) are
identical and have a minimum around 206 nm. The same minimum and behaviour toward
TFE was observed in the present work on the peptides containing two or three (+)-β-ACC
units. On the contrary, with cT5 as well as with (+)-37a and (+)-39 (incorporating only one
(+)-11 unit) some helix-induction was observed upon addition of TFE. This suggests that the
structure-inducing effect of (+)-11 is manifested already on short peptides (5-6 residues) and
leads to the same kind of structure as that of longer peptides.
The peptides (+)-42 and (+)-46 containing two and three β-ACC units respectively, have been
synthesised as building blocks for other NPY analogues, but not yet built in the sequence and
biologically tested.
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The interesting results on the structural properties of β-ACC containing peptides rise the
problem that the synthesis of longer peptides is not practicable in solution. A method which
allows the coupling of the β-ACC on the solid phase should be developed.
The solid phase synthesis can be performed by two alternative protecting group (PG)
strategies: Boc (temporary PG)/Bzl (permanent PG) and Fmoc (temporary PG)/ tBu
(permanent PG). The Boc strategy implies the use of Merrifield linker (Figure 1) requiring
liquid HF for the cleavage from the resin, highly acidic conditions which need a specialised
apparatus and catalyse several possible rearrangements. In contrast, in the Fmoc strategy the
cleavage of the peptide from the resin occurs under milder acidic conditions (TFA 50 % in
CH2Cl2 for the Wang linker), therefore Fmoc protection is widely used. Another kind of
linker has been developed to introduce extremely mild cleaving conditions, it is called
SasrinTM (super acid labile resin), it is highly labile to acids (1% TFA in CH2Cl2) and
therefore suitable for combinatorial chemistry and in peptide synthesis, for example, it allows
the cleavage of side chain protected peptides.
Cl O OH
O
OH
O-
Merrifield linker
(HF)
Wang linker
(50 % TFA)
Sasrin linker
(1 % TFA)
Figure 1. Various types of linkers for solid phase synthesis (cleaving conditions).
To make use of the β-ACC on acid labile resins, a N-protecting group is requested to be
cleaved under neutral or weakly basic conditions. The protecting group should also allow in
situ deprotection/coupling to prevent ring opening. The N-Fmoc protected β-ACC has been
already synthesised but the coupling with acyl chlorides was unsuccessful, resulting only in
ring-opening products.26
Among the many other N-protecting groups known in the peptide chemistry, the allyl
carbamate (Alloc) seemed to be the most promising for the β-ACC unit. In fact, the
deprotection is achieved under non-acidic conditions by catalytic amounts of palladium (0) in
the presence of a nucleophile acting as allyl scavenger to avoid allylation at the free amine
after deprotection to give 52 (Scheme 2).59a N-Alloc-β-ACC 16a is already known, it can be
synthesised in high yield and without epimerisation and it has been coupled with various acyl
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chlorides giving 50 up to 70 % yields.26 Compound 16b could be obtained under the same
conditions.
CO2R
1
BocHN CO2R
2
1. HCl/ethyl acetate
2. AllocCl, pyridine
85-90 %
CO2R
1
N
H
CO2R
2O
O
11 16aR1= Me, R2= Bn
12 R1= Bn, R2= Me 16b
Scheme 1. Synthesis of N-Alloc β-ACCs (16a and 16b).
6.1 Tandem deprotection/coupling of N-Alloc protected amino acids in solution
In the present work the reaction conditions for one pot deprotection/coupling of 16a to amino
acids (Boc and Fmoc protected) has been optimised in solution and applied to the solid phase.
The choice of the allyl scavenger has been a critical point. In fact, non acidic deprotection
conditions are requested for the Fmoc strategy and strong nucleophile scavengers
(β-dicarbonyl compounds59a or secondary amines59b-f) capable to react with the preactivated
amino acids are also not suitable. Only two categories of allyl scavengers fit these
requirements: tertiary amines and some hydrides (Scheme 2).
Among the tertiary amines which have been reported as allyl scavengers there are pyridine,60
triethylamine,60 and N-methylmorpholine, but the latter is normally used in the presence of an
acid (HCl or acetic acid).59a Pyridine and triethylamine have been rarely used in Alloc
deprotection and, moreover, with low yields.60
Among the hydrides tributyltin hydride, sodium borohydride and phenylsilane have been
successfully applied as allyl scavengers to the Alloc-peptide synthesis. The use of a hydride as
allyl scavenger requires an acidic treatment after deprotection to isolate the free amine (53),
while direct coupling with activated amino acids avoids the employment of acids (Scheme 2,
b). Using tributyltin hydride the yields are good to excellent but the reactant is highly
toxic.61a,b Sodium borohydride leads to significant amounts of the N-allylated amine (52,
Scheme 2, a) in the only deprotection step, while in the one pot deprotection/coupling
procedure it gives high yields (68-84 %) of 54 (Scheme 2). The deprotection/coupling
protocol can be successfully applied to EDC/HOBt activated amino acids but fails with
pentafluorophenyl activated amino acids which are reduced by NaBH4 to the corresponding
amino alcohols.61c The most efficient allyl scavenger, widely used in peptide chemistry, is
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phenylsilane. It has been used to obtain free amines and for one pot deprotection/coupling
with excellent yields, in solution as well as on solid phase. For the one pot
deprotection/coupling protocol, many carboxy activated species (pentafluorphenyl esters, N-
hydroxysuccinimmide esters, acyl fluorides and N-urethane-N-carboxy anhydrides) but so far
no EDC/HOBt preactivated amino acids were used.61d-g
"PdL2"
ORHN
O
Pd
L L
+RNHCO2
-
Nu-
Nu
DH
RNHCO2D + H
HX or R
1 X
O
D (hydride donor) = Bu3Sn, NaBH3, PhSiH2
Nu- = amines, thiols, carboxylates,
β-dicarbonyl compounds
51
53 54
RNH2 or RNHCOR1
53 5451 HX or R
1 X
O
Pd[PPh3]4
CO2
52
a
bb
or
ORHN
O
NHR+CO2
Scheme 2. Cycle of the palladium (0) catalyst in Alloc deprotection reactions: a) N-allylation side
reaction; b) in the presence of nucleophiles or hydride donors as allyl scavengers.
The first attempt to couple 16a to an activated amino acid was performed with PhSiH3.
Compound 16a was coupled with Fmoc-alanine in high yields (90 %) but, unfortunately, also
5 % ring opening was observed (Table 2, entry 7), which made the purification of the product
a difficult task. Moreover, the use of phenylsilane (as any hydride) is complicated by the
requirement of rigorously anhydrous conditions and by some difficulties in its storage for a
prolonged period.
Therefore, the efficiency of pyridine as allyl scavenger was investigated. The coupling of
N-Alloc natural amino acids was performed as test reaction (Table 1). Indeed, the dipeptides
56 were obtained in high yields (94-99 %) and N-Boc as well as N-Fmoc protected amino
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acids were found to be compatible with the reaction conditions. Nevertheless, the reactions
proceeded slowly (Table 1, entry 1) making 20  mol % of palladium (0) catalyst necessary to
stay within acceptable reaction times (Table 1, entries 2-4).
Among the amines used as allyl scavengers pyridine is the less basic and the less nucleophilic
(pKa (piperidine, triethyl- and diethylamine) > 10; pKa (morpholine) = 8.7; pKa (pyridine) =
5.3). DABCO is a tertiary amine which has not yet been used as allyl scavenger in Alloc
deprotection reactions, it is a stronger base (pKa = 8.9)62a than pyridine and a good
nucleophile.62b Indeed, the rate of the deprotection/coupling reactions performed with
DABCO as allyl scavenger (Table 1, entries 5-8) dramatically accelerated, giving rise to
56a-e after a reaction time of only 10-20 minutes when 10 mol % of palladium (0) were
employed.
Table 1. Peptide coupling of Alloc protected amino acids with preactivated Boc and Fmoc
amino acids.
entry
1
2
3
4
5
6
HN NHO
O
CO2R
1R
Pd[PPh3]4
Base
EDC/HOBt
CH2Cl2
CO2R
1R
PGHN
O
R2
55 56
eq. activated a.a. basea) time
 CHMe2
yieldPd[PPh3]4
3
3
1.5
Py
1.5
10
20
20
20
Py
Py
Py
15 h
1.5 h
1.5 h
1.5 h
94
99
94
98
7
8
3
3
3
1.5
10
10
10
10
10 min
10 min
20 min
20 min
99
99
97
87
R R1 R2 PG
Me Bn Me Boc
Me Bn Bn Boc
Me Bn Me Fmoc
Me Me Fmoc
Me Bn Me Boc
Me Bn Bn Boc
 CHMe2 Me Me Boc
 CHMe2 Me Me Fmoc
56a
56b
56c
56d
56a
56b
56e
56d
DABCO
DABCO
DABCO
DABCO
[mol %] [%]
a) 20 eq. of pyridine or 5 eq. of DABCO were employed.
amino acid
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Most notably, under these reaction conditions N-Fmoc protected amino acids (Table 1, entries
3, 4 and 8) are tolerated as coupling partners, so that the synthesis of peptide fragments with
the Fmoc strategy is possible.
Both pyridine and DABCO deprotection/coupling protocols were applicable to 16a: the
dipeptides 25 could be obtained in high yields (92-97 %) (Table 2). Again the use of DABCO
resulted in considerable shortened reaction times, but another advantage of this procedure in
comparison to the use of pyridine became apparent: although ring opening side products
formation could be suppressed in both cases, epimerisation was observed to a substantial extent
(up to 20 %) when pyridine was employed. In contrast, epimerisation was minimal (< 3 %)
when DABCO was used, indicating that this reagent is not responsible solely for the cleavage of
the allyl group but might also activate the HOBt ester of the amino acid used as the coupling
partner. Again, N-Boc and N-Fmoc protected amino acids could be used as substrates.
Table 2. Peptide coupling of 16a with preactivated Boc and Fmoc amino acids.
entry
1
2
3
4
eq. activated a.a. scavengera) time yieldPd[PPh3]4
3
3
3
1.5
20
10
10
10
2 h
15 h
15 min
15 min
93
95
96
93
N
H
CO2Bn
CO2Me
Pd[PPh3]4
Scavenger
EDC/HOBt
CH2Cl2
16a 25a-b and 25g-h
R PG
5 H Boc 3 10 92
6 Me Boc 3 10 15 min 97
Me Boc
H Boc
Bn Boc
Me Fmoc
Py
Py
15 min
25g
25a
25h
25b
25g
25a
O
O
N
H
CO2Bn
CO2Me
O
PGHN
R
7 Me Fmoc 25b 1.5 10 15 min 90 b)
b) Contaminated with 5 % ring opening product.
DABCO
DABCO
DABCO
DABCO
PhSiH3
[mol %] [%]
a) 10 eq. of pyridine or 5 eq. of DABCO or PhSiH3 were employed.
amino acid
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6.2 Suppression of DKP formation by DABCO protocol
Several residue- or sequence-specific side reactions can occur during the solid phase peptide
synthesis (SPPS). One of the most important is the formation of diketopiperazines (DKP, 59)
as side products in peptide chemistry (Scheme 3).63a Due to the presence of particular
sequences prone to DKP formation, when the terminal amino group is liberated (58) an
intramolecular aminolysis at the i-1 peptide bond occurs with formation of the corresponding
cyclic dipeptide (DKP) and interruption of the chain elongation.63b
X
H
N
NHPG
O
O
X = OR or NHR
R
R
X
H
N
NH2
O
OR
R
N
H
H
N O
O R
R
57 58 59
DKP
N-deprotection
intramolecular
aminolysis
Scheme 3. DKP side-reaction.
Sequences containing amino acids able to reverse the chain direction, and thus bringing in 58
the free amino group near to the i-1 peptide bond, are particularly prone to DKP formation.
Proline and N-methyl amino acids can adopt cis peptide bond conformations, glycine favours
any type of turn, due to the lack of a side chain. These amino acids in either the first or the
second position of the elongating chain produce substantial amounts of DKP during the
deprotection step. The cyclisation can be hardly avoided when a strong turn forming sequence
involves the first and the second residue of the peptide. A combination of a D- and a L-amino
acids is very unfavourable and the presence of two adjacent prolines is particularly
troublesome.
On the solid phase the DKP problem is relevant at the third coupling cycle, because the ester
bond between the peptide and the linker is prone to intramolecular aminolysis.
Various solutions have been proposed to avoid this undesired side-reaction: the use of a
sterically hindered linkers (trytil-resins)63b preventing a nucleophilic attack at the ester bond;
the use of the Boc/Bzl specially designed coupling protocols involving in situ neutralisation63b
and some other particular Fmoc/tBu protocols. Nevertheless, these solution can be applied to
solve specific problems but are not of general use. Moreover, the incorporation of a Pro-Pro
sequence in a peptide remains a difficult task which is often resolved by the incorporation of
the second and third amino acid as the protected dipeptide 61 (Scheme 4).
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N
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X
R
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H
NN
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N
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O
PG
N
O
HO
+
coupling
55 61 62
63 64 65
i.
ii.
coupling
deprotection
Convergent synthesis
X = OR or NHR
NH
O
X
55
+
Sequential synthesis
no DKP
DKP
Scheme 4. Convergent synthesis (top) to prevent DKP formation (bottom) in the presence of
the Pro-Pro sequence.
An efficient way to suppress DKP formation in solution and on the solid phase is the
entrapment of the free amine in situ by acylation prior to intramolecular aminolysis. An early
example is the Cbz deprotection/coupling in the presence of Pd/C and activated Boc- or
Teoc-amino acids.64 This strategy is not very efficient since it is not compatible with Fmoc
chemistry and makes use of a heterogeneous catalyst, which would not be washed out during
the solid phase synthesis.
The Alloc-protection followed by the Pd (0)/PhSiH3 tandem deprotection/coupling reaction
already proved to prevent DKP formation.61f Therefore the efficiency of the
deprotection/coupling protocol using DABCO as allyl scavenger was tested. The coupling of
a peptide containing two prolines at the N-terminus with a further amino acid is one of the
most DKP sensitive sequences, thus the dipeptide 66 chain elongation was taken as a
representative example (Table 3).
Indeed, the coupling successfully afforded the tripeptides 67 in high yields and short reaction
times, moreover, no DKP 65 was observed.
Chapter 6 95
Table 3. Suppression of DKP formation with the Alloc/DABCO tandem deprotection/
coupling protocol.
entry
1
2
3
time yield
94
activated a.a.
N-Boc-Gly-OH
N-Fmoc-Ala-OH
N-Fmoc-Pro-OH
15 min.
15 min.
30 min.
90
96
coupling product
BnO-Pro-Pro-Gly-NHBoc
BnO-Pro-Pro-Ala-NHFmoc
BnO-Pro-Pro-Pro-NFmoc
66 67
67a
67b
67c
a) Reaction conditions: Pd[PPh3]4 (10 mol %), DABCO (5 eq.), EDC/HOBt/amino acid (3 eq.),
CH2Cl2, room temperature.
a)
N
O
N
O O
BnO2C
N
O
N
O
BnO2C
N
PG
R2
R1
[%]
6.3 Application of the DABCO protocol to the solid phase synthesis
The efficiency of the DABCO protocol was then tested on the solid phase.
The first problem which arises is the synthesis of the free acids 68 or 69 (Scheme 5) to be
coupled on the resin. The strategy so far employed to arrive at free carboxylic acids of the
β-ACC structure has been the hydrogenolysis of the corresponding benzyl esters such as 24 or
25. However, the hydrogenolysis of the benzyl ester would also affect the Alloc protecting
group. At the present there is only one synthesis developed affording selectively 68 and 69,
but it requires many steps on the N-Boc pyrrole 13 (Scheme 5).65
NHAlloc
HO2C CO2R
2
Boc
N
13
68
NHAlloc
R1O2C CO2H
69
Scheme 5. Synthesis of N-Alloc β-ACC free acids 68 and 69.
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Another efficient possibility to arrive at 68 or 69 acids would be to cleave one of the two ester
groups on 16 selectively by enzymatic hydrolysis. The enzymatic resolution of racemic
cyclopropanes bearing two methyl ester groups has been already successfully carried out.66
The enantiomeric mixture of the cyclopropanated Boc-pyrrole 13 has been also enzymatically
resolved,21d while no success was obtained on the enantiomeric mixture of 11 analogue
having two methyl ester functions. Nevertheless, only a regioselective hydrolysis of 16a is
required to achieve the synthesis of 68a or 69a. Such a strategy would permit to obtain the
free acids in only two steps starting from the well known and efficient synthesis of 11 and 12.
Three different β-ACC derivatives (16a-b and 70) were hydrolysed by treatment with PLE-E1
(Pig Liver Esterase), to investigate the dependence of the enzymatic regioselectivity on the
ester nature and on its stereochemistry (Scheme 6). It could be observed that the benzyl and
the phenacetyl (Phac) esters are more efficiently hydrolysed compared to the methyl ester,
probably due to the better interaction of the more lipophylic aromatic group with the enzyme
binding site. On the other hand the stereochemistry plays also an important role, in fact, the
benzyl ester group is more extensively hydrolysed when it occurs in the trans position with
respect to the amino group (cf. 16a and 16b).
NHPG
R1O2C CO2R
2
NHPG
HO2C CO2R
2
NHPG
R1O2C CO2H
PLE-E1R1= Bn, R2= Me, PG = Alloc 68a 69a
R1= Phac, R2= Me, PG = Boc PLE-E1 71 72
R1= Me, R2= Bn, PG = Alloc PLE-E1 68b 69b
16a
16b
70
2:1
5:1
1:8
+
Phosphate buffer
pH 7.4
70-80 %
Scheme 6. Enzymatic hydrolysis of β-ACC derivatives 16a, 70 and 16b.
The hydrolysis of 70 and 16b gave the best enrichment in only one free acid (the cis and trans
respectively as racemate); 69b could be isolated pure by recrystallisation and was then
employed as building block in the solid phase synthesis.
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OH O O
O
HO
N
HO
O H
N
Ph
O
NHFmoc
73 74
7576
Wang resin
Ala-Fmoc Ala-Phe-Alloc
Ala-Phe-Ala-Fmoc
a b
d
c
Scheme 7. a: Fmoc-Ala-OH/DIC/HOBt (3 eq.), DMAP (0.1 eq.), DMF. b: i. piperidine/DMF.
ii. Alloc-Phe-OH/DIC/HOBt (3 eq.), DMF. c: Fmoc-Ala-OH/EDC/HOBt (15 eq.),
Pd[PPh3]4 (0.2 eq.), DABCO (18 eq.),CH2Cl2,  2 h, r.t.. d: TFA/CH2Cl2 2:1. Yield: 99 %.
First, the Alloc deprotection/coupling protocol with DABCO as allyl scavenger was brought
on the solid phase for the synthesis of a non critical sequence to prove its applicability
(Scheme 7). The tripeptide Fmoc-Ala-Phe-Ala 76 was obtained in high yields confirming the
quality of the coupling method also on the solid phase.
The coupling conditions were then optimised and applied to the troublesome synthesis of the
sequence Fmoc-Ala-Pro-Pro-OH (80) and of a tripeptide containing the β-ACC 69b (Scheme
8). For a direct comparison of the results, the reactions on the solid phase were performed
with both DABCO and phenylsilane protocols. DABCO resulted of comparable efficiency
with phenylsilane, affording high yields and short reaction times. The advantage of DABCO
on phenylsilane is the stability of the reagent to moisture67 which allows an easy application
to the automated synthesis.
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CO2Me
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O H
N
CO2Me
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O
NHFmoc
HO
N
HO
O H
N
CO2Me
Ph
O
NHFmoc
DABCO protocol 85 % f)
PhSiH3 protocol 83 % f)
O Pro-Pro-Alloc
O Pro-Pro-Ala-Fmoc
Pro-Pro-Ala-Fmoc
DABCO protocol 99 % e)
PhSiH3 protocol 99 % e)
17
19
77
78
79
80
d
a
b
c
b
Scheme 8. a: i. Fmoc-Pro-OH/DIC/HOBt (3 eq.), DMAP (0.1 eq.), DMF. Loading 0.85
mmol/g. ii. piperidine/DMF. iii. Alloc-Pro-OH/DIC/HOBt (3 eq.), DMF. b:
Fmoc-Ala-OH/EDC/HOBt (6 eq.), Pd[PPh3]4 (0.2 eq.), Allyl scavenger (12 eq.),
CH2Cl2, 2 h, r.t.. c: TFA/CH2Cl2 2:1. d: i. Fmoc-Phe-OH/DIC/HOBt (3 eq.),
DMAP (0.1 eq.), DMF. Loading 0.6 mmol/g. ii. piperidine/DMF. iii.
69b/DIC/HOBt (1.5 eq.), DMF. e: Without further purification after cleavage
from the resin. f: The product was purified by column chromatography after
cleavage from the resin.
In conclusion the coupling of the N-Alloc protected β-ACCs was developed and optimised in
solution (16a) and on the solid phase (69b). A new tandem deprotection/coupling protocol
was applied on N-Alloc protected amino acids (or peptides) making use of Pd(0) as catalyst,
DABCO as allyl scavenger and EDC/HOBt preactivated Boc- and Fmoc-amino acids. This
protocol affords good to excellent yields within short reaction times. DABCO was found to be
an allyl scavenger as effective as phenylsilane, but cheaper, easier to store and to employ.
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Summary
In this work the synthesis of α-peptides containing the β-ACC building blocks (+)-11 and
(-)-11 was developed and their structure was investigated by IR, CD and NMR spectroscopy.
The synthesis of β-ACC containing peptides was achieved in solution by Boc/Bn protection
strategy (Scheme 1).
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Scheme 1. a: i. HCl/ethyl acetate. ii. N-protected amino acid/EDC/HOBt, pyridine. b: i. Pd/C,
cyclohexadiene or formic acid. ii. EDC/HOBt, C-protected amino acid, pyridine.
By means of IR spectroscopy, the extent of the hydrogen-bonding network in derivatives of
β-ACC 11 could be estimated. Molecular modelling calculations assisted to give reasonable
hypotheses for the location of the hydrogen-bonds, however, only calculation in vacuum have
been carried out, therefore the hydrogen-bond contribution is overestimated. It could be
proved that the β-ACC unit can force hydrogen-bonded sharp turns forming 6-membered
(C6), 7-membered (C7), 8-membered (C8) or 9-membered (C9) rings.
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The 6-membered conformation is the most constrained (Figure 1). It has been encountered
only in 34 and 35c (Figure 2) with only the cyclopropyl NH free for binding and containing a
tertiary amide group at the β-ACC C-terminus, which makes the carboxyl amide group a
particularly good hydrogen-bond acceptor. If other hydrogen-bonding patterns were possible,
C8 and C9 rings resulted to be more stable (Figure 2). Moreover, the presence of an amino
acid at the β-ACC N-terminus seems to favour a γ-turn structure.
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Figure 2. C8 hydrogen bonded structure calculated for (+)-35b, C9 for (+)-50 and γ-turn for
(+)-25a.
The mixture of the two diastereomers of the dipeptide Boc-Ala-β-ACC-OBn (25a) could be
resolved by recrystallisation allowing an easy access to dia- and enantiomerically pure
peptides containing the unit Ala-β-ACC. Circular dichroism (CD) measurements for
oligomers incorporating (-)-11 showed often β-turn like CD patterns, while the derivatives of
(+)-11 displayed helix-like CD patterns.
A detailed picture of the conformations of (+)-39, (-)-39, (+)-43 and (-)-43 in solution (Figure
3) could be achieved by CD and 2D NMR spectroscopy. Since 39 and 43 are unprotected
peptides, they are not soluble in CH2Cl2 and IR measurements were performed only on the
corresponding protected forms (+)-37a, (-)-37a, (+)-40 and (-)-40 (Table 1). The IR spectra of
37a and 40 diastereomers showed a substantial difference in the hydrogen-bonding extent
stabilised by the two β-ACC enantiomers, demonstrating the influence of the chirality of the
β-ACC building block when combined with α-amino acids. It was found that (+)-11 promotes
the formation of fewer hydrogen-bonds than (-)-11 (Table 1). This effect was surprisingly not
observed on the hexapeptide (+)-45 containing three (+)-11 units, in which five of the six NHs
are hydrogen-bonded, suggesting some regular structure to occur.
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Table 1. Extent of the hydrogen-bonding network on pentapeptides measured by IR
spectroscopy in CH2Cl2.
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The CD spectra of the protected (37a and 40) and unprotected (39 and 43) diastereomers
displayed similar patterns suggesting that the protecting groups do not substantially influence
their conformation. Once again, it was striking the difference in the influence of the two
β-ACC enantiomers on the peptides structure. The CD spectra of (-)-11 containing peptides
were usually solvent dependent (Figure 3, (-)-39 and (-)-43, right) and occasionally typical
random coil CD spectra were observed ((-)-43 in TFE, Figure 3). In contrast, the (+)-11 unit
induced helix-like CD patterns (Figure 3, (+)-39 and (+)-43, left) which showed little solvent
dependence. Moreover, the introduction of two or three (+)-11 units resulted in very similar
CD spectra, so stable to any change of solvent that even TFE could exert no structuring effect
(cf. (+)-43 in methanol and in TFE, Figure 3).
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Figure 3. CD spectra of (+)-39 and (+)-43 (left) and (-)-39 and (-)-43 (right) in various solvents.
Finally, by means of high resolution NMR spectroscopy the conformation of the
pentapeptides 39 and 43 in methanol-d3 could be more precisely depicted. The temperature
coefficients were indicative for hydrogen-bonding only in the case of (-)-43. Successively,
ROESY spectra provided distance restraints for molecular dynamics calculations. The number
of interproton distances obtained for each oligomer by ROESY spectra, resulted to be high for
so small peptides, suggesting that their structure should be well defined. The molecular
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dynamics calculation did not converge for (+)-43, probably due to the presence of at least two
different conformations differing for the cis/trans configuration at the peptide bond between
the 4th and 5th residue. In contrast, (+)-39, (-)-39 and (-)-43 calculations converged to turn like
structures (Figure 4): (+)-39 turn is the sharpest, having an Ω like N- and C-terminus
divergence; (-)-39 and (-)-43 turns are both helix-like structured but in (-)-43 it seems to be
sharper.
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Figure 4. Structures calculated for (+)-39, (-)-39 and (-)-43.
A further aim of this work was the design of a synthetic procedure for the incorporation of the
β-ACC unit in peptides making use of the solid phase technique. Compatibility with the
common Fmoc-coupling strategy could be achieved by protection of the β-ACC N-terminus
with the allyloxycarbonyl (Alloc) group, which can be removed by treatment with
palladium (0) as the catalyst in the presence of an allyl scavenger. To avoid ring opening
under deprotection conditions, an in situ deprotection/coupling protocol was developed.
DABCO was found to be an especially suitable allyl scavenger for the coupling of  β-ACC
derivatives (Scheme 2), affording high yields, short reaction times and preventing ring
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opening and epimerisation, in solution as well as on the solid phase as depicted with the
synthesis of 77.
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Scheme 2. Two examples of the application of the Alloc/DABCO protocol to the synthesis of
77 and 80 on the solid phase.
The Alloc/DABCO protocol was also successfully applied to the chain-elongation of the
Pro-Pro dimer (in solution and on the solid phase), being a sequence particularly prone to
intramolecular aminolysis with consequent interruption of the chain elongation. For instance
78 could be coupled with Fmoc-Ala giving rise to the tripeptide 80 in almost quantitative
yield.
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Experimental part
1. Instruments and general techniques
1H NMR Bruker ARX 400 (400 MHz), Bruker AC 250 (250 MHz). The chemical shifts are
reported in δ (ppm) relative to chloroform (CDCl3, 7.26 ppm), dymethylsulfoxide (DMSO-d6,
2.49 ppm), methanol (CD3OD, 3.34 ppm) and tetramethylsilane (TMS, 0 ppm). The spectra
were analysed by first order, the coupling constants are reported in Hertz (Hz).
Characterisation of signals: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, s br
= broad singlet, dd = double douplet, dt = double triplet, dq = double quartet, ddd = double
double doublet. Integration is determined as the relative number of atoms. Diastereomeric
ratios were determined by comparing the integrals of corresponding protons in the 1H NMR
spectra.
13C NMR Bruker ARX 400 (100.6 MHz), Bruker AC 250 (62.9 MHz). The chemical shifts
are reported in δ (ppm) relative to chloroform (CDCl3, 77.0 ppm), dymethylsulfoxide
(DMSO-d6, 36.9 ppm), methanol (CD3OD, 49.0 ppm) and tetramethylsilane (TMS, 0 ppm).
13C NMR resonance assignment were aided by the use of the DEPT 135 (DEPT =
distortionless enhancement by polarisation transfer) technique to determine the number of
hydrogens attached to each carbon atom and is declared as: + = primary or tertiary (positive
DEPT signal intensity), - = secondary (negative DEPT signal) and quat = quaternary (no
DEPT signal intensity) carbon atoms. In some cases DEPT 90 spectra were recorded to
distinguish between primary and tertiary carbon atoms. This is marked with the CH or CH3
notation at the corresponding signal.
2D-NMR Bruker DRX-500 spectrometer operating at a basic 1H frequency of 500 MHz at
298 K. The spectra were recorded at 280 K, using the solvent line (CD3OH, 1H δ 3.31) for
referencing. DQF-COSY, 80 ms-TOCSY and 500 ms-ROESY standard experiments were
performed with suppression of the methanol OH line by low-power presaturation.
IR-spectra were recorded with an ATI Mattson Genesis Series FT-IR or a Bio-Rad Excalibur
series FT-IR.
MS-spectra: masspectroscopy department of the University of Regensburg, Varian Mat 311 A.
Elemental analysis: microanalytical department of the University of Regensburg.
Melting points (m p) were determined with a Buchi SMP 20 and are uncorrected.
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Thin layer chromatography (TLC) was performed on alumina plates coated with silica gel
(Merck silica gel 60 F 254, layer thickness 0.2 mm). Visualisation was accomplished by UV-
light (wavelenght λ = 254 nm) and a vanillin/sulphuric acid solution.
Optical rotations were measured on a Perkin-Elmer-Polarimeter 241 with sodium lamp at
589 nm in the specified solvent. The optical rotation was calculated with the following
formula:
[ ]ϑα D  = ([α]exp x 100)/ (c x d)
CD spectra were measured on a JASCO model J-710/720 at the Institut für Bioanalytic und
Sensorik of the University of Regensburg (research group of Prof. Dr. O. Wolfbeis) at 21° C
between 300 and 180 nm in the specified solvent, the number of scans ranging between 10
and 50. The length of the cylindrical cuvettes was 1 or 0.1 mm, the resolution was 0.2 nm, the
band width 1.0 nm, the sensitivity 100 mdeg, the response 0.25 s, the speed 50 nm/min. The
background was subtracted to each spectrum. The absorption value is measured as Molar
Ellipticity per Residue (deg cm2 dmol-1). The spectra were smoothed by the adjacent
averaging algorithm with the Origin 6.0 program.
Column chromatography was performed on silica gel Geduran SI 60 (70-230 mesh)
purchased from Merck and flash chromatography on flash-silica gel 60 (230-400 mesh
ASTM) purchased from Merck.
Solvents were purified according to standard laboratory methods. THF, diethyl ether and
toluene were distilled over sodium/benzophenone before use. Dichlormethane, DMSO and
DMF were distilled over calcium hydride and acetonitrile over P2O5. Methanol was refluxed
2 h over magnesia, distilled and stored under nitrogen over 4 Å molecular sieves. The hexanes
used had a boiling point of 40-60 °C. All solvents were distilled before use. Other chemicals
were purchased from commercial suppliers and used as received.
All reactions with oxygen or moisture sensitive reactants were performed under nitrogen
atmosphere.
For some peptide coupling the peptide synthesiser ACT90 of Advanced ChemTech was used.
θ = temperature (°C)
[α]exp = measured value
c = concentration (g/100 ml)
d = length of the cuvette
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2 Synthesis of compounds
2.1 General procedures
General procedure for solid phase loading. GP1
The resin (Wang resin) was swelled in CH2Cl2 for 20 min.. The mixture was drained and N-
Fmoc amino acid (3 eq.), DIC (3 eq.); HOBt (3 eq.) and DMAP (0.1 eq.) in DMF (12 ml/g of
resin) were added. The resin was agitated at room temperature overnight. The mixture was
drained and the resin washed with DMF (5 x 15 ml/g of resin), CH2Cl2 (5 x 15 ml/g of resin),
methanol (5 x 15 ml/g of resin) and diethyl ether (5 x 15 ml/g of resin). The resin was dried
under vacuum at room temperature overnight. The loading of the resin was estimated from the
weight gain of the resin; spectrophotometrically from the amount of Fmoc released from a
weighed sample of resin; by elemental analysis and by estimation of the amount of amino acid
released by cleavage from the resin (about 200 mg).
General procedure for solid phase coupling of Fmoc/Alloc-protected amino
acids on Fmoc-protected amino acids loaded on a resin. GP2
The resin was swelled in CH2Cl2 (15 ml/g of resin) for 20 min.. The mixture was drained and
piperidine 20 % in DMF (15 ml/g of resin) was added. The resin was agitated for 20-40 min..
The mixture was drained, the resin was washed 10 x with DMF and a solution of N-
Fmoc/Alloc amino acid (3 eq.), DIC (3 eq.) and HOBt (3eq.) in DMF (12 ml/g of resin) was
added. The resin was agitated 2 h at room temperature. The solution was filtrated and the
resin was washed with DMF (5 x 15 ml/g of resin), CH2Cl2 (5 x 15 ml/g of resin), methanol
(5 x 15 ml/g of resin) and diethyl ether (5 x 15 ml/g of resin). The coupling yield was verified
by cleavage of the dipeptide from the resin (about 200 mg), or by the Kaiser test.
The number of equivalents of amino acid, DIC and HOBt used when the reactions were
performed on the synthesiser ACT90 of Advanced ChemTech was increased three times.
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2.2 Preparation of compounds
2.2.1 Coupling at the N-terminus
HN
MeO2C CO2Bn
O
O
(±)-16b
(1R*, 2R*, 3R*) 3-Allyloxycarbonylamino-cyclopropane-1,2-dicarboxylic acid 1-bezyl
ester 2-methyl ester ((±)-16b): A solution of (±)-11 (209 mg, 0.60 mmol) in HCl 3 M in
ethyl acetate (4 ml) was stirred at 0 °C for 3 h. The solution was concentrated in vacuum and
the salt resuspended in CH2Cl2 (20 ml). Allyloxycarbonyl chloride (64 µl, 0.6 mmol, 1 eq.)
was added, then the mixture was cooled down at 0 °C and pyridine (97 µl, 1.2 mmol, 2 eq.)
was added dropwise. The mixture was stirred overnight at room temperature. The solvent was
evaporated and the product purified by chromatography (ethyl acetate/hexanes 1:2) to afford a
yellow oil (188 mg, 95 %). - Rf ((±)-16b): 0.21. - 1H NMR (CDCl3, 250 MHz) δ 2.33 (dd, J =
4.9, 4.9 Hz, 1H, cyclopropyl-CH), 2.50 (dd, J = 3.1, 8.3 Hz, 1H, cyclopropyl-CH), 3.74 (s,
3H, CH3O), 3.86-4.03 (m, 1H, cyclopropyl-CHN), 4.57-4.59 (m, 2H, =CH2), 5.08-5.16 (m,
2H, PhCH2O), 5.15-5.34 (m, 2H, OCH2CH), 5.76 (s br, 1H, NHAlloc), 5.78-5.97 (m, 1H,
CH=CH2), 7.30-7.38 (m, 5H, Ph-CH). - 13C NMR (CDCl3, 62.9 MHz) δ 26.1 (+, cyclopropyl-
CH), 28.8 (+, cyclopropyl-CH), 37.6 (+, cyclopropyl-CHN), 52.6 (+, CH3O), 66.1 (-, CH2O),
67.3 (-, CH2O), 118.0 (-, =CH2), 128.4 (+, Ph-CH, 2C), 128.5 (+, Ph-CH), 128.7 (+, Ph-CH,
2C), 132.5 (+, =CH), 135.2 (Cquat, Ph-C), 155.9 (Cquat, N(CO)O), 169.5 (Cquat, C=O), 170.3
(Cquat, CO). - MS  CI (NH3) m/z (%) 351 (MNH4+, 100), 334 (MH+, 7). - IR (film) 3360, 3067,
3033, 2954, 1727, 1522, 1428, 1356 cm-1. - Anal. Calcd for C17H19NO6 (333.34): C, 61.25; H,
5.74; N, 4.20. Found: C, 61.36; H, 5.96; N, 4.10.
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NH
BnO2C CO2Me
O
(±)-24
(1R*, 2R*, 3S*) 3-Acetylamino-cyclopropane-1,2-dicarboxylic acid 1-bezyl ester 2-
methyl ester ((±)-24): A solution of (±)-11 (470 mg, 1.35 mmol) in HCl 3 M in ethyl acetate
(4 ml) was stirred at 0 °C for 3 h. The solution was concentrated in vacuum and the salt
resuspended in CH2Cl2 (20 ml). Acetyl chloride (173 µl, 2.4 mmol, 1.8 eq.) was added, then
the solution was cooled down at 0 °C and triethylamine (598 µl, 4.3 mmol, 3.2 eq.) was added
dropwise. The mixture was stirred overnight at room temperature. The solvent was evaporated
and the product purified by chromatography (CHCl3/MeOH 60:1) to afford a white solid
(380 mg, 97 %). - Rf ((±)-24): 0.21. - mp 68-70 °C. - 1H NMR (CDCl3, 250 MHz) δ 1.92 (s,
3H, CH3C=O), 2.28 (dd, J = 5.0, 5.0 Hz, 1H, cyclopropyl-CH), 2.54 (dd, J = 5.2, 8.3 Hz, 1H,
cyclopropyl-CH), 3.66 (s, 3H, CH3O), 4.07 (ddd, J = 4.8, 8.1, 8.1 Hz, 1H, cyclopropyl-CHN),
5.09 (d, J = 12.2 Hz, 1H, CH2O), 5.19 (d, J = 12.2 Hz, 1H, CH2O), 6.64 (d, J = 7.6 Hz, 1H,
NH), 7.31-7.39 (m, 5H, Ph-CH). - 13C NMR (CDCl3, 62.9 MHz) δ 23.0 (+, CH3C=O), 26.2
(+, cyclopropyl-CH), 28.6 (+, cyclopropyl-CH), 36.2 (+, cyclopropyl-CHN), 52.3 (+, CH3O),
67.4 (-, CH2O), 128.3 (+, Ph-CH, 2C), 128.5 (+, Ph-CH, 2C), 128.7 (+, Ph-CH), 135.1 (Cquat,
Ph-C), 169.8 (Cquat, C=O), 170.0 (Cquat, C=O), 170.6 (Cquat, C=O). - MS  CI (NH3) m/z (%)
309 (MNH4+, 100), 292 (MH+, 18), 274 (20), 257 (17), 201 (21). - IR (KBr) 3332, 3063,
2959, 1728, 1654, 1525, 1453, 1385, 1317 cm-1. - Anal. Calcd for C15H17NO5 (292.30): C,
61.85; H, 5.88; N, 4.81. Found: C, 61.47; H, 5.88; N, 4.71.
HN
BnO2C CO2Me
O
NHBoc
HN
BnO2C CO2Me
O
NHBoc
(1R, 2R, 3S) and (1S, 2S, 3R) 3-(2S-tert-Butoxycarbonylamino-propionylamino)-
cyclopropane-1,2-dicarboxylic acid 1-bezyl ester 2-methyl ester ((+)-25a and (-)-25a): A
solution of (±)−11 (1.170 g, 3.35 mmol) in HCl 3 M in ethyl acetate (11 ml) was stirred at
0 °C for 3 h. The solvent was evaporated and a solution of Boc-alanine (950 mg, 5.02 mmol,
(+)-25a (-)-25a
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1.5 eq.), EDC (964 mg, 5.02 mmol, 1.5 eq) and HOBt (677 mg, 5.02 mmol, 1.5 eq.) in
CH2Cl2 (250 ml) (previously stirred 1 h at 0 °C and 1 h at room temperature) was added.
Triethylamine (510 µl, 3.64 mmol, 1.1 eq.) was then added dropwise at 0 °C. The mixture
was stirred overnight at room temperature. The solution was washed with saturated NaHCO3
(200 ml), 1 M KHSO4 (200 ml) and saturated NaHCO3 (200 ml). The organic phase was dried
over MgSO4 and concentrated. The mixture of the two diastereomers was purified by
chromatography (CH2Cl2/MeOH 40:1).Yield: 1.34 g (95 %). 5-12 % epimerisation was
observed. (+)-25a was isolated as a white solid by recrystallization from ethyl
acetate/hexanes. (-)-25a was obtained pure as a white solid by recrystallization of the mother
liquor. (+)-25a - Rf ((+)-25a): 0.17. - mp 148-150 °C. - [ ]21Dα  -33.8 (c 1, CHCl3). - 1H NMR
(CDCl3, 250 MHz) δ 1.31 (d, J= 7.1 Hz, 3H, CH3CH), 1.46 (s, 9H, (CH3)3C), 2.29 (dd, J =
5.0, 4.9 Hz, 1H, cyclopropyl-CH), 2.56 (dd, J = 5.2, 8.3 Hz, 1H, cyclopropyl-CH), 3.70 (s,
3H, CH3O), 4.01-4.18 (m, 2H, cyclopropyl-CHN + Ala-CHN), 4.88 (s br, 1H, NHBoc), 5.11
(d, J = 12.1 Hz, 1H, CH2O), 5.20 (d, J = 12.1 Hz, 1H, CH2O), 7.16 (d, J = 8.1 Hz, 1H, NH),
7.31-7.39 (m, 5H. Ph-CH). - 13C NMR (CDCl3, 62.9 MHz) δ 18.4 (+, CH3CH), 26.1 (+,
cyclopropyl-CH), 28.3 (+, (CH3)3C, 3C), 28.7 (+, cyclopropyl-CH)), 36.0 (+, cyclopropyl-
CHN), 50.4 (+, CHN), 52.3 (+, CH3O), 67.4 (-, CH2O), 80.2 (Cquat, (CH3)3C), 128.4 (+, Ph-
CH, 2C), 128.6 (+, Ph-CH, 2C), 128.7 (+, Ph-CH), 135.1 (Cquat, Ph-C), 155.2 (Cquat,
N(CO)O), 167.8 (Cquat, C=O), 169.9 (Cquat, C=O), 173.2 (Cquat, C=O). - MS  CI (NH3) m/z (%)
858 (2MNH4+, <1), 841 (2MH+, <1), 741 (2MH+-Boc, 7), 438 (MNH4+, 100), 421 (MH+, 82),
382 (MNH4+-tBu, 44), 365 (MH+-tBu, 9), 338 (MNH4+-Boc, 2), 321 (MH+-Boc, 54). - IR
(KBr) 3348, 3316, 2987, 1739, 1687, 1495 cm-1. - Anal. Calcd for C21H28N2O7 (420.46): C,
59.99; H, 6.71; N, 6.66. Found: C, 60.06; H, 6.73; N, 6.56. (-)-25a - Rf ((-)-25a): 0.17. - mp
93-95 °C. - [ ]21Dα  -12.0 (c 1, CHCl3). - 1H NMR (CDCl3, 250 MHz) δ 1.30 (d, J = 7.2 Hz, 3H,
CH3CH), 1.46 (s, 9H, (CH3)3C), 1.29 (dd, J = 5.0, 4.9 Hz, 1H, cyclopropyl-CH), 2.57 (dd, J =
5.2, 8.3 Hz, 1H, cyclopropyl-CH), 3.71 (s, 3H, CH3O), 4.02-4.18 (m, 2H, cyclopropyl-CHN +
Ala-CHN), 4.78 (s br, 1H, NHBoc), 5.13 (d, J = 12.2 Hz, 1H, CH2O), 5.20 (d, J = 12.2 Hz,
1H, CH2O), 7.08 (d, J = 7.7 Hz, 1H, NH), 7.36-7.40 (m, 5H, Ph-CH). - 13C NMR (CDCl3,
62.9 MHz) δ 18.1 (+, CH3CH), 26.3 (+, cyclopropyl-CH), 28.3 (+, (CH3)3C, 3C), 28.6 (+,
cyclopropyl-CH), 36.0 (+, cyclopropyl-CHN), 50.3 (+, Ala-CHN), 52.3 (+, CH3O), 67.4 (-,
CH2O), 80.23 (Cquat, C(CH3)3), 128.4 (+, Ph-CH, 2C), 128.5 (+, Ph-CH, 2C), 128.6 (+, Ph-
CH), 135.2 (Cquat, Ph-C), 155.3 (Cquat, C=O Boc), 169.7 (Cquat, C=O), 169.8 (Cquat, C=O),
173.4 (Cquat, C=O). - MS  CI (NH3) m/z (%) 859 (2MNH4+, <1), 841 (2MH+, <1), 741 (3), 438
(MNH4+, 100), 421(30), 382 (25), 321 (20). - IR (KBr) 3359, 3058, 2982, 1727, 1690, 1667,
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1519, 1435, 1311 cm-1. - Anal. Calcd for C21H28N2O7 (420.46): C, 59.99; H, 6.71; N, 6.66.
Found: C, 59.89; H, 6.72; N, 6.53.
HN
BnO2C CO2Me
O
NHBoc
(±)-25a
(1R*, 2R*, 3S*) 3-(2S-tert-Butoxycarbonylamino-propionylamino)-cyclopropane-1,2-
dicarboxylic acid 1-bezyl ester 2-methyl ester ((±)-25a): Boc-alanine (170 mg, 0.9 mmol,
3 eq.) was preactivated with EDC (174 mg, 0.9 mmol, 3 eq.) and HOBt (121 mg, 0.9 mmol,
3 eq.) in dry CH2Cl2 (5 ml) and under nitrogen atmosphere 1 h at 0 °C and 1 h at room
temperature. This solution was added under nitrogen atmosphere to Pd[PPh3]4 (35 mg,
0.03 mmol, 0.1 eq.), then (±)-16a (100 mg, 0.3 mmol) and finally DABCO (168 mg,
1.5 mmol, 5 eq.) or pyridine (242 µl, 3  mmol, 10 eq.) were added. The solution was stirred 10
min. (DABCO) or 15 h (pyridine) at room temperature, then CH2Cl2 (10 ml) was added and
the organic phase was washed with saturated NaHCO3 (10 ml), 1 M KHSO4 (10 ml) and
saturated NaHCO3 (10 ml) . The organic phase was dried over MgSO4 and concentrated. The
mixture of the two diastereomers was purified by chromatography (ethyl acetate/hexanes 1:1)
to yield the product as a white solid (DABCO: 122 mg, 97 %, pyridine: 120 mg, 95 %) with
4 % (DABCO) or 20 % (pyridine) epimerization.
HN
BnO2C CO2Me
O
NHFmoc
(±)-25b
(1R*, 2R*, 3S*) 3-[2S-(9H-fluoren-9-ylmethoxycarbonylamino)-propionylamino]-
cyclopropane-1,2-dicarboxylic acid 1-bezyl ester 2-methyl ester ((±)-25b): Fmoc-alanine
(168 mg, 0.54 mmol, 1.5 eq.) was preactivated with EDC (104 mg, 0.54 mmol, 1.5 eq.) and
HOBt (73 mg, 0.54 mmol, 1.5 eq.) in dry CH2Cl2 (5 ml) and under nitrogen atmosphere 1 h at
0 °C and 1 h at room temperature. This solution was added under nitrogen atmosphere to
Pd[PPh3]4 (41 mg, 0.036 mmol, 0.1 eq.), then (±)-16a was added (120 mg, 0.36 mmol) and
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finally DABCO (201 mg, 1.8 mmol, 5 eq.) or, in a parallel experiment, phenylsilane (221 µl,
1.8 mmol, 5 eq.). The solution was stirred for 20 min. at room temperature, then CH2Cl2
(10 ml) was added and the organic phase was washed with saturated NaHCO3 (10 ml), 1 M
KHSO4 (10 ml) and saturated NaHCO3 (10 ml). The organic phase was dried over MgSO4 and
concentrated. The product (mixture of two diastereomers) was purified by chromatography
(ethyl acetate/hexanes 1:1) to afford a white solid (181 mg, 93 % with DABCO-protocol;
175 mg, 90 % contaminated with 5 % of ring opening product with the phenylsilane-
protocol). - Rf ((±)-25b): 0.37. - mp 65-67 °C. - 1H NMR (CDCl3, 400 MHz) δ 1.32 (d, J =
6.8 Hz, 3H, CH3CH, 1 diast.), 1.34 (d, J = 6.2 Hz, 3H, CH3CH, 1 diast.), 2.31 (dd, J = 4.7,
4.7 Hz, 1H, cyclopropyl-CH), 2.56 (dd, J = 5.2, 8.2 Hz, 1H, cyclopropyl-CH), 3.69 (s, 3H,
CH3O, 1 diast.), 3.70 (s, 3H, CH3O, 1 diast.), 4.03-4.07 (m, 1H, cyclopropyl-CHN, 1 diast.),
4.10 (ddd, J = 4.7, 8.1, 8.1 Hz, 1H, cyclopropyl-CHN, 1 diast.), 4.18-4.25 (m, 2H, Fmoc-CH
+ CHN), 4.33-4.48 (m, 2H, Fmoc-CH2), 5.04 (d, J = 12.2 Hz, 1H, CH2O, 1 diast.), 5.08-5.12
(m, 2H, CH2O, 1 diast.), 5.13 (d, J = 12.2 Hz, 1H, CH2O, 1 diast.), 5.18 (d, J = 6.6 Hz, 1H,
NH, 1 diast.), 5.35 (d, J = 7.0 Hz, 1H, NH, 1 diast.), 7.06 (d, J = 7.9 Hz, 1H, NH, 1 diast.),
7.12 (d, J = 7.9 Hz, 1H, NH, 1 diast.), 7.28-7.41 (m, 9H, Ar-CH), 7.51-7.59 (m, 2H, Fmoc-
Ar-CH), 7.75-7.77 (m, 2H, Fmoc-Ar-CH).  − 13C NMR (CDCl3, 100.6 MHz) δ 18.3 (+,
CH3CH, 1 diast.), 18.5 (+, CH3CH, 1diast.), 26.0 (+, cyclopropyl-CH, 1 diast.), 26.2 (+,
cyclopropyl-CH, 1 diast.), 28.6 (+, cyclopropyl-CH, 1 diast.), 28.7 (+, cyclopropyl-CH, 1
diast.), 35.9 (+, cyclopropyl-CHN), 47.1 (+, Fmoc-CH), 50.5 (+, Ala-CHN, 1 diast.), 50.6 (+,
Ala-CHN, 1 diast.), 52.4 (+, CH3O), 67.06 (-, CH2O, 1 diast.), 67.13 (-, CH2O, 1 diast.), 67.4
(-, Fmoc-CH2), 119.9-128.6 (+, Ar-CH, 13C), 134.9 (Cquat, Ph-C, 1 diast.), 135.0 (Cquat, Ph-C,
1 diast.), 141.22 (Cquat, Fmoc-Ar-C, 1 diast.), 141.25 (Cquat, Fmoc-Ar-C, 1 diast.), 141.27
(Cquat, Fmoc-Ar-C, 1 diast., 2C), 143.64 (Cquat, Fmoc-Ar-C, 1 diast.), 143.68 (Cquat, Fmoc-Ar-
C, 1 diast.), 143.8 (Cquat, Fmoc-Ar-C, 1 diast., 2C), 155.8 (Cquat, N(CO)O, 1 diast.), 155.9
(Cquat, N(CO)O, 1 diast.), 169.73 (Cquat, C=O, 1 diast.), 169.75 (Cquat, C=O, 1 diast.), 169.8
(Cquat, C=O, 1 diast.), 169.9 (Cquat, C=O, 1 diast.), 172.7 (Cquat, C=O, 1 diast.), 172.8 (Cquat,
C=O, 1 diast.). - MS  FAB (NH3) m/z (%) 543 (MH+, 9), 307 (100). - IR (KBr) 3322, 3064,
2953, 1724, 1678, 1524, 1450, 1311 cm-1. - Anal. Calcd for C31H30N2O7 (542.59): C, 68.62;
H, 5.57; N, 5.16. Found: C, 68.31; H, 5.61; N, 5.08.
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HN
BnO2C CO2Me
O Me
N
Boc
(±)-25c
(1R*, 2R*, 3S*) 3-(2S-tert-Butoxycarbonyl-methyl-amino-propionylamino)-
cyclopropane-1,2-dicarboxylic acid 1-bezyl ester 2-methyl ester ((±)-25c): A solution of
 (±)−11 (500 mg, 1.43 mmol) in HCl 3 M in ethyl acetate (5 ml) was stirred at 0 °C for 3 h.
The solvent was then evaporated and a solution of N-methyl-Boc-alanine (500 mg,
2.46 mmol, 1.7 eq.), EDC (411 mg, 2.04 mmol, 1.5 eq), HOBt (289 mg, 2.04 mmol, 1.5 eq.)
in CH2Cl2 (100 ml) (previously stirred 1 h at 0 °C and 1 h at room temperature) was added.
Triethylamine (200 µl, 1.43 mmol, 1 eq.) was then added dropwise at 0 °C. The mixture was
stirred at room temperature overnight. The solution was washed with saturated NaHCO3
(100 ml), 1 M KHSO4 (100ml) and then saturated NaHCO3 (100 ml). The organic phase was
dried over MgSO4 and concentrated. The mixture of the two diastereomers (at least one of
them exists as a mixture of two rotamers) was obtained as a colourless oil (546 mg, 88 %) by
chromatography (ethyl acetate/hexanes 1:2). 10 % epimerization was observed. - Rf
((±)-25c): 0.24. - 1H NMR (measured on a mixture of diastereomers enriched in one of them):
(CDCl3, 250 MHz) δ 1.31 (d, J = 6.7 Hz, 3H, CH3CH, major diast.), 1.34 (d, J = 6.9 Hz, 3H,
CH3CH, minor diast.), 1.47 (s, 9H, (CH3)3C, minor diast.), 1.49 ( s, 9H, (CH3)3C, major
diast.), 2.22 (dd, J = 5.0, 5.0 Hz, 1H, cyclopropyl-CH, major diast.), 2.28 (dd, J = 4.7, 4.7 Hz,
1H, cyclopropyl-CH, 1 minor diast.), 2.31 (dd, J = 5.0, 5.0 Hz, 1H, cyclopropyl-CH, 1 diast.),
2.29-2.32 (m, 1H, cyclopropyl-CH, minor diast.), 2.63 (s br, 3H, CH3N, major diast. 1
epimer), 2.71 (s br, 3H, CH3N, major diast., 1 epimer), 2.78 (s, CH3N, minor diast.), 3.70 (s,
3H, CH3O, major diast.), 3.71 (s, 3H, CH3O, minor diast.), 4.05-4.17 (m, 1H, cyclopropyl-
CHN), 4.62-4.83 (m, 1H, CHN), 5.13-5.20 (m, 2H, CH2O), 7.10 (d, J = 7.1 Hz, 1H, NH,
major diast.), 7.19 (s br, 1H, NH, minor diast.), 7.32-7.41 (m, 5H, Ph-CH). - 13C NMR
(CDCl3, 62.9 MHz) δ 13.6 (+, CH3CH, 1 diast.), 14.2 (CH3CH, 1 diast.), 25.9 (+, cyclopropyl-
CH, 1 diast.), 26.2 (+, cyclopropyl-CH, 1 diast.), 28.4 (+, (CH3)3C + cyclopropyl-CH, 4C, 1
diast.), 28.7(+, cyclopropyl-CH, 1 diast.), 29.1 (+, cyclopropyl-CH, 1 diast. 1 epimer), 29.9
(+, CH3N, 1 diast.), 36.09 (+, CH3N, 1 diast.), 36.13 (+, cyclopropyl-CHN), 52.4 (+, CH3O),
53.9 (+, CHN), 67.3 (-, CH2O, 1 diast.), 67.4 (-, CH2O, 1 diast.), 80.7 (Cquat, C(CH3)3), 128.4
(+, Ph-CH), 128. 5 (+, PH-CH), 128.57 (+, Ph-CH), 128.62 (+, Ph-CH), 128.68 (+, Ph-CH),
135.0 (Cquat, Ph-CH, 1 diast.), 135.2 (Cquat, Ph-C, 1 diast.), 155.9 (Cquat, N(C=O)O), 169.4
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(Cquat, C=O, 1 diast.), 169.9 (Cquat, C=O, 1 diast.), 169.91 (Cquat , C=O), 1 diast.), 170.1 (Cquat,
C=O, 1 diast.), 172.3 (Cquat, C=O). - MS CI (NH3)  m/z (%) 886 (2MNH4+, <1), 769 (2MH+-
Boc, 16), 452 (MNH4+, 78), 435 (MH+, 100), 396 (2MH+-tBu, 13), 335 (MH+-Boc, 40), 267
(12). - IR (CH2Cl2) 3394, 1722, 1687, 1606, 1515 cm-1. - Anal. Calcd for C22H30N2O7
(434.488): C, 60.82; H, 6.96; N, 6.45. Found: C, 60.36; H, 6.91; N, 6.41.
HN
BnO2C CO2Me
O
NHFmoc
CH2Ph
(±)-25d
(1R*, 2R*, 3S*) 3-[2S-(9H-fluoren-9-ylmethoxycarbonylamino)-phenyl-
propionylamino]-cyclopropane-1,2-dicarboxylic acid 1-bezyl ester 2-methyl ester
((±)-25d): A solution of (±)-11 (300 mg, 0.86 mmol) in HCl 3 M in ethyl acetate (4 ml) was
stirred at 0 °C for 3 h. The solution was then evaporated, the salt was resuspended in CH2Cl2
(10 ml) and Fmoc-phenylalanine (399 mg, 1.03 mmol, 1.2 eq.), EDC (330 mg, 1.72 mmol,
2 eq), and pyridine (83 µl, 1.03 mmol, 1.2 eq.) were added. The mixture was stirred overnight
at room temperature. The solution was washed with saturated NaHCO3 (50 ml), 1 M KHSO4
(50 ml) and then saturated NaHCO3 (50 ml). The organic phase was dried over MgSO4 and
concentrated. The mixture of the two diastereomers was purified by chromatography
(CH2Cl2/MeOH 50:1) to give a white solid (477 g, 88 %). No epimerization was observed. -
Rf ((±)-25d): 0.30. - mp 164-166 °C. - 1H NMR (CDCl3, 250 MHz): δ 1.97 (dd, J = 5.0,
5.8 Hz, 1H, cyclopropyl-CH, 1 diast.), 2.20 (dd, J = 4.6, 4.6 Hz, 1H, cyclopropyl-CH, 1
diast.), 2.49 (dd, J = 5.2, 8.3 Hz, 1H, cyclopropyl-CH), 3.00-3.09 (m, 2H, CH2Ph), 3.68 (s,
3H, CH3O, 1 diast.), 3.70 (s, 3H, CH3O, 1 diast.), 4.02-4.10 (m, 1H, cyclopropyl-CHN), 4.17-
4.22 (m, 1H, Fmoc-CH), 4.33-4.39 (m, 3H, Fmoc-CH2 + CHN), 4.97-5.12 (m, 2H, Ph-CH2O),
5.27 (s br, 1H, NHFmoc), 6.76 (d, J = 7.3 Hz, 1H, NH, 1 diast.), 7.00 (d, J = 8.3 Hz, NH, 1
diast.), 7.18-7.42 (m, 14H, Ar-CH), 7.50-7.56 (m, 2H, Fmoc-Ar-CH), 7.75 (pseudo d, J =
7.3 Hz, 2H, Fmoc -Ar-CH). - 13C NMR (CDCl3, 62.9 MHz): δ 25.7 (+, cyclopropyl-CH, 1
diast.), 25.8 (+, cyclopropyl-CH, 1 diast.), 28.6 (+, cyclopropyl-CH, 1 diast.), 28.8 (+,
cyclopropyl-CH, 1 diast.), 35.7 (+, cyclopropyl-CHN, 1 diast.), 35.9 (+, cyclopropyl-CHN, 1
diast.), 38.5 (-, CH2Ph, 1 diast.), 38.7 (-, CH2Ph, 1 diast.), 47.1 (+, Fmoc-CH), 52.5 (+,
CH3O), 56.3 (+, CHN), 67.2 (-, CH2O, 1 diast.), 67.3 (-, CH2O, 1 diast.), 67.5 (-, CH2O),
120.0 (+, Fmoc-Ar-CH, 2C), 125.1 (+, Fmoc-Ar-CH, 2C), 127.1 (+, Ar-CH, 3C), 127.8 (+,
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Ar-CH, 2C), 128.3 (+, Ar-CH), 128.4 (Ar-CH), 128.6 (+, Ar-CH), 129.3 (+, Ar-CH, 2C),
134.9 (Cquat, Ph-C, 1 diast.), 135.0 (Cquat, Ph-C, 1 diast.), 136.16 (Cquat, Ph-C, 1 diast.), 136.24
(Cquat, Ph-C, 1 diast.), 141.30 (Cquat, Fmoc-Ar-C, 1 diast.), 141.33 (Cquat, Fmoc-Ar-C, 1 diast.),
141.34 (Cquat, Fmoc-Ar-C), 143.68 (Cquat, Fmoc-Ar-C, 1 diast.), 143.74 (Cquat, Fmoc-Ar-C, 1
diast.), 143.8 (Cquat, Fmoc-Ar-C), 155.8 (Cquat, N(CO)O), 169.7 (Cquat, C=O, 1 diast.), 169.77
(Cquat, C=O, 1 diast.), 169.84 (Cquat, C=O, 1 diast.), 170.0 (Cquat, C=O, 1 diast.), 171.43 (Cquat,
C=O, 1 diast.), 171.45 (Cquat, C=O, 1 diast.). - MS  FAB (MeOH/Glycerine) m/z (%) 619
(MH+, 100), 482 (24), 397 (MH+-Fmoc, 40). - IR (KBr) 3212, 3062, 3033, 2953, 1727, 1692,
1662, 1532, 1449, 1309, 1259 cm-1. - Anal. Calcd for C37H34N2O7 · 0.7 H2O (631.30): C,
70.39; H, 5.65; N, 4.43. Found: C, 70.09; H, 5.38; N, 4.17.
HN
BnO2C CO2Me
O
NHFmoc
O OtBu
(±)-25e
(1R*, 2R*, 3S*) 3-[4-tert-Butoxycarbonyl-2S-(9H-fluoren-9-ylmethoxycarbonylamino)-
butyrylamino]-cyclopropane-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester
((±)-25e): A solution of (±)-11 (300 mg, 0.86 mmol) in HCl 3 M in ethyl acetate (4 ml) was
stirred at 0 °C for 3 h. The mixture was evaporated, the salt was resuspended in CH2Cl2
(10 ml) and Fmoc-Asp(OtBu) (534 mg, 1.3 mmol, 1.5 eq.), EDC (336 mg, 1.7 mmol, 2 eq),
and pyridine (83 µl, 1.03 mmol, 1.2 eq.) were added. The mixture was stirred overnight at
room temperature. The solution was washed with saturated NaHCO3 (50 ml), 1 M KHSO4
(50 ml) and saturated NaHCO3 (50 ml). The organic phase was dried over MgSO4 and
concentrated. The mixture of the two diastereomers was purified by chromatography (ethyl
acetate/hexanes 1:3) to afford the product as a white solid (400 g, 72 %). No epimerization
was observed. - Rf ((±)-25e): 0.23. - mp 55-57 °C. - 1H NMR (CDCl3, 250 MHz): δ 1.46 (s,
9H, (CH3)3C, 1 diast.), 1.47 (s, 9H, (CH3)3C, 1 diast.), 2.29-2.33 (m, 1H, cyclopropyl-CH),
2.55-2.65 (m, 2H, cyclopropyl-CH + CH2CO2tBu), 2.86-2.95 (m, 1H, CH2CO2tBu), 3.70 (s,
3H, CH3O), 3.98-4.10 (m, 1H, cyclopropyl-CHN), 4.16-4.40 8m, 2H, Fmoc-CH + CHN),
4.45-4.54 (m, 2H, CH2Fmoc), 5.00-5.16 (m, 2H, CH2O), 5.84 (d, J = 8.7 Hz, 1H, NH, 1
diast.), 5.92 (d, J = 7.0 Hz, 1H, NH, 1 diast.), 7.28-7.40 (m, 10H, Ar-CH + NH), 7.52-7.63
(m, 2H, Fmoc-Ar-CH), 7.75-7.77 (m, 2H, Fmoc-Ar-CH). - 13C NMR (CDCl3, 62.9 MHz): δ
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18.2 (+, (CH3)3C, 3C), 26.2 (+, cyclopropyl-CH), 28.6 (+, cyclopropyl-CH, 1 diast.), 28.7 (+,
cyclopropyl-CH, 1 diast.), 36.0 (+, cyclopropyl-CHN, 1 diast.), 36.1 (+, cyclopropyl-CHN, 1
diast.), 36.9 (-, CH2CO2tBu, 1 diast.), 37.2 (-,CH2CO2tBu, 1 diast.), 47.2 (+, Fmoc-CH), 51.4
(+, CHN), 52.5 (+, CH3O, 1 diast.), 52.6 (+, CH3O, 1 diast.), 67.4 (-, CH2O), 67.5 (-, CH2O),
81.9 (Cquat, C(CH3)3, 1 diast.), 82.0 (+, C(CH3)3, 1 diast.), 120.0 (+, Fmoc-Ar-CH, 2C), 125.2
(+, Fmoc-Ar-CH, 2C), 127.1 (+, Ar-CH, 2C), 127.8 (+, Ar-CH, 2C), 128.4 (+, Ar-CH),
128.46 (+, Ar-CH), 128.53 (+, Ar-CH), 128.6 (+, Ar-CH, 2C), 135.0 (Cquat, Ph-C, 1 diast.),
135.1 (Cquat, Ph-C, 1 diast.), 141.29 (Cquat, Fmoc-Ar-C, 1 diast.), 141.35 (Cquat, Fmoc-Ar-C,
3C, 1 diast.), 143.6 (Cquat, Fmoc-Ar-C, 1 diast.), 143.7 (Cquat, Fmoc-Ar-C, 1 diast.), 143.9
(Cquat, Fmoc-Ar-C), 156.2 (Cquat, N(CO)O), 160.7 (Cquat, C=O, 1 diast.), 169.8 (Cquat, C=O, 1
diast.), 169.9 (Cquat, C=O), 171.2 (Cquat, C=O, 2C). - MS  FAB (MeOH/Glycerine) m/z (%)
643 (MH+, 80), 587 (100). - IR (KBr) 3348, 3065, 2955, 1727, 1526 cm-1. - Anal. Calcd for
C36H38N2O9 (642.70): C, 67.28; H, 5.96; N, 4.36. Found: C, 67.06; H, 5.96; N, 3.92.
HN
BnO2C CO2Me
O
NHFmoc
(-)-25f
(1S, 2S, 3R) 3-[(9H-fluoren-9-ylmethoxycarbonylamino)-acetylamino]-cyclopropane-1,2-
dicarboxylic acid 1-bezyl ester 2-methyl ester ((-)-25f): A solution of (−)−11 (200 mg,
0.57 mmol) in HCl 3 M in ethyl acetate (4 ml) was stirred at 0 °C for 3 h. The solution was
then evaporated, the salt was resuspended in CH2Cl2 (10 ml) and Fmoc-glycine (252 mg,
0.85 mmol, 1.5 eq.), EDC (219 mg, 1.14 mmol, 2 eq), and pyridine (91 µl, 1.14 mmol, 2 eq.)
were added. The mixture was stirred overnight at room temperature. The solution was washed
with saturated NaHCO3 (50 ml), 1 M KHSO4 (50 ml) and saturated NaHCO3 (50 ml). The
organic phase was dried over MgSO4 and concentrated. The product was purified by
chromatography (CH2Cl2/MeOH 40:1). Yield: 284 g (95 %). No epimerization was observed.
- Rf ((-)-25f): 0.31. - mp 57-58 °C. - [ ]21Dα  +22.8 (c 0.5, MeOH). - 1H NMR (CDCl3,
250 MHz): δ 2.31 (dd, J = 4.9, 4.9 Hz, 1H, cyclopropyl-CH), 2.56 (dd, J = 5.2, 8.3 Hz, 1H,
cyclopropyl-CH), 3.69 (s, 3H, CH3O), 3.81-3.83 (m, 2H, CH2N), 4.10 (ddd, J = 4.7, 8.1,
8.1 Hz, 1H, cyclopropyl-CHN), 4.21-4.27 (m, 1H, Fmoc-CH), 4.41-4.43 (m, 2H, Fmoc-CH2),
5.06-5.15 (m, 2H, CH2O), 5.35 (s br, 1H, NHFmoc), 7.09 (d, J = 7.9 Hz, 1H, NH), 7.25-7.42
(m, 9H, Ar-CH), 7.58-7.61 (m, 2H, Fmoc-Ar-CH), 7.74-7.77 (m, 2H, Fmoc-Ar-CH). -
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13C NMR (CDCl3, 62.9 MHz): δ 26.0 (+, cyclopropyl-CH), 28.6 (+, cyclopropyl-CH), 35.8
(+, cyclopropyl-CHN), 44.6 (-, CH2N), 47.1 (+, Fmoc-CH), 52.5 (+, CH3O), 67.4 (-, CH2O),
67.5 (-, CH2O), 120.0 (+, Fmoc-Ar-CH, 2C), 125.1 (+, Fmoc-Ar-CH), 127.1 (+, Ar-CH, 2C),
127.8 (+, Ar-CH, 2C), 128.4 (+, Ar-CH, 2C), 128.6 (+, Ar-CH, 2C), 128.7 (+, Ar-CH, 2C),
135.0 (Cquat, Ph-C), 141.3 (Cquat, Fmoc-Ar-C, 2C), 143.75 (Cquat, Fmoc-Ar-C), 143.78 (Cquat,
Fmoc-Ar-C), 156.5 (Cquat, N(CO)O), 169.5 (Cquat, C=O), 169.7 (Cquat, C=O), 170.0 (Cquat,
CO). - MS  FAB (MeOH/Glycerine) m/z (%) 1057 (2MH+, 8), 529 (MH+, 100), 307 (MH+-
NHFmoc, 31). - IR (KBr) 3245, 3056, 2803, 1708, 1638, 1505, 1427, 1303 cm-1. - Anal.
Calcd for C30H28N2O7 ⋅ 0.3 H2O (533.965): C, 67.48; H, 5.39; N, 5.25. Found: C, 67.57; H,
5.49; N, 4.88.
HN
BnO2C CO2Me
O
NHFmoc
(+)-25f
(1R, 2R, 3S) 3-[(9H-Fluoren-9-ylmethoxycarbonylamino)-acetylamino]-cyclopropane-
1,2-dicarboxylic acid 1-bezyl ester 2-methyl ester ((+)-25f): A solution of (+)−11 (200 mg,
0.57 mmol) in HCl 3 M in ethyl acetate (4 ml) was stirred at 0 °C for 3 h. The solution was
then evaporated, the salt was resuspended in CH2Cl2 (10 ml) and Fmoc-glycine (252 mg,
0.85 mmol, 1.5 eq.), EDC (219 mg, 1.14 mmol, 2 eq), and pyridine (91 µl, 1.14 mmol, 2 eq.)
were added. The mixture was stirred overnight at room temperature. The solution was washed
with saturated NaHCO3 (50 ml), 1 M KHSO4 (50 ml) and saturated NaHCO3 (50 ml). The
organic phase was dried over MgSO4 and concentrated. The product was purified by
chromatography (CH2Cl2/MeOH 40:1). Yield: 231 g (77 %). No epimerization was observed.
- Rf ((+)-25f): 0.31. - mp 56-58 °C. - [ ]21Dα  -21.1 (c 0.5, MeOH). - 1H NMR (CDCl3,
250 MHz): δ 2.31 (dd, J = 4.8, 4.8 Hz, 1H, cyclopropyl-CH), 2.56 (dd, J = 5.3, 8.3 Hz, 1H,
cyclopropyl-CH), 3.70 (s, 3H, CH3O), 3.81-3.83 (m, 2H, CH2N), 4.10 (ddd, J = 4.7, 8.1,
8.1 Hz, 1H, cyclopropyl-CHN), 4.21-4.27 (m, 1H, Fmoc-CH), 4.41-4.44 (m, 2H, Fmoc-CH2),
5.06-5.14 (m, 2H, CH2O), 5.35 (s br, 1H, NHFmoc), 7.09 (d, J = 7.9 Hz, 1H, NH), 7.25-7.42
(m, 9H, Ar-CH), 7.58-7.63 (m, 2H, Ar-CH), 7.74-7.78 (m, 2H, Ar-CH). - 13C NMR (CDCl3,
62.9 MHz): δ 26.0 (+, cyclopropyl-CH), 28.6 (+, cyclopropyl-CH), 35.8 (+, cyclopropyl-
CHN), 44.5 (-, CH2N), 47.1 (+, Fmoc-CH), 52.5 (+, CH3O), 67.4 (-, CH2O), 67.5 (-, CH2O),
120.0 (+,Fmoc-Ar-CH, 2C), 125.1 (+, Fmoc-Ar-CH), 127.2 (+, Ar-CH, 2C), 127.8 (+, Ar-CH,
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2C), 128.4 (+, Ar-CH, 2C), 128.6 (+, Ar-CH, 2C), 128.7 (+, Ar-CH, 2C), 135.0 (Cquat, Ph-C),
141.3 (Cquat, Fmoc-Ar-C, 2C), 143.75 (Cquat, Fmoc-Ar-C), 143.78 (Cquat, Fmoc-Ar-C), 156.5
(Cquat, N(CO)O), 169.5 (Cquat, C=O), 169.7 (Cquat, C=O), 170.0 (Cquat, CO). - MS  FAB
(MeOH/Glycerine) m/z (%) 1057 (2MH+, 8), 529 (MH+, 100), 307 (MH+-NHFmoc, 30). - IR
(KBr) 3247, 3054, 2801, 1710, 1635, 1507, 1427, 1303 cm-1. - Anal. Calcd for C30H28N2O7 ⋅
0.6 H2O (539.369): C, 66.81; H, 5.46; N, 5.19. Found: C, 66.74; H, 5.17; N, 5.02.
HN
BnO2C CO2Me
O
NHBoc
(±)-25f
(1R*, 2R*, 3S*) 3-[(tert-Butoxycarbonylamino]-acetylamino)-cyclopropane-1,2-
dicarboxylic acid 1-bezyl ester 2-methyl ester ((±)-25f):68 Boc-glycine (87 mg, 0.5 mmol,
3 eq.) was preactivated with EDC (95 mg, 0.5 mmol, 3 eq.) and HOBt (67 mg, 0.5 mmol,
3 eq.) in dry CH2Cl2 (4 ml) and under nitrogen atmosphere 1 h at 0 °C and 1 h at room
temperature. This solution was added under nitrogen atmosphere to Pd[PPh3]4 (19 mg,
0.016 mmol, 0.1 eq. for DABCO protocol, 38 mg, 0.032 mmol, 0.2 eq. for pyridine protocol),
then (±)-16a (57 mg, 0.17 mmol) and finally DABCO (94 mg, 0.85 mmol, 5 eq.) or pyridine
(137 µl, 1.7 mmol, 10 eq.) were added. The solution was stirred 10 min. (DABCO) or 2 h
(pyridine) at room temperature, then CH2Cl2 (10 ml) was added and the organic phase was
washed with saturated NaHCO3 (10 ml), 1 M KHSO4 (10 ml) and of saturated NaHCO3
(10 ml) . The organic phase was dried over MgSO4 and concentrated. The mixture of the two
diastereomers was purified by chromatography (ethyl acetate/hexanes 1:1) to yield the
product as a white solid (DABCO: 63 mg, 92 %, 4 % epimerisation; pyridine: 64 mg, 93 %,
15 % epimerisation). Rf ((±)-25f): 0.36. - 1H NMR (CDCl3, 250 MHz) δ 1.44 (s, 9H,
(CH3)3C), 2.30 (dd, J = 5.2; 4.7 Hz, 1H, cyclopropyl-CH), 2.55 (dd, J = 8.3; 5.2 Hz, 1H,
cyclopropyl-CH), 3.67 (s, 3H, CH3O), 3.74 (m, 2H, CH2N), 4.08 (ddd, J = 8.1; 8.1; 4.7 Hz,
1H, cyclopropyl-CH), 5.08 (d, J = 12.1 Hz, 1H, CH2O), 5.17 (d, J = 12.1 Hz, CH2O), 5.20 (t,
J = 5.8 Hz, 1H, NHBoc), 7.24 (d, J = 8.0 Hz, 1H, NH), 7.33-7.35 (m, 5H, Ph-CH).
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HN
BnO2C CO2Me
O
NHBoc
CH2Ph
(±)-25h
(1R*, 2R*, 3S*) 3-(2S-tert-Butoxycarbonylamino-phenyl-propionylamino)-
cyclopropane-1,2-dicarboxylic acid 1-bezyl ester 2-methyl ester ((±)-25h): Boc-
phenylalanine (444 mg, 1.67 mmol, 3.1 eq.) was preactivated with EDC (305 mg, 1.59 mmol,
3 eq.) and HOBt (215 mg, 1.59 mmol, 3 eq.) in dry CH2Cl2 (5 ml) and under nitrogen
atmosphere 1 h at 0 °C and 1 h at room temperature. This solution was added under nitrogen
atmosphere to Pd[PPh3]4 (61 mg, 0.053 mmol, 0.1 eq.), then (±)-16a (177 mg, 0.53 mmol)
and finally DABCO (314 mg, 2.8 mmol, 5.3 eq.) were added. The solution was stirred 10
min. at room temperature, then CH2Cl2 (10 ml) was added and the organic phase was washed
with saturated NaHCO3 (10 ml), 1 M KHSO4 (10 ml) and of saturated NaHCO3 (10 ml). The
organic phase was dried over MgSO4 and concentrated. The mixture of the two diastereomers
was purified by chromatography (ethyl acetate/hexanes 1: 1) to yield the product as a white
solid (257 mg, 96 %) with 4-5 % epimerization. - Rf ((±)-25h): 0.33. - mp 138-140 °C. -
1H NMR (CDCl3, 250 MHz) δ 1.41 (s, 9H, (CH3)3C, 1 diast.), 1.42 (s, 9H, (CH3)3C, 1 diast.),
1.95-1.97 (m, 1H, cyclopropyl-CH, 1 diast.), 2.18 (dd, J = 5.0, 5.0 Hz, 1 H, cyclopropyl-CH,
1 diast.), 2.47-2.52 (m, 1H, cyclopropyl-CH), 2.99-3.05 (m, 2H, CH2Ph), 3.69 (s, 3H, CH3O,
1 diast.), 3.70 (s, 3H, CH3O, 1 diast.), 4.03 (ddd, J = 4.5, 8.1,8.1 Hz, 1H, cyclopropyl-CHN, 1
diast.), 4.11 (ddd, J = 4.7, 8.3, 8.3 Hz, 1H, cyclopropyl-CHN, 1 diast.), 4.28-4.39 (m, 1H,
CHN), 4.93 (s br, 1H, NH), 5.01-5.16 (m, 2H, CH2O), 6.74 (d, J = 7.6 Hz, 1H, NH, 1 diast.),
7.04 (d, J = 8.3 Hz, 1H, NH, 1 diast.), 7.16-7.37 (m, 10H, Ph-CH). - 13C NMR (CDCl3,
62.9 MHz) δ 25.66 (+, cyclopropyl-CH, 1 diast.), 25.74 (+, cyclopropyl-CH, 1 diast.), 28.3 (+,
(CH3)3C, 3C), 28.6 (+, cyclopropyl-CH, 1 diast.), 28.9 (+, cyclopropyl-CH, 1 diast.), 35.7 (+,
cyclopropyl-CHN, 1 diast.), 35.9 (+, cyclopropyl-CHN, 1 diast.), 38.4 (-, CH2Ph, 1 diast.),
38.7 (-, CH2Ph, 1 diast.), 52.5 (+, CH3O), 55.9 (+, CHN, 1 diast.), 56.1 (+, CHN, 1 diast.),
67.4 (-, CH2O, 1 diast.), 67.5 (-, CH2O, 1 diast.), 80.3 (Cquat, (CH3)3C), 126.98 (+, Ph-CH, 1
diast.), 127.03 (+, Ph-CH, 1 diast.), 128.4 (+, Ph-CH, 2C, 1 diast.), 128.5 (+, Ph-CH, 2C, 1
diast.), 128.64 (+, Ph-CH, 1 diast.), 128.67 (+, Ph-CH, 1 diast.), 128.69 (+, Ph-CH, 2C, 1
diast.), 128.71 (+, Ph-CH, 2C, 1 diast.), 128.78 (+, Ph-CH, 2C, 1 diast.), 128.8 (+, Ph-CH, 2C,
1 diast.), 129.2 (+, Ph-CH, 2C, 1 diast.), 129.3 (+, Ph-CH, 2C, 1 diast.), 134.9 (Cquat, Ph-C, 1
diast.), 135.0 (Cquat, Ph-C, 1 diast.), 136.4 (Cquat, Ph-C, 1 diast.), 136.5 (Cquat, Ph-C, 1 diast.),
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155.2 (Cquat, N(CO)O), 169.7 (Cquat, C=O, 1 diast.), 169.78 (Cquat, C=O, 1 diast.), 169.82
(Cquat, C=O, 1 diast.), 170.0 (Cquat, C=O, 1 diast.), 171.8 (Cquat, C=O, 1 diast.), 171.9 (Cquat,
C=O, 1 diast.). - MS  FAB (NBA/CH2Cl2) m/z (%) 993 (2MH+, 16), 497 (MH+, 91), 441 (93),
397 (MH+-Boc, 100). - IR (KBr) 3350, 3325, 2955, 1726, 1691, 1664, 1455, 1309, 1170 cm-1.
- Anal. Calcd for C27H32N2O7 (496.563): C, 65.31; H, 6.49; N, 5.64. Found: C, 65.15; H, 6.53;
N, 5.55.
HN
BnO2C CO2Me
O
NHBoc
(±)-26
(1R*, 2R*, 3R*) 3-(2S-tert-Butoxycarbonylamino-propionylamino)-cyclopropane-1,2-
dicarboxylic acid 1-bezyl ester 2-methyl ester ((±)-26): A solution of (±)−12 (2.00 g,
5.73 mmol) in HCl 3 M in ethyl acetate (20 ml) was stirred at 0 °C for 3 h. The solvent was
evaporated and a solution of Boc-alanine (1.62 mg, 8.59 mmol, 1.5 eq.), EDC (1.65 g,
8.59 mmol, 1.5 eq) and HOBt (1.16 g, 8.59 mmol, 1.5 eq.) in CH2Cl2 (250 ml) (previously
stirred 1 h at 0 °C and 1 h at room temperature) was added. Triethylamine (797 µl,
5.73 mmol, 1 eq.) was then added dropwise at 0°C. The mixture was stirred at room
temperature overnight. The solution was washed with saturated NaHCO3 (200 ml), 1 M
KHSO4 (200ml) and then saturated NaHCO3 (200 ml). The organic phase was dried over
MgSO4 and concentrated. The mixture of the two diastereomers was purified by
chromatography (ethyl acetate/hexanes 1:2). Yield: 2.12 g (88 %). Any attempt to separate the
two diastereomers by recrystallization failed. - Rf ((±)-26): 0.10. - mp 75-77 °C. - 1H NMR
(CDCl3, 250 MHz) δ 1.33 (d, J = 7.1 Hz, 3H, CH3CH), 1.42 (s, 9H, (CH3)3C, 1 diast.), 1.43
(s, 9H, (CH3)3C, 1 diast.), 2.31 (dd, J = 4.9, 4.9 Hz, 1H, cyclopropyl-CH), 2.55 (dd, J = 5.2,
8.3 Hz, 1H, cyclopropyl-CH), 3.71 (s, 3H, CH3O, 1 diast.), 3.72 (s, 3H, CH3O, 1 diast.), 4.03-
4.17 (m, 2H, cyclopropyl-CHN + Ala-CHN), 4.98 (d, J = 7.33 Hz, 1H, NH), 5.07-5.18 (m,
2H, CH2O), 7.13 (d, J = 7.6 Hz, 1H, NH, 1 diast.), 7.23 (d, J = 8.2 Hz, 1H, 1diast.), 7.29-7.36
(m, 5H, Ph-CH). - 13C NMR (CDCl3, 62.9 MHz) δ 18.2 (+, CH3CH, 1 diast.), 18.3 (+,
CH3CH, 1 diast.), 26.10 (+, cyclopropyl-CH, 1 diast.), 26.14 (+, cyclopropyl-CH, 1 diast.),
28.3 (+, (CH3)3C, 3C), 28.77 (+, cyclopropyl-CH, 1 diast.), 28.83 (+, cyclopropyl-CH, 1
diast.), 36.0 (+, cyclopropyl-CHN), 50.4 (+, CHN), 52.4 (+, CH3O), 67.3 (-, CH2O), 80.2
(Cquat, C(CH3)3), 128.4 (+, Ph-CH, 2C), 128.5 (+, Ph-CH, 2C), 128.6 (+, Ph-CH), 135.2 (Cquat,
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Ph-C), 155.3 (Cquat, C=O), 169.3 (Cquat, C=O), 170.3 (Cquat, C=O), 173.3 (Cquat, C=O, 1diast.),
173.4 (Cquat, C=O, 1 diast.). - MS  CI (NH3) m/z (%) 858 (2MNH4+, <1), 841 (2MH+, <1), 741
(2MH+-Boc, 11), 438 (MNH4+, 100), 421 (MH+, 26), 382 (23), 321 (MH+-Boc, 9). - IR (KBr)
3345, 2980, 2929, 1722, 1688, 1666, 1523, 1451 cm-1. - Anal. Calcd for C21H28N2O7
(420.461): C, 59.99; H, 6.71; N, 6.66. Found: C, 60.05; H, 6.76; N, 6.43.
HN
BnO2C CO2Me
O H
N
O
NHBoc
CH2Ph
(+)-27a
(1R, 2R, 3S) 3-[2S-(2S-tert-Butoxycarbonylamino-3-phenyl-propionylamino)-
propionylamino] cyclopropane-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester
((+)-27a): Recrystallized (+)-25a (310 mg, 0.74 mmol) was stirred in HCl 3 M in ethyl
acetate (11 ml) at 0 °C for 3 h. The solvent was then evaporated and a solution of Boc-
phenylalanine (303 mg, 1.14 mmol, 1.5 eq.), EDC (219 mg, 1.14 mmol, 1.5 eq) and HOBt
(153 mg, 1.14 mmol, 1.5 eq.) in CH2Cl2 (12 ml) (previously stirred 1 h at 0 °C and 1 h at
room temperature) was added. Finally triethylamine (103 µl, 0.74 mmol, 1 eq.) was added
dropwise. The mixture was stirred at room temperature overnight. The solution was washed
with saturated NaHCO3 (15 ml), 1 M KHSO4 (15 ml) and then saturated NaHCO3 (15 ml).
The organic phase was dried over MgSO4 and concentrated. The crude was purified by
chromatography (ethyl acetate/hexanes 1:1) to afford a white solid (390 mg, 93 %). - Rf
((+)-27a): 0.16. - mp 73-75 °C. - [ ]21Dα  -24.9 (c 1, CHCl3). - 1H NMR (CDCl3, 250 MHz)
δ 1.24 (d, J = 7.1 Hz, 3H, CH3CH), 1.40 (s, 9H, (CH3)3C), 2.37 (dd, J = 5.0, 5.1 Hz, 1H,
cyclopropyl-CH), 2.56 (dd, J = 5.2, 8.3 Hz, 1H, cyclopropyl-CH), 3.05-3.16 (m, 2H, CH2Ph),
3.71 (s, 3H, CH3O), 4.00-4.06 (m, 1H, cyclopropyl-CHN), 4.28-4.40 (m, 2H, 2 CHN), 4.95 (s
br, 1H, NHBoc), 5.11-5.22 (m, 2H, CH2O), 6.40 (d, J = 7.2 Hz, 1H, NH), 7.05 (d, J = 7.5 Hz,
1H, NH), 7.20-7.36 (m, 10H, Ph-CH). - 13C NMR (CDCl3, 62.9 MHz) δ 18.1 (+, cyclopropyl-
CH), 26.8(+, cyclopropyl-CH), 28.1 (+, (CH3)3C, 3C), 36.01 (+, cyclopropyl-CHN), 38.3 (-,
CH2Ph), 48.9 (+, CHN), 52.34 (CH3O), 55.9 (+, CHN), 67.3 (-, CH2O), 80.2 (Cquat, C(CH3)3),
126.9 (+, Ph-CH, 2C), 128.3 (+, Ph-CH, 2C), 128.5 (+, Ph-CH, 2C), 128.6 (+, Ph-CH, 2C),
129.3 (+, Ph-CH, 2C), 135.2 (Cquat, Ph-C), 136.6 (Cquat, Ph-C), 155.5 (Cquat, C=O Boc), 169.2
(Cquat, C=O), 169.9 (Cquat, C=O), 171.4 (Cquat, C=O), 172.5 (Cquat, C=O). - MS  FAB
(NBA/CH2Cl2) m/z (%) 1136 (2MH+, 17, 568 (MH+, 100), 512 (MH+-tBu, 42), 468 (MH+-
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Boc, 30), 307 (34), 263 (32), 154 (100). - IR (KBr) 3296, 3065, 2979, 1729, 1693, 1648,
1533, 1454, 1388 cm-1. - Anal. Calcd for C30H37N3O8 (567.64): C, 63.48; H, 6.57; N, 7.40.
Found: C, 63.21; H, 6.62; N, 7.64.
HN
BnO2C CO2Me
O H
N
O
NHBoc
CH2Ph
(-)-27a
(1S, 2S, 3R) 3-[2S-(2S-tert-Butoxycarbonylamino-3-phenyl-propionylamino)-
propionylamino] cyclopropane-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester
((-)-27a): A recrystallisation fraction of (±)-25a enriched in the (-)-25a diastereomer (418 mg,
0.99 mmol) was stirred in HCl 3 M in ethyl acetate (20 ml) at 0 °C for 3 h. The solvent was
then evaporated and a solution of Boc-phenylalanine (398 mg, 1.5 mmol, 1.5 eq.), EDC
(288 mg, 1.5 mmol, 1.5 eq) and HOBt (270 mg, 2 mmol, 2 eq.) in CH2Cl2 (12 ml) (previously
stirred 1 h at 0 °C and 1 h at room temperature) were added. Finally triethylamine (140 µl,
1.0 mmol, 1 eq.) was added dropwise. The mixture was stirred at room temperature overnight.
The solution was washed with saturated NaHCO3 (15 ml), 1 M KHSO4 (15 ml) and then
saturated NaHCO3 (15 ml). The organic phase was dried over MgSO4 and concentrated. The
crude was purified by chromatography (ethyl acetate/hexanes 1:1) to give a white solid
(510 mg, 91 %). Diastereomerically pure (-)-27a was obtained by recrystallization by CH2Cl2/
hexanes. - Rf ((-)-27a): 0.16. - mp 180-183 °C. - [ ]21Dα  -4.2 (c 1, CHCl3). - 1H NMR (CDCl3,
250 MHz) δ 1.27 (d, J = 7.1 Hz, 3H, CH3CH), 1.41 (s, 9H, (CH3)3C), 2.30 (dd, J = 5.0,
4.9 Hz, 1H, cyclopropyl-CH), 2.56 (dd, J = 5.2, 8.2 Hz, 1H, cyclopropyl-CH), 3.05-3.15 (m,
2H, CH2Ph), 3.71 (s, 3H, CH3O), 3.88-3.96 (m, 1H, cyclopropyl-CHN), 4.32-4.43 (m, 2H,
CHN), 4.86 (s br, 1H, NH Boc), 5.12 (d, J = 12.2 Hz, 1H, CH2O), 5.20 (d, J = 12.2 Hz, 1H,
CH2O), 6.38 (d, J = 7.4 Hz, 1H, NH), 6.95 (d, J = 6.9 Hz, 1H, NH), 7.18-7.27 (m, 5H, Ph-
CH), 7.30-7.39 (m, 5H, Ph-CH). - 13C NMR (CDCl3, 62.9 MHz) δ 17.7 (+, CH3CH), 26.5 (+,
cyclopropyl-CH), 28.3 (+, (CH3)3C, 3C), 28.5 (+, cyclopropyl-CH), 35.93 (+, cyclopropyl-
CHN), 38.0 (-, CH2Ph), 48.9 (+, CHN), 52.4 (+, CH3O), 56.0 (+, CHN), 67.4 (-, CH2O), 80.5
(Cquat, (CH3)3C), 127.0 (+, Ph-CH, 2C), 128.3 (+, Ph-CH, 2C), 128.5 (+, Ph-CH, 2C), 128.6
(+, Ph-CH, 2C), 129.3 (+, Ph-CH, 2C), 135.2 (Cquat, Ph-C), 136.5 (Cquat, Ph-C), 155.6 (Cquat,
C= Boc), 169.5 (Cquat, C=O), 169.8 (Cquat, C=O), 171.2 (Cquat, C=O), 172.5 (Cquat, C=O). –
MS  CI (NH3) m/z (%) 1152 (2MNH4+, 9), 1135 (2MH+, 4), 1035 (2MH+-Boc, 2), 585
Experimental part 123
(MNH4+, 100), 568 (MH+, 22). - IR (KBr) 3291, 2980, 1728, 1675, 1638, 1534 cm-1. - Anal.
Calcd for C30H37N3O8 (567.64): C, 63.48; H, 6.57; N, 7.40. Found: C, 63.25; H, 6.56; N, 7.31.
HN
BnO2C CO2Me
O H
N
O
NHBoc
(+)-27b
(1R, 2R, 3S) 3-[2S-(tert-Butoxycarbonylamino-acetylamino)-propionylamino]
cyclopropane-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester ((+)-27b): (+)-25a
(600 mg, 1.43 mmol) was stirred in HCl 3 M in ethyl acetate (15 ml) at 0 °C for 3 h. The
solvent was then evaporated and a solution of Boc-glycine (375 mg, 2.14 mmol, 1.5 eq.),
EDC (411 mg, 2.14 mmol, 1.5 eq) and HOBt (289 mg, 2.14 mmol, 1.5 eq.) in CH2Cl2 (20 ml)
(previously stirred 1 h at 0 °C and 1 h at room temperature) was added. Finally triethylamine
(200 µl, 1.43 mmol, 1 eq.) was added dropwise. The mixture was stirred at room temperature
overnight. The solution was washed with saturated NaHCO3 (20 ml), 1 M KHSO4 (20 ml) and
saturated NaHCO3 (20 ml). The organic phase was dried over MgSO4 and concentrated. The
crude product was purified by chromatography (ethyl acetate/hexanes 2:1) to afford a white
solid (645 mg, 94 %). - Rf ((+)-27b): 0.30. - mp 44-46 °C. - [ ]21Dα  -23.2 (c 1, CHCl3). -
1H NMR (CDCl3, 250 MHz) δ 1.31 (d, J = 7.0 Hz, 3H, CH3CH), 1.45 (s, 9H, (CH3)3C), 2.36
(dd, J = 5.0, 5.0 Hz, 1H, cyclopropyl-CH), 2.56 (dd, J = 5.2, 8.1 Hz, 1H, cyclopropyl-CH),
3.69 (s, 3H, CH3O), 3.80-3.85 (m, 2H, CH2N), 4.01 (ddd, J = 4.8, 7.9, 7.9 Hz, 1H,
cyclopropyl-CHN), 4.43-4.50 (m, 1H, CHN), 5.14-5.21 (m, 2H, CH2O), 5.32 (s br, 1H, NH),
6.81 (d, J = 6.4 Hz, 1H, NH), 7.16 (d, J = 5.9 Hz, 1H, NH), 7.30-7.39 (m, 5H, Ph-CH). -
13C NMR (CDCl3, 62.9 MHz) δ 18.0 (+, CH3CH), 26.5 (+, cyclopropyl-CH), 28.3
(+,(CH3)3C, 3C), 28.4 (+, cyclopropyl-CH), 35.9 (+, cyclopropyl-CHN), 44.4 (-, CH2N), 48.9
(+, CHN), 52.5 (+, CH3O), 67.5 (-, CH2O), 80.4 (Cquat, (CH3)3C), 128.4 (+, Ph-CH, 2C), 128.6
(+, Ph-CH), 128.7 (+, Ph-CH, 2C), 135.1 (Cquat, Ph-C), 156.1 (Cquat, N(CO)O), 169.5 (Cquat,
C=O), 169.7 (Cquat, C=O), 169.8 (Cquat, C=O), 172.6 (Cquat, C=O). - MS  CI (NH3) m/z (%)
495 (MNH4+, 100), 478 (MH+, 23), 439 (20), 252 (36), 189 (29). - IR (KBr) 3303, 2980,
1726, 1661, 1524, 1173 cm-1. - Anal. Calcd for C23H31N3O8(477.513): C, 57.85; H, 6.54; N,
8.80. Found: C, 57.24; H, 6.74; N, 8.39. - HR MS  calcd for C23H31N3O8 + H 478.21894,
found 478.21845.
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HN
BnO2C CO2Me
O H
N
O
NHBoc
(-)-27b
(1S, 2S, 3R) 3-[2S-(tert-Butoxycarbonylamino-acetylamino)-propionylamino]
cyclopropane-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester ((-)-27b): (-)-25a
(920 mg, 2.19 mmol) was stirred in HCl 3 M in ethyl acetate (14 ml) at 0 °C for 3 h. The
solvent was evaporated and a solution of Boc-glycine (574 mg, 3.28 mmol, 1.5 eq.), EDC
(631 mg, 3.28 mmol, 1.5 eq.) and HOBt (443 mg, 3.28 mmol, 1.5 eq.) in CH2Cl2 (50 ml)
(previously stirred 1 h at 0 °C and 1 h at room temperature) was added. Triethylamine
(300 µl, 2.19 mmol, 1 eq.) was finally added dropwise. The mixture was stirred at room
temperature overnight. The solution was washed with saturated NaHCO3 (50 ml), 1 M
KHSO4 (50 ml) and then saturated NaHCO3 (50 ml). The organic phase was dried over
MgSO4 and concentrated. The crude product was purified by chromatography (CHCl3/MeOH
80:1) to afford a white solid (966 mg, 92 %). - Rf ((-)-27b): 0.05. - mp 55-57°C. - [ ]21Dα  -17.9
(c 1, CHCl3). - 1H NMR (CDCl3, 250 MHz) δ 1.33 (d, J = 7.2 Hz, 3H, CH3CH), 1.45 (s, 9H,
(CH3)3C), 2.37 (dd, J = 4.9, 4.9 Hz, 1H, cyclopropyl-CH), 2.56 (dd, J = 5.4, 8.1 Hz, 1H,
cyclopropyl-CH), 3.70 (s, 3H, CH3O), 3.78-3.84(m, 2H, CH2N), 3.88-3.96 (ddd, J = 4.8, 7.9,
7.9 Hz, 1H, cyclopropyl-CHN), 4.48 (dq, J = 3.6, 3.6 Hz, 1H, CHN), 5.12-5.21 (m, 2H,
CH2O), 5.37 (s br, 1H, NH), 6.68 (d, J = 7.4 Hz, 1H, NH), 7.28 (d, J = 4.9 Hz, 1H, NH), 7.30-
7.37 (m, 5H, Ph-CH). - 13C NMR (CDCl3, 62.9 MHz) δ 17.6 (+, CH3CH), 26.7 (+,
cyclopropyl-CH), 28.3 (+, (CH3)3C, 3C), 28.4 (+, cyclopropyl-CH), 35.9 (+, cyclopropyl-
CHN), 48.7 (-, CH2N), 48.9 (+, CHN), 52.5 (+, CH3O), 67.4 (-, CH2O), 80.5 (Cquat, (CH3)3C),
128.3 (+, Ph-CH, 2C), 128.5 (+, Ph-CH), 128.7 (+, Ph-CH, 2C), 135.2 (Cquat, Ph-C), 156.2
(Cquat, N(CO)O), 169.6 (Cquat, C=O), 169.7 (Cquat, C=O), 169.9 (Cquat, C=O), 172.9 (Cquat,
C=O). - MS  CI (NH3) m/z (%) 495 (MNH4+, 100), 478 (MH+, 27), 439 (18), 263 (19), 252
(95), 189 (88). - IR (KBr) 3319, 3268, 3063, 2979, 1727, 1675, 1649, 1539, 1173 cm-1. -
Anal. Calcd for C23H31N3O8 (477.513): C, 57.85; H, 6.54; N, 8.80. Found: C, 57.27; H, 6.60;
N, 8.57. HR MS  calcd for C23H31N3O8 + H 478.21894, found 478.21834.
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HN
BnO2C CO2Me
O H
N
O
NHBoc
CH2Ph
(±)-28
(1S*, 2S*, 3S*) 3-[2S-(2S-tert-Butoxycarbonylamino-3-phenyl-propionylamino)-
propionylamino] cyclopropane-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester
((±)-28): (±)-26 (1.130 g, 2.69 mmol) was stirred in HCl 3 M in ethyl acetate (11 ml) at 0 °C
for 3 h. The solvent was evaporated and a solution of Boc-phenylalanine (1.015 g, 3.83 mmol,
1.4 eq.), EDC (723 mg, 3.77 mmol, 1.4 eq) and HOBt (508 mg, 3.77 mmol, 1.4 eq.) in
CH2Cl2 (30 ml) (previously stirred 1 h at 0 °C and 1 h at room temperature) was added.
Triethylamine (374 µl, 2.69 mmol, 1 eq.) was finally added dropwise. The mixture was stirred
at room temperature overnight. The solution was washed with saturated NaHCO3 (50 ml),
1 M KHSO4 (50 ml) and then saturated NaHCO3 (50 ml). The organic phase was dried over
MgSO4 and concentrated. The crude product was purified by chromatography (ethyl
acetate/hexanes 1:1) to give a white solid (1.44 g, 94 %). - Rf ((±)-28): 0.16. - mp 71-73 °C. -
1H NMR (CDCl3, 250 MHz) δ 1.25 (d, J = 7.0 Hz, 3H, CH3CH, 1 diast.), 1.29 (d, J =  7.0 Hz,
3H, CH3CH, 1 diast.), 1.37 (s, 9H, (CH3)3C, 1 diast.), 1.39 (s, 9H, (CH3)3C, 1 diast.), 2.33 (dd,
J = 5.1, 5.1 Hz, 1H, cyclopropyl-CH, 1 diast.), 2.40 (dd, J = 5.0, 5.0 Hz, 1H, cyclopropyl-CH,
1 diast.), 2.53 (dd, J = 5.5, 8.3 Hz, 1H, cyclopropyl-CH), 3.03-3.12 (m, 2H, CH2Ph), 3.72 (s,
3H, CH3O, 1 diast.), 3.73 (s, 3H, CH3O, 1 diast.), 3.88-3.97 (m, 1H, cyclopropyl-CHN , 1
diast.), 3.99-4.06 (m, 1H, cyclopropyl-CH, 1 diast.), 4.32-4.45 (m, 2H, CHN), 4.91 (d, J =
7.6 Hz, 1H, NHBoc, 1 diast.), 4.95 (d, J = 8.4 Hz, 1H, NHBoc, 1 diast.), 5.14 (s, 2H, CH2O),
6.44 (d, J = 7.3 Hz, 1H, NH, 1 diast.), 6.46 (d, J = 7.3 Hz, 1H, NH, 1 diast.), 6.96 (d, J =
6.8 Hz, 1H, NH, 1 diast.), 7.11 (d, J = 7.6 Hz, 1H, NH, 1 diast.). 7.17-7.32 (m, 5H, Ph-CH),
7.32-7.40 (m, 5H, Ph-CH). - 13C NMR (CDCl3, 62.9 MHz) δ 17.7 (+, CH3CH, 1 diast.), 17.8
(+, CH3CH, 1 diast.), 26.5 (+, cyclopropyl-CH), 28.2 (+, (CH3)3C, 3C), 28.3 (+, cyclopropyl-
CH, 1 diast.), 28.5 (+, cyclopropyl-CH, 1 diast.), 35.8 (+, cyclopropyl-CHN, 1 diast.), 35.9 (+,
cyclopropyl-CHN, 1 diast.), 38.0 (-, CH2Ph), 48.9 (+, CHN), 52.3 (+, CH3O), 55.9 (+, CHN),
67.3 (-, CH2O), 80.5 (Cquat., C(CH3)3, 1 diast.), 80.6 (Cquat., C(CH3)3, 1 diast), 126.98 (+, Ph-
CH, 1 diast.), 127.0 (+, Ph-CH, 1 diast.), 128.39 (+, Ph-CH, 1 diast.), 128.42 (+, Ph-CH, 1
diast.), 128.48 (+, Ph-CH, 2C), 128.60 (+, Ph-CH, 2C), 128.63 (+, Ph-CH), 128.64 (+, Ph-
CH), 129.23 (+, Ph-CH); 129.24 (+, Ph-CH), 135.2 (Cquat., Ph-C), 136.5 (Cquat., Ph-C), 155.5
(Cquat., N(C=O)O), 169.3 (Cquat., C=O), 169.9 (Cquat., C=O), 171.2 (Cquat., C=O), 172.3 (Cquat.,
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C=O, 1 diast.), 172.5 (Cquat., C=O, 1 diast.). - MS  FAB (NBA/CH2Cl2) m/z (%) 1135 (2MH+,
7), 568 (MH+, 100), 512 (MH+-tBu, 42), 468 (MH+-Boc, 37 ), 307 (66), 263 (38). - IR (KBr)
3288, 3065, 2979, 1733, 1696, 1649, 1520, 1455, 1367 cm-1. - Anal. Calcd for C30H37N3O8
(567.64): C, 63.48; H, 6.57; N, 7.40. Found: C, 63.37; H, 6.60; N, 7.33.
2.2.2 Deprotection of the C-terminus
NH
HO2C CO2Me
O
(±)-29
(1R*, 2R*, 3R*) 3-(2S-tert-Butoxycarbonylamino-propionyl)-cyclopropane-1,2-
dicarboxylic acid mono methyl ester ((±)-29): (±)-24 (438 mg, 1.5 mmol) was dissolved
under nitrogen atmosphere in MeOH (10 ml), then 1,4-cyclohexadiene (3.5 ml, 40 % in
pentane) and of Pd/C 10 % (85 mg) were added. The reaction mixture was stirred under inert
atmosphere overnight, then it was filtrated on a 2 cm celite pad and concentrated to afford the
product as a white solid (300 mg, 99 %). - mp 62-64 °C. - 1H NMR (CD3OD, 250 MHz)
δ 1.93 (s, 3H, CH3C=O), 2.31-2.50 (m, 2H, cyclopropyl-CH), 3.53-3.58 (m, 1H, cyclopropyl-
CHN), 3.72 (s, 3H, CH3O). - 13C NMR (CD3OD, 62.9 MHz) δ 22.3 (+, CH3C=O), 28.1 (+,
cyclopropyl-CH), 28.2 (+, cyclopropyl-CH), 36.9 (+, cyclopropyl-CHN), 52.9 (+, CH3O),
172.1 (Cquat, C=O, 2C), 174.4 (Cquat, C=O). - MS EI (70 eV) m/z (%) 201 (M+, 3), 183 (MH+-
H2O, 9), 169 (14), 158 (M+-acetyl, 16), 141 (38), 114 (47), 100 (86), 82 (56), 43 (100). - IR
(KBr) 3358, 3266, 3071, 2657, 1727, 1663, 1638, 1541, 1439, 1312 cm-1. - HR MS  calcd for
C8H10NO5 201.06372, found 201.06365.
HN
HO2C CO2Me
O
NHBoc
HN
HO2C CO2Me
O
NHBoc
(1R, 2R, 3R) and
cyclopropane-1,2-di
(819 mg, 1.95 mmol)
(-)-30a(+)-30a (1S, 2S, 3S) 3-(2S-tert-Butoxycarbonylamino-propionylamino)-
carboxylic acid mono methyl ester ((+)-30a and (-)-30a): (±)-25a
 was dissolved under nitrogen atmosphere in MeOH (100 ml), then 1,4-
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cyclohexadiene (4.5 ml, 40 % in pentane) and Pd/C 5 % (100 mg) were added. The reaction
mixture was stirred under inert atmosphere overnight, then it was filtrated on a 2 cm celite pad
and concentrated to afford the product as a white solid (640 mg, 99 %). The two
diastereomers can be obtained diastereomerically pure from the corresponding dipeptides. -
(+)-30a- mp 70-72 °C. - [ ]21Dα  -72.0° (c 1, CH3OH). - 1H NMR (CDCl3, 250 MHz) δ 1.28 (d,
J = 6.9 Hz, 3H, CH3CH), 1.43 (s, 9H, (CH3)3C), 2.32 (dd, J = 4.7, 4.7 Hz, 1H, cyclopropyl-
CH), 2.53 (dd, J = 5.2, 8.3 Hz, 1H, cyclopropyl-CH), 3.73 (s, 3H, CH3O), 4.13-4.21 (m, 1H,
cyclopropyl-CHN), 4.51-4.57(m, 1H, CHN), 5.43 (d, J = 5.3 Hz, 1H, NH), 7.54 (d, J =
8.3 Hz, 1H, NH). - 13C NMR (CDCl3, 62.9 MHz) δ 19.3 (+, CH3CH), 26.0 (+, cyclopropyl-
CH), 28.3 (+,(CH3)3C, 3C), 28.6 (+, cyclopropyl-CH), 36.1 (+, cyclopropyl-CHN), 49.6 (+,
CHN), 52.5 (+, CH3O), 81.0 (Cquat, (CH3)3C), 156.0 (Cquat, N(CO)O), 170.0 (Cquat, C=O),
172.6 (Cquat, C=O), 173.7 (Cquat, C=O). - MS  FAB (NBA/CH2Cl2) m/z (%) 331 (MH+, 29),
275 (MH+-tBu, 35), 154 (100). - IR (KBr) 3352, 2981, 1718, 1526, 1306 cm-1. - HR MS  calcd
for 331.15053, found 331.14958. - (-)-30a- mp 78-80 °C. - [ ]21Dα  -16.5° (c 1, CH3OH). -
1H NMR (CDCl3, 250 MHz) δ 1.33 (d, J = 6.6 Hz, 3H, CH3CH), 1.44 (s, 9H, (CH3)3C), 2.30-
2.38 (m, 1H, cyclopropyl-CH), 2.53 (dd, J = 5.2, 8.2 Hz, 1H, cyclopropyl-CH), 3.73 (s, 3H,
CH3O), 4.02-4.07 (m, 1H, cyclopropyl-CHN), 4.37-4.41(m, 1H, CHN), 5.37 (d, J = 5.3 Hz,
1H, NH), 7.36 (d, J = 8.3 Hz, 1H, NH), 9.05 (s br, 1H, COOH). - 13C NMR (CDCl3,
62.9 MHz) δ 18.4 (+, CH3CH), 26.2 (+, cyclopropyl-CH), 28.3 (+,(CH3)3C, 3C), 28.7 (+,
cyclopropyl-CH), 36.0 (+, cyclopropyl-CHN), 50.0 (+, CHN), 52.5 (+, CH3O), 80.8 (Cquat,
(CH3)3C), 156.0 (Cquat, N(CO)O), 170.1 (Cquat, C=O), 172.2 (Cquat, C=O), 174.3 (Cquat, C=O).
- MS  FAB (NBA/CH2Cl2) m/z (%) 353 (MNa+, 27), 331 (MH+, 100), 275 (MH+-tBu, 123),
231 (MH+-Boc, 49). - IR (KBr) 3352, 2982, 1719, 1526, 1305 cm-1. - HR MS  calcd for
C14H22N2O5 + H 331.15053, found 331.14943.
HN
HO2C CO2Me
O
NHFmoc
CH2Ph
(±)-30d
(1R*, 2R*, 3R*) 3-[2S-(9H-fluoren-9-ylmethoxycarbonylamino)-phenyl-
propionylamino]-cyclopropane-1,2-dicarboxylic acid mono methyl ester ((±)-30d):
(±)-25d (400 mg, 0.65 mmol) was dissolved under nitrogen atmosphere in a mixture 2:1 of
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THF and MeOH (50 ml), then 1,4-cyclohexadiene (4 ml, 40 % in pentane) and Pd/C 10 %
(180 mg) were added. The reaction mixture was stirred under inert atmosphere 24 h, then it
was filtrated on a 2 cm Celite pad and concentrated to afford the product as a white solid
(335 mg, 98 %). - mp 150 °C decomp. - 1H NMR (CDCl3, 250 MHz): δ 2.04 (dd, J = 4.3,
4.3 Hz, 1H, cyclopropyl-CH, 1 diast.), 2.20 (dd, J = 4.6, 4.6 Hz, 1H, cyclopropyl-CH, 1
diast.), 2.24-2.29 (m, 1H, cyclopropyl-CH), 2.78-2.86 (m, 1H, CH2Ph), 3.12-3.22 (m, 1H,
CH2Ph), 3.64 (s, 3H, CH3O), 3.67-3.77 (m, 1H, cyclopropyl-CHN), 3.98-4.15 (m, 2H, Fmoc-
CH + CHN), 4.24-4.29 (m, 2H, Fmoc-CH2), 6.20 (d, J = 9.7 Hz, 1H, NH, 1 diast.), 6.22 (d,
J = 9.8 Hz, 1H, NH, 1 diast.), 7.14-7.23 (m, 7H, Ar-CH), 7.24-7.34 (m, 2H, Ar-CH), 7.43-
7.51 (m, 2H, Fmoc-Ar-CH), 7.71-7.73 (m, 2H, Fmoc-Ar-CH). - 13C NMR (CDCl3,
62.9 MHz): δ 28.8 (+, cyclopropyl-CH, 1 diast.), 28.9 (+, cyclopropyl-CH, 1 diast.), 30.06 (+,
cyclopropyl-CH, 1 diast.), 30.12 (+, cyclopropyl-CH, 1 diast.), 36.3 (+, cyclopropyl-CHN, 1
diast.), 36.4 (+, cyclopropyl-CHN, 1 diast.), 38.6 (-, CH2Ph, 1 diast.), 38.8 (-, CH2Ph, 1
diast.), 48.2 (+, Fmoc-CH), 52.6 (+, CH3O), 58.0 (+, CHN, 1 diast.), 58.2 (+, CHN, 1 diast.),
67.6 (-, Fmoc-CH2, 1 diast.), 67.8 (-, Fmoc-CH2, 1 diast.), 120.9 (+, Fmoc-Ar-CH, 2C), 126.2
(+, Ar-CH), 126.29 (+, Ar-CH, 1 diast.), 126.33 (+, Ar-CH, 1 diast.), 127.7 (+, Ar-CH, 1
diast.), 127.8 (+, Ar-CH, 1 diast.), 128.1 (+, Ar-CH, 2C), 128.7 (+, Ar-CH, 2C), 129.47 (+,
Ar-CH), 129.52 (+, Ar-CH), 130.3 (+, Ar-CH, 2C), 138.5 (Cquat, Ph-C, 1 diast.), 138.6 (Cquat,
Ph-C, 1 diast.), 142.4 (Cquat, Fmoc-Ar-C, 2C), 145.1 (Cquat, Fmoc-Ar-C, 2C), 158.2 (Cquat,
N(CO)O, 1 diast.), 158.3 (Cquat, N(CO)O, 1 diast.), 172.9 (Cquat, C=O), 174.5 (Cquat, C=O, 1
diast.), 174.6 (Cquat, C=O, 1 diast.), 176.5 (Cquat, CO). - MS  FAB (MeOH/Glycerine) m/z (%)
529 (MH+, 100). - IR (KBr) 3387, 3065, 2929, 1723, 1669, 1444, 1320 cm-1. - HR MS  calcd
for C30H28N2O7 + H 529.19748, found 529.19750.
HN
HO2C CO2Me
O
NHFmoc
O OtBu
(±)-30e
(1R*, 2R*, 3R*) 3-[4-tert-Butoxycarbonyl-2S-(9H-fluoren-9-ylmethoxycarbonylamino)-
butyrylamino]-cyclopropane-1,2-dicarboxylic acid mono methyl ester ((±)-30e): (±)-25e
(345 mg, 0.54 mmol) was dissolved under nitrogen atmosphere in MeOH (25 ml), then 1,4-
cyclohexadiene (2.5 ml, 40 % in pentane) and Pd/C 10 % (250 mg) were added. The reaction
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mixture was stirred under inert atmosphere 24 h, then it was filtrated on a 2 cm celite pad and
concentrated to afford the product as a white solid (256 mg, 86 %). - mp 74-76 °C. - 1H NMR
(CDCl3, 250 MHz): δ 1.42 (s, 9H, (CH3)3C), 2.34-2.38 (m, 1H, cyclopropyl-CH), 2.45-2.49
(m, 1H, cyclopropyl-CH), 2.55-2.77 (m, 2H, CH2CO2tBu), 3.69 (s, 3H, CH3O), 3.87-4.03 (m,
1H, cyclopropyl-CHN), 4.16-4.20 (m, 1H, Fmoc-CH), 4.34-4.40 (m, 2H, Fmoc-CH2), 4.56-
4.63 (m, 1H, CHN), 6.20 (d, J = 9.7 Hz, 1H, NH, 1 diast.), 6.23 (d, J = 9.6 Hz, 1H, NH,
1diast.), 7.26-7.40 (m, 4H, Ar-CH), 7.55-7.64 (m, 3H, Fmoc-Ar-CH + NH), 7.73-7.76 (m,
2H, Fmoc-Ar-CH). - 13C NMR (CDCl3, 62.9 MHz): δ 26.4 (+, cyclopropyl-CH), 27.9 (+,
(CH3)3C, 3C), 28.4 (+, cyclopropyl-CH, 1 diast.), 28.5 (+, cyclopropyl-CH, 1 diast.), 36.1 (+,
cyclopropyl-CHN, 1 diast.),36.2 (+, cyclopropyl-CHN, 1 diast.), 37.6 (-, CH2CO2tBu, 1
diast.), 37.7 (-, CH2CO2tBu, 1 diast.), 46.9 (+, Fmoc-CH), 51.2 (+, CHN, 1 diast.), 51.4 (+,
CHN, 1 diast.), 52.4 (+, CH3O), 67.5 (-, CH2O), 82.0 (Cquat, (CH3)3C, 1 diast.), 82.1 (Cquat,
(CH3)3C, 1 diast.), 120.0 (+, Fmoc-Ar-CH, 2C), 125.1 (+, Fmoc-Ar-CH, 2C), 126.9 (+, Fmoc-
Ar-CH), 127.1 (+, Fmoc-Ar-CH), 127.7 (+, Fmoc-Ar-CH, 2C), 141.21 (Cquat, Fmoc-ArC),
141.23 (Cquat, Fmoc-Ar-C), 143.5 (Cquat, Fmoc-Ar-C), 143.7 (Cquat, Fmoc-Ar-C), 156.2 (Cquat,
N(CO)O, 1 diast.), 156.3 (Cquat, N(CO)O, 1 diast.), 169.96 (Cquat, C=O, 1 diast.), 170.0 (Cquat,
C=O, 1 diast.), 171.6 (Cquat, C=O), 171.7 (Cquat, C=O), 172.5 (Cquat, CO). - MS  FAB
(MeOH/Glycerine) m/z (%) 553 (MH+, 12), 497 (MH+-tBu, 62), 275 (100). - IR (KBr) 3337,
3066, 2979, 1724, 1530, 1449, 1370, 1302 cm-1. - HR MS  calcd for C29H32N2O9 + H
553.21861, found 553.21846.
HN
HO2C CO2Me
O
NHFmoc
(+)-30f
(1R, 2R, 3R) 3-[(9H-fluoren-9-ylmethoxycarbonylamino)-ethylamino]-cyclopropane-1,2-
dicarboxylic acid mono methyl ester ((+)-30f): (+)-25f (210 mg, 0.40 mmol) was dissolved
under nitrogen atmosphere in MeOH (15 ml), then 1,4-cyclohexadiene (2 ml, 40 % in
pentane) and Pd/C 10 % (100 mg) were added. The reaction mixture was stirred under inert
atmosphere 24 h, then filtrated on a 2 cm celite pad and concentrated to afford the product as
a white solid (123 mg, 71 %). - mp 78-80 °C. - [ ]21Dα  -22.4 (c 0.5, MeOH). - 1H NMR (CDCl3,
250 MHz): δ 2.24-2.40 (m, 1H, cyclopropyl-CH), 2.50-2.53 (m, 1H, cyclopropyl-CH), 3.67
(s, 3H, CH3O), 3.86-4.03 (m, 3H, CH2N + cyclopropyl-CHN), 4.16 (dd, J = 6.8, 7.0 Hz, 1H,
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Fmoc-CH), 4.32-4.35 (m, 2H, Fmoc-CH2), 6.05 (s br, 1H, NHFmoc), 7.23-7.39 (m, 5H, Ar-
CH + NH), 7.49-7.56 (m, 2H, Ar-CH), 7.70-7.77 (m, 2H, Ar-CH), 8.64 (s br, CO2H). -
13C NMR (CDCl3, 62.9 MHz): δ 26.5 (+, cyclopropyl-CH), 28.3 (+, cyclopropyl-CH), 35.9
(+, cyclopropyl-CHN), 44.3 (-, CH2N), 47.0 (+, Fmoc-CH), 52.6 (+, CH3O), 67.5 (-, CH2O),
120.0 (+, Ar-CH, 2C), 125.1 (+, Ar-CH, 2C), 127.1 (+, Ar-CH, 2C), 127.8 (+, Ar-CH, 2C),
141.3 (Cquat, ArC, 2C), 143.6 (Cquat, ArC, 2C), 157.1 (Cquat, N(CO)O), 170.0 (Cquat, C=O),
170.9 (Cquat, C=O), 172.2 (Cquat, CO). - MS  FAB (MeOH/Glycerine) m/z (%) 877 (2MH+, 2),
715 ((MH + 3 Glyc.)+, <1), 623 (MH++2Glyc., <1), 531 (MH+ + Glyc., 2), 439 (MH+, 23). -
IR (CDCl3) 3431, 3377, 3070, 2956, 1725, 1603, 1516, 1445 cm-1. - HR MS  calcd for
C23H22N2O7 + H 439.15053, found 439.15008.
HN
HO2C CO2Me
O
NHFmoc
(-)-30f
(1S, 2S, 3S) 3-[(9H-fluoren-9-ylmethoxycarbonylamino)-ethylamino]-cyclopropane-1,2-
dicarboxylic acid mono methyl ester ((-)-30f): (-)-25f (200 mg, 0.38 mmol) was dissolved
under nitrogen atmosphere in MeOH (15 ml), then 1,4-cyclohexadiene (2 ml, 40 % in
pentane) and Pd/C 10 % (100 mg) were added. The reaction mixture was stirred under inert
atmosphere 24 h, then filtrated on a 2 cm celite pad and concentrated to afford the product as
a white solid (100 mg, 60 %). - mp 77-79 °C. - [ ]21Dα  +18.2 (c 0.5, MeOH). - 1H NMR
(CDCl3, 250 MHz): δ 2.23-2.40 (m, 1H, cyclopropyl-CH), 2.50-2.54 (m, 1H, cyclopropyl-
CH), 3.67 (s, 3H, CH3O), 3.86-4.02 (m, 3H, CH2N + cyclopropyl-CHN), 4.16 (dd, J = 6.7,
7.0 Hz, 1H, Fmoc-CH), 4.31-4.35 (m, 2H, Fmoc-CH2), 6.05 (s br, 1H, NHFmoc), 7.23-7.39
(m, 5H, Fmoc-Ar-CH + NH), 7.49-7.55 (m, 2H, Fmoc-Ar-CH), 7.70-7.77 (m, 2H, Fmoc-Ar-
CH), 8.60 (s br, CO2H). - 13C NMR (CDCl3, 62.9 MHz): δ 26.5 (+, cyclopropyl-CH), 28.3 (+,
cyclopropyl-CH), 35.9 (+, cyclopropyl-CHN), 44.2 (-, CH2N), 47.0 (+, Fmoc-CH), 52.6 (+,
CH3O), 67.4 (-, CH2O), 120.0 (+, Fmoc-Ar-CH, 2C), 125.1 (+, Fmoc-Ar-CH, 2C), 127.2 (+,
Fmoc-Ar-CH, 2C), 127.8 (+, Fmoc-Ar-CH, 2C), 141.3 (Cquat, Fmoc-Ar-C, 2C), 143.6 (Cquat,
Fmoc-Ar-C, 2C), 157.0 (Cquat, N(CO)O), 170.0 (Cquat, C=O), 170.9 (Cquat, C=O), 172.2 (Cquat,
CO). - MS  FAB (MeOH/Glycerine) m/z (%) 877 (2MH+, 3), 715 ((MH + 3 Glyc.)+, <1), 623
(MH++2Glyc., <1), 531 (MH+ + Glyc., 1), 439 (MH+, 25). - IR (CDCl3) 3434, 3380, 3068,
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2958, 1726, 1602, 1517, 1445 cm-1. - HR MS  calcd for C23H22N2O7 + H 439.15053, found
439.15008.
HN
HO2C CO2Me
O H
N
O
NHBoc
CH2Ph
(+)-31a
(1R*, 2R*, 3R*) 3-[2S-(2S-tert-Butoxycarbonylamino-3-phenyl-propionylamino)-
propionylamino] cyclopropane-1,2-dicarboxylic acid mono methyl ester ((+)-31a):
(+)-27a (200 mg, 0.35 mmol) was dissolved under nitrogen atmosphere in MeOH (10 ml),
then 1,4-cyclohexadiene (0.5 ml, 40 % in pentane) and Pd/C 5 % (100 mg) were added. The
reaction mixture was stirred under inert atmosphere overnight, then it was filtrated on a 2 cm
celite pad and concentrated to afford the product as a white solid (160 mg, 96 %). mp 101-
103 °C. - [ ]21Dα  -19.6 (c 1, CHCl3). - 1H NMR (CDCl3, 250 MHz) δ 1.15 (d, J = 7.0 Hz, 3H,
CH3CH), 1.27 (s, 9H, (CH3)3C), 2.22 (dd, J = 5.5, 8.0 Hz, 1H, cyclopropyl-CH), 2.34 (dd, J =
5.1, 5.1 Hz, 1H, cyclopropyl-CH), 2.68 (dd, J = 11.1, 13.5 Hz, 1H, CH2Ph), 2.97 (dd, J = 3.4,
13.7 Hz, 1H, CH2Ph), 3.37-3.44 (m, 1H, cyclopropyl-CHN), 3.65 (s, 3H, CH3O), 4.09-4.25
(m, 2H, CHN), 6.90 (d, J = 8.6 Hz, 1H, NH), 7.14-7.26 (m, 5H, Ph-CH), 8.03 (d, J = 7.3 Hz,
1H, NH), 8.37 (d, J = 4.7 Hz, 1H, NH), 12.69 (s br, 1H, COOH). - 13C NMR (CDCl3,
62.9 MHz) δ 18.6 (+, CH3CH), 26.4 (+, cyclopropyl-CH), 28.2 (+, cyclopropyl-CH), 28.3 (+,
(CH3)3C, 3C), 36.1 8+, cyclopropyl-CHN), 38.4 (-, CH2Ph), 48.8 (+, CHN), 52.4 (+, CH3O),
55.9 (+, CHN), 80.7 (Cquat, C(CH3)3), 127.0 (+, Ph-CH), 128.6 (+, Ph-CH, 2C), 129.3 (+, Ph-
CH, 2C), 136.3 (Cquat, Ph-C), 155.7 (Cquat, N(CO)O), 170.0 (Cquat, C=O), 171.6 (Cquat, C=O),
171.9 (Cquat, C=O), 172.9 (Cquat, C=O). - MS  FAB (Glycerin/MeOH) m/z (%) 977 (2MNa+,
2), 955 (2MH+, 2), 855 (2MH+-Boc), 500 (MNa+, 3), 478 (MH+, 17), 422 (MH+-t-Bu, 37),
378 (MH+-Boc, 46), 263 (48), 120 (100). - IR (KBr) 3311, 3065, 2980, 1721, 1656, 1526,
1453 cm-1. - HR MS  calcd for C23H31N3O8 + H 478.2189, found 478.22038.
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HN
HO2C CO2Me
O H
N
O
NHBoc
CH2Ph
(-)-31a
(1R*, 2R*, 3R*) 3-[2S-(2S-tert-Butoxycarbonylamino-3-phenyl-propionylamino)-
propionylamino] cyclopropane-1,2-dicarboxylic acid mono methyl ester ((-)-31a): (-)-27a
(1.6 g, 2.82 mmol) was dissolved under nitrogen atmosphere in MeOH (300 ml), then 1,4-
cyclohexadiene (4 ml, 40 % in pentane) and Pd/C 10 % (100 mg) were added. The reaction
mixture was stirred under inert atmosphere overnight, then it was filtrated on a 2 cm celite pad
and concentrated to afford the product as a white solid (1.34 g, 99 %). - mp 108-110 °C. -
[ ]21Dα  -4.9 (c 1, CHCl3). - 1H NMR (DMSO-d6, 250 MHz) δ 1.23 (d, J = 7.0 Hz, 3H, CH3CH),
1.32 (s, 9H, (CH3)3C), 2.18-2.22 (m, 2H, cyclopropyl-CH), 2.80 (dd, J = 9.3, 14.0 Hz, 1H,
CH2Ph), 3.07 (dd, J = 4.76, 14.0 Hz, 1H, CH2Ph), 3.51, (dd, J = 4.7, 8.0 Hz, 1H, cyclopropyl-
CHN), 3.66 (s, 3H, CH3O), 4.19-4.27 (m, 2H, CHN), 6.31 (d, J = 8.7 Hz, 1H, NH), 7.15-7.22
(m, 1H, Ph-CH), 7.23-7.24 (m, 4H, Ph-CH), 7.67 (d, J = 7.6 Hz, 1H, NH), 8.03 (s br, 1H,
NH). - 13C NMR (DMSO-d6, 62.9 MHz) δ 17.8 (+, CH3CH), 27.1 (+, cyclopropyl-CH), 28.1
(+, cyclopropyl-CH), 28.3 (+, (CH3)3C), 36.1 (+, cyclopropyl-CHN), 38.2 (-, CH2Ph), 49.0 (+,
CHN), 52.4 (+, CH3O), 55.9 (+, CHN), 81.0 (Cquat, C(CH3)3), 127.2 (+, Ph-CH), 128.5 (+, Ph-
CH, 2C), 128.7 (+, Ph-CH, 2C), 136.3 (Cquat, Ph-C), 156.0 (Cquat, N(CO)O), 170.2 (Cquat,
C=O, 2C), 172.0 (Cquat, C=O), 173.1 (Cquat, C=O). - MS  FAB (Glycerin/MeOH) m/z (%) 977
(2MNa+, 7), 955 (2MH+, 2), 500 (MNa+, 10), 478 (MH+, 16), 422 (MH+-t-Bu, 24), 378 (MH+-
Boc, 23), 263 (35), 219 (30). - IR (KBr) 3319, 3063, 2980, 1721, 1711, 1662, 1528,
1453 cm-1. - HR MS  calcd for C23H31N3O8 + H 478.2189, found 478.22043.
HN
HO2C CO2Me
O H
N
O
NHBoc
(+)-31b
(1R*, 2R*, 3R*) 3-[2S-(tert-Butoxycarbonylamino-ethylamino)-propionylamino]
cyclopropane-1,2-dicarboxylic acid mono methyl ester ((+)-31b): (+)-27b (490 mg,
1.03 mmol) was dissolved under nitrogen atmosphere in 30 ml of MeOH, then 2.5 ml of 1,4-
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cyclohexadiene (40 % in pentane) and 60 mg of Pd/C 5 % were added. The reaction mixture
was stirred under inert atmosphere overnight, then it was filtrated on a 2 cm celite pad and
concentrated to afford 402 mg (>99 %) of product as a white solid. - mp 112-115 °C. - [ ]21Dα
-23.7 (c 1, CHCl3). - 1H NMR (CDCl3, 250 MHz) δ 1.34 (d, J = 6.6 Hz, 3H, CH3CH), 1.45 (s,
9H, (CH3)3C), 2.39-2.40 (m, 1H, cyclopropyl-CH), 2.43-2.52 (m, 1H, cyclopropyl-CH), 3.71
(s, 3H, CH3O), 3.81-3.94 (m, 3H, cyclopropyl-CHN + CH2N), 4.57-4.70 (m, 1H, CHN), 5.78
(s, br, 1H, NH), 7.46 (d, J = 7.5 Hz, 1H, NH), 7.73 (s br, 1H, NH), 9.30 (s br, 1H, COOH). -
13C NMR (CDCl3, 62.9 MHz) δ 18.0 (+, CH3CH), 26.8 (+, cyclopropyl-CH), 28.3 (+,(CH3)3C
+ cyclopropyl-CH, 4C), 35.9 (+, cyclopropyl-CHN), 44.1 (-, CH2N), 49.0 (+, CHN), 52.5 (+,
CH3O), 80.6 (Cquat, (CH3)3C), 156.6 (Cquat, N(CO)O), 170.2 (Cquat, C=O), 170.6 (Cquat, C=O),
172.2 (Cquat, C=O), 173.5 (Cquat, C=O). - MS  FAB (NBA/CH2Cl2) m/z (%) 775 (2MH+, 2),
388 (MH+, 24), 332 (15), 307 (32), 289 (15), 154 (100). - IR (KBr) 3317, 2981, 1721, 1669,
1527, 1302, 1252 cm-1. - HR MS  calcd for C16H25N3O8 + H 388.17199, found 388.17042.
HN
HO2C CO2Me
O H
N
O
NHBoc
(-)-31b
(1S*, 2S*, 3S*) 3-[2S-(tert-Butoxycarbonylamino-ethylamino)-propionylamino]
cyclopropane-1,2-dicarboxylic acid mono methyl ester ((-)-31b): (-)-27b (915 mg,
1.92 mmol) was dissolved under nitrogen atmosphere in MeOH (100 ml), then 1,4-
cyclohexadiene (4.5 ml, 40 % in pentane) and Pd/C 5 % (110 mg) were added. The reaction
mixture was stirred under inert atmosphere overnight, then it was filtrated on a 2 cm celite pad
and concentrated to afford the product as a white solid (765 mg, >99 %). - mp 69-72 °C. -
[ ]21Dα  -13.7 (c 1, CHCl3). - 1H NMR (CDCl3, 250 MHz) δ 1.34 (d, J = 4.8 Hz, 3H, CH3CH),
1.43 (s, 9H, (CH3)3C), 2.36-2.51 (m, 2H, cyclopropyl-CH), 3.70 (s, 3H, CH3O), 3.81-3.99 (m,
3H, cyclopropyl-CHN + CH2N), 4.57-4.61 (m, 1H, CHN), 5.77 (s, br, 1H, NH), 7.56 (s br,
1H, NH), 7.97 (s br, 1H, NH), 10.78 (s br, 1H, COOH). - 13C NMR (CDCl3, 62.9 MHz)
δ 17.5 (+, CH3CH), 27.5 (+, cyclopropyl-CH), 28.3 (+, (CH3)3C) + cyclopropyl-CH, 4C), 36.9
(+, cyclopropyl-CHN), 44.0 (-, CH2N), 48.8 (+, CHN), 52.5 (+, CH3O), 80.6 (Cquat,
(CH3)3C)), 156.6 (Cquat, N(CO)O), 170.2 (Cquat, C=O), 171.0 (Cquat, C=O), 172.0 (Cquat, C=O),
173.9 (Cquat, C=O). - MS  FAB (Glycerin/MeOH) m/z (%) 775 (2MH+, 11), 388 (MH+, 60),
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332 (100). - IR (KBr) 3337, 2982, 1721, 1669, 1533 cm-1. - HR MS  calcd for C16H25N3O8 +
H 388.17199, found 388.17119.
HN
CO2MeHO2C
O H
N
O
NHBoc
CH2Ph
(±)-32
(1S*, 2S*, 3R*) 3-[2S-(2S-tert-Butoxycarbonylamino-3-phenyl-propionylamino)-
propionylamino] cyclopropane-1,2-dicarboxylic acid mono methyl ester ((±)-32): (±)-28
(230 mg, 0.40 mmol) was dissolved under nitrogen atmosphere in MeOH (10 ml), then 1,4-
cyclohexadiene (3 ml, 40 % in pentane) and Pd/C 10 % (50 mg) were added. The reaction
mixture was stirred under inert atmosphere overnight, then it was filtrated on a 2 cm celite pad
and concentrated to afford the product as a white solid (188 mg, 99%). - mp 105-107 °C. -
1H NMR (CD3OD, 250 MHz) δ 1.28 (d, J = 6.6 Hz, 3H, CH3CH), 1.35 (s, 9H, (CH3)3C),
2.31-2.45 (m, 2H, cyclopropyl-CH), 2.76-2.93 (m, 1H, CH2Ph), 3.14 (ddd, J = 2.3, 2.3,
11.8 Hz, 1H, CH2Ph), 3.49-3.63 (m, 1H, cyclopropyl-CHN), 3.66 (s, 3H, CH3O, 1 diast.),
3.67 (s, 3H, CH3O, 1 diast.), 4.23-4.42 (m, 2H, CHN), 7.12-7.34 (m, 5H, Ph-CH). - 13C NMR
(CD3OD, 62.9 MHz) δ 18.1 (+, CH3CH, 1 diast.), 18.2 (+, CH3CH, 1 diast.), 28.5 (+,
cyclopropyl-CH), 28.7 (+, (CH3)3C, 3C), 36.6 (+, cyclopropyl-CH), 39.1 (-, CH2Ph), 50.4 (+,
CHN), 52.8 (+, CHN), 52.9 (+, CH3O, 1 diast.), 53.0 (+, CH3O, 1 diast.), 57.4 (+, CHN), 80.5
(Cquat., C(CH3)3, 1 diast.), 80.7 (Cquat., C(CH3)3, 1 diast.), 127.7 (+, Ph-CH, 1 diast.), 127.8 (+,
Ph-CH, 1 diast.), 129.4 (+, Ph-CH, 2C, 1 diast.), 129.5 (+, Ph-CH, 2C, 1 diast.), 130.3 (+, Ph-
CH, 2C, 1 diast.), 130.5 (+, Ph-CH, 2C, 1 diast.), 138.4 (Cquat., Ph-C, 1 diast.), 138.7 (Cquat.,
Ph-C, 1 diast.), 157.7 (Cquat., N(C=O)O), 170.5 (Cquat., C=O), 170.7 (Cquat., C=O), 174.1 (Cquat.,
C=O), 175.8 (Cquat., C=O). - MS  FAB (NBA/CH2Cl2) m/z (%) 978 (2MNa+, 27), 500 (MNa+,
25), 478 (MH+, 100), 422 (MH+-tBu, 84 ), 378 (MH+-Boc, 51), 277 (46), 263 (82), 219 (46). -
IR (KBr) 3336, 3065, 2980, 1717, 1653, 1540, 1455, 1368 cm-1. - HR MS  calcd for
C23H31N3O8 + H 478.2189, found 478.22002.
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N
H
H
N
O
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H
FmocHN
O
CO2MeCO2Me
CO2H
(+)-42
(1R, 2R, 3R) 3-[2S-({2R-[2S-(9H-fluoren-9-ylmethoxycarbonylamino)-propionylamino]-3R-
methoxycarbonyl-cyclopropane-1R-carbonyl}-amino)-propionylamino]-cyclopropane-1, 2-
dicarboxylic acid mono methyl ester ((+)-42): (+)-41 (200 mg, 0.26 mmol) was dissolved
under nitrogen atmosphere in a mixture MeOH/Benzene/HCO2H 5/5/2 (15 ml), then Pd/C
10 % (180 mg) was added. The reaction mixture was stirred under inert atmosphere 2.5 h,
then it was filtrated on a 2 cm celite pad and concentrated to afford the product as a white
solid (175 mg, 99 %). - mp 220 °C decomp. - [ ]21Dα  -70.8 (c 0.5, MeOH). - 1H NMR (CD3OD,
400 MHz): δ 1.22 (d, J = 7.1 Hz, 3H, CH3CH), 1.28 (d, J = 7.2 Hz, 3H, CH3CH), 2.31-2.42
(m, 3H, cyclopropyl-CH), 2.45-2.51 (m, 1H, cyclopropyl-CH), 3.51-3.62 (m, 2H,
cyclopropyl-CHN), 3.67 (s, 3H, CH3O), 3.69 (s, 3H, CH3O), 4.04-4.09 (m, 1H, CHN), 4.18-
4.23 (m, 2H, CHN + Fmoc-CH), 4.28-4.38 (m, 2H, Fmoc-CH2), 7.28-7.31 (m, 2H, Fmoc-Ar-
CH), 7.35-7.39 (m, 2H, Fmoc-Ar-CH), 7.63-7.69 (m, 2H, Fmoc-Ar-CH), 7.76-7.78 (m, 2H,
Fmoc-Ar-CH). - 13C NMR (CD3OD, 62.9 MHz): δ 17.9 (+, CH3CH), 18.0 (+, CH3CH), 28.1
(+, cyclopropyl-CH), 28.5 (+, cyclopropyl-CH), 28.6 (+, cyclopropyl-CH), 29.0 (+,
cyclopropyl-CH), 36.6 (+, cyclopropyl-CHN, 2C), 48.4 (+, Fmoc-CH), 50.4 (+, CHN), 52.0
(+, CHN), 52.8 (+, CH3O), 52.9 (+, CH3O), 68.0 (-, Fmoc-CH2), 120.9 (+, Fmoc-Ar-CH, 2C),
126.2 (+, Fmoc-Ar-CH), 126.4 (+, Fmoc-Ar-CH), 128.2 (+, Fmoc-Ar-CH, 2C), 128.8 (+,
Fmoc-Ar-CH, 2C), 142.5 (Cquat, Fmoc-Ar-C), 142.6 (Cquat, Fmoc-Ar-C), 145.1 (Cquat, Fmoc-
Ar-C), 145.4 (Cquat, Fmoc-Ar-C), 158.2 (Cquat, N(CO)O), 169.4 (Cquat, C=O), 171.6 (Cquat,
C=O), 171.9 (Cquat, C=O), 172.4 (Cquat, C=O), 175.9 (Cquat, C=O), 176.5 (Cquat, C=O). –
MS  FAB (MeOH/Glycerine) m/z (%) 665 (MH+, 6), 179 (Fluorenyl cation, 100). - IR (KBr)
3298, 3066, 2955, 1724, 1664, 1529, 1448, 1312 cm-1. - HR MS  calcd for C33H36N4O11 + H
665.24588, found 665.24705.
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CO2MeCO2Me CO2Me
CO2H
(+)-46
(1R, 2R, 3R) 3-{2S-[2R-(2S-{2R-[2S-(9H-fluoren-9-ylmethoxycarbonylamino)-
propionylamino]-3R-methoxycarbonyl-cyclopropane-1R-carbonylamino}-propionylamino)-
3R-methoxycarbonyl-cyclopropane-1R-carbonylamino]-propionylamino}-cyclopropane-1,
2-dicyrboxylic acid mono methyl ester ((+)-46): (+)-45 (200 mg, 0.21 mmol) was dissolved
under nitrogen atmosphere in a mixture MeOH/HCO2H 1/1 (25 ml), then Pd/C 10 % (180 mg)
was added. The reaction mixture was stirred under inert atmosphere 5 h, then it was filtrated
on a 2 cm celite pad and concentrated to afford the product as a white solid (160 mg, 88 %). -
mp 180 °C decomp. - [ ]21Dα  -48.7 (c 0.5, MeOH) - 1H NMR (CD3OD, 250 MHz): δ 1.25 (d,
J = 7.7 Hz, 3H, CH3CH), 1.29(d, J =7.2 Hz, 6H, CH3CH), 2.29-2.32 (m, 2H, cyclopropyl-
CH), 2.44-2.80 (m, 4H, cyclopropyl-CH), 3.58-3.69 (m, 3H, cyclopropyl-CHN), 3.66 (s, 6H,
CH3O), 3.69 (s, 3H, CH3O), 4.07-4.36 (m, 6H, 3 CHN + Fmoc-CH + Fmoc-CH2), 7.25-7.39
(m, 4H, Fmoc-Ar-CH), 7.62-7.68 (m, 2H, Fmoc-Ar-CH), 7.75-7.78 (m, 2H, Fmoc-Ar-CH). -
13C NMR (CD3OD, 62.9 MHz): δ 17.8 (+, CH3CH), 18.0 (+, CH3CH), 18.1 (+, CH3CH), 27.5
(+, cyclopropyl-CH), 27.6 (cyclopropyl-CH, 2C), 28.6 (cyclopropyl-CH), 29.1 (cyclopropyl-
CH, 2C), 36.5 (+, cyclopropylCHN), 36.6 (cyclopropyl-CHN, 2C), 48.4 (+, Fmoc-CH), 50.06
(+, CHN), 50.13 (+, CHN), 52.1 (+, CHN), 52.9 (+, CH3O), 53.0 (+, CH3O), 53.1 (+, CH3O),
68.1 (-, Fmoc-CH2), 121.0 (+, Fmoc-Ar-CH, 2C), 126.3 (+, Fmoc-Ar-CH), 126.4 (+, Fmoc-
Ar-CH), 128.3 (+, Fmoc-Ar-CH, 2C), 128.9 (+, Fmoc-Ar-CH, 2C), 142.55 (Cquat, Fmoc-Ar-
C), 142.60 (Cquat, Fmoc-Ar-C), 145.1 (Cquat, Fmoc-Ar-C), 145.4 (Cquat, Fmoc-Ar-C), 158.3
(Cquat, N(CO)O), 169.5 (Cquat, C=O), 169.6 (Cquat, C=O), 172.48 (Cquat, C=O), 172.54 (Cquat,
C=O), 172.7 (Cquat, C=O), 173.8 (Cquat, C=O), 175.5 (Cquat, C=O), 175.7 (Cquat, C=O), 176.6
(Cquat, C=O). - MS  NI-FAB (MeOH/Glycerine) m/z (%) 875 ((M-H)-, 100). - IR (KBr) 3320,
3065, 2955, 1729, 1656, 1602, 1447, 1317 cm-1. - HR MS calcd for C42H48N6O15 – H
875.30994, found 875.30801.
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MeO2C CO2H
O
O
(±)-69b
(1R*, 2R*, 3S*) 3-Allyloxycarbonyl-cyclopropane-1,2-dicarboxylic acid mono methyl
ester ((±)-69b): (±)-16b (1.353 g, 4.06 mmol) was dissolved in acetone (13 ml). The solution
was added dropwise to a 0.1 M (pH = 7.4) phosphate buffer (170 ml) in an ultrasonic bad. To
this suspension PLE (300 mg, 50 U/mg) was added and the reaction mixture was stirred at
room temperature and at constant pH by addition of a 0.1 M solution of NaOH. After 4 h the
pH was brought to 8 by addition of a 0.1 M NaOH solution and the water solution was
extracted with diethyl ether (100 ml), then the pH of the water phase was brought to 2 by
addition of a 1 M solution of H3PO4, saturated with NaCl and extracted twice with diethyl
ether (150 ml). The organic phase was dried over Na2SO4 and concentrated to yield a mixture
8:1 of the hydrolysed benzyl ester and hydrolysed methyl ester (770 mg, 78 %). (±)-69b
(550 mg, 56 %) could be isolated pure by recrystallisation from diethyl ether/hexanes. - mp
100-101 °C. - 1H NMR (CDCl3, 250 MHz): δ 2.24-2.28 (m, 1H, cyclopropyl-CH), 2.53 (dd,
J = 5.2, 8.5 Hz, 1H, cyclopropyl-CH), 3.77 (s, 3H, CH3O), 3.91-4.06 (m, 1H, cyclopropyl-
CHN), 4.59-4.61 (m, 2H, CH2=), 5.21-5.35 (m, 2H, CH2O), 5.83-5.98 (m, 1H, CH=CH2),
6.21 (s br, 1H, NHAlloc), 10.48 (s br, 1H, CO2H). - 13C NMR (CDCl3, 62.9 MHz): δ 26.0 (+,
cyclopropyl-CH), 28.7 (+, cyclopropyl-CH), 37.6 (+, cyclopropyl-CHN), 52.7 (+, CH3O),
66.3 (-, PhCH2O), 118.5 (-, CH2=), 132.2 (+, CH=CH2), 156.5 (Cquat, N(CO)O), 170.4 (Cquat,
C=O), 174.0 (Cquat, C=O). - MS  PI-EI (70 eV) m/z (%) 243 (M+, 1), 225 (M+-H2O, 3), 211
(M+-CH3OH, 3), 202 (M+-C3H5, 3), 158 (M+-Alloc, 27), 140 (22), 114 (23), 82 (23), 41
(C3H5+, 100). - IR (KBr) 3354, 3069, 3022, 2890, 1737, 1700, 1516, 1441, 1316, 1236 cm-1. -
HR MS  calcd for C10H13NO6 243.07429, found 243.07441.
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2.2.3 Coupling at the C-terminus
NH
CO2Me
O
Et2N
O
(±)-34
(1R*, 2R*, 3R*) 2-acetylamino-3-diethyl-carbamoyl-cyclopropane carboxylic acid
methyl ester ((±)-34): (±)-29 (200 mg, 0.99 mmol) was dissolved in CH2Cl2 (60 ml) and
DMF to ensure solubilisation (3 ml). To this solution EDC (190 mg, 0.99 mmol, 1 eq.) and
HOBt (133 mg, 0.99 mmol, 1 eq.) were added. The mixture was cooled in an ice bath, then
diethylamine (156 µl, 109 mg, 1.5 mmol, 1.5 eq.) was added. The mixture was stirred
overnight at room temperature. The solution was then concentrated in vacuum and the product
was isolated by chromatography (CHCl3/MeOH 50:1) as a white solid (165 mg, 65 %). The
reaction resulted in 25 % epimerization, but the epimer could be easily separated by
chromatography. - Rf ((±)-34): 0.18. - mp 97-98 °C. - 1H NMR (CDCl3, 250 MHz) δ 1.06 (t,
J = 7.1 Hz, 3H, CH3CH2), 1.17 (t, J = 7.1 Hz, 3H, CH3CH2), 1.89 (s, 3H, CH3C=O), 2.28 (dd,
J = 5.1, 5.1 Hz, 1H, cyclopropyl-CH), 2.48 (dd, J = 5.2, 8.3 Hz, 1H, cyclopropyl-CH), 3.27-
3.54 (m, 4H, CH2CH3), 3.64 (s, 3H, CH3O), 3.98 (ddd, J = 4.4, 8.1, 8.1 Hz, 1H, cyclopropyl-
CHN), 7.35 (d, J = 7.7 Hz, 1H, NH). - 13C NMR (CDCl3, 62.9 MHz) δ 12.9 (+, CH3CH2),
14.6 (+, CH3CH2), 23.1 (+, CH3C=O), 24.7 (+, cyclopropyl-CH), 27.6 (+, cyclopropyl-CH),
36.6 (+, cyclopropyl-CHN), 41.1 (-, CH2), 42.6 (-, CH2), 52.1 (+, CH3O), 167.7 (Cquat, C=O),
170.6 (Cquat, C=O), 171.1 (Cquat, C=O). - MS  CI( NH3) m/z (%) 513 (2MH+, 12), 272
(MNH4+, 4), 257 (MH+, 100). - IR (KBr) 3297, 3035, 2973, 1732, 1677, 1626, 1534, 1446,
1314 cm-1. - Anal. Calcd for C12H20N2O4 (256.301): C, 56.24; H, 7.86; N, 10.93. Found: C,
56.25; H, 7.84; N, 10.76.
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MeO2C
(±)-35a
(1R*, 2R*, 3R*) 2-acetylamino-3-(methoxycarbonyl-methyl-carbamoyl)-cyclopropane
carboxylic acid methylester ((±)-35a): Glycine methylester hydrochloride (328 mg,
2.61 mmol, 1.5 eq.) was suspended in CH2Cl2 (50 ml) and triethylamine (363 µl, 2.61 mmol,
1.5 eq.) was added. To this solution EDC (334 mg, 1.74 mmol, 1 eq.), HOBt (234 mg,
1.74 mmol, 1 eq.) and (±)-29 (350 mg, 1.74 mmol, 1 eq.) were added at 0 °C. The mixture
was stirred overnight at room temperature. The solution was then concentrated in vacuum and
the product was obtained by chromatography (CHCl3/MeOH 60:1) as a white solid (459 mg,
97 %). - Rf ((±)-35a): 0.05. - mp 125-126 °C. - 1H NMR (CDCl3, 250 MHz) δ 1.98 (s, 3H,
CH3C=O), 2.33 (dd, J = 5.0,5.0 Hz, 1H, cyclopropyl-CH), 2.46 (dd, J = 5.1, 8.3 Hz, 1H,
cyclopropyl-CH), 3.70 (s, 3H, CH3O), 3.77 (s, 3H, CH3O), 4.03-4.12 (m, 3H, cyclopropyl-
CHN + CH2N), 6.90 (t, J = 4.9 Hz, 1H, NH), 7.00 (d, J = 8.3 Hz, 1H, NH). - 13C NMR
(CDCl3, 62.9 MHz) δ 23.2 (+, CH3C=O), 27.1 (+, cyclopropyl-CH), 27.8 (+, cyclopropyl-
CH), 36.3 (+, cyclopropyl-CHN), 41.5 (-, CH2N), 52.3 (+, CH3O), 52.5 (+, CH3O), 169.1
(Cquat, C=O), 169.7 (Cquat, C=O), 170.58 (Cquat, C=O), 170.65 (Cquat, C=O). - MS  CI (NH3)
m/z (%) 290 (MNH4+, 18), 273 (MH+, 12), 258 (MH+-CH3, 100), 241 (MH+-CH3O), 216 (6),
201 (8). - IR (KBr) 3315, 3248, 3069, 2955, 1760, 1731,. 1670, 1649, 1565, 1547, 1445,
1375, 1319 cm-1. - Anal. Calcd for C11H16N2O6 (272.26): C, 48.53; H, 5.92; N, 10.29. Found:
C, 48.25; H, 5.88; N, 10.10.
NH
CO2Me
O
H
N
O
BnO2C
(±)-35b
(1R*, 2R*, 3R*) 2-acetylamino-3 (1S-benzyloxycarbonyl-ethylcarbamoyl)-cyclopropane
carboxylic acid methylester ((±)-35b): The Boc-alanine benzyl ester (474 mg, 1.7 mmol,
1.5 eq.) was deprotected by treatment with HCl 3 M in ethyl acetate (15 ml) for 3 h at 0 °C.
The solution was then concentrated in vacuum, the salt resuspended in CH2Cl2 (50 ml) and
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triethylamine (236 µl, 1.7 mmol, 1.5 eq.) was added dropwise. To this solution EDC (219 mg,
1.14 mmol, 1 eq.) and HOBt (154 mg, 1.14 mmol, 1 eq.) were added. The mixture was cooled
in an ice bath, then (±)-29 (230 mg, 1.14 mmol) dissolved in CH2Cl2 (20 ml) was added. The
mixture was stirred at room temperature overnight. The solution was then concentrated in
vacuum and the product was obtained by chromatography (CHCl3/MeOH 60:1) as a white
solid (285 mg, 69 %). - Rf ((±)-35b): 0.06. - mp 106-108 °C. - 1H NMR (CDCl3, 400 MHz)
δ 1.43 (d, J = 7.2 Hz, 3H, CH3CH, 1 diast.), 1.44 (d, J = 7.2 Hz, 3H, CH3CH, 1 diast.), 1.93
(s, 3H, CH3C=O, 1 diast.), 1.96 (s, 3H, CH3O, 1 diast.), 2.29 (dd, J = 5.2, 9.9 Hz, 1H,
cyclopropyl-CH), 2.37-2.44 (m, 1H, cyclopropyl-CH), 3.68 (s, 3H, CH3O, 1 diast.), 3.69 (s,
3H, CH3O, 1 diast.), 4.03-4.12 (m, 1H, cyclopropyl-CHN), 4.55-4.63 (m, 1H, Ala-CHN),
5.14-5.23 (m, 2H, CH2O), 7.04 (d, J = 8.3 Hz, 1H, NH, 1 diast.), 7.11-7.12 (m, 3H, NH, 2 NH
of one diast. + 1 NH of the other), 7.32-7.39 (m, 5H, Ph-CH). - 13C NMR (CDCl3,
100.6 MHz) δ 17.9 (+, CH3CH, 1 diast.), 18.0 (+, CH3CH, 1 diast.), 23.20 (+, CH3C=O, 1
diast.), 23.22 (+, CH3C=O, 1 diast.), 26.90 (+, cyclopropyl-CH, 1 diast.), 26.94 (+,
cyclopropyl-CH, 1 diast.), 27.56 (+, cyclopropyl-CH, 1 diast.), 27.61 (+, cyclopropyl-CH, 1
diast.), 36.18 (+, cyclopropyl-CHN, 1 diast.), 36.20 (+, cyclopropyl-CHN, 1 diast.), 48.49 (+,
CHN, 1 diast.), 48.54 (+, CHN, 1 diast.), 52.29 (+, CH3O, 1 diast.), 52.31 (+, CH3O, 1 diast.),
67.2 (-, CH2O, 1 diast.), 67.3 (-, CH2O, 1 diast.), 128.06 (+, Ph-CH, 1 diast., 2C), 128.12 (+,
Ph-CH, 1 diast., 2C), 128.4 (+, Ph-CH), 128.6 (+, Ph-CH, 2C), 135.1 (Cquat, Ph-C), 168.4
(Cquat, C=O, 1 diast.), 168.5 (Cquat, C=O, 1 diast.), 170.71 (Cquat, C=O, 1 diast.), 170.76 (Cquat,
C=O, 1 diast.), 170.79 (Cquat, C=O, 1 diast.), 170.81 (Cquat, C=O, 1 diast.), 172.26 (Cquat, C=O,
1 diast.), 172.31 (Cquat, C=O, 1 diast). - MS  CI (NH3) m/z (%) 725 (2MH+, 6), 380 (MNH4+,
100), 363 (MH+, 45), 348 (14). - IR (KBr) 3297, 3059, 2980, 2935, 1734, 1654, 1546, 1450,
1370, 1319, 1213 cm-1. - Anal. Calcd for C18H22N2O6 (362.38): C, 59.66; H, 6.12; N, 7.73.
Found: C, 59.55; H, 6.12; N, 7.67.
NH
CO2Me
O
Me
N
O
BnO2C
(±)-35c
(1R*, 2R*, 3R*) 2-acetylamino-3-(1S-benzyloxycarbonyl-ethyl-methylcarbamoyl)-
cyclopropane carboxylic acid methylester ((±)-35c): N-methyl Boc-alanine benzyl ester
(589 mg, 2.01 mmol, 1.5 eq.) was deprotected by treatment with HCl 3 M in ethyl acetate
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(8 ml) for 3 h at 0 °C. The solution was then concentrated in vacuum, the salt was
resuspended in CH2Cl2 (50 ml) and triethylamine (280 µl, 2.01 mmol, 1.5 eq.) was added
dropwise. To this solution EDC (257 mg, 1.34 mmol, 1 eq.) and HOBt (181 mg, 1.34 mmol,
1 eq.) were added. The mixture was cooled in an ice bath and (±)-29 (270 mg, 1.34 mmol)
dissolved in CH2Cl2 (20 ml) was added. The mixture was stirred overnight at room
temperature. The solution was then concentrated in vacuum and the product was obtained by
chromatography (CHCl3/MeOH 80:1) as a colourless oil (488 mg, 97 %). 10 % epimerisation
was observed. - Rf ((±)-35c): 0.07. - 1H NMR (CDCl3, 250 MHz) δ 1.43 (d, J = 5.7 Hz,
CH3CH, 3H, 1 diast.), 1.46 (d, J = 5.8 Hz, 3H, CH3CH, 1 diast.), 1.52 (d, J = 5.7 Hz, 3H,
CH3CH, 1 diast. epimer), 1.54 (d, J = 5.7 Hz, 3H, CH3CH, 1 diast. epimer), 1.90 (s, 3H,
CH3C=O, 1 diast. epimer), 1.91 (s, 3H, CH3C=O, 1 diast. epimer), 1.94 (s, 3H, CH3C=O, 1
diast.), 1.95 (s, 3H, CH3C=O, 1 diast.), 2.26 (dd, J = 4.9, 4.9 Hz, 1H, cyclopropyl-CH 1 diast.
epimer), 2.34 (dd, J = 4.6, 5.2 Hz, 1H, cyclopropyl-CH, 1 diast.), 2.39 (dd, J = 4.5, 5.1 Hz,
1H, cyclopropyl-CH, 1 diast.), 2.52 (dd, J = 5.2, 8.4 Hz, 1H, cyclopropyl-CH, 1 diast.
epimer), 2.56 (dd, J = 5.3, 8.3 Hz, 1H, cyclopropyl-CH, 1 diast. epimer), 2.62 (dd, J = 4.9,
4.9 Hz, 1H, cyclopropyl-CH, 1 diast.), 2.66 (dd, J = 4.9, 4.9 Hz, 1H, cyclopropyl-CH, 1
diast.), 2.85 (s, 3H, CH3N, 1 diast. epimer), 2.86 (s, 3H, CH3N, 1 diast. epimer), 3.08 (s, 3H,
CH3N, 1 diast.), 3.09 (s, 3H, CH3N, 1 diast.), 3.71 (s, 3H, CH3O, 1 diast. epimer + 1 diast.),
3.72 (s, 3H, CH3O, 1 diast.), 3.76 (s, 3H, CH3O, 1 diast. epimer), 3.99-4.08 (m, 1H,
cyclopropyl-CHN), 5.07-5.20 (m, 3H, CH2O + CHN), 6.58 (d, J = 7.5 Hz, 1H, NH, 1 diast.
epimer), 6.88 (d, J = 7.3 Hz, 1H, NH, 1 diast.), 7.00 (d, J = 7.5 Hz, 1H, NH, 1 diast. epimer),
7.11 (d, J = 7.2 Hz, 1H, NH, 1 diast.), 7.29-7.38 (m, 5H, Ph-CH). - 13C NMR (CDCl3,
62.9 MHz) δ 14.3 (+, CH3CH, 1 diast.), 14.5 (+, CH3CH, 1 diast.), 15.6 (+, CH3CH, 1 diast.
epimer), 23.1 (+, CH3C=O, 1 diast. + epimer), 23.2 (+, CH3C=O, 1 diast. + epimer), 24.8 (+,
cyclopropyl-CH, 1 diast. epimer), 24.9 (+, cyclopropyl-CH, 1 diast.), 25.4 (+, cyclopropyl-
CH, 1 diast. epimer), 25.8 (+, cyclopropyl-CH, 1 diast.), 27.6 (+, cyclopropyl-CH, 1 diast.),
27.9 (+, cyclopropyl-CH, 1 diast.), 28.0 (+, cyclopropyl-CH, 1 diast. epimer), 28.8 (+,
cyclopropyl-CH, 1 diast. epimer), 29.3 (+, CH3N, 1 diast. epimer), 29.5 (+, CH3N, 1 diast.
epimer), 32.2 (+, CH3N,1 diast.), 32.5 (+, CH3N,1 diast.), 36.1 (+, cyclopropyl-CHN, 1 diast.
epimer), 36.4 (+, cyclopropyl-CHN, 1 diast.), 36.6 (+, cyclopropyl-CHN, 1 diast. epimer),
36.7 (+, cyclopropyl-CHN, 1 diast.), 52.3 (+, CH3O, 1 diast. + epimer), 52.37 (+, CH3O, 1
diast. + 1 diast. epimer), 53.18 (+, CHN, 1 diast ), 53.22 (+, CHN, 1 diast.), 55.5 (+, CHN, 1
diast. epimer), 55.6 (+, CHN, 1 diast. epimer), 67.06 (-, CH2O, 1 diast.), 67.15 (-, CH2O, 1
diast.), 67.5 (-, CH2O, 1 diast. epimer), 67.6 (+, CH2O, 1 diast. epimer), 128.1-135.5
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(Aromatics CH and Cquat), 168.8 (Cquat, C=O, 1 diast. + 1 diast. epimer), 169.2 (Cquat, C=O, 1
diast. + 1 diast. epimer), 170.6 (Cquat, C=O, 1 diast. + 1 diast. epimer), 170.91 (Cquat, C=O, 1
diast. + 1 diast. epimer), 170.97 (Cquat, C=O, 1 diast. + 1 diast. epimer), 171.0 (Cquat, C=O, 1
diast. + epimer), 171.1 (Cquat, C=O, 1 diast. + 1 diast. epimer), 171.3 (Cquat, C=O, 1 diast. + 1
diast. epimer). - MS  CI (NH3) m/z (%) 753 (2MH+, 4), 394 (MNH4+, 53), 377 (MH+, 100),
301 (MH+-Phenyl, 6). - IR (CH2Cl2) 3373, 1732, 1679, 1634, 1606 cm-1. - Anal. Calcd for
C19H24N2O6 ⋅ 0.33 H2O (381.81): C, 59.77; H, 6.49; N, 7.34. Found: C, 59.76; H, 6.51; N,
7.34. - HR MS  calcd for C19H24N2O6 376.16344, found 376.16285.
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(1R, 2R, 3R) and (1S, 2S, 3S) 2-(1S-Benzyloxycarbonyl-ethylcarbamoyl)-3-(2S-tert-
butyloxycarbonylamino-propionyl)-cyclopropane carboxylic acid methyl ester ((+)-36a
and (-)-36a): The N-Boc alanine benzyl ester (381 mg, 1.36 mmol, 1.5 eq.) was deprotected
by treatment with HCl 3 M in ethyl acetate (4 ml) for 3 h at 0 °C. The solution was then
concentrated in vacuum, the salt resuspended in CH2Cl2 (50 ml) and triethylamine (190 µl,
1.36 mmol, 1.5 eq.) was added dropwise. To this mixture EDC (175 mg, 0.91 mmol, 1 eq.)
and HOBt (123 mg, 0.91 mmol, 1 eq.) were added. The mixture was cooled in an ice bath,
then (±)-30a (300 mg, 0.91 mmol) dissolved in CH2Cl2 (20 ml) was added. The mixture was
stirred overnight at room temperature. The solution was then concentrated in vacuum and the
product was obtained by chromatography (CHCl3/MeOH 40:1) as a white solid (410 mg,
92 %, a mixture of two diastereomer). The two diastereomers can be separated by
recrystallization from ethyl acetate/hexanes. The pure diastereomers can be obtained with the
same procedure from diastereomerically pure 30a (yield 92 % for (+)-36a and 90 % for
(-)-36a). – (+)-36a: Rf ((+)-36a): 0.17. - mp 157-159 °C. - [ ]21Dα  -18.7 ° (c 1, CHCl3). -
1H NMR (CDCl3, 250 MHz) δ 1.32 (d, J = 7.1 Hz, 3H, CH3CH), 1,40 (d, J = 7.5 Hz, 3H,
CH3CH), 1.43 (s, 9H, (CH3)3C), 2.31 (dd, J = 4.8, 4.9 Hz, 1H, cyclopropyl-CH), 2.39 (dd, J =
5.2, 8.2 Hz, 1H, cyclopropyl-CH), 3.69 (s, 3H, CH3O), 4.01-4.14 (m, 2H, CHN), 4.59 (dq, J =
7.2, 7.2 Hz, 1H, CHN), 5.06 (d, J = 7.3 Hz, 1H, NHBoc), 5.12-5.23 (m, 2H, CH2O), 6.90 (d,
J = 7.3 Hz, 1H, NH), 7.33-7.37 (m, 5H, Ph-CH), 7.61 (d, J = 8.2 Hz, 1H, NH). - 13C NMR
(CDCl3, 62.9 MHz) δ 18.2 (+, CH3CH), 18.8 (+, CH3CH), 27.2 (+, cyclopropyl-CH), 27.6 (+,
(+)-36a (-)-36a
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cyclopropyl-CH), 28.3 (+, (CH3)3C, 3C), 36.1 (+, cyclopropyl-CHN), 48.5 (+, CHN), 50.3 (+,
CHN), 52.4 (+, CH3O), 67.4 (-, CH2O), 80.0 (Cquat, (CH3)3C), 128.2 (+, Ph-CH, 2C), 128.5 (+,
Ph-CH), 128.7 (+, Ph-CH, 2C), 135.2 (Cquat, Ph-C), 155.2 (Cquat, N(CO)O), 168.2 (Cquat,
C=O), 170.7 (Cquat, C=O), 172.5 (Cquat, C=O), 173.4 (Cquat, C=O). - MS  CI (NH3) m/z (%)
509 (MNH4+, 50), 492 (MH+, 78), 392 (MH+-Boc, 30), 293 (37), 279 (100), 182 (44). - IR
(KBr) 3331, 3294, 2983, 1739, 1657, 1538, 1451 cm-1. - Anal. Calcd for C24H33N3O8
(491.54): C, 58.64; H, 6.77; N, 8.55. Found: C, 58.70; H, 6.74; N, 8.44. – (-)-36a: Rf
((-)-36a): 0.17. - mp 65-67 °C. - [ ]α Dr t. .  -21.6 ° (c 1, CHCl3). - 1H NMR (CDCl3, 250 MHz)
δ 1.30 (d, J = 7.1 Hz, 3H, CH3CH), 1,43 (d, J = 7.0 Hz, 3H, CH3CH), 1.42 (s, 9H, (CH3)3C),
2.32 (dd, J = 4.8, 4.8 Hz, 1H, cyclopropyl-CH), 2.42 (dd, J = 5.1, 8.3 Hz, 1H, cyclopropyl-
CH), 3.70 (s, 3H, CH3O), 4.01 (ddd, J = 4.5, 8.0, 8.0 Hz, 1H, cyclopropyl-CHN), 4.07-4.16
(m, 1H, CHN), 4.57 (dq, J = 7.2, 7.2 Hz, 1H, CHN), 5.04 (s br, 1H, NH), 5.13-5.23 (m, 2H,
CH2O), 6.85 (d, J = 7.2 Hz, 1H, NH), 7.29-7.36 (m, 6H, Ph-CH + NH). - 13C NMR (CDCl3,
62.9 MHz) δ 17.9 (+, CH3CH), 18.6 (+, CH3CH), 27.4 (+, cyclopropyl-CH), 27.5 (+,
cyclopropyl-CH), 28.3 (+, (CH3)3C, 3C), 36.0 (+, cyclopropyl-CHN), 48.5 (+, CHN), 48.7 (+,
CHN), 52.4 (+, CH3O), 67.4 (-, CH2O), 80.0 (Cquat, (CH3)3C), 128.2 (+, Ph-CH, 2C), 128.6 (+,
Ph-CH), 128.7 (+, Ph-CH, 2C), 135.2 (Cquat, Ph-C), 155.2 (Cquat, N(CO)O), 168.0 (Cquat,
C=O), 170.8 (Cquat, C=O), 172.4 (Cquat, C=O), 173.0 (Cquat, C=O). - MS  CI (NH3) m/z (%)
1000 (2MNH4+, <1), 983 (2MH+, <1), 883 (2MH+-Boc, <1), 509 (MNH4+, 70), 492 (MH+,
100), 477 (88), 392 (MH+-Boc, 69), 279 (82). - IR (KBr) 3321, 3281, 2983, 1739, 1664, 1539,
1520, 1457 cm-1. - Anal. Calcd for C24H33N3O8 (491.54): C, 58.64; H, 6.77; N, 8.55. Found:
C, 58.36; H, 6.67; N, 8.49.
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(1R, 2R, 3R) and (1S, 2S, 3S) 2-[(1S-Benzyloxycarbonyl-ethyl)-methyl-carbamoyl]-3-(2S-
tert-butyloxycarbonylamino-propionyl)-cyclopropane carboxylic acid methyl ester
((+)-36b and (-)-36b): N-methyl Boc-alanine benzyl ester (510 mg, 1.74 mmol, 1.5 eq.) was
deprotected by treatment with HCl 3 M in ethyl acetate (10 ml) for 3 h at 0 °C. Then the
solution was concentrated in vacuum, the salt was resuspended in CH2Cl2 (50 ml) and
triethylamine (201 µl, 1.4 mmol, 1.7 eq.) was added dropwise. To this mixture EDC (180 mg,
(+)-36b (-)-36b
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0.93 mmol, 1.1 eq.) and HOBt (125 mg, 0.93 mmol, 1.1 eq.) were added. The mixture was
cooled in an ice bath, then (±)-30a (280 mg, 0.85 mmol) dissolved in CH2Cl2 (20 ml) was
added. The mixture was stirred overnight at room temperature. The solution was then
concentrated in vacuum and the product was obtained by chromatography (CHCl3/MeOH
60:1) as a white solid (337 mg, 78 %, a mixture of two diastereomer). The two diastereomers
can be obtained pure by reacting the diastereomerically pure acid with the same procedure
described before and with the same yields. - Rf (36b): 0.16. – (+)-36b: mp 52-54 °C. - [ ]21Dα
-59.3 ° (c 1, MeOH). - 1H NMR (CDCl3, 400 MHz) δ  1.32 (d, J = 7.1 Hz, 3H, CH3CH), 1.40
(d, J = 7.4 Hz, 3H, CH3CH), 1.43 (s, 9H, (CH3)3C), 2.36 (dd, J = 4.9, 4.9 Hz, 1H,
cyclopropyl-CH), 2.62 (dd, J = 5.3, 8.3 Hz, 1H, cyclopropyl-CH), 3.05 (s, 3H, CH3N), 3.72
(s, 3H, CH3O), 4.03 (ddd, J = 4.4, 8.0, 8.0 Hz, 1H, cyclopropyl-CHN), 4.09-4.15 (m, 1H,
CHN), 4.99 (d, J = 7.0 Hz, 1H, NH), 5.16 (s, 2H, CH2O), 5.19-5.23 (m, 1H, CHN), 7.33-7.36
(m, 5H, Ph-CH), 7.64 (d, J = 7.5 Hz, 1H, NH). - 13C NMR (CDCl3, 100.6 MHz) δ 14.5 (+,
CH3CH), 18.8 (+, CH3CH), 24.7 (+, cyclopropyl-CH), 28.0 (+, cyclopropyl-CH), 28.3 (+,
(CH3)3C, 3C), 32.0 (+, CH3N), 36.6 (+, cyclopropyl-CHN), 52.4 (+, CHN), 52.6 (+, CH3O),
55.6 ( +, CHN), 67.1 (-, CH2O), 80.0 (Cquat, C(CH3)3), 128.1 (+, Ph-CH, 2C), 128.4 (+, Ph-
CH), 128.6 (+, Ph-CH, 2C), 135.5 (Cquat, Ph-C), 155.1 (Cquat, N(C=O)O), 169.1(Cquat, C=O),
170.9 (Cquat, C=O), 171.2 (Cquat, C=O), 173.4 (Cquat, C=O). - MS  FAB (NBA/CH2Cl2) m/z
(%) 1011 (2M+, 9), 506 (MH+, 100), 317 (32), 307 (37). - IR (CH2Cl2) 3322,2980, 1737,
1676, 1640, 1519 cm-1. - Anal. Calcd for C25H35N3O8 (505.57): C, 59.39; H, 6.98; N, 8.31.
Found: C, 59.14; H, 7.11; N, 8.19. – (-)-36b: mp not measurable, very hygroscopic. - [ ]21Dα
-52.5 (c 1, MeOH). - 1H NMR (CDCl3, 400 MHz) δ  1.30 (d, J = 7.1 Hz, 3H, CH3CH), 1.43-
1.46 (d, J = not measurable: it lays under the Boc signal, 3H, CH3CH), 1.43 (s, 9H, (CH3)3C),
2.43-2.45 (m, 1H, cyclopropyl-CH), 2.66 (dd, J = 5.2, 8.4 Hz, 1H, cyclopropyl-CH), 3.07 (s,
3H, CH3N), 3.72 (s, 3H, CH3O), 3.99 (ddd, J = 4.3, 8.0, 8.0 Hz, 1H, cyclopropyl-CHN), 4.16-
4.18 (m, 1H, CHN), 5.09-5.21 (m, 4H, CH2O + CHN + NH), 7.18 (d, J = 6.3 Hz, 1H, NH),
7.34-7.36 (m, 5H, Ph-CH). - 13C NMR (CDCl3, 100.6 MHz) δ 14.3 (+, CH3CH), 18.5 (+,
CH3CH), 26.5 (+, cyclopropyl-CH), 27.2 (+, cyclopropyl-CH), 28.3 (+, (CH3)3C, 3C), 31.9
(+, CH3N), 36.1 (+, cyclopropyl-CHN), 52.4 (+, CHN), 53.0 (+, CH3O), 55.5 ( +, CHN), 67.2
(-, CH2O), 79.9 (Cquat, C(CH3)3), 128.1 (+, Ph-CH, 2C), 128.5 (+, Ph-CH), 128.8 (+, Ph-CH,
2C), 135.3 (Cquat, Ph-C), 155.3 (Cquat, N(C=O)O), 168.4 (Cquat, C=O), 170.9 (Cquat, C=O),
171.6 (Cquat, C=O), 173.7 (Cquat, C=O). - MS  FAB (MeOH/Glycerine) m/z (%) 506 (MH+,
100), 450 (MH+-tBu, 42), 407 (MH+-Boc, 75), 317 (69). - IR (CDCl3) 3431, 3370, 2982,
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1727, 1685, 1639, 1494 cm-1. - HR MS  calcd for C25H35 N3O8 + H506.25024, found
506.24853.
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(+)-37a
(1R, 2R, 3R) 2-[1S-(1S-Benzyloxycarbonyl-2-phenyl-ethylcarbamoyl)-ethylcarbamoyl]-3-[2S-
(2S-tert-butoxycarbonylamino-3-phenyl-propionylamino)-propionylamino]-cyclopropane
carboxylic acid methyl ester ((+)-37a): Boc-phenylalanylalanine benzyl ester (492 mg,
1.15 mmol, 1.1 eq.) was deprotected by treatment with HCl 3 M in ethyl acetate (20 ml) for
3 h at 0 °C. The solution was concentrated in vacuum, the salt was resuspended in CH2Cl2
(50 ml) and triethylamine (160 µl, 1.15 mmol, 1.1 eq.) was added dropwise. To this mixture
EDC (201 mg, 1.05 mmol, 1 eq.) and HOBt (142 mg, 1.05 mmol, 1 eq.) were added. The
mixture was cooled in an ice bath, then (+)-31a acid (500 mg, 1.05 mmol) dissolved in
CH2Cl2 (20 ml) was added. The mixture was stirred overnight at room temperature. The
solution was concentrated in vacuum and the product was obtained by chromatography
(CHCl3/MeOH 20:1) as a white solid (820 mg, 99 %). - Rf ((+)-37a): 0.27. - mp 185-186 °C. -
[ ]α Dr t. .  -56.0 (c 1, MeOH). - 1H NMR (CD3OD, 250 MHz) δ 1.19 (d, J = 7.1 Hz, 3H, CH3CH),
1.29 (d, J = 7.1 Hz, 3H, CH3CH), 1.34 (s, 9H, (CH3)3C), 2.38-2.48 (m, 2H, cyclopropyl-CH),
2.80 (dd, J = 13.7, 9.7 Hz, 1H, CH2Ph), 2.98 (dd, J = 13.8, 8.0 Hz, 1H, CH2Ph), 3.08-3.18 (m,
2H, CH2Ph), 3.61 (dd, J 8.4, 4.7 Hz, 1H, cyclopropyl-CHN), 3.73 (s, 3H, CH3O), 4.25-4.33
(m, 3H, CHN), 4.65 (dd, J = 7.9, 6.2 Hz, 1H, CHN), 5.10 (s, 2H, CH2O), 7.09-7.36 (m, 15H,
Ph-CH). - 13C NMR (CD3OD, 62.9 MHz) δ 17.8 (+, CH3CH), 18.0 (+, CH3CH), 27.4 (+,
cyclopropyl-CH), 28.6 (+, (CH3)3C, 3C), 29.3 (+, cyclopropyl-CH), 36.7 (+, cyclopropyl-
CHN), 38.3 (-, CH2Ph), 39.1 (-, CH2Ph), 50.3 (+, CHN), 50.4 (+, CHN), 55.3 (+, CHN), 57.2
(+, CHN), 68.1 (-, CH2O), 80.7 (Cquat, C(CH3)3), 127.7 (+, Ph-CH), 127.8 (+, Ph-CH), 129.37
(+, Ph-CH), 129.42 (+, Ph-CH, 2C) 129.47 (+, Ph-CH, 2C), 129.49 (+, Ph-CH, 2C), 129.6 (+,
Ph-CH, 2C), 130.4 (+, Ph-CH, 2C), 130.5 (+, Ph-CH, 2C), 137.0 (Cquat, Ph-C), 137.9 (Cquat,
Ph-C), 138.7 (Cquat, Ph-C), 157.6 (Cquat, C=O Boc), 169.1 (Cquat, C=O), 172.4 (Cquat, C=O),
172.6 (Cquat, C=O), 174.1 (Cquat, C=O), 174.5 (Cquat, C=O), 175.6 (Cquat, C=O). - MS FAB
(Glycerin/MeOH) m/z (%) 786 (MH+, 40), 686 (MH+-Boc). - IR (KBr) 3302, 3064, 2978,
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1734, 1649, 1526, 1453 cm-1. - Anal. Calcd for C42H51N5O10 (785.89): C, 64.19; H, 6.54; N,
8.91. Found: C, 64.09; H, 6.54; N, 8.88.
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(-)-37a
(1S, 2S, 3S) 2-[1S-(1S-Benzyloxycarbonyl-2-phenyl-ethylcarbamoyl)-ethylcarbamoyl]-
3-[2S-(2S-tert-butoxycarbonylamino-3-phenyl-propionylamino)-propionylamino]-
cyclopropane carboxylic acid methyl ester ((-)-37a) : Boc-phenylalanylalanine benzyl ester
(492 mg, 1.15 mmol, 1 eq.) was deprotected by treatment with HCl 3 M in ethyl acetate
(15 ml) for 3 h at 0 °C. Then the solution was concentrated in vacuum, the salt resuspended in
CH2Cl2 (50 ml) and triethylamine (160 µl, 1.15 mmol, 1.1 eq.) was added dropwise. To this
mixture EDC (201 mg, 1.05 mmol, 1 eq.) and HOBt (142 mg, 1.05 mmol, 1 eq.) were added.
The mixture was cooled in an ice bath, then (-)-31a (500 mg, 1.05 mmol) dissolved in CH2Cl2
(20 ml) was added. The mixture was stirred overnight at room temperature. The solution was
then concentrated in vacuum and the product was obtained by chromatography
(CHCl3/MeOH 25:1) as a white solid (700 mg, 85 %). - Rf ((-)-37a): 0.31. - mp 52-54 °C. -
[ ]α Dr t. .  -34.0 ° (c 1, CHCl3). - 1H NMR (CDCl3, 400 MHz) δ 1.25 (d, J = 7.0 Hz, 3H, CH3CH),
1.30 (d, J = 7.0 Hz, 3H, CH3CH), 1.36 (s, 9H, (CH3)3C), 2.32-2.33 (m, 2H, cyclopropyl-CH),
2.99-3.08 (m, 1H, CH2Ph), 3.10-3.15, m, 2H, CH2Ph), 3.21 (dd, J = 5.8, 13.6, 1H, CH2Ph),
3.71 (s, 3H, CH3O), 3.78 (dd, J = 6.3, 12.2 , 1H, cyclopropyl-CHN), 4.40-4.49 (m, 3H, CHN),
4.86 ( dd, J = 6.4, 13.7 , 1H, CHN), 5.03 (d, J = 7.8 Hz, 1H, NH), 5.14 (d, J = 12.2 Hz, 1H,
CH2O), 5.20 (d, J = 12.2 Hz, 1H, CH2O), 6.49 (d, J = 7.3 Hz, 1H, NH), 6.83 (d, J = 6.2 Hz,
1H, NH), 6.92 (d, J = 7.5 Hz, 1H, NH), 7.06 (s br, 1H, NH), 7.17-7.38 (m, 15H, Ph-CH). -
13C NMR (CDCl3, 100.6 MHz) δ 17.7 (+, CH3CH), 18.0 (+, CH3CH), 27.5 (+, cyclopropyl-
CH), 27.9 (+, cyclopropyl-CH), 28.2 (+, (CH3)3C, 3C), 35.7 (+, CHN), 37.3 (-, CH2Ph), 38.2
(-, CH2Ph), 48.7 (+, CHN), 49.0 (+, CHN), 52.4 (+, CH3O), 53.3 (+, CHN), 53.6 (+, CHN),
67.6 (-, CH2O), 80.0 (Cquat, C(CH3)3), 126.9 (+, Ph-CH), 127.2 (+, Ph-CH), 128.51 (+, Ph-CH,
2C), 128.53 (+, Ph-CH, 2C), 128.55 (+, Ph-CH), 128.56 (+, Ph-CH, 2C), 128.6 (+, Ph-CH,
2C), 129.31 (+, Ph-CH, 2C), 129.35 (+, Ph-CH, 2C), 134.9 (Cquat, Ph-C), 135.7 (Cquat, Ph-C),
136.7 (Cquat, Ph-C), 155.4 (Cquat, C=O Boc), 167.7 (Cquat, C=O), 170.7 (Cquat, C=O), 171.31
(Cquat, C=O), 171.34 (Cquat, C=O), 171.7 (Cquat, C=O), 172.9 (Cquat, C=O). - MS  FAB
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(NBA/CH2Cl2) m/z (%) 1571 (2MH+, 5), 786 (MH+, 82), 686 (M+-Boc, 100), 450 (19), 307
(59), 289 (24). - IR (KBr) 3300, 3062, 2978, 1727, 1659, 1641, 1529, 1170 cm-1. - Anal.
Calcd for C42H51N5O10 . 0.5H2O (794.90): C, 63.46; H, 6.59; N, 8.81. Found: C, 63.49; H,
6.61; N, 8.75.
N
H
CO2Me
OH
N
O
BocHN
H
N
O
N
H
O
CO2Me
(+)-37b
(1R, 2R, 3R) 2-[1S-(Methyloxycarbonyl-methyl-carbamoyl)-ethylcarbamoyl]-3-[2S-(tert-
butoxycarbonylamino-acetylamino)-propionylamino]-cyclopropane carboxylic acid
methyl ester ((+)-37b): Boc-glycylalanine methyl ester (227 mg, 1.16 mmol, 1.5 eq.) was
deprotected by treatment with HCl 3 M in ethyl acetate (10 ml) for 3 h at 0 °C. The solution
was concentrated in vacuum, the salt was resuspended in CH2Cl2 (50 ml) and triethylamine
(161 µl, 1.16 mmol, 1.5 eq.) was added dropwise. To this mixture EDC (163 mg, 0.85 mmol,
1.1 eq.) and HOBt (114 mg, 0.85 mmol, 1.1 eq.) were added. The mixture was cooled in an
ice bath, then (+)-31b (300 mg, 0.77 mmol, 1 eq.) dissolved in CH2Cl2 (30 ml) was added.
The addition of DMF (6 ml) ensured solubilisation. The mixture was stirred overnight at room
temperature. The solution was then concentrated in vacuum and the product was obtained by
chromatography (CHCl3/MeOH 20:1) as a white solid (328 mg, 80 %). The product could be
recrystallized from ethyl acetate/MeOH/hexanes. - Rf ((+)-37b): 0.05. - mp 180-182 °C. -
[ ]21Dα  -76.7 (c 1, CH3OH). - 1H NMR (CD3OD, 250 MHz) δ 1.31 (d, J = 7.2 Hz, 3H, CH3CH),
1.36 (d, J = 7.2 Hz, 3H, CH3CH), 1.45 (s, 9H, (CH3)3C), 2.41 (dd, J = 5.1, 5.1 Hz, 1H,
cyclopropyl-CH), 2.52 (dd, J = 5.4, 8.2 Hz, 1H, cyclopropyl-CH), 3.65-3.78 (m, 3H,
cyclopropyl-CHN + CH2N), 3.70 (s, 3H, CH3O), 3.71 (s, 3H, CH3O), 3.94-3.97 (m, 2H,
CH2N), 4.32 (q, J = 7.2 Hz, 1H, CHN), 4.39 (q, J = 7.2 Hz, 1H, CHN). - 13C NMR (CD3OD,
62.9 MHz) δ 18.0 (+, CH3CH), 18.1 (+, CH3CH), 27.4 (+, cyclopropyl-CH), 28.8 (+,
(CH3)3C, 3C), 29.3 (+, cyclopropyl-CH), 36.6 (+, cyclopropyl-CHN), 41.9 (-, CH2N), 44.6 (-,
CH2N), 50.4 (+, CHN), 50.6 (+, CHN), 52.7 (+, CH3O), 52.9 (+, CH3O), 80.8 (Cquat,
(CH3)3C), 158.4 (Cquat, N(CO)O), 169.4 (Cquat, C=O), 171.7 (Cquat, C=O), 172.3 (Cquat, C=O),
172.4 (Cquat, C=O), 175.6 (Cquat, C=O), 175.7 (Cquat, C=O). - MS  FAB (Glycerin/MeOH) m/z
(%) 1060 (2MH+, 7), 530 (MH+, 71), 430 (MH+-Boc, 80), 285 (100). - IR (KBr) 3300, 3079,
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2981, 1734, 1654, 1532, 1449 cm-1. - Anal. Calcd for C22H35N5O10 (529.546): C, 49.90; H,
6.66; N, 13.20. Found: C, 49.55; H, 6.59; N, 13.02.
N
H
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(-)-37b
(1S, 2S, 3S) 2-[1S-(Methyloxycarbonyl-methyl-carbamoyl)-ethylcarbamoyl]-3-[2S-(tert-
butoxycarbonylamino-acetylamino)-propionylamino]-cyclopropane carboxylic acid
methyl ester ((-)-37b): Boc-glycylalanine benzyl ester (253 mg, 1.58 mmol, 1.4 eq.) was
deprotected by treatment with HCl 3 M in ethyl acetate (5 ml) for 3 h at 0 °C. Then the
solution was concentrated in vacuum, the salt was resuspended in CH2Cl2 (50 ml) and
triethylamine (220 µl, 1.58 mmol, 1.4 eq.) was added dropwise. To this mixture EDC
(303 mg, 1.58 mmol, 1.4 eq.) and HOBt (213 mg, 1.58 mmol, 1.4 eq.) were added. The
mixture was cooled in an ice bath and (-)-31b (442 mg, 1.14 mmol, 1 eq.) dissolved in
CH2Cl2 (30 ml) was added. The addition of DMF (4 ml) ensured solubilisation. The mixture
was stirred at room temperature overnight. The solution was then concentrated in vacuum and
the product was obtained by chromatography (CHCl3/MeOH 20:1) as a white solid (560 mg,
93 %). - Rf ((-)-37b): 0.06. - mp 88-90 °C. - [ ]21Dα  -64.8 (c 1, CH3OH). - 1H NMR (CD3OD,
250 MHz) δ 1.29 (d, J = 7.2 Hz, 3H, CH3CH), 1.38 (d, J = 7.2 Hz, 3H, CH3CH), 1.44 (s, 9H,
(CH3)3C), 2.36 (dd, J = 4.8, 4.8 Hz, 1H, cyclopropyl-CH), 2.51 (dd, J = 5.3, 8.1 Hz, 1H,
cyclopropyl-CH), 3.51 (dd, J = 4.2, 8.0 Hz, 1H, cyclopropyl-CHN), 3.70 (s, 3H, CH3O), 3.72
(s, 3H, CH3O), 3.70-3.72 (m, 2H, CH2N), 3.93-4.00 (m, 2H, CH2N), 4.33 (q, J = 7.3 Hz, 1H,
CHN), 4.40 (q, J = 7.3 Hz, 1H, CHN). - 13C NMR (CD3OD, 62.9 MHz) δ 17.6 (+, CH3CH),
17.8 (+, CH3CH), 27.8 (+, cyclopropyl-CH), 28.7 (+, (CH3)3C, 3C), 29.2 (+, cyclopropyl-
CH), 36.4 (+, cyclopropyl-CHN), 41.9 (-, CH2N), 44.8 (-, CH2N), 50.46 (+, CHN), 50.53 (+,
CHN), 52.8 (+, CH3O), 52.9 (+, CH3O), 80.8 (Cquat, (CH3)3C), 158.1 (Cquat, N(CO)O), 169.4
(Cquat, C=O), 171.9 (Cquat, C=O), 172.4 (Cquat, C=O), 172.5 (Cquat, C=O), 175.6 (Cquat, C=O),
176.1 (Cquat, C=O). - MS  FAB (Glycerin/MeOH) m/z (%) 1060 (2MH+, 9), 530 (MH+, 82),
430 (MH+-Boc, 45), 153 (100). - IR (KBr) 3319, 2982, 1734, 1662, 1654, 1539, 1449 cm-1. -
HR MS  calcd for C22H35N5O10 + H 530.24622, found 530.24923.
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(1R*, 2R*, 3S*) 2-[1S-(1S-Benzyloxycarbonyl-2-phenyl-ethylcarbamoyl)-ethylcarbamoyl]-
3-[2S-(2S-tert-butoxycarbonylamino-3-phenyl-propionylamino)-propionylamino]-
cyclopropane carboxylic acid methyl ester ((±)-38): Boc-phenylalanylalanine benzyl ester
(552 mg, 1.3 mmol, 1.1 eq.) was deprotected by treatment with HCl 3 M in ethyl acetate (5 ml)
for 3h at 0 °C. Then the solution was concentrated in vacuum, the salt was resuspended in
CH2Cl2 (50 ml) and triethylamine (180 µl, 1.3 mmol, 1 eq.) was added dropwise. To this
mixture EDC (226 mg, 1.18 mmol, 1 eq.) and HOBt (159 mg, 1.18 mmol, 1 eq.) were added.
The solution was cooled in an ice bath, then (±)-32 (567 mg, 1.18 mmol, 1 eq.) dissolved in
CH2Cl2 (20 ml) was added. The mixture was stirred at room temperature overnight. The
solution was then concentrated in vacuum and the product was obtained by chromatography
(CHCl3/MeOH 25:1) as a white solid (830 mg, 90 %). The two diastereomers can be almost
completely separated by several recrystallizations performed by cooling down their solution in
CHCl3/MeOH at -18 °C overnight. – Recrystallized isomer - Rf : 0.30. - mp 300 °C decomp. -
[ ]α Dr t. .  not measurable because of solubility problems. - 1H NMR (DMSO-d6, 250 MHz) δ 1.13
(d, J = 7.0 Hz, 3H, CH3CH), 1.19 (d, J = 6.7 Hz, 3H, CH3CH), 1.27 (s, 9H, (CH3)3C), 2.11 (dd,
J = 5.2, 7.9 Hz, 1H, cyclopropyl-CH), 2.68 (dd, J = 10.6, 13.7 Hz, 1H, cyclopropyl-CH), 2.96-
3.04 (m, 4H, CH2Ph), 3.23-3.40 (m , 1H, cyclopropyl-CHN), 3.57 (s, 3H, CH3O), 4.12-4.18 (m,
1H, CHN), 4.27-4.36 (m , 1H, CHN), 4.48 (dd, J = 7.2, 14.2 Hz, 1H, CHN), 5.04 (dd, J = 7.2,
14.2 Hz, 1H, CHN), 4.94-5.09 (m, 2H, CH2O),  6.92 (d, J = 8.6 Hz, 1H, NH), 7.16-7.25 (m,
12H, Ph-CH), 7.30-7.33 (m, 3H, Ph-CH), 7.99 (d, J = 7.5 Hz, 1H, NH), 8.16 (d, J = 4.8 Hz, 1H,
NH), 8.42 (d, J = 7.3 Hz, 1H, NH), 8.62 (d, J = 7.6 Hz, 1H, NH). - 13C NMR (DMSO-d6, 250
MHz) δ 18.1 (+, CH3CH), 18.4 (+, CH3CH), 26.3 (+, cyclopropyl-CH), 27.6 (+, cyclopropyl-
CH), 28.1 (+, (CH3)3C, 3C), 34.7 (+, CHN), 36.5 (-, CH2Ph), 37.3 (-, CH2Ph), 48.0 (+, CHN,
2C), 51.8 (+, CH3O), 53.7 (+, CHN), 55.6 (+, CHN), 66.0 (-, CH2O), 78.1 (Cquat., C(CH3)3),
(+)-38
(-)-38
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126.1 (+, Ph-CH), 126.5 (+, Ph-CH), 127.8 (+, Ph-CH, 2C), 127.9 (+, Ph-CH, 2C), 128.0 (+,
Ph-CH), 128.2 (+, Ph-CH, 2C), 128.3 (+, Ph-CH, 2C), 129.0 (+, Ph-CH, 2C), 129.2 (+, Ph-CH,
2C), 135.7 (Cquat., Ph-C), 136.9 (Cquat., Ph-C), 138.2 (Cquat., Ph-C), 155.2 (Cquat., N(CO)O), 167.4
(Cquat., C=O), 168.7 (Cquat., C=O), 171.1 ( C=O), 171.2 (Cquat., C=O), 172.1 (Cquat., C=O), 173.2
(Cquat., C=O). - MS  FAB (NBA/CH2Cl2) m/z (%) 1572 (2MH+, <1), 787 (MH+, 9), 687 (MH+-
Boc, 19), 307 (32), 154 (100). - IR (KBr) 3329, 3286, 3061, 2977, 1754, 1717, 1689, 1640,
1530, 1453, 1368 cm-1. - Anal. Calcd for C42H51N5O10 (785.89): C, 64.19; H, 6.54; N, 8.91.
Found: C, 63.99; H, 6.58; N, 8.83. – Isomer isolated in the mother liquor - Rf : 0.30. - mp
207-209 °C. - 1H NMR (CDCl3, 400 MHz) δ 1.13 (d, J = 7.0 Hz, 6H, CH3CH), 1.27 (s, 9H,
(CH3)3C), 2.08 (dd, J = 5.2, 7.9 Hz, 1H, cyclopropyl-CH), 2.55 (dd, J = 5.1, 5.1 Hz, 1H,
cyclopropyl-CH), 2.68 (dd, J = 11.1, 13.1 Hz, 1H, CH2Ph), 2.89-3.07 (m, 3H, CH2Ph), 3.30-
3.40 (m, 1H, cyclopropyl-CHN), 3.57 (s, 3H, CH3O), 4.10-4.17 ( m, 1H, CHN), 4.23-4.35 ( m,
2H, CHN), 4.46 (dd, J = 7.9, 14.2 Hz, 1H, CHN), 5.02 (d, J = 15.9 Hz, 1H, CH2O), 5.07 (d, J =
15.9 Hz, 1H, CH2Ph), 6.91 (d, J = 8.6 Hz, 1H, NH), 7.17-7.23 (m, 15H, Ph-CH), 7.99 (d, J =
7.6 Hz, 1H, NH), 8.30 (d, J = 4.7 Hz, 1H, NH), 8.40 (d, J = 7.5 Hz, 1H, NH), 8.66 (d, J =
7.8 Hz, 1H, NH). - 13C NMR (CDCl3, 100.6 MHz) δ 18.1 (+, CH3CH), 18.4 (+, CH3CH), 26.7
(+cyclopropyl-CH), 27.2 (+, cyclopropyl-CH), 28.1 (+, (CH3)3C, 3C), 34.4 (+, cyclopropyl-
CHN), 36.4 (-, CH2Ph), 37.3 (-, CH2Ph), 47.7 (+, CHN), 47.9 (+, CHN), 51.7 (+, CH3O), 53.7
(+, CHN), 55.6 (+, CHN), 65.9 (-, CH2O), 78.0 (Cquat, C(CH3)3), 126.1 (+, Ph-CH), 126.5 (+,
Ph-CH), 127.8 (+, Ph-CH, 2C), 127.9 (+, Ph-CH, 2C), 128.0 (+, Ph-CH), 128.2 (+, Ph-CH, 2C),
128.3 (+, Ph-CH, 2C), 129.1 (+, Ph-CH, 2C), 129.2 (+, Ph-CH, 2C), 135.7 (Cquat, Ph-C), 137.0
(Cquat, Ph-C), 138.3 (Cquat, Ph-C), 155.24 (Cquat, N(C=O)O), 167.4 (Cquat, C=O), 168.5 (Cquat,
C=O), 171.1 (Cquat, C=O), 171.3 (Cquat, C=O), 172.2 (Cquat, C=O), 173.5 (Cquat, C=O). –
MS  FAB (Glycerin/DMSO) m/z (%)1572 (2M H+, <1), 787 (MH+, 11), 687 (MH+-Boc, 100),
596 (14), 451 (16), 327 (12), 256 (24). - IR (KBr) 3310, 2977, 1721, 1689, 1643, 1530, 1449,
1353 cm-1. - HR MS  calcd for C42H51N5O10 786.371, found 786.3701.
NHBoc
CO2Me
O
O
Ph
O
(±)-50
(1R*, 2R*, 3S*) 3-(tert-Butylcarbonylamino)-cyclopropane-1, 2-dicarboxylic acid 1-
phenacil ester 2-methyl ester ((±)-50): Phenacylbromid (388 mg, 1.95 mmol, 5 eq.) and
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potassiumfluorid (49 mg, 0.85 mmol, 2.2 eq.) were dissolved in DMF (4 ml) and stirred
1 min., then (1R*, 2R*, 3R*)-N-tert-Butoxycarbonyl-3-aminocyclopropane-1,2-dicarboxylic
acid monomethyl ester (100 mg, 0.39 mmol) was added. After 5 h, diethyl ether (20 ml) was
added and the organic phase was washed with a water solution of 1 M KHSO4 (15 ml). The
organic phase was dried over Na2SO4 and evaporated. The product was purified by
chromatography (ethyl acetate/hexanes 2:3). Yield: 140 mg (96 %). – Rf ((±)-50): 0.35. - mp
129-131 °C. - 1H NMR (CDCl3, 250 MHz): δ 1.46 (s, 9H, (CH3)3C), 2.38-2.41 (m, 1H,
cyclopropyl-CH), 2.68 (dd, J = 5.3, 8.6 Hz, 1H, cyclopropyl-CH), 3.73 (s, 3H, CH3O), 3.87-
3.91 (m, 1H, cyclopropyl-CHN), 5.35 (d, J = 16.4 , 1H, CH2O), 5.52 (d, J = 16.4 Hz, 1H,
CH2O), 5.81 (s br, 1H, NHBoc), 7.49-7.53 (m, 2H, Ph-CH), 7.61-7.64 (m, 1H, Ph-CH), 7.90-
7.93 (m, 1H, Ph-CH). - 13C NMR (CDCl3, 62.9 MHz): δ 26.3 (+, cyclopropyl-CH), 28.3 (+,
(CH3)3C, 3C), 28.8 (+, cyclopropyl-CH), 37.6 (+, cyclopropyl-CHN), 52.3 (+, CH3O), 66.7 (-,
CH2O), 80.2 (Cquat, (CH3)3C), 127.8 (+, Ph-CH, 2C), 128.9 (+, Ph-CH, 2C), 133.7 (Cquat, Ph-
C), 134.2 (+, Ph-CH), 155.6 (Cquat, N(CO)O), 168.9 (Cquat, C=O), 170.0 (Cquat, C=O), 191.4
(Cquat, Ph(C=O)CH2). - MS  CI (NH3) m/z (%) 395 (MNH4+, 52), 378 (MH+, 2), 339 (MH+-
tBu, 100), 295 (MH+-Boc, 14), 277 (33), 221 (34). - IR (KBr) 3370, 3087, 3066, 2986, 2952,
1731, 1708, 1689, 1510,1323 cm-1. - Anal. Calcd for C19H23NO7 (377.393): C, 60.47; H, 6.14;
N, 3.71. Found: C, 60.45; H, 6.23; N, 3.60.
2.2.4 Compounds containing multiple β-ACCs
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(+)-40
(1R, 2R, 3R) 2-(2S-Benzyloxycarbonyl-ethylcarbamoyl)-3-{2S-[2R-(2S-tert-
butylcarbonylamino-propionylamino)-3R-methoxycarbonyl-cyclopropane-1R-carbonyl-
amino]-propionylamino}-cyclopropane carboxylic acid methyl ester ((+)-40): (+)-36a
(541 mg, 1.10 mmol) was deprotected by treatment with HCl 3 M in ethyl acetate (7 ml) for
3 h at 0 °C. The solution was concentrated in vacuum, the salt was resuspended in CH2Cl2
(50 ml) and triethylamine (168 µl, 1.21 mmol, 1.1 eq.) was added dropwise. To this mixture
EDC (232 mg, 1.21 mmol, 1.1 eq.) and HOBt (163 mg, 1.21 mmol, 1.1 eq.) were added. The
mixture was cooled in an ice bath and (+)-30a (375 mg, 1.13 mmol, 1.03 eq.) dissolved in
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CH2Cl2 (20 ml) was added. The mixture was stirred at room temperature 60 h. The solution
was then concentrated in vacuum and the product was obtained by chromatography
(CHCl3/MeOH 20:1) as a white solid (741 mg, 96 %). 15 % epimerisation was observed. - Rf
((+)-40): 0.23. - mp 134-136 °C. - [ ]21Dα  -86.2 (c 1, CH3OH). - 1H NMR (CD3OD, 250 MHz)
δ 1.24 (d, J = 7.3 Hz, 3H, CH3CH), 1.29 (d, J = 7.3 Hz, 3H, CH3CH), 1.39 (d, J= 7.4 Hz, 3H,
CH3CH), 1.42 (s, 9H, (CH3)3C), 2.33-2.38 (m, 2H, cyclopropyl-CH), 2.49-2.54 (m, 2H,
cyclopropyl-CH), 3.64 (s, 3H, CH3O), 3.70 (s, 3H, CH3O), 3.68-3.77 (m, 2H, cyclopropyl-
CHN), 3.94-4.03 (m, 1H, Ala-CHN), 4.24 (q, J = 7.3 Hz, 1H, Ala-CHN), 4.50 (q, J = 7.3 Hz,
1H, Ala-CHN), 5.11 (d, J = 12.3 Hz, 1H, CH2O), 5.19 (d, J = 12.3 Hz, 1H, CH2O), 7.33-7.37
(m, 5H, Ph-CH). - 13C NMR (CD3OD, 62.9 MHz) δ 17.6 (+, CH3CH), 17.7 (+, CH3CH), 18.2
(+, CH3CH), 27.6 (+, cyclopropyl-CH), 28.5 (+, cyclopropyl-CH), 28.7 (+, (CH3)3C, 3C),
28.9 (+, cyclopropyl-CH, 2C), 36.5 (+, cyclopropyl-CHN), 36.7 (+, cyclopropyl-CHN), 49.6
(+, CHN), 50.8 (+, CHN), 51.6 (+, CHN), 52.9 (+, CH3O, 2C), 68.0 (-, CH2O), 80.7 (Cquat,
(CH3)3C), 129.2 (+, Ph-CH, 2C), 129.4 (+, Ph-CH), 129.6 (+, Ph-CH, 2C), 137.3 (Cquat, Ph-
C), 157.6 (Cquat, N(CO)O), 169.68 (Cquat, C=O), 169.73 (Cquat, C=O), 172.3 (Cquat, C=O),
172.4 (Cquat, C=O), 173.9 (Cquat, C=O), 175.5 (Cquat, C=O), 176.8 (Cquat, C=O). - MS  FAB
(NBA/CH2Cl2) m/z (%) 1408 (2MH+, 2), 704 (MH+, 58), 604 (MH+-Boc, 79), 307 (100). - IR
(KBr) 3310, 2982, 1736, 1660, 1521, 1451, 1314 cm-1. - Anal. Calcd for C33H45N5O12
(703.745): C, 56.32; H, 6.44; N, 9.95. Found: C, 55.77; H, 6.54; N, 0.37.
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(1S, 2S, 3S) 2-(2S-Benzyloxycarbonyl-ethylcarbamoyl)-3-{2S-[2S-(2S-tert-
butylcarbonylamino-propionylamino)-3S-methoxycarbonyl-cyclopropane-1S-carbonyl-
amino]-propionylamino}-cyclopropane carboxylic acid methyl ester ((-)-40): (-)-36a
(750 mg, 1.53 mmol) was deprotected by treatment with HCl 3 M in ethyl acetate (10 ml) for
3 h at 0 °C. Then the solution was concentrated in vacuum, the salt resuspended in CH2Cl2
(50 ml) and triethylamine (230 µl, 1.68 mmol, 1.1 eq.) was added dropwise. To this mixture
EDC (323 mg, 1.68 mmol, 1.1 eq.) and HOBt (227 mg, 1.68 mmol, 1.1 eq.) were added. The
mixture was cooled in an ice bath and the (-)-30a (503 mg, 1.53 mmol, 1.0 eq.) dissolved in
CH2Cl2 (30 ml) was added. The mixture was stirred 60 h at room temperature. The solution
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was then concentrated in vacuum and the product was obtained by chromatography
(CHCl3/MeOH 20:1) as a white solid (1.052 g, 97 %). 15 % epimerisation was observed. - Rf
((-)-40): 0.24. - mp 103-105 °C. - [ ]21Dα  -117.3 (c 1, CH3OH). - 1H NMR (CDCl3, 400 MHz)
δ 1.21 (d, J = 6.7 Hz, 3H, CH3CH), 1.33 (d, J = 7.0 Hz, 3H, CH3CH), 1.44 (d, J= 6.9 Hz, 3H,
CH3CH), 1.44 (s, 9H, (CH3)3C), 2.29 (dd, J = 5.1, 5.1 Hz, 1H, cyclopropyl-CH), 2.42-2.45
(m, 3H, cyclopropyl-CH), 3.69 (s, 3H, CH3O), 3.70 (s, 3H, CH3O), 3.85 (dd, J = 6.6, 6.6 Hz,
1H, cyclopropyl-CHN), 3.96-3.98 (m, 1H, cyclopropyl-CHN), 4.35 (dq, J = 7.2, 7.2 Hz, 1H,
CHN), 4.43 (dq, J = 7.0, 7.0 Hz, 1H, CHN), 4.51 (dq, J = 7.1, 7.1 Hz, 1H, CHN), 5.17 (d, J =
12.2 Hz, 1H, CH2O), 5.28 (d, J = 12.2 Hz, 1H, CH2O), 5.48 (d, J = 8.3 Hz, 1H, NH), 6.52 (s
br, 1H, NH), 7.31-7.38 (m, 6H, Ph-CH + NH), 7.48 (d, J = 6.3 Hz, 1H, NH), 7.64 (d, J =
7.2 Hz, 1H, NH). - 13C NMR (CDCl3, 100.6 MHz) δ 16.4 (+, CH3CH), 17.2 (+, CH3CH), 19.3
(+, CH3CH), 26.9 (+, cyclopropyl-CH), 27.3 (+, cyclopropyl-CH), 27.9 (+, cyclopropyl-CH),
28.3 (+, cyclopropyl-CH, + (CH3)3C, 4C), 35.8 (+, cyclopropyl-CHN), 36.0 (+, cyclopropyl-
CHN), 48.5 (+, CHN), 48.7 (+, CHN), 49.7 (+, CHN), 52.2 (+, CH3O), 52.3 (+, CH3O), 67.3
(-, CH2O), 79.9 (Cquat, (CH3)3C), 128.1 (+, Ph-CH, 2C), 128.4 (+, Ph-CH), 128.6 (+, Ph-CH,
2C), 135.3 (Cquat, Ph-C), 155.4 (Cquat, N(CO)O), 167.7 (Cquat, C=O), 168.0 (Cquat, C=O), 170.7
(Cquat, C=O), 170.9 (Cquat, C=O), 172.7 (Cquat, C=O), 172.8 (Cquat, C=O), 173.6 (Cquat, C=O). -
MS  FAB (NBA/CH2Cl2) m/z (%) 1408 (2MH+, 7), 704 (MH+, 55), 604 (MH+-Boc, 100), 307
(27). - IR (KBr) 3325, 2982, 1734, 1663, 1528, 1450, 1315 cm-1. - Anal. Calcd for
C33H45N5O12 (703.745): C, 56.32; H, 6.44; N, 9.95. Found: C, 55.77; H, 6.54; N, 9.58.
N
H
H
N
O
O
N
H
FmocHN
O
CO2MeCO2Me
CO2Bn
(+)-41
(1R, 2R, 3R) 3-[2S-({2R-[2S-(9H-Fluoren-9-ylmethoxycarbonylamino)-propionylamino]-
3R-methoxycarbonyl-cyclopropane-1R-carbonyl}-amino)-propionylamino]-cyclopropane-1,
2-dicarboxylic acid 1-benzy ester 2-methyl ester ((+)-41): (+)-25a (40 mg, 0.095 mmol) was
(2 ml) at 0 °C for 3 h. The solution was concentrated in vacuum, the salt was resuspended in
CH2Cl2 (5 ml), then (+)-30b (43 mg, 0.095 mmol, 1 eq.), EDC (36 mg, 0.19 mmol, 2 eq), and
pyridine (11 µl, 0.14 mmol, 1.5 eq.) were added. The mixture was stirred at room temperature
overnight. The solution was washed with saturated NaHCO3 (8 ml), 1 M KHSO4 (8 ml) and
saturated NaHCO3 (8 ml). The organic phase was dried over MgSO4 and concentrated. The
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product was purified by chromatography (CH2Cl2/MeOH 40:1). Yield: 49 mg (68 %). 10 to
15 % epimerization was observed. - Rf ((+)-41): 0.15. - mp 188-189 °C. - [ ]21Dα  -58.1 (c 0.5,
MeOH/CHCl3 1:1). - 1H NMR (CDCl3, 250 MHz): δ 1.16 (d, J= 6.7 Hz, 3H, CH3CH), 1.34
(d, J = 7.0 Hz, 3H, CH3CH), 2.32-2.47 (m, 3H, cyclopropyl-CH), 2.56 (dd, J = 5.3, 8.0 Hz,
1H, cyclopropyl-CH), 3.61 (s, 3H, CH3O), 3.68 (s, 3H, CH3O), 3.89-3.96 (m, 1H,
cyclopropyl-CHN), 4.02-4.10 (m, 1H, cyclopropyl-CHN), 4.17-4.22 (m, 1H, Fmoc-CH),
4.26-4.48 (m, 4H, Fmoc-CH2 + 2 CHN), 5.05-5.15 (m, 2H, CH2O), 5.77 (d, J = 7.5 Hz, 1H,
NHFmoc), 7.11 (d, J = 7.3 Hz, 1H, NH), 7.23-7.41 (m, 10H, Ar-CH + NH), 7.57-7.60 (m, 2H,
Ar-CH), 7.73-7.76 (m, 3H, Ar-CH + NH). - 13C NMR (CDCl3, 62.9 MHz): δ 18.9 (+,
CH3CH), 19.3 (+, CH3CH), 26.7 (+, cyclopropyl-CH), 27.0 (+, cyclopropyl-CH), 27.9 (+,
cyclopropyl-CH), 28.1 (+, cyclopropyl-CH), 35.9 (+, cyclopropyl-CHN), 36.1 (+,
cyclopropyl-CHN), 47.1 (+, Fmoc-CH), 49.0 (+, CHN), 50.5 (+, CHN), 52.4 (+, CH3O, 2C),
67.2 (-, CH2O), 67.3 (-, CH2O), 120.0 (+, Fmoc-Ar-CH, 2C), 125.2 (+, Fmoc-Ar-CH, 2C),
127.1 (+, Ar-CH, 2C), 127.7 (+, Ar-CH, 2C), 128.3 (+, Ar-CH, 2C), 128.5 (+, Ar-CH), 128.6
(+, Ar-CH, 2C), 135.1 (Cquat, Ph-C), 141.3 (Cquat, Fmoc-Ar-C, 2C), 143.8 (Cquat, Fmoc-Ar-C),
143.9 (Cquat, Fmoc-Ar-C), 155.9 (Cquat, N(CO)O), 167.8 (Cquat, C=O), 169.3 (Cquat, C=O),
169.7 (Cquat, C=O), 170.6 (Cquat, C=O), 172.5 (Cquat, C=O), 173.2 (Cquat, CO). - MS  FAB
(CH2Cl2/NBA) m/z (%) 755 (MH+, 91), 444 (19), 179 (Fluorenyl cation, 100). - IR (KBr)
3418, 3345, 1728, 1685, 1504 cm-1. - Anal. Calcd for C40H42N4O11 ⋅ 2 H2O (790.822): C,
60.75; H, 5.86; N, 7.08. Found: C, 60.56; H, 5.41; N, 6.98. - HR MS  calcd for 755.29283,
found 755.29165.
N
H
H
N
O
O
N
H
FmocHN
O H
N
O
N
H
O
CO2MeCO2Me CO2Me
CO2Bn
(+)-45
(1R, 2R, 3R) 3-{2S-[2R-(2S-{2R-[2S-(9H-Fluoren-9-ylmethoxycarbonylamino)-
propionylamino]-3R-methoxycarbonyl-cyclopropane-1R-carbonylamino}-propionylamino)-
3R-methoxycarbonyl-cyclopropane-1R-carbonylamino]-propionylamino}-cyclopropane-1,
2-dicarboxylic acid 1-benzyl ester 2-methyl ester ((+)-45): (+)-25b (72 mg, 0.22 mmol,
1.5 eq.) was deprotected by treatment with HCl 3 M in ethyl acetate (10 ml) for 3 h at 0 °C.
The solution was concentrated in vacuum, the salt was resuspended in CH2Cl2 (5 ml) and
(+)-42 (100 mg, 0.15 mmol, 1 eq.), EDC (58 mg, 0.30 mmol, 2 eq) and pyridine (24 µl,
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0.30 mmol, 2 eq.) were added. The mixture was stirred at room temperature overnight. The
product was purified by chromatography (CH2Cl2/MeOH 40:1). Yield: 70 mg (48 %). 5 to
10 %  epimerization was observed. - Rf ((+)-45): 0.18. - mp 174-176 °C. - [ ]21Dα  -77.1 (c 0.5,
MeOH/CHCl3 1:1). - 1H NMR (CDCl3/CD3OD 1:1, 250 MHz): δ 1.26 (d, J = 7.1 Hz, 6H,
CH3CH), 1.34 (d, J = 7.1 Hz, 3H, CH3CH), 2.31-2.41 (m, 2H, cyclopropyl-CH), 2.45-2.57
(m, 4H, cyclopropyl-CH), 3.68 (s, 3H, CH3O), 3.71 (s, 3H, CH3O), 3.72 (s, 3H, CH3O), 3.80-
3.88 (m, 3H, cyclopropyl-CHN), 4.12-4.41 (m, 6H, 3 CHN + Fmoc-CH2 + Fmoc-CH), 5.09-
5.20 (m, 2H, CH2O), 7.31-7.39 (m, 9H, Ar-CH), 7.60-7.68 (m, 2H, Fmoc-Ar-CH), 7.76-7.78
(m, 2H, Fmoc-Ar-CH), 8.02 (s br, 1H, NH), 8.20 (s br, 1H, NH), 8.46 (s br, 2H, NH). -
13C NMR (CDCl3/CD3OD 1:1, 62.9 MHz): δ 17.6 (+, CH3CH), 17.7 (+, CH3CH), 18.2 (+,
CH3CH), 27.38 (+, cyclopropyl-CH), 27.43 (cyclopropyl-CH), 27.8 (cyclopropyl-CH), 28.0
(cyclopropyl-CH, 2C), 28.2 (cyclopropyl-CH), 36.2 (+, cyclopropyl-CHN, 2C), 36.3 (+,
cyclopropyl-CHN), 47.7 (+, Fmoc-CH), 49.7 (+, CHN), 50.0 (+, CHN), 51.4 (+, CHN), 52.7
(+, CH3O), 52.8 (CH3O), 52.9 (CH3O), 67.6 (-, CH2O), 67.8 (-, CH2O), 120.4 (+, Fmoc-Ar-
CH, 2C), 125.6 (+, Fmoc-Ar-CH), 125.8 (+, Fmoc-Ar-CH), 127.7 (+, Ar-CH, 2C), 128.3 (+,
Ar-CH, 2C), 128.8 (+, Ar-CH, 2C), 129.0 (+, Ar-CH), 129.1 (+, Ar-CH, 2C), 136.0 (Cquat, Ph-
C), 141.87 (Cquat, Fmoc-Ar-C), 141.90 (Cquat, Fmoc-Ar-C), 144.3 (Cquat, Fmoc-Ar-C), 144.6
(Cquat, Fmoc-Ar-C), 157.4 (Cquat, N(CO)O), 169.03 (Cquat, C=O), 169.06 (Cquat, C=O), 169.5
(Cquat, C=O), 171.0 (Cquat, C=O), 171.7 (Cquat, C=O), 171.9 (Cquat, C=O), 174.4 (Cquat, C=O),
174.6 (Cquat, C=O), 175.4 (Cquat, C=O). - MS  FAB (CH2Cl2/NBA) m/z (%) 967 (MH+, 100). -
IR (CDCl3) 3426, 3335, 3070, 2984, 1726, 1678, 1505, 1450, 1314 cm-1. - HR MS  calcd for
C49H54N6O15 + H 967.37254, found 967.37171.
2.2.5 Completely deprotected peptides
N
H
CO2Me
OH
N
O
+H3N
H
N
O
N
H
O
CO2H
PhH2C CH2Ph
Cl-
(+)-39
(1R, 2R, 3R) 2-[2S-(2S-Amino-3-phenyl-propionylamino)-propionylamino]-3-[1S-(1S-
carboxy-2-phenyl-ethylcarbamoyl)-ethylcarbamoyl]-cyclopropane carboxylic acid
methyl ester; HCl salt ((+)-39): (+)-37a (390 mg, 0.50 mmol) was stirred in HCl 3 M in
ethyl acetate (5 ml) at 0°C for 3 h. The solution was concentrated in vacuum and the salt
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redissolved in methanol (25 ml). Then Pd/C 10 % (100 mg) and cyclohexadiene (1.1 ml, 40 %
in pentane) were added. The reaction mixture was stirred overnight, filtrated over a celite pad
and concentrated in vacuum to afford the deprotected peptide as a white solid (295 mg, 94 %).
- mp 260 °C decomp. - [ ]21Dα  -39.9° (c 1, MeOH). - 1H NMR (CD3OD, 250 MHz) δ 1.22 (d,
J = 6.1 Hz, 3H, CH3CH), 1.32 (d, J = 6.6 Hz, 3H, CH3CH), 2.41 (dd, J = 5.2, 5.2 Hz, 1H
cyclopropyl-CH), 2.47 (dd, J = 5.4, 8.2 Hz, 1H, cyclopropyl-CH), 2.93-3.10 (m, 2H, CH2Ph),
3.20 (dd, J = 5.2, 13.9 Hz, 1H, CH2Ph), 3.59-3.71 (m, 2H, cyclopropyl-CHN + CH2Ph), 3.74
(s, 3H, CH3O), 4.10 (dd, J = 5.4, 8.8 Hz, 1H, Phe-CHN), 4.22-4.36 (m, 2H, Ala-CHN), 4.62
(dd, J = 5.2, 8.2 Hz, 1H, CHN), 7.17-7.24 (m, 5H, Ph-CH), 7.29-7.36 (m, 5H, Ph-CH). -
13C NMR (CD3OD, 100.6 MHz) δ 17.8 (+, CH3CH), 18.0 (+, CH3CH), 27.4 (+, cyclopropyl-
CH), 29.3 (+, cyclopropyl-CH), 36.6 (+, cyclopropyl-CHN), 38.2 (-, CH2Ph), 38.5 (-, CH2Ph),
50.49 (+, CHN), 50.53 (+, CHN), 52.9 (+, CH3O), 55.1 (+, CHN), 55.6 (+, CHN), 127.7 (+,
Ph-CH), 128.8 (+, Ph-CH), 129.4 (+, Ph-CH, 2C), 130.1 (+, Ph-CH, 2C), 130.4 (+, Ph-CH,
2C), 130.6 (+, Ph-CH, 2C), 135.6 (Cquat, Ph-CH), 138.2 (Cquat, Ph-C), 169.1 (Cquat, C=O),
169.5 (Cquat, C=O), 172.4 (Cquat, C=O), 174.5 (Cquat, C=O, 2C), 175.1 (Cquat, C=O). –
MS  FAB (Glycerin/MeOH) m/z (%) 1191 (2MH+, 3), 597 (MH+, 100), 361 (28), 219 (20). -
IR (KBr) 3318, 3297, 3063, 2933, 1732, 1654, 1540 cm-1. - HR MS  calcd for C30H38N5O8
596.27204, found 596.27248.
N
H
CO2Me
OH
N
O
+H3N
H
N
O
N
H
O
CO2H
PhH2C CH2Ph
Cl-
(-)-39
(1S, 2S, 3S) 2-[2S-(2S-Amino-3-phenyl-propionylamino)-propionylamino]-3-[1S-(1S-
carboxy-2-phenyl-ethylcarbamoyl)-ethylcarbamoyl]-cyclopropane carboxylic acid
methyl ester; HCl salt ((-)-39): (-)-37a (400 mg, 0.51 mmol) was stirred in HCl 3 M in ethyl
acetate (5 ml) at 0°C for 3 h. The solution was then concentrated in vacuum and the salt
redissolved in methanol (25 ml). Then Pd/C 10 % (200 mg) and cyclohexadiene (1.2 ml, 40 %
in pentane) were added. The reaction mixture was stirred overnight, filtrated over a celite pad
and concentrated in vacuum to afford (321 mg, >99 %) of the unprotected peptide as a white
solid. - mp 115-120 °C. - [ ]21Dα  -43.7 (c 1, MeOH). - 1H NMR (CD3OD, 250 MHz) δ 1.25 (d,
J = 7.1 Hz, 3H, CH3CH), 1.32 (d, J = 7.1 Hz, 3H, CH3CH), 2.26 (dd, J = 5.2, 5.2 Hz, 1H
cyclopropyl-CH), 2.52 (dd, J = 5.5, 8.3 Hz, 1H, cyclopropyl-CH), 2.97-3.14 (m, 2H, CH2Ph),
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3.20-3.44 (m, 2H, CH2Ph), 3.56 (dd, J = 4.4, 8.3 Hz, 1 H, cyclopropyl-CHN), 3.72 (s, 3H,
CH3O), 4.17 (dd, J = 4.8, 9.5 Hz, 1H, Phe-CHN), 4.31 (q, J = 7.1 Hz, 1H, Ala-CHN), 4.41 (q,
J = 6.7 Hz, 1H, Ala-CHN), 4.60-4.69 (m, 1H, Phe-CHN), 7.19-7.35 (m, 10H, Ph-CH). -
13C NMR (CD3OD, 100.6 MHz) δ 17.4 (+, CH3CH), 18.2 (+, CH3CH), 28.3 (+, cyclopropyl-
CH), 28.8 (+, cyclopropyl-CH), 36.5 (+, cyclopropyl-CHN), 38.1 (-, CH2Ph), 38.6 (-, CH2Ph),
50.6 (+, CHN), 52.9 (+, CH3O), 55.5 (+, CHN), 55.6 (+, CHN), 55.9 (+, CHN), 127.9 (+, Ph-
CH), 128.8 (+, Ph-CH), 129.5 (+, Ph-CH, 2C), 130.2 (+, Ph-CH, 2C), 130.5 (+, Ph-CH, 2C),
130.7 (+, Ph-CH, 2C), 135.9 (Cquat, Ph-CH), 138.4 (Cquat, Ph-C), 169.6 (Cquat, C=O), 172.3
(Cquat, CO, 3C), 174.9 (Cquat, CO, 2C). - MS  FAB (NBA/CH2Cl2) m/z (%) 597 (MH+, 15),
460 (8), 307 (55), 154 (100). - IR (KBr) 3318, 3063 2954, 1727, 1661, 1527, 1453, 1316 cm-1.
- HR MS  calcd for C30H38N5O8 596.27204, found 596.27085.
N
H
CO2Me
OH
N
O
H
N
O
CO2HN
H
CO2Me
O
+H3NCl-
(+)-43
(1R, 2R, 3R) 2-(2S-Carboxyl-ethylcarbamoyl)-3-{2S-[2R-(2S-amino-propionylamino)-
3R-methoxycarbonyl-cyclopropane-1R-carbonyl-amino]-propionylamino}-cyclopropane
carboxylic acid methyl ester; HCl salt ((+)-43): (+)-40 (300 mg, 0.43 mmol) was stirred in
HCl 3 M in ethyl acetate (5 ml) at 0 °C for 3 h. The solution was concentrated in vacuum and
the salt redissolved in methanol (25 ml). Then Pd/C 10 % (150 mg) and cyclohexadiene
(1.2 ml, 40 % in pentane) were added. The reaction mixture was stirred overnight, filtrated
over a celite pad and concentrated in vacuum to afford the unprotected peptide as a white
solid (218 mg, 92 %). - mp 193-195 °C. - [ ]21Dα  -72.4 (c 0.5, MeOH). - 1H NMR (CD3OD,
400 MHz) δ 1.30 (d, J = 7.3 Hz, 3H, CH3CH), 1.38 (d, J = 7.3 Hz, 3H, CH3CH), 1.39 (d, J =
7.1 Hz, 3H, CH3CH), 2.34 (dd, J = 4.5, 5.2 Hz, 1H, cyclopropyl-CH), 2.47 (dd, J = 5.0,
5.0 Hz, 1H, cyclopropyl-CH), 2.49 (dd, J = 5.2, 8.3 Hz, 1H, cyclopropyl-CH), 2.54 (dd, J =
5.4, 7.9 Hz, 1H, cyclopropyl-CH), 3.52 (dd, J = 4.6, 8.0 Hz, 1H, cyclopropyl-CHN), 3.70 (s,
3H, CH3O), 3.72-3.75 (m, 1H, cyclopropyl-CHN), 3.73 (s, 3H, CH3O), 3.88 (q, J = 7.0 Hz,
1H, CHN), 4.20 (q, J = 7.2 Hz, 1H, CHN), 4.41 (q, J = 7.2 Hz, 1H, CHN). - 13C NMR
(CD3OD, 100.6 MHz) δ 17.6 (+, CH3CH), 17.7 (+, CH3CH), 17.8 (+, CH3CH), 26.9 (+,
cyclopropyl-CH), 27.5 (+, cyclopropyl-CH), 28.6 (+, cyclopropyl-CH), 29.9 (+, cyclopropyl-
CH), 36.3 (+, cyclopropyl-CHN), 36.5 (+, cyclopropyl-CHN), 49.3 (+, Ala-CHN), 50.1 (+,
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Ala-CHN), 50.9 (+, Ala-CHN), 52.9 (+, CH3O), 53.0 (+, CH3O), 168.7 (Cquat, C=O), 169.5
(Cquat, C=O), 172.1 (Cquat, C=O), 172.27 (Cquat, C=O), 172.33 (Cquat, C=O), 175.6 (Cquat,
C=O), 175.8 (Cquat, C=O). - MS  FAB (HCO2H/MeOH/Glycerin) m/z (%) 514 (M+, 27), 369
(32), 277 (100). - IR (KBr) 3326, 3061, 1731, 1538, 1452, 1351, 1211, 1173 cm-1. - HR MS
calcd for C21H32N5O10 514.21492, found 514.21296.
N
H
CO2Me
OH
N
O
H
N
O
CO2HN
H
CO2Me
O
+H3NCl-
(-)-43
(1S, 2S, 3S) 2-(2S-Carboxy-ethylcarbamoyl)-3-{2S-[2S-(2S-amino-propionylamino)-3S-
methoxycarbonyl-cyclopropane-1S-carbonyl-amino]-propionylamino}-cyclopropane
carboxylic acid methyl ester; HCl salt ((-)-43): (-)-40 (357 mg, 0.51 mmol) was stirred in
HCl 3 M in ethyl acetate (5 ml) at 0°C for 3 h. The solution was then concentrated in vacuum
and the salt redissolved in methanol (25 ml). Then Pd/C 10 % (60 mg) and cyclohexadiene
(1.2 ml, 40 % in pentane) were added. The reaction mixture was stirred overnight, filtrated
over a celite pad and concentrated in vacuum to afford the deprotected peptide as a white
solid (270 mg, 96 %). - mp 195-197 °C. - [ ]21Dα  -116.6 (c 1, MeOH). - 1H NMR (CD3OD,
250 MHz) δ 1.35 (d, J = 7.2 Hz, 3H, CH3CH), 1.44 (d, J = 7.3 Hz, 3H, CH3CH), 1.51 (d, J =
7.0 Hz, 3H, CH3CH), 2.35 (dd, J = 4.8, 4.8 Hz, 1H, cyclopropyl-CH), 2.42 (d, J = 4.9, 4.9 Hz,
1H, cyclopropyl-CH), 2.52 (dd, J = 5.5, 8.0 Hz, 1H, cyclopropyl-CH), 2.60 (dd, J = 5.4,
6.0 Hz, 1H, cyclopropyl-CH), 3.45 (dd, J = 4.5, 8.0 Hz, 1H, cyclopropyl-CHN), 3.59 (dd, J =
4.4, 8.3 Hz, 1H, cyclopropyl-CHN), 3.71 (s, 6H, CH3O), 3.97 (q, J = 7.1 Hz, 1H, CHN), 4.27
(q, J = 7.1 Hz, 1H, CHN), 4.38 (q, J = 7.2 Hz, 1H, CHN), 7.93 (d, J = 5.4 Hz, 1H, NH), 8.32
(d, J = 3.5 Hz, 1H, NH), 8.55 (d, J = 5.9 Hz, 1H, NH), 8.82 (d, J = 6.8 Hz, 1H, NH). -
13C NMR (CD3OD, 62.9 MHz) δ 17.3 (+, CH3CH), 17.4 (+, CH3CH), 17.5 (+, CH3CH), 27.7
(+, cyclopropyl-CH, 2C), 28.9 (+, cyclopropyl-CH), 29.6 (+, cyclopropyl-CH), 36.2 (+,
cyclopropyl-CHN), 36.6 (+, cyclopropyl-CHN), 50.0 (+, CHN), 50.4 (+, CHN), 51.0 (+,
CHN), 52.92 (+, CH3O), 52.93 (+, CH3O), 168.9 (Cquat, C=O), 169.4 (Cquat, C=O), 172.29
(Cquat, C=O), 172.35 (Cquat, C=O, 2C), 176.0 (Cquat, C=O), 176.1 (Cquat, C=O). - MS  FAB
(NBA/CH2Cl2) m/z (%) 514 (M+, 23), 443 (3). - IR (KBr) 3449, 3307, 3061, 1742, 1660,
1542, 1451, 1313, 1173 cm-1. - HR MS  calcd for C21H32N5O10 514.21492, found 514.2144.
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2.2.6 Synthesis of α-peptides in solution
BocHN
H
N
O
OPhH2C
N
H
H
N
N
HO
O
CO2Bn
CH2Ph
49
2S-(2S-{2S-[2S-(2S-tert-Butoxycarbonylamino-3-phenyl-propionylamino)-propionylamino]-
propionylamino}-propionylamino)-3-phenyl-propionic acid benzyl ester (49):
Boc-alanylalanylalanylphenylalanine benzyl ester (198 mg, 0.35 mmol, 1 eq.) was
deprotected by treatment with HCl 3 M in ethyl acetate (3 ml) for 3 h at 0 °C. The solution
was concentrated in vacuum, the salt was resuspended in CH2Cl2 (20 ml) and triethylamine
(56 µl, 0.4 mmol, 1.1 eq.) was added dropwise. To this mixture EDC (115 mg, 0.6 mmol,
1.7 eq.), HOBt (81 mg, 0.6 mmol, 1.7 eq.) and Boc-phenylalanine (159 mg, 0.6 mmol,
1.7 eq.) were added. The mixture was stirred at room temperature overnight. The solution was
then concentrated in vacuum and the product was obtained by chromatography
(CHCl3/MeOH 20:1) as a white solid (225 mg, 90 %). - Rf (49): 0.12. - mp 217-218 °C. - [ ]21Dα
-43.2 (c 0.5, CHCl3). - 1H NMR (CDCl3/CD3OD 1:1, 400 MHz) δ 1.32 (d, J = 7.2 Hz, 3H,
CH3CH), 1.36 (d, J = 7.2 Hz, 3H, CH3CH), 1.37 (d, J = 6.9 Hz, 3H, CH3CH), 1.40 (s, 9H,
(CH3)3C), 2.90 (dd, J = 8.6, 13.7 Hz, 1H, CH2Ph), 3.04-3.18 (m, 3H, CH2Ph), 4.19-4.25 (m,
1H, CHN), 4.26-4.32 (m, 2H, CHN), 4.36 (q, J = 7.2 Hz, 1H, CHN), 4.76 (dd, J = 6.2, 7.5 Hz,
1H, CHN), 5.09-5.15 (m, 2H, CH2O), 7.12-7.37 (m, 15H, Ph-CH). - 13C NMR
(CDCl3/CD3OD 1:1, 100.6 MHz) δ 17.3 (+, CH3CH), 17.4 (+, CH3CH), 17.6 (+, CH3CH),
28.4 (+, (CH3)3C, 3C), 37.9 (-, CH2Ph), 38.1 (-, CH2Ph), 49.2 (+, CHN), 49.8 (+, CHN), 50.4
(+, CHN), 54.1 (+, CHN), 56.8 (+, CHN), 67.4 (-, CH2O), 80.9 (Cquat, (CH3)3C), 127.2 (+, Ph-
CH), 127.3 (+, Ph-CH), 128.7 (+, Ph-CH, 3C), 128.78 (+, Ph-CH, 2C), 128.83 (+, Ph-CH,
2C), 128.9 (+, Ph-CH, 2C), 129.5 (+, Ph-CH, 2C), 129.6 (+, Ph-CH, 2C), 135.6 (Cquat, Ph-C),
136.6 (Cquat, Ph-C), 136.8 (Cquat, Ph-C), 156.8 (Cquat, N(CO)O), 171.7 (Cquat, CO, 2C), 173.2
(Cquat, C=O), 173.5 (Cquat, C=O), 173.7 (Cquat, C=O). - MS  FAB (NBA/MeOH/CH2Cl2) m/z
(%) 1432 (2MH+, <1), 717 (MH+, 17), 616 (MH+-Boc, 3), 154 (100). - IR (KBr) 3382, 3287,
2978, 2933, 1710, 1636, 1525, 1451 cm-1. - Anal. Calcd for C39H49N5O8 (715.845): C, 65.44;
H, 6.90; N, 9.78, found: C, 65.30; H, 6.92; N, 9.77.
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2S-(2S-tert-Butoxycarbonylamino-propionylamino)-propionic acid benzyl ester (56a):69
N-Boc-alanine (144 mg, 0.76 mmol, 2 eq.) was preactivated by stirring with EDC (146 mg,
0.76 mmol, 2 eq.) and HOBt (103 mg, 0.76 mmol, 2 eq.) in dry CH2Cl2 (5 ml), under nitrogen
atmosphere 1 h at 0 °C and 1 h at room temperature. The solution was added under nitrogen
atmosphere to Pd[PPh3]4 (44 mg, 0.038 mmol, 0.1 eq.), then 55a (100 mg, 0.38 mmol, 1 eq.)
and finally DABCO (191 mg, 1.71 mmol, 4.5 eq.) were added. The solution was stirred
10 min. at room temperature, then CH2Cl2 (10 ml) was added and the solution was washed
with saturated NaHCO3 (10 ml), 1 M KHSO4 (10 ml) and saturated NaHCO3 (10 ml). The
organic phase was dried over MgSO4 and concentrated. The product was purified by
chromatography (ethyl acetate/hexanes 2:3) to afford a white solid (131 mg, 99 %). - Rf (56a):
0.15. - mp 65-67 °C. - [ ]21Dα  -59.4 (c 0.5, MeOH). - 1H NMR (CDCl3, 250 MHz) δ 1.24 (d, J =
7.2 Hz, 3H, CH3CH), 1.41 (d, J = 7.2 Hz, 3H, CH3CH), 1.44 (s, 9H, (CH3)3C), 4.10-4.17 (m,
1H, CHN), 4.61 (dq, J = 7.3, 7.3 Hz, 1H, CHN), 5.04 (s br, 1H, NHBoc), 5.22-5.22 (m, 2H,
CH2O), 6.69 (d, J = 6.9 Hz, 1H, NH), 7.32-7.36 (m, 5h, Ph-CH).
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2S-(2S-tert-Butoxycarbonylamino-3-phenyl-propionylamino)-propionic acid benzyl ester
(56b):70 N-Boc-phenylalanine (263 mg, 0.97 mmol, 2.7 eq.) was preactivated by stirring with
EDC (187 mg, 0.97 mmol, 2.7 eq.) and HOBt (132 mg, 0.97 mmol, 2.7 eq.) in dry CH2Cl2
(5 ml), under nitrogen atmosphere 1 h at 0 °C and 1 h at room temperature. The solution was
added under nitrogen atmosphere to Pd[PPh3]4 (40 mg, 0.036 mmol, 0.1 eq.), then 55b
(96 mg, 0.36 mmol, 1 eq.) and finally DABCO (190 mg, 1.7 mmol, 4.7 eq.) were added. The
solution was stirred 10 min. at room temperature, then CH2Cl2 (10 ml) was added and the
solution was washed with saturated NaHCO3 (10 ml), 1 M KHSO4 (10 ml) and saturated
NaHCO3 (10 ml). The organic phase was dried over MgSO4 and concentrated. The product
was purified by chromatography (ethyl acetate/hexanes 2:3) to afford a white solid (155 mg,
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quantitative). - Rf (56b): 0.45. - mp 93-95 °C. - [ ]21Dα  -19.4 (c 1, MeOH). - 1H NMR (CDCl3,
250 MHz) δ 1.35 (d, J = 7.2 Hz, 3H, CH3CH), 1.39 (s, 9H, (CH3)3C), 3.03-3.06 (m, 2H,
CH2Ph), 4.35-4.38 (m, 1H, CHN), 4.56 (dq, J = 7.2, 7.2, 1H, CHN), 5.08 (s br, 1H, NH), 5.14
(s, 2H, CH2O), 6.52 (d, J = 7.1 Hz, 1H, NH), 7.16-7.39 (m, 10H, Ph-CH).
FmocHN
H
N
O
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O
56c
2S-[2S-(9H-Fluoren-9-ylmethoxycarbonylamino)-propionylamino]-propionic acid methyl
ester (56c): N-Fmoc-alanine (177 mg, 0.57 mmol, 3 eq.) was preactivated by stirring with
EDC (109 mg, 0.57 mmol, 3 eq.) and HOBt (77 mg, 0.57 mmol, 3 eq.) in dry CH2Cl2 (5 ml),
under nitrogen atmosphere 1 h at 0 °C and 1 h at room temperature. The solution was added
under nitrogen atmosphere to Pd[PPh3]4 (22 mg, 0.019 mmol, 0.1 eq.), then 55c (50 mg,
0.19 mmol, 1 eq.) and finally DABCO (106 mg, 0.95 mmol, 5 eq.) were added. The solution
was stirred 10 min. at room temperature, then CH2Cl2 (10 ml) was added and the solution was
washed with saturated NaHCO3 (10 ml), 1 M KHSO4 (10 ml) and saturated NaHCO3 (10 ml).
The organic phase was dried over MgSO4 and concentrated. The product was purified by
chromatography (ethyl acetate/hexanes 2:3) to afford a white solid (85 mg, 94 %). - Rf (56c):
0.17. - mp 157-158 °C. - [ ]21Dα  -48.2 (c 1, MeOH). - 1H NMR (CDCl3, 250 MHz) δ 1.37 (d,
J = 4.6 Hz, 3H, CH3CH), 1.40 (d, J = 7.1 Hz, 3H, CH3CH), 4.20 (t, J = 7.0 Hz, 1H, Fmoc-
CH), 4.26-4.32 (m, 1H, CHN), 4.38 (d, J = 7.0 Hz, 2H, Fmoc-CH2), 4.61 (dq, J = 7.2, 7.2 Hz,
1H, CHN), 5.09-5.21 (m, 2H, CH2O), 5.49 (d, J = 6.5 Hz, 1H, NHFmoc), 6.64 (d, J = 6.0 Hz,
1H, NH), 7.25-7.41 (m, 9H, Ar-CH), 7.56-7.59 (m, 2H, Fmoc-Ar-CH), 7.74-7.77 (m, 2H,
Fmoc-Ar-CH). - 13C NMR (CDCl3, 62.9 MHz) δ 18.3 (+, CH3CH), 18.9 (+, CH3CH), 47.1 (+,
Fmoc-CH), 48.3 (+, CHN), 50.4 (+, CHN), 67.1 (-, CH2O), 67.3 (-, CH2O), 120.0 (+, Fmoc-
Ar-CH, 2C), 125.1 (+, Fmoc-Ar-CH, 2C), 127.1 (+, Ar-CH, 2C), 127.8 (+, Ar-CH, 2C), 128.2
(+, Ar-CH, 2C), 128.5 (+, Ar-CH), 128.7 (+, Ar-CH, 2C), 135.3 (Cquat, Ph-C), 141.3 (Cquat,
Fmoc-Ar-C, 2C), 143.81 (Cquat, Fmoc-Ar-C), 143.84 (Fmoc-Cquat-, ArC), 155.9 (Cquat,
N(CO)O), 171.9 (Cquat, C=O), 172.5 (Cquat, C=O). - MS  CI (NH3) m/z (%) 490 (MNH4+, 31),
473 (MH+, 2), 400 (10), 294 (15), 251 (15), 214 (100). - IR (KBr) 3304, 3065, 2979, 1737,
1690, 1654, 1537, 1450 cm-1. - Anal. Calcd for C28H28N2O5.0.3 H2O (477.944): C, 70.36; H,
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6.03; N, 5.86. Found: C, 70.35; H, 5.99; N, 5.82. - HR MS  calcd for C28H28N2O5 472.19982,
found 472.20010.
FmocHN
H
N
O
OMe
O
56d
2S-[2S-(9H-Fluoren-9-ylmethoxycarbonylamino)-propionylamino]3-methyl-butyric acid
methyl ester (56d):71 N-Fmoc-alanine (130 mg, 0.42 mmol, 1.5 eq.) was preactivated by
stirring with EDC (81 mg, 0.42 mmol, 1.5 eq.) and HOBt (57 mg, 0.42 mmol, 1.5 eq.) in dry
CH2Cl2 (5 ml), under nitrogen atmosphere 1 h at 0 °C and 1 h at room temperature. The
solution was added under nitrogen atmosphere to Pd[PPh3]4 (32 mg, 0.028 mmol, 0.1 eq.),
then 55d (60 mg, 0.28 mmol, 1 eq.) and finally DABCO (110 mg, 0.98 mmol, 3.5 eq.) were
added. The solution was stirred 10 min. at room temperature, then CH2Cl2 (10 ml) was added
and the solution was washed with saturated NaHCO3 (10 ml), 1 M KHSO4 (10 ml) and
saturated NaHCO3 (10 ml). The organic phase was dried over MgSO4 and concentrated. The
product was purified by chromatography (ethyl acetate/hexanes 2:3) to afford a white solid
(103 mg, 87 %). - Rf (56d): 0.21. - mp 151-153 °C. - [ ]21Dα  -33.9 (c 0.5, MeOH). - 1H NMR
(CDCl3, 250 MHz) δ 0.88 (t, J = 6.9 Hz, 3H, (CH3)2CH), 0.91 (t, J = 6.9 Hz, 3H, (CH3)2CH),
1.40 (d, J = 7.0 Hz, 3H, CH3CH), 2.09-2.20 (m, 1H, (CH3)2CH), 3.72 (s, 3H, CH3O), 4.18-
4.23 (m, 1H, Fmoc-CH), 4.31-4.40 (m, 3H, Fmoc-CH2 + Ala-CHN), 4.54 (dd, J = 4.9, 8.8 Hz,
1H, Val-CHN), 5.49 (d, J = 7.6 Hz, 1H, NHFmoc), 6.61 (d, J = 8.3 Hz, 1H, NH), 7.25-7.42
(m, 4H, Fmoc-Ar-CH); 7.56-7.59 (m, 2H, Fmoc-Ar-CH), 7.74-7.77 (m, 2H, Fmoc-Ar-CH).
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2S-(2S-tert-Butoxycarbonylamino-propionylamino)-3-methyl-butyric acid methyl ester
(56e):72 N-Boc-alanine (261 mg, 1.38 mmol, 3 eq.) was preactivated by stirring with EDC
(265 mg, 1.38 mmol, 3 eq.) and HOBt (186 mg, 1.38 mmol, 3 eq.) in dry CH2Cl2 (5 ml),
under nitrogen atmosphere 1 h at 0 °C and 1 h at room temperature. The solution was added
under nitrogen atmosphere to Pd[PPh3]4 (50 mg, 0.046 mmol, 0.1 eq.), then 55e (107 mg,
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0.46 mmol, 1 eq.) and finally DABCO (283 mg, 2.53 mmol, 5.5 eq.) were added. The solution
was stirred 10 min. at room temperature, then CH2Cl2 (10 ml) was added and the solution was
washed with saturated NaHCO3 (10 ml), 1 M KHSO4 (10 ml) and saturated NaHCO3 (10 ml).
The organic phase was dried over MgSO4 and concentrated. The product was purified by
chromatography (ethyl acetate/hexanes 2:3) to afford a white solid (145 mg, 97 %). - Rf (56e):
0.18. - mp 82-84 °C. - [ ]21Dα  -49.8 (c 0.5, MeOH). - 1H NMR (CDCl3, 250 MHz) δ 0.90 (d, J =
7.0 Hz, 3H, (CH3)2CH), 0.93 (d, J = 7.0 Hz, 3H, (CH3)2CH), 1.36 (d, J = 7.0 Hz, 3H,
CH3CH), 1.45 (s, 9H, (CH3)3C), 2.11-2.21 (m, 1H, (CH3)2CH), 3.74 (s, 3H, CH3O), 4.13-4.22
(m, 1H, Ala-CHN); 4.53 (dd, J = 4.9, 13.8 Hz, 1H, Val-CHN), 5.04 (d, J = 6.7 Hz, 1H,
NHBoc), 6.69 (s br, 1H, NH).
N
CO2BnO
N
O
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1-{1-[(tert-Butoxycarbonylamino)-acetylamino]-pyrrolidine-2S-carbonyl}-pyrrolidine-2S-
carboxylic acid benzyl ester (67a):73 N-Boc-glycine (272 mg, 1.55 mmol, 3eq.) was
preactivated by stirring with EDC (298 mg, 1.55 mmol, 3 eq.) and HOBt (209 mg,
1.55 mmol, 3 eq.) in dry CH2Cl2 (8 ml), under nitrogen atmosphere 1 h at 0 °C and 1 h at
room temperature. The solution was added under nitrogen atmosphere to Pd[PPh3]4 (60 mg,
0.05 mmol, 0.1 eq.), then 66 (200 mg, 0.52 mmol, 1 eq.) and finally DABCO (349 mg,
3.1 mmol, 6 eq.) were added. The solution was stirred 20 min. at room temperature, then
CH2Cl2 (10 ml) was added and the solution was washed with saturated NaHCO3 (15 ml), 1 M
KHSO4 (10 ml) and saturated NaHCO3 (15 ml). The organic phase was dried over MgSO4
and concentrated. The product was purified by chromatography (CHCl3/MeOH 40:1) to
afford a white solid (215 mg, 90 %). - Rf  (67a): 0.6. - mp 58-60 °C. - [ ]21Dα  -105.7 (c 1,
CHCl3). - 1H NMR (CDCl3, 400 MHz) δ 1.43 (s, 9H, (CH3)3C), 2.01-2.24 (m, 8H, CH2-CH2),
3.40-3.49 (m, 1H, proline-CH2N), 3.54-3.65 (m, 2H, proline-CH2N), 3.81-3.90 (m, 2H,
proline-CH2N + glycine CH2N), 4.03 (dd, J = 5.4; 17.1 Hz, 1H, gycine-CH2N), 4.59-4.69 (m,
2H, proline-CHN), 5.06 (d, J = 12.3 Hz, 1H, CH2O), 5.22 (d, J = 12.3 Hz, CH2O), 5.30 (s br,
1H, NH), 7.32-7.34 (m, 5H, Ph-CH).
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1-{1-[2S-(9H-Fluoren-9-ylmethoxycarbonyl-amino)-propionyl]-pyrrolidine-2S-carbonyl}-
pyrrolidine-2S-carboxylic acid benzyl ester (67b): N-Fmoc-alanine (805 mg, 2.59 mmol,
4 eq.) was preactivated by stirring with EDC (497 mg, 2.59 mmol, 4 eq.) and HOBt (349 mg,
2.59 mmol, 4 eq.) in dry CH2Cl2 (10 ml), under nitrogen atmosphere 1 h at 0 °C and 1 h at
room temperature. The solution was added under nitrogen atmosphere to Pd[PPh3]4 (99 mg,
0.086 mmol, 0.13 eq.), then 66 (247 mg, 0.64 mmol, 1 eq.) and finally DABCO (532 mg,
4.75 mmol, 7.5 eq.) were added. The solution was stirred 20 min. at room temperature, then
CH2Cl2 (10 ml) was added and the solution was washed with saturated NaHCO3 (15 ml), 1 M
KHSO4 (10 ml) and saturated NaHCO3 (15 ml). The organic phase was dried over MgSO4
and concentrated. The product was purified by chromatography (CHCl3/MeOH 90:1) to
afford a white solid (375 mg, 98 %). - Rf  (67b): 0.14. - mp 58-60 °C. - [ ]21Dα  -127.1 (c 0.5,
MeOH). - 1H NMR (CDCl3, 400 MHz) δ 1.41 (d, J = 6.9 Hz, 3H, CH3CH), 1.93-2.06 (m, 5H,
CH2CH2CH2), 2.08-2.24 (m, 3H, CH2CH2CH2), 3.57-3.70 (m, 3H, CH2N), 3.77-3.81 (m, 1H,
CH2N), 4.20 (dd, J = 7.2, 7.2 Hz, 1H, Fmoc-CH), 4.34 (d, J = 7.1 Hz, 2H, Fmoc-CH2), 4.54
(pseudo p, J = 7.6 Hz, 1H, Ala-CHN), 4.66 (dd, J = 3.9, 9.1 Hz, 1H, Pro-CHN), 4.68-4.70 (m,
1H, Pro-CHN), 5.04 (d, J = 12.3 Hz, 1H, CH2O), 5.24 (d, J = 12.3 Hz, 1H, CH2O), 5.69 (d,
J = 8.0 Hz, 1H, NH), 7.30-7.40 (m, 9H, Ar-CH), 7.57-7.60 (m, 2H, Fmoc-Ar-CH), 7.74-7.76
(m, 2H, Fmoc-Ar-CH). - 13C NMR (CDCl3, 100.6 MHz) δ 18.2 (+, CH3CH), 24.77 (-, CH2),
24.81 (-, CH2), 28.0 (-, CH2), 28.7 (-, CH2), 46.6 (-, CH2N), 47.06 (+, Fmoc-CH), 47.10 (-,
CH2N), 48.3 (+, CHN), 57.8 (+, CHN), 58.7 (+, CHN), 66.8 (-, CH2O), 66.9 (-, CH2O), 119.9
(+, Fmoc-Ar-CH, 2C), 125.1 (+, Fmoc-Ar-CH, 2C), 127.0 (+, Ar-CH, 2C), 127.6 (+, Ar-CH,
2C), 128.1 (+, Ar-CH, 2C), 128.2 (+, Ar-CH), 128.5 (+, Ar-CH, 2C), 135.5 (Cquat, Ph-C),
141.19 (Cquat, Fmoc-Ar-C), 141.20 (Cquat, Fmoc-Ar-C), 143.8 (Cquat, Fmoc-Ar-C), 143.9
(Cquat, Fmoc-Ar-C), 155.6 (Cquat, N(CO)O), 170.2 (Cquat, C=O), 171.0 (Cquat, C=O), 171.9
(Cquat, C=O). - MS  FAB (MeOH/Glycerin) m/z (%) 596 (MH+, 25), 391 (9), 303 (23), 179
(100). - IR (KBr) 3388, 3209, 2942, 2786, 1739, 1700, 1609, 1521, 1420 cm-1. - HR MS
calcd for C35H37N3O6 + H 596.27606, found 596.27622.
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1-{1-[1-(9H-Fluoren-9-ylmethoxycarbonyl)-pyrrolidine-2S-carbonyl]-pyrrolidine-2S-
carbonyl}-pyrrolidine-2S-carboxylic acid benzyl ester (67c): N-Fmoc-proline (526 mg,
1.56 mmol, 3 eq.) was preactivated by stirring with EDC (299 mg, 1.56 mmol, 3 eq.) and
HOBt (210 mg, 1.56 mmol, 3 eq.) in dry CH2Cl2 (10 ml), under nitrogen atmosphere 1 h at
0 °C and 1 h at room temperature. The solution was added under nitrogen atmosphere to
Pd[PPh3]4 (60 mg, 0.052 mmol, 0.1 eq.), then 66 (200 mg, 0.52 mmol, 1 eq.) and finally
DABCO (323 mg, 2.86 mmol, 5.5 eq.) were added. The solution was stirred 20 min. at room
temperature, then CH2Cl2 (10 ml) was added and the solution was washed with saturated
NaHCO3 (15 ml), 1 M KHSO4 (10 ml) and saturated NaHCO3 (15 ml). The organic phase was
dried over MgSO4 and concentrated. The product was purified by chromatography
(CHCl3/MeOH 90:1) to afford a mixture of two rotamers 70:30 (310 mg, 96 %). - Rf (67c):
0.13. - mp 74-76 °C. - [ ]21Dα  -140.0 (c 0.5, MeOH). - 1H NMR (CDCl3, 62.9 MHz) δ 1.79-2.25
(m, 12H, CH2), 3.19-3.22 (m, 1H, CH2N, minor rotamer), 3.43-3.82 (m, 6H, CH2N, major
rotamer + 5H minor rotamer), 4.14-4.46 (m, 3H, Fmoc-CH2 + Fmoc-CH), 4.48-4.65 (m, 2H,
CHN, major rotamer + 3H minor rotamer), 4.76 (dd, J = 3.6, 7.7 Hz, 1H, CHN, major
rotamer), 5.01 (d, J = 12.3 Hz, 1H, CH2O, minor rotamer), 5.02 (d, J = 12.3 Hz, 1H, CH2O,
major rotamer), 5.23 (d, J =12.3 Hz, 1H, CH2O, minor rotamer + 1H major rotamer), 7.29-
7.41 (m, 9H, Ar-CH), 7.54-7.64 (m, 2H, Fmoc-Ar-CH), 7.74-7.77 (m, 2H, Fmoc-Ar-CH). -
13C NMR (CDCl3, 62.9 MHz) δ major rotamer: 23.4 (-, CH2), 24.9 (-, CH2, 2C), 27.9 (-,
CH2), 28.8 (-, CH2), 29.1 (-, CH2), 46.6 (-, CH2N), 46.89 (-, CH2N), 46.94 (-, CH2N), 47.3 (+,
Fmoc-CH), 57.9 (+, CHN), 58.3 (+, CHN), 58.8 (+, CHN), 66.8 (-, CH2O), 67.4 (-, CH2O),
119.9 (+, Fmoc-Ar-CH, 2C), 125.2 (+, Fmoc-Ar-CH), 125.3 (+, Ar-CH), 127.0 (+, Ar-CH),
127.1 (+, Ar-CH), 127.64 (+, Ar-CH), 127.65 (+, Ar-CH), 128.20 (+, Ar-CH, 2C), 128.3 (+,
Ar-CH), 128.6 (+, Ar-CH, 2C), 135.7 (Cquat, Ph-C), 141.28 (Cquat, Fmoc-Ar-C), 141.31 (Cquat,
Fmoc-Ar-C), 144.0 (Cquat, Fmoc-Ar-C), 144.3 (Cquat, Fmoc-Ar-C), 155.0 (Cquat, N(CO)O),
170.68 (Cquat, C=O), 170.71 (Cquat, C=O), 172.1 (Cquat, C=O). Minor rotamer: 23.2 (-, CH2),
24.8 (-, CH2), 24.9 (-, CH2N), 27.8 (-, CH2), 28.8 (-, CH2), 29.9 (-, CH2), 46.5 (-, CH2N), 46.6
(-, CH2N), 47.3 (-, CH2N), 47.7 (+, Fmoc-CH), 57.69 (+, CHN), 57.73 (+, CHN), 58.7 (+,
CHN), 66.3 (-, CH2O), 66.8 (-, CH2O), 119.8 (+, Fmoc-Ar-CH, 2C), 124.9 (+, Fmoc-Ar-CH),
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125.0 (+, Fmoc-Ar-CH), 126.8 (+, Ar-CH), 127.0 (+, Ar-CH), 127.4 (+, Ar-CH), 127.6 (+,
Ar-CH), 128.18 (+, Ar-CH, 2C), 128.3 (+, Ar-CH), 128.6 (+, Ar-CH, 2C), 135.68 (Cquat, Ph-
C), 141.26 (Cquat, Fmoc-Ar-C), 141.35 (Cquat, Fmoc-Ar-C), 143.9 (Cquat, Fmoc-Ar-C), 144.6
(Cquat, Fmoc-Ar-C), 154.3 (Cquat, N(CO)O), 170.5 (Cquat, C=O), 170.6 (Cquat, C=O), 172.0
(Cquat, C=O). - MS  FAB (MeOH/Glycerine) m/z (%) 1243 (2MH+, <1), 622 (MH+, 28), 179
(Fuorenyl cation, 100). - IR (KBr) 2971, 2875, 1742, 1702, 1649, 1421 cm-1. - HR MS  calcd
for C37H39N3O6 + H 622.29171, found 622.29072.
2.2.7 Solid-phase synthesis
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2S-{2S-[2S-(9H-Fluoren-9-ylmethoxycarbonylamino)-propionylamino]-3-phenyl-
propionylamino}-propionic acid (76): The solid phase synthesis was performed on a Wang
resin. The loading of N-Fmoc-alanine (0.35 mmol/g) on the resin was performed following
the Advanced ChemTech catalogue protocol (GP1). Fmoc group removal was carried out with
20 % piperidine in DMF (20 min.). The coupling of N-Alloc-phenylalanine was achieved
following the Advanced ChemTech Synthesiser (Model 90) manual protocol (GP2) for
HOBt/DIC/amino acid method. Then the resin (495 m, 0.15 mmol) was swelled in CH2Cl2
(10 ml) for 25 min.. The resin was drained and a solution (previously stirred 1 h at 0 °C and
1 h at room temperature for preactivation) of N-Fmoc-alanine (700 mg, 2.25 mmol, 15 eq.),
EDC (432 mg, 2.25 mmol, 15 eq.) and HOBt (304 mg, 2.25 mmol, 15 eq.) in freshly distilled
CH2Cl2 (8 ml) was added under nitrogen atmosphere. Pd[PPh3]4 (34 mg, 0.03 mmol, 0.2 eq.)
and finally DABCO (302 mg, 2.7 mmol, 18 eq.) were added. The reaction mixture was
agitated 2 h, the resin was drained and washed with CH2Cl2 (10 x 10 ml). The product was
cleaved from the resin by stirring for 1 h with a 2:1 mixture of TFA/CH2Cl2 (10 ml). After
solvent evaporation the pure product was isolated as a white solid (78 mg, 99 %). - mp 176-
178 °C. - [ ]21Dα  -37.3 (c 0.5, MeOH). - 1H NMR (DMSO-d6, 250 MHz): δ 1.11 (d, J = 7.0 Hz,
3H, CH3CH), 1.27 (d, J = 7.2 Hz, 3H, CH3CH), 2.78 (dd, J = 9.3, 13.8 Hz, 1H, CH2Ph), 3.03
(dd, J = 4.0, 13.8 Hz, 1H, CH2Ph), 3.95-4.03 (m, 1H, Fmoc-CH), 4.16-4.21 (m, 4H, Fmoc-
CH2 + 2 CHN), 4.27-4.51 (m, 1H, CHN), 7.19-7.48 (m, 10H, Ar-CH + NH), 7.69-7.71 (m,
2H, Fmoc-Ar-CH), 7.87-7.89 (m, 3H, Fmoc-Ar-CH + NH), 8.22 (d, J = 7.0 Hz, 1H, NH),
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12.52 (s br, 1H, CO2H). - 13C NMR (DMSO-d6, 62.9 MHz): δ 17.2 (+, CH3CH), 18.1 (+,
CH3CH), 37.3 (-, CH2Ph), 46.6 (+, Fmoc-CH), 47.5 (+, CHN), 50.2 (+, CHN), 53.3 (+, CHN),
65.6 (-, CH2O), 120.1 (+, Fmoc-Ar-CH, 2C), 125.3 (+, Fmoc-Ar-CH, 2C), 126.2 (+, Ar-CH),
127.1 (+, Ar-CH, 2C), 127.6 (+, Ar-CH, 2C), 127.9 (+, Ar-CH, 2C), 129.3 (+, Ar-CH, 2C),
137.6 (Cquat, Ph-C), 140.7 (Cquat, Fmoc-Ar-C, 2C), 143.7 (Cquat, Fmoc-Ar-C), 143.8 (Cquat,
Fmoc-Ar-C), 155.6 (Cquat, N(CO)O), 170.6 (Cquat, C=O), 172.2 (Cquat, C=O), 173.9 (Cquat,
C=O). - MS  FAB (MeOH/Glycerine) m/z (%) 530 (MH+, 13), 441 (MH+-Alanine, 8), 237 (7),
179 (Fluorenyl cation, 100). - IR (KBr) 3298, 3066, 1711, 1688, 1645, 1536, 1450 cm-1. - HR
MS  FAB (MeOH/Glycerine) calcd for C30H31N3O6 + H 530.22911, found 596.27622.
N
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(1R*, 2R*, 3S*) 2-(1S-Carboxy-2-phenyl-ethylcarbamoyl)-3-[2S-(9H-fluoren-9-
ylmethoxycarbonylamino)-propionylamino]-cyclopropane carboxylic acid methyl ester (77):
The solid phase synthesis was performed on a Wang resin. The loading of Fmoc-phenylalanine
(0.85 mmol/g) on the resin was performed following the Advanced ChemTech catalogue protocol
(GP1). Fmoc group removal was carried out with 20 % piperidine in DMF (20 min.). The
coupling of (±)-69b was achieved following the Advanced ChemTech Synthesiser (Model 90)
manual protocol (GP2) for HOBt/DIC/amino acid method. Then the resin (200 mg, 0.13 mmol)
was swelled in CH2Cl2 (10 ml) for 25 min.. The resin was drained and a solution (previously
stirred 1 h at 0 °C and 1 h at room temperature for preactivation) of N-Fmoc-alanine (248 mg,
0.80 mmol, 6 eq.), EDC ( 154 mg, 0.80 mmol, 6 eq.) and HOBt (108 mg, 0.80 mmol, 6 eq.) in
freshly distilled CH2Cl2 (4 ml) was added under nitrogen atmosphere. Pd[PPh3]4 (30 mg,
0.026 mmol, 0.2 eq.) and finally DABCO (175 mg, 1.56 mmol, 12 eq.) were added. A parallel
experiment was performed under the same conditions but with the addition of PhSiH3 (192 µl,
1.56 mmol, 12 eq.) instead of DABCO. The reaction mixture was agitated 2 h, the resin was then
drained and washed CH2Cl2 with (10 x 10 ml). The product was cleaved from the resin by stirring
1 h with a 2:1 mixture of TFA/CH2Cl2 (10 ml). After solvent evaporation the product (as a
mixture of two diastereomers) was purified by chromatography (CHCl3/MeOH 15:1 + 1 %
AcOH) as a white solid (66 mg, 85 % for DABCO protocol, 62 mg, 82 % for PhSiH3 protocol). -
Rf (77): 0.3 - mp 200 °C decomp. - 1H NMR (CD3OD, 400 MHz): δ 1.26-1.29 (m, 3H, CH3CH),
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2.19 (dd J = 5.4, 7.9 Hz, 1H, cyclopropyl-CH, 1 diast.), 2.32 (dd, J = 5.4, 7.8 Hz, 1H,
cyclopropyl-CH, 1 diast.), 2.42 (dd, J = 5.1, 5.1 Hz, 1H, cyclopropyl-CH, 1 diast.), 2.46-2.49 (m,
1H, cyclopropyl-CH, 1 diast.), 2.90-2.97 (m, 1H, PhCH2), 3.17-3.22 (m, 1H, PhCH2), 3.45-3.50
(m, 1H, cyclopropyl-CHN), 3.59 (s, 3H, CH3O, 1 diast.), 3.61 (s, 3H, CH3O, 1 diast.), 4.04-4.09
(m, 1H, Ala-CHN), 4.19-4.2 (m, 1H, Fmoc-CH), 4.29-4.39 (m, 2H, Fmoc-CH2), 4.62-4.67 (m,
1H, Phe-CHN), 7.13-7.39 (m, 9H, Ar-CH), 7.64-7.68 (m, 2H, Fmoc-Ar-CH), 7.77-7.79 (m, 2H,
Fmoc-Ar-CH). - 13C NMR (CD3OD, 100.6 MHz): δ 18.0 (+, CH3CH, 1 diast.), 18.1 (+, CH3CH,
1 diast.), 27.6 (+, cyclopropyl-CH, 1 diast.), 27.7 (+, cyclopropyl-CH, 1 diast.), 29.4 (+,
cyclopropyl-CH, 1 diast.), 29.7 (+, cyclopropyl-CH, 1 diast.), 35.7 (+, cyclopropylCHN, 1 diast.),
35.9 (+, cyclopropyl-CHN, 1 diast.), 38.4 (-, CH2Ph, 1 diast.), 38.6 (-, CH2Ph, 1 diast.), 48.4 (+,
Fmoc-CH), 51.9 (+, CH3O, 1 diast.), 52.0 (+, CH3O, 1 diast.), 52.7 (+, CHN, 1 diast.), 52.8 (+,
CHN, 1 diast.), 55.4 (+, CHN, 1 diast.), 55.5 (+, CHN, 1 diast.), 68.0 (-, Fmoc-CH2), 120.9 (+,
Fmoc-Ar-CH, 2C), 126.2 (+, Ar-CH, 2C, 1 diast.), 126.3 (+, Ar-CH, 2C, 1 diast.), 127.78 (+, Ar-
CH, 1 diast.), 127.81 (+, Ar-CH, 1 diast.), 128.14 (+, Ar-CH, 2C, 1 diast.), 128.18 (+, Ar-CH, 2C,
1 diast.), 128.8 (+, Ar-CH, 2C), 129.4 (+, Ar-CH, 2C, 1 diast.), 129.5 (+, Ar-CH, 2C, 1 diast.),
130.28 (+, Ar-CH, 2C, 1 diast.), 130.31 (+, Ar-CH, 2C, 1 diast.), 138.2 (Cquat, Ph-C, 1 diast.),
138.3 (Cquat, Ph-C, 1 diast.), 142.57 (Cquat, Fmoc-Ar-C, 2C, 1 diast.), 142.59 (Cquat, Fmoc-Ar-C,
2C, 1 diast.), 145.51 (Cquat, Fmoc-Ar-C, 1 diast.), 145.2 (Cquat, Fmoc-Ar-C, 1 diast.), 145.4 (Cquat,
Fmoc-Ar-C), 158.2 (Cquat, N(CO)O), 170.5 (Cquat, C=O, 1 diast.), 170.6 (Cquat, C=O, 1 diast.),
170.8 (Cquat, C=O, 1 diast.), 170.9 (Cquat, C=O, 1 diast.), 174.56 (Cquat, C=O, 1 diast.), 174.65
(Cquat, C=O, 1 diast.), 176.6 (Cquat, C=O). - MS  FAB (MeOH/Glycerine) m/z (%) 600 (MH+,
100), 442 (18). - IR (KBr) 3500-277 (OH broad signal), 3292, 3047, 2961, 1719, 1649, 1529,
1439, 1247 cm-1. - HR MS  calcd for C33H33N3O8 + H 600.23459, found 600.23475.
N
CO2HO
N
O
FmocHN
80
1-{1-[2S-(9H-Fluoren-9-ylmethoxycarbonyl-amino)-propionyl]-pyrrolidine-2S-carbonyl}-
pyrrolidine-2S-carboxylic acid (80): The solid phase synthesis was performed on a Wang resin.
The loading of N-Fmoc-proline (0.6 mmol/g) on the resin was performed following the
Advanced ChemTech catalogue protocol (GP1). Fmoc group removal was carried out with
20 % piperidine in DMF (20 min.). The coupling of N-Alloc-proline was achieved following
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the Advanced ChemTech Synthesiser (Model 90) manual protocol (GP2) for
HOBt/DIC/amino acid method. Then the resin (300 mg, 0.15 mmol) was swelled in CH2Cl2
(10 ml) for 25 min.. The resin was drained and a solution (previously stirred 1 h at 0 °C and
1 h at room temperature for preactivation) of N-Fmoc-alanine (299 mg, 0.96 mmol, 6 eq.),
EDC ( 184 mg, 0.96 mmol, 6 eq.) and HOBt (130 mg, 0.96 mmol, 6 eq.) in freshly distilled
CH2Cl2 (4 ml) was added under nitrogen atmosphere. Pd[PPh3]4 (34 mg, 0.03 mmol, 0.2 eq.)
and finally DABCO (201 mg, 1.8 mmol, 12 eq.) were added. A parallel experiment was
performed under the same conditions but with the addition of PhSiH3 (221 µl, 1.8 mmol,
12 eq.) instead of DABCO. The reaction mixture was agitated 2 h, the resin was then drained
and washed with CH2Cl2 (10 x 10 ml). The product was cleaved from the resin by stirring 1 h
with a 2:1 mixture of TFA/CH2Cl2 (10 ml). After solvent evaporation the pure product was
isolated as a white solid (77 mg, quantitative for DABCO protocol, 76 mg, 99 % for PhSiH3
protocol). - mp 96-99 °C. - [ ]21Dα  -107.5 (c 0.5, MeOH). - 1H NMR (CDCl3, 400 MHz): δ 1.38
(d, J = 6.8 Hz, 3H, CH3CH), 1.97-2.06 (m, 4H, CH2CH2CH2), 2.09-2.20 (m, 4H,
CH2CH2CH2), 3.54-3.80 (m, 4H, CH2N), 4.20 (dd, J = 7.4, 7.4 Hz, 1H, Fmoc-CH), 4.33 (d,
J = 6.8 Hz, 2H, Fmoc-CH2), 4.54 (dq, J = 7.3, 7.3 Hz, 1H, Ala-CHN), 4.60 (dd, J = 4.2,
7.7 Hz, 1H, CHN), 4.67 (dd, J = 4.6, 7.9 Hz, 1H, CHN), 5.82 (d, J = 8.3 Hz, 1H, NH), 7.26-
7.31 (m, 2H, Fmoc-Ar-CH), 7.37-7.41 (m, 2H, Fmoc-Ar-CH), 7.57-7.70 (m, 2H, Fmoc-Ar-
CH), 7.74-7.76 (m, 2H, Fmoc-Ar-CH), 9.23 (s br, 1H, CO2H). - 13C NMR (CDCl3,
100.6 MHz): δ 17.9 (+, CH3CH), 24.9 (-,CH2CH2CH2), 28.0 (-,CH2CH2CH2), 28.1 (-
,CH2CH2CH2), 29.6 (-,CH2CH2CH2), 47.09 (+, Fmoc-CH), 47.12 (-, CH2N), 47.2 (-, CH2N),
48.3 (+, CHN), 57.9 (+, CHN), 59.4 (+, CHN), 67.0 (-, CH2O), 119.9 (+, Fmoc-Ar-CH, 2C),
125.1 (+, Fmoc-Ar-CH, 2C), 127.0 (+, Fmoc-Ar-CH, 2C), 127.6 (+, Fmoc-Ar-CH, 2C), 141.2
(Cquat, Fmoc-Ar-C, 2C), 143.8 (Cquat, Fmoc-Ar-C), 143.9 (Cquat, Fmoc-Ar-C), 155.8 (Cquat,
N(CO)O), 171.6 (Cquat, C=O), 171.8 (Cquat, C=O), 173.9 (Cquat, C=O). - MS  FAB
(MeOH/Glycerine) m/z (%) 506 (MH+, 17), 319 (MH+-Pro, 9), 213 (25), 179 (Fluorenyl
cation, 100). - IR (KBr) 3414, 3308, 2978, 1715, 1637, 1449, 1248 cm-1. - HR MS  calcd for
C28H31N3O6 + H 506.22911, found 506.2293.
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NMR
1H-Spectra (top of the page)
13C-Spectra (DEPT) (bottom of the page)
In some cases DQF-COSY, 80 ms TOCSY and 500 ms ROESY are given in this order after
the 13C spectrum.
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11.0
(1R*, 2R*, 3
18
(1R*, 2R*, 3
O(ppm)
1.02.03.04.05.06.07.08.09.010.0
S*) 3-Allyloxycarbonyl-cyclopropane-1,2-dicarboxylic acid mono methyl ester, 250 MHz, CDCl3.
(ppm)
1020304050607080901001101201301401501601700
S*) 3-Allyloxycarbonyl-cyclopropane-1,2-dicarboxylic acid mono methyl ester, 62.9 MHz, CDCl3.
HN
MeO2C CO2H
O
69b
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(1R, 2
methoxyc
carbonyla
CDCl3/C
(1R, 2
methoxyc
carbonyla
MHz, CD
CO2MeCO2Me CO2Me(ppm)
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
R, 3R) 3-{2S-[2R-(2S-{2R-[2S-(9H-Fluoren-9-ylmethoxycarbonylamino)-propionylamino]-3R-
arbonyl-cyclopropane-1R-carbonylamino}-propionylamino)-3R-methoxycarbonyl-cyclopropane-1R-
mino]-propionylamino}-cyclopropane-1, 2-dicarboxylic acid 1-benzyl ester 2-methyl ester, 250 MHz,
D3OD 1:1.
(ppm)
102030405060708090100110120130140150160170180
R, 3R) 3-{2S-[2R-(2S-{2R-[2S-(9H-Fluoren-9-ylmethoxycarbonylamino)-propionylamino]-3R-
arbonyl-cyclopropane-1R-carbonylamino}-propionylamino)-3R-methoxycarbonyl-cyclopropane-1R-
mino]-propionylamino}-cyclopropane-1, 2-dicarboxylic acid 1-benzyl ester 2-methyl ester, 100.6
Cl3/CD3OD 1:1.
N
H
H
N
O
O
N
H
FmocHN
O H
N
O
N
H
O
CO2Bn
(+)-45
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(ppm)
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
(1R, 2R, 3R) 2-[2S-(2S-Amino-3-phenyl-propionylamino)-propionylamino]-3-[1S-(1S-carboxy-2-phenyl-
ethylcarbamoyl)-ethylcarbamoyl]-cyclopropane carboxylic acid methyl ester, HCl salt, 400 MHz, CD3OD.
(ppm)
102030405060708090100110120130140150160170180
(1R, 2R, 3R) 2-[2S-(2S-Amino-3-phenyl-propionylamino)-propionylamino]-3-[1S-(1S-carboxy-2-phenyl-
ethylcarbamoyl)-ethylcarbamoyl]-cyclopropane carboxylic acid methyl ester, HCl salt, 100.6 MHz, CD3OD.
N
H
CO2Me
OH
N
O
H3N
H
N
O
N
H
O
CO2H
PhPh
Cl
(+)-39
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(ppm) 8.0 6.0 4.0 2.0 0.0
10.0
8.0
6.0
4.0
2.0
0.0
(ppm)
(1R, 2R, 3R) 2-[2S-(2S-Amino-3-phenyl-propionylamino)-propionylamino]-3-[1S-(1S-carboxy-2-phenyl-
ethylcarbamoyl)-ethylcarbamoyl]-cyclopropane carboxylic acid methyl ester HCl salt. COSY: 500 MHz, 280 K,
CD3OH.
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(ppm) 8.0 6.0 4.0 2.0
10.0
8.0
6.0
4.0
2.0
(ppm)
(1R, 2R, 3R) 2-[2S-(2S-Amino-3-phenyl-propionylamino)-propionylamino]-3-[1S-(1S-carboxy-2-phenyl-
ethylcarbamoyl)-ethylcarbamoyl]-cyclopropane carboxylic acid methyl ester HCl salt. TOCSY: 500 MHz,
280 K, CD3OH.
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(ppm) 8.0 6.0 4.0 2.0
10.0
8.0
6.0
4.0
2.0
(ppm)
(1R, 2R, 3R) 2-[2S-(2S-Amino-3-phenyl-propionylamino)-propionylamino]-3-[1S-(1S-carboxy-2-phenyl-
ethylcarbamoyl)-ethylcarbamoyl]-cyclopropane carboxylic acid methyl ester HCl salt. ROESY: 500 MHz,
500 ms spin lock, 280 K, CD3OH.
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(1S, 2
ethylcar
(1S, 2
ethylcar
CO2Me PhPh(ppm)
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
S, 3S) 2-[2S-(2S-Amino-3-phenyl-propionylamino)-propionylamino]-3-[1S-(1S-carboxy-2-phenyl-
bamoyl)-ethylcarbamoyl]-cyclopropane carboxylic acid methyl ester, HCl salt, 400 MHz, CD3OD.
(ppm)
102030405060708090100110120130140150160170180
S, 3S) 2-[2S-(2S-Amino-3-phenyl-propionylamino)-propionylamino]-3-[1S-(1S-carboxy-2-phenyl-
bamoyl)-ethylcarbamoyl]-cyclopropane carboxylic acid methyl ester, HCl salt, 100.6 MHz, CD3OD.
N
H
OH
N
O
H3N
H
N
O
N
H
O
CO2HCl
(-)-39
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(ppm) 8.0 6.0 4.0 2.0 0.0
10.0
8.0
6.0
4.0
2.0
0.0
(ppm)(1S, 2S, 3S) 2-[2S-(2S-Amino-3-phenyl-propionylamino)-propionylamino]-3-[1S-(1S-carboxy-2-phenyl-
ethylcarbamoyl)-ethylcarbamoyl]-cyclopropane carboxylic acid methyl ester HCl salt. COSY: 500 MHz, 280 K,
CD3OH.
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(ppm) 8.0 6.0 4.0 2.0
10.0
8.0
6.0
4.0
2.0
(ppm)
(1S, 2S, 3S) 2-[2S-(2S-Amino-3-phenyl-propionylamino)-propionylamino]-3-[1S-(1S-carboxy-2-phenyl-
ethylcarbamoyl)-ethylcarbamoyl]-cyclopropane carboxylic acid methyl ester HCl salt. TOCSY: 500 MHz,
280 K, CD3OH.
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(ppm) 8.0 6.0 4.0 2.0
10.0
8.0
6.0
4.0
2.0
(ppm)
(1S, 2S, 3S) 2-[2S-(2S-Amino-3-phenyl-propionylamino)-propionylamino]-3-[1S-(1S-carboxy-2-phenyl-
ethylcarbamoyl)-ethylcarbamoyl]-cyclopropane carboxylic acid methyl ester HCl salt. ROESY: 500 MHz,
500 ms spin lock, 280 K, CD3OH.
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(1R, 2R
cyclopro
MHz, C
(1R, 2R
cyclopro
MHz, C
CO2MeCO2Me(ppm)
0.40.81.21.62.02.42.83.23.64.04.44.85.25.6
, 3R) 2-(2S-Carboxyl-ethylcarbamoyl)-3-{2S-[2R-(2S-amino-propionylamino)-3R-methoxycarbonyl-
pane-1R-carbonyl-amino]-propionylamino}-cyclopropane carboxylic acid methyl ester, HCl salt, 400
D3OD.
(ppm)
102030405060708090100110120130140150160170180
, 3R) 2-(2S-Carboxyl-ethylcarbamoyl)-3-{2S-[2R-(2S-amino-propionylamino)-3R-methoxycarbonyl-
pane-1R-carbonyl-amino]-propionylamino}-cyclopropane carboxylic acid methyl ester, HCl salt, 100.6
D3OD.
N
H
OH
N
O
H
N
O
CO2HN
H
O
H3NCl (+)-43
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(ppm) 8.0 6.0 4.0 2.0 0.0
0
146
292
438
584
730
876
(pts)
(1R, 2R, 3R) 2-(2S-Carboxyl-ethylcarbamoyl)-3-{2S-[2R-(2S-amino-propionylamino)-3R-methoxycarbonyl-
cyclopropane-1R-carbonyl-amino]-propionylamino}-cyclopropane carboxylic acid methyl ester HCl salt.
COSY: 500 MHz, 280 K, CD3OH.
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(ppm) 8.0 6.0 4.0 2.0
4800
4000
3200
2400
1600
800
(Hz)
(1R, 2R, 3R) 2-(2S-Carboxyl-ethylcarbamoyl)-3-{2S-[2R-(2S-amino-propionylamino)-3R-methoxycarbonyl-
cyclopropane-1R-carbonyl-amino]-propionylamino}-cyclopropane carboxylic acid methyl ester HCl salt.
TOCSY: 500 MHz, 280 K, CD3OH.
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(ppm) 8.0 6.0 4.0 2.0
10.0
8.0
6.0
4.0
2.0
(ppm)(1R, 2R, 3R) 2-(2S-Carboxyl-ethylcarbamoyl)-3-{2S-[2R-(2S-amino-propionylamino)-3R-methoxycarbonyl-
cyclopropane-1R-carbonyl-amino]-propionylamino}-cyclopropane carboxylic acid methyl ester HCl salt.
ROESY: 500 MHz, 500 ms spin lock, 280 K, CD3OH.
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(1S, 2
cyclopro
MHz, C
(1S, 2
cyclopro
MHz, C
CO2MeCO2Me(ppm)
0.40.81.21.62.02.42.83.23.64.04.44.85.25.6
S, 3S) 2-(2S-Carboxy-ethylcarbamoyl)-3-{2S-[2S-(2S-amino-propionylamino)-3S-methoxycarbonyl-
pane-1S-carbonyl-amino]-propionylamino}-cyclopropane carboxylic acid methyl ester, HCl salt, 250
D3OD.
(ppm)
102030405060708090100110120130140150160170180
S, 3S) 2-(2S-Carboxy-ethylcarbamoyl)-3-{2S-[2S-(2S-amino-propionylamino)-3S-methoxycarbonyl-
pane-1S-carbonyl-amino]-propionylamino}-cyclopropane carboxylic acid methyl ester, HCl salt, 62.9
D3OD.
N
H
OH
N
O
H
N
O
CO2HN
H
O
H3NCl (-)-43
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(ppm) 8.0 6.0 4.0 2.0 0.0
10.0
8.0
6.0
4.0
2.0
0.0
(ppm)
(1S, 2S, 3S) 2-(2S-Carboxy-ethylcarbamoyl)-3-{2S-[2S-(2S-amino-propionylamino)-3S-methoxycarbonyl-
cyclopropane-1S-carbonyl-amino]-propionylamino}-cyclopropane carboxylic acid methyl ester, HCl salt.
COSY: 500 MHz, 280 K, CD3OH.
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(ppm) 8.0 6.0 4.0 2.0
0
146
292
438
584
730
876
(pts)
(1S, 2S, 3S) 2-(2S-Carboxy-ethylcarbamoyl)-3-{2S-[2S-(2S-amino-propionylamino)-3S-methoxycarbonyl-
cyclopropane-1S-carbonyl-amino]-propionylamino}-cyclopropane carboxylic acid methyl ester, HCl salt.
TOCSY: 500 MHz, 280 K, CD3OH.
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(ppm) 8.0 6.0 4.0 2.0
10.0
8.0
6.0
4.0
2.0
(ppm)
(1S, 2S, 3S) 2-(2S-Carboxy-ethylcarbamoyl)-3-{2S-[2S-(2S-amino-propionylamino)-3S-methoxycarbonyl-
cyclopropane-1S-carbonyl-amino]-propionylamino}-cyclopropane carboxylic acid methyl ester, HCl salt.
ROESY: 500 MHz, 500 ms spin lock, 280 K, CD3OH.
Appendix of NMR and X-ray data 197
77.58.08.5
1-{1-[2S-(9H-Fluoren-9-ylm
carboxylic acid, 400 MHz, C
15160170180
1-{1-[2S-(9H-Fluoren-9-ylm
carboxylic acid, 100.6 MHz,
O(ppm)
0.51.01.52.02.53.03.54.04.55.05.56.06.5.0
ethoxycarbonyl-amino)-propionyl]-pyrrolidine-2S-carbonyl]-pyrrolidine-2S-
DCl3.
(ppm)
1020304050607080901001101201301400
ethoxycarbonyl-amino)-propionyl]-pyrrolidine-2S-carbonyl]-pyrrolidine-2S-
 CDCl3.
N
CO2HO
NFmocHN
80
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(1R*, 
propiony
(1R*, 
propiony
CO2Me(ppm)
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
2R*, 3S*) 2-(1S-Carboxy-2-phenyl-ethylcarbamoyl)-3-[2S-(9H-fluoren-9-ylmethoxycarbonylamino)-
lamino]-cyclopropane carboxylic acid methyl ester, 400 MHz, CD3OD.
(ppm)
102030405060708090100110120130140150160170180
2R*, 3S*) 2-(1S-Carboxy-2-phenyl-ethylcarbamoyl)-3-[2S-(9H-fluoren-9-ylmethoxycarbonylamino)-
lamino]-cyclopropane carboxylic acid methyl ester, 100.6 MHz, CD3OD.
N
H
H
N
O
O
FmocHN CO2H
Ph
77
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X-ray data of compound (±)-34
(1R*, 2R*, 3R*) 2-acetylamino-3-diethyl-carbamoyl-cyclopropane carboxylic acid
methyl ester ((±)-34)
Table 1. Crystal data and structure refinement for (±)-34.
      Identification code mc11b
      Empirical formula C12 H20 N2 O4
      Formula weight 256.30
      Temperature 293(2) K
      Wavelength 1.54178 Å
      Crystal system, space group Monoclinic, P2(1)/c
      Unit cell dimensions a = 8.873(3) Å alpha = 90 deg.
b = 14.219(4) Å beta = 93.28(5) deg.
c = 10.839(4) Å gamma = 90 deg.
      Volume 1365.3(8) Å3
      Z, Calculated density 4,  1.247 Mg/m3
      Absorption coefficient 0.778 mm-1
      F(000) 552
      Crystal size 0.60 x 0.60 x 0.40 mm
      Theta range for data collection 5.14 to 59.99 deg.
      Limiting indices -9<=h<=9, -1<=k<=15, 0<=l<=12
      Reflections collected / unique 2323 / 2013 [R(int) = 0.0289]
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      Completeness to theta = 59.99 99.7 %
      Refinement method Full-matrix least-squares on F2
      Data / restraints / parameters 2013 / 0 / 164
      Goodness-of-fit on F2 1.097
      Final R indices [I>2sigma(I)] R1 = 0.0582, wR2 = 0.1552
      R indices (all data) R1 = 0.0595, wR2 = 0.1569
      Extinction coefficient 0.074(5)
      Largest diff. peak and hole 0.258 and -0.319 e. Å-3
Table 2. Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2 x 103)
for (±)-34. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.
x y z U (eq)
C01 5453(3) 5423(2) 3276(2) 65(1)
C0 5132(2) 4426(1) 2888(2) 48(1)
O0 5526(2) 3757(1) 3531(1) 68(1)
N1 4385(2) 4323(1) 1789(1) 47(1)
C1 4071(2) 3416(1) 1261(2) 43(1)
C2 5225(2) 2967(1) 484(2) 42(1)
C3 3806(2) 3391(1) -120(2) 44(1)
C4 6690(2) 3454(1) 329(2) 43(1)
O1 6799(2) 4105(1) -414(1) 58(1)
NT 7878(2) 3154(1) 1029(2) 49(1)
CT1 7799(2) 2435(1) 1994(2) 55(1)
CT2 8357(3) 1490(2) 1589(3) 84(1)
CT3 9340(2) 3607(2) 893(2) 64(1)
CT4 9478(3) 4536(2) 1557(3) 84(1)
C5 2671(2) 2757(1) -726(2) 49(1)
O2 2005(2) 2922(1) -1698(1) 71(1)
O3 2479(2) 1978(1) -73(1) 61(1)
C6 1515(3) 1278(2) -660(3) 80(1)
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Table 3. Bond lengths [Å] and angles [deg] for (±)-34.
C01-C0 1.500(3) N1-C1-C3 115.82(15)
C0-O0 1.219(2) N1-C1-C2 118.88(16)
C0-N1 1.338(3) C3-C1-C2 60.32(12)
N1-C1 1.432(2) C4-C2-C1 119.45(15)
C1-C3 1.502(3) C4-C2-C3 118.45(15)
C1-C2 1.505(3) C1-C2-C3 59.75(12)
C2-C4 1.491(3) C5-C3-C1 121.42(17)
C2-C3 1.511(2) C5-C3-C2 118.62(16)
C3-C5 1.478(3) C1-C3-C2 59.92(12)
C4-O1 1.235(2) O1-C4-NT 121.52(17)
C4-NT 1.333(2) O1-C4-C2 121.53(16)
NT-CT3 1.464(3) NT-C4-C2 116.95(15)
NT-CT1 1.466(2) C4-NT-CT3 118.57(16)
CT1-CT2 1.506(3) C4-NT-CT1 124.12(16)
CT3-CT4 1.506(4) CT3-NT-CT1 117.19(16)
C5-O2 1.201(2) NT-CT1-CT2 112.60(19)
C5-O3 1.331(3) NT-CT3-CT4 112.7(2)
O3-C6 1.437(3) O2-C5-O3 123.91(18)
O0-C0-N1 122.35(18) O2-C5-C3 123.99(19)
O0-C0-C01 122.24(17) O3-C5-C3 112.10(15)
N1-C0-C01 115.41(17) C5-O3-C6 115.62(17)
C0-N1-C1 121.98(15)
Table 4. Anisotropic displacement parameters (Å2 x 103) for (±)-34. The anisotropic displacement
factor exponent takes the form: -2 pi2 [ h2 a*2 U11 + ... + 2 h k a* b* U12]
U11 U22 U33 U23 U13 U12
C01 95(2) 47(1) 54(1) -9(1) -5(1) -1(1)
C0 65(1) 41(1) 39(1) -1(1) 1(1) 4(1)
O0 106(1) 48(1) 48(1) 5(1) -16(1) 7(1)
N1 67(1) 32(1) 42(1) 1(1) -4(1) 5(1)
C1 54(1) 34(1) 41(1) 2(1) -3(1) 1(1)
C2 51(1) 31(1) 44(1) 1(1) -6(1) 3(1)
C3 50(1) 40(1) 42(1) 1(1) -4(1) 4(1)
C4 52(1) 31(1) 45(1) 2(1) -3(1) 4(1)
O1 60(1) 48(1) 65(1) 21(1) -5(1) -1(1)
NT 47(1) 39(1) 59(1) 10(1) -7(1) 0(1)
CT1 58(1) 48(1) 58(1) 13(1) -10(1) 3(1)
CT2 87(2) 51(1) 114(2) 27(1) 13(2) 21(1)
CT3 49(1) 56(1) 85(2) 14(1) -9(1) -3(1)
CT4 81(2) 57(1) 110(2) 10(1) -31(2) -17(1)
C5 47(1) 54(1) 45(1) -6(1) -3(1) 7(1)
O2 71(1) 83(1) 56(1) -4(1) -23(1) 1(1)
O3 62(1) 54(1) 64(1) -3(1) -13(1) -13(1)
C6 71(2) 74(2) 93(2) -17(1) -9(1) -25(1)
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Table 5. Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2 x 103) for (±)-34.
U11 U22 U33 U23 U13 U12
C01 95(2) 47(1) 54(1) -9(1) -5(1) -1(1)
C0 65(1) 41(1) 39(1) -1(1) 1(1) 4(1)
O0 106(1) 48(1) 48(1) 5(1) -16(1) 7(1)
N1 67(1) 32(1) 42(1) 1(1) -4(1) 5(1)
C1 54(1) 34(1) 41(1) 2(1) -3(1) 1(1)
C2 51(1) 31(1) 44(1) 1(1) -6(1) 3(1)
C3 50(1) 40(1) 42(1) 1(1) -4(1) 4(1)
C4 52(1) 31(1) 45(1) 2(1) -3(1) 4(1)
O1 60(1) 48(1) 65(1) 21(1) -5(1) -1(1)
NT 47(1) 39(1) 59(1) 10(1) -7(1) 0(1)
CT1 58(1) 48(1) 58(1) 13(1) -10(1) 3(1)
CT2 87(2) 51(1) 114(2) 27(1) 13(2) 21(1)
CT3 49(1) 56(1) 85(2) 14(1) -9(1) -3(1)
CT4 81(2) 57(1) 110(2) 10(1) -31(2) -17(1)
C5 47(1) 54(1) 45(1) -6(1) -3(1) 7(1)
O2 71(1) 83(1) 56(1) -4(1) -23(1) 1(1)
O3 62(1) 54(1) 64(1) -3(1) -13(1) -13(1)
C6 71(2) 74(2) 93(2) -17(1) -9(1) -25(1)
Table 6. Torsion angles [deg] for (±)-34.
O0-C0-N1-C1 -3.6(3) C3-C2-C4-NT 169.40(15)
C01-C0-N1-C1 176.40(18) O1-C4-NT-CT3 -0.8(3)
C0-N1-C1-C3 -156.56(17) C2-C4-NT-CT3 179.29(17)
C0-N1-C1-C2 -87.7(2) O1-C4-NT-CT1 175.06(18)
N1-C1-C2-C4 2.7(2) C2-C4-NT-CT1 -4.9(3)
C3-C1-C2-C4 107.70(18) C4-NT-CT1-CT2 102.5(2)
N1-C1-C2-C3 -104.96(17) CT3-NT-CT1-CT2 -81.6(2)
N1-C1-C3-C5 -142.86(17) C4-NT-CT3-CT4 79.1(3)
C2-C1-C3-C5 107.15(19) CT1-NT-CT3-CT4 -97.0(2)
N1-C1-C3-C2 109.99(18) C1-C3-C5-O2 151.01(19)
C4-C2-C3-C5 138.91(17) C2-C3-C5-O2 -138.6(2)
C1-C2-C3-C5 -111.74(19) C1-C3-C5-O3 -29.4(2)
C4-C2-C3-C1 -109.36(18) C2-C3-C5-O3 41.0(2)
C1-C2-C4-O1 -79.9(2) O2-C5-O3-C6 6.0(3)
C3-C2-C4-O1 -10.5(3) C3-C5-O3-C6 -173.57(18)
C1-C2-C4-NT 100.0(2)
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Table 7. Hydrogen bonds for (±)-34 [Å and deg.].
D-H...A d(D-H) d(H...A) d(D...A) <(DHA)
N1-H1...O1#1 0.86 2.00 2.853(2) 174.4
Symmetry transformations used to generate equivalent atoms: #1 -x+1,-y+1,-z.
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